ID,SMILES,IC50,pIC50,Assay Type,Document ChEMBL ID,Category,Category_broad,Assay Description,Source ID,Source Description,Document Journal,Document Year,Molecular Weight,AlogP,bioactivity,bio_code,MW,LogP,LogS,nHA,nHD,TPSA,Druglikeness,Molecular_Flexibility,Molecular_Complexity,nHET,nRot,nAro,Globularity_SVD,Globularity_Vol,pc1,pc2,pc3,CSK_frequency,Scaffold_frequency
CHEMBL101454,O=C1Cc2ccccc2N1C1CCN(C2CCCCCCC2)CC1,99,7,F,CHEMBL2385080,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem Lett,2013,326.48,4.15,active,2,326.482,4.5975,-4.284,3,0,23.55,1.227,0.37161,0.77933,3,2,1,0.29139,0.74085,-1.790312509,0.08453775461,-0.03414877615,4,3
CHEMBL102900,O=C1Cc2ccccc2N1C1CCN(C2C3CCCC2CCC3)CC1,29,7.54,F,CHEMBL2385080,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem Lett,2013,338.5,4.01,active,2,338.493,3.7714,-4.42,3,0,23.55,3.7542,0.38783,0.8003,3,2,1,0.33446,0.76282,-1.669264642,0.1361678278,-0.1849170589,1,1
CHEMBL107207,COc1ccc2c(c1O)[C@]13CCN(C)C(C2)[C@@]12CC(=C(C)C)[C@@H]3c1[nH]c3ccccc3c1C2,1016,5.99,F,CHEMBL1145844,agonist,agonist,Effective concentration agonistic activity towards Opioid receptor mu 1,1,Scientific Literature,J Med Chem,2003,440.59,5.45,inactive,0,440.585,5.643,-5.248,4,2,48.49,4.9241,0.15663,1.1057,4,1,3,0.57684,0.74987,-1.358927171,-0.7318504802,-0.319699584,1,1
CHEMBL107420,COc1ccc2c(c1O)[C@]13CCN(C)C(C2)[C@@]12C/C(=C(/C)c1ccccc1)[C@@H]3c1[nH]c3ccccc3c1C2,139,6.86,F,CHEMBL1145844,agonist,agonist,Effective concentration agonistic activity towards Opioid receptor mu 1,1,Scientific Literature,J Med Chem,2003,502.66,6.58,intermediate,1,502.656,6.3734,-6.081,4,2,48.49,5.1371,0.19057,1.1111,4,2,4,0.42802,0.72149,-1.264420929,-1.420830424,-0.3086178463,2,2
CHEMBL1083062,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CS1,120,6.92,F,CHEMBL1155455,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2010,482.69,4.7,intermediate,1,482.687,4.7497,-4.929,5,3,98.1,7.1671,0.41639,0.85083,6,6,2,0.31928,0.69167,-0.5486351109,-0.4739512667,0.003148239739,9,1
CHEMBL1083372,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2C[S+]1[O-],120,6.92,F,CHEMBL1155455,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2010,498.69,3.71,intermediate,1,498.686,3.4102,-3.846,6,3,109.08,5.2747,0.42053,0.87019,7,6,2,0.38333,0.69684,-0.2629343409,0.3827413734,0.04527775414,1,1
CHEMBL1084529,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@@H]1Cc2ccc(O)cc2CO1,120,6.92,F,CHEMBL1155455,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2010,466.62,3.98,intermediate,1,466.62,3.2301,-4.099,6,3,82.03,5.8407,0.44526,0.85083,6,6,2,0.32708,0.6873,-0.4275739455,0.2921026075,0.001508972464,9,1
CHEMBL1085023,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@@H]1CCc2cc(O)ccc2C1,120,6.92,F,CHEMBL1155455,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2010,464.65,4.64,intermediate,1,464.648,4.7222,-4.612,5,3,72.8,4.5501,0.42046,0.84784,5,6,2,0.36991,0.69859,-0.7298505,-0.2683361413,0.1206329638,9,1
CHEMBL1085024,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1CCc2cc(O)ccc2C1,120,6.92,F,CHEMBL1155455,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2010,464.65,4.64,intermediate,1,464.648,4.7222,-4.612,5,3,72.8,4.5501,0.42061,0.84784,5,6,2,0.32701,0.68922,-0.7298505,-0.2683361413,0.1206329638,9,1
CHEMBL1085025,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CO1,120,6.92,F,CHEMBL1155455,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2010,466.62,3.98,intermediate,1,466.62,3.2301,-4.099,6,3,82.03,5.8407,0.44101,0.85083,6,6,2,0.36548,0.68741,-0.4275739455,0.2921026075,0.001508972464,9,1
CHEMBL108608,COc1ccc2c(c1O)[C@]13CCN(C)C(C2)[C@@]12C/C(=C\c1ccccc1)[C@@H]3c1[nH]c3ccccc3c1C2,44.7,7.35,F,CHEMBL1145844,agonist,agonist,Effective concentration agonistic activity towards Opioid receptor mu 1,1,Scientific Literature,J Med Chem,2003,488.63,6.19,active,2,488.629,6.153,-6.352,4,2,48.49,5.4585,0.18734,1.1026,4,2,4,0.37852,0.71741,-1.247953555,-1.528900773,-0.4089512537,2,2
CHEMBL10872,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccccc2CN1,41,7.39,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,449.64,3.85,active,2,449.637,3.4323,-4.259,5,3,64.6,6.511,0.4554,0.84047,5,6,2,0.3676,0.70773,-0.6459806548,0.1757248374,0.02964718721,9,2
CHEMBL109040,COc1ccc2c(c1O)[C@]13CCN(C)C(C2)[C@]12CCC(=O)[C@H]3/C(=C/c1ccccc1)C2,6.7,8.17,F,CHEMBL1145844,agonist,agonist,Effective concentration agonistic activity towards Opioid receptor mu 1,1,Scientific Literature,J Med Chem,2003,415.53,4.35,highly_active,3,415.531,4.1771,-4.689,4,1,49.77,4.3454,0.21443,1.0841,4,2,2,0.36279,0.74679,-1.291648398,-0.1490892255,-0.2669067659,2,2
CHEMBL110124,COc1ccc2c(c1O)[C@]13CCN(C)C(C2)[C@]12CCC(=O)[C@H]3/C(=C(\C)c1ccccc1)C2,15.2,7.82,F,CHEMBL1145844,agonist,agonist,Effective concentration agonistic activity towards Opioid receptor mu 1,1,Scientific Literature,J Med Chem,2003,429.56,4.74,active,2,429.558,4.3975,-4.418,4,1,49.77,4.0729,0.21851,1.0923,4,2,2,0.36593,0.74648,-1.308115695,-0.04101907433,-0.1665735441,2,2
CHEMBL110461,CN1CC[C@]23c4c5ccc(O)c4O[C@@]2(C)c2[nH]c4ccccc4c2C[C@@]3(C/C=C/c2ccccc2)C1C5,804,6.09,F,CHEMBL1145844,agonist,agonist,Effective concentration agonistic activity towards Opioid receptor mu 1,1,Scientific Literature,J Med Chem,2003,488.63,6.33,intermediate,1,488.629,6.3196,-6.533,4,2,48.49,4.369,0.24532,1.127,4,3,4,0.45302,0.71315,-1.21368843,-1.677178077,-0.3295151009,2,1
CHEMBL112035,CN1CCC23c4c5ccc(O)c4OC2c2n[nH]cc2CC3(O)C1C5,19.26,7.71,F,CHEMBL1131901,agonist,agonist,Agonistic activity against human opioid Mu receptor transfected into Chinese hamster ovary (CHO) cells using [3H]-DAMGO as radioligand,1,Scientific Literature,Bioorg Med Chem Lett,1999,325.37,1.03,active,2,325.367,0.3989,-1.73,6,3,81.61,6.6015,0.17472,1.0718,6,0,2,0.54505,0.81788,-0.6984954531,2.388982304,-0.4473493603,1,1
CHEMBL112656,CN1CCC23c4c5ccc(O)c4OC2c2nc(-c4ccccc4)ncc2CC3(O)C1C5,58.42,7.23,F,CHEMBL1131901,agonist,agonist,Agonistic activity against human opioid Mu receptor transfected into Chinese hamster ovary (CHO) cells using [3H]-DAMGO as radioligand,1,Scientific Literature,Bioorg Med Chem Lett,1999,413.48,2.77,active,2,413.476,2.5851,-4.298,6,2,78.71,5.4697,0.2091,1.0845,6,1,3,0.40073,0.74412,-0.7516294158,0.3888907613,-0.6083646285,1,1
CHEMBL114803,CN1CCC23c4c5ccc(O)c4OC2c2nc(O)ncc2CC3(O)C1C5,110.25,6.96,F,CHEMBL1131901,agonist,agonist,Agonistic activity against human opioid Mu receptor transfected into Chinese hamster ovary (CHO) cells using [3H]-DAMGO as radioligand,1,Scientific Literature,Bioorg Med Chem Lett,1999,353.38,0.81,intermediate,1,353.377,0.9659,-2.128,7,3,98.94,5.4697,0.17524,1.0791,7,0,2,0.47471,0.80344,-0.5273049274,2.032945132,-0.4989891264,3,3
CHEMBL1190199,CN(C(=O)C(c1ccccc1)c1ccccc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1,60000,4.22,F,CHEMBL3393059,agonist,agonist,Agonist activity at human mu opioid receptor expressed in COS7 cells after 60 mins IP1 assay,1,Scientific Literature,Bioorg Med Chem Lett,2015,414.55,4.08,inactive,0,414.547,3.8278,-3.177,4,1,43.78,6.3234,0.52895,0.75547,4,7,3,0.49472,0.72428,-1.115016342,0.7375874373,0.558892772,1,1
CHEMBL1198307,CCOc1ccc(Nc2c3ccccc3nc3ccccc23)cc1,43795,4.36,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,314.39,5.53,inactive,0,314.387,5.1592,-5.719,3,1,34.15,-2.6308,0.39687,0.78115,3,4,4,0.31722,0.72217,-1.594289201,-0.8582124619,-0.1552678521,1,1
CHEMBL1200531,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1.Cl,781.41,6.11,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,452.99,1.38,intermediate,1,452.985,2.1214,-2.317,9,0,81.05,6.9871,0.56959,0.83603,9,9,1,0.42888,0.69769,-0.17839029,1.472307822,0.6276012535,1,1
CHEMBL1201776,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C,670,6.17,F,CHEMBL2046316,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 1 hr by HTRF assay,1,Scientific Literature,ACS Med Chem Lett,2012,221.34,3.08,intermediate,1,221.343,2.9215,-2.014,2,1,23.47,4.4515,0.63295,0.63799,2,5,1,0.62097,0.8048,-1.756322691,1.78525574,0.5442459997,1,1
CHEMBL1204084,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)c1ccc2cc(O)ccc2c1.Cl,120,6.92,F,CHEMBL1155455,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2010,497.08,5.31,intermediate,1,497.077,5.2519,-5.504,5,3,72.8,4.6603,0.45849,0.82887,5,6,3,0.37945,0.6906,-0.7003995204,-0.9162854422,-0.0159864677,9,1
CHEMBL1204085,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@@H]1Cc2ccc(O)cc2CS1.Cl,120,6.92,F,CHEMBL1155455,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2010,519.15,4.7,intermediate,1,519.148,4.7497,-4.929,5,3,98.1,7.1671,0.41918,0.85083,6,6,2,0.32847,0.68982,-0.4922927993,-0.5086234425,0.00883582725,9,1
CHEMBL1223815,Cc1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](Oc2cccc(C(N)=O)c2)C3)s1,721,6.14,F,CHEMBL1221377,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,356.49,3.73,intermediate,1,356.489,3.245,-4.539,4,1,83.8,3.7242,0.39266,0.79656,5,5,2,0.32481,0.71846,-0.9745292812,0.123189454,-0.1340257423,7,1
CHEMBL1223816,NC(=O)c1cccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3CC2CCCCC2)c1,1826,5.74,F,CHEMBL1221377,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,342.48,3.74,inactive,0,342.481,3.2846,-4.378,4,1,55.56,-1.7132,0.41184,0.80188,4,5,1,0.32881,0.73322,-1.159816225,0.2208909788,-0.04029739046,27,2
CHEMBL1223870,CN(C)C(=O)N[C@H]1CC[C@H](CCN2[C@@H]3CC[C@H]2C[C@@H](Oc2cccc(C(N)=O)c2)C3)CC1,18862,4.72,F,CHEMBL1221377,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,442.6,3.38,inactive,0,442.602,2.8928,-4.34,7,2,87.9,2.2856,0.48087,0.808,7,7,1,0.2677,0.6747,-0.3195780607,0.2078982619,-0.00104867718,3,2
CHEMBL1223871,CN(C)C(=O)N[C@H]1CC[C@@H](CN2[C@@H]3CC[C@H]2C[C@@H](Oc2cccc(C(N)=O)c2)C3)CC1,18513,4.73,F,CHEMBL1221377,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,428.58,2.99,inactive,0,428.575,2.4384,-4.07,7,2,87.9,2.4229,0.47357,0.81339,7,6,1,0.35466,0.69742,-0.3460888411,0.471799054,-0.1024866989,27,2
CHEMBL1223872,CN(C)C(=O)N[C@H]1CC[C@@H](CCN2[C@@H]3CC[C@H]2C[C@@H](Oc2cccc(C(N)=O)c2)C3)CC1,16334,4.79,F,CHEMBL1221377,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,442.6,3.38,inactive,0,442.602,2.8928,-4.34,7,2,87.9,2.2856,0.48087,0.808,7,7,1,0.29409,0.67222,-0.3195780607,0.2078982619,-0.00104867718,3,2
CHEMBL1223873,NC(=O)c1cccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,10682,4.97,F,CHEMBL1221377,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,336.44,3.36,inactive,0,336.434,2.9523,-4.075,4,1,55.56,1.8402,0.3986,0.80497,4,5,2,0.32851,0.72828,-1.144393417,0.4626676791,-0.01513169225,27,6
CHEMBL1223951,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,10681,4.97,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,336.44,3.36,inactive,0,336.434,2.9523,-4.075,4,1,55.56,1.8402,0.3986,0.80497,4,5,2,0.35698,0.72409,-1.144393417,0.4626676791,-0.01513169225,27,8
CHEMBL1223952,NC(=O)c1cccc(C[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,3941,5.4,F,CHEMBL1221377,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,334.46,3.77,inactive,0,334.461,3.5702,-4.312,3,1,46.33,1.6882,0.46702,0.80497,3,5,2,0.3582,0.73011,-1.357537792,0.2162554677,0.04519171359,27,1
CHEMBL1223953,NC(=O)c1cccc(C[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,11910,4.92,F,CHEMBL1221377,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,334.46,3.77,inactive,0,334.461,3.5702,-4.312,3,1,46.33,1.6882,0.46702,0.80497,3,5,2,0.38419,0.72595,-1.357537792,0.2162554677,0.04519171359,27,1
CHEMBL1223954,NC(=O)c1cccc(S[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,3077,5.51,F,CHEMBL1221377,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,352.5,4.07,inactive,0,352.501,3.5713,-4.655,3,1,71.63,3.3338,0.49149,0.79764,4,5,2,0.3834,0.73375,-1.172049251,-9.85E-05,-0.08246841827,27,1
CHEMBL1224065,NC(=O)c1cccc(N[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,17039,4.77,F,CHEMBL1221377,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,335.45,3.39,inactive,0,335.45,2.6693,-4.117,4,2,58.36,1.8545,0.4148,0.80497,4,5,2,0.33993,0.71788,-1.013219631,0.5001847511,-0.1042451559,27,1
CHEMBL1224139,NC(=O)c1cc(F)cc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,8084,5.09,F,CHEMBL1221377,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,354.43,3.5,inactive,0,354.424,3.0531,-4.389,4,1,55.56,0.50024,0.39735,0.82494,5,5,2,0.38144,0.72768,-1.05507602,0.2411689112,-0.08616488104,27,6
CHEMBL1224140,Cc1cc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)cc(C(N)=O)c1,17039,4.77,F,CHEMBL1221377,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,350.46,3.67,inactive,0,350.46,3.2962,-4.419,4,1,55.56,1.7982,0.39735,0.82134,4,5,2,0.36989,0.71713,-1.146951215,0.1871470713,-0.04740689214,27,6
CHEMBL1224215,Cc1cc(C(N)=O)ccc1O[C@H]1C[C@H]2CC[C@@H](C1)N2Cc1ccccc1,419,6.38,F,CHEMBL1221377,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,350.46,3.67,intermediate,1,350.46,3.2962,-4.419,4,1,55.56,1.7982,0.32413,0.81625,4,5,2,0.34602,0.72624,-1.146951215,0.1871470713,-0.04740689214,27,6
CHEMBL1224216,NC(=O)c1ccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c(F)c1,8188,5.09,F,CHEMBL1221377,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,354.43,3.5,inactive,0,354.424,3.0531,-4.389,4,1,55.56,0.50024,0.32413,0.82714,5,5,2,0.3209,0.72725,-1.05507602,0.2411689112,-0.08616488104,27,6
CHEMBL1224288,Oc1cccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1,22230,4.65,F,CHEMBL1221377,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,309.41,3.97,inactive,0,309.408,3.5193,-3.69,3,1,32.7,1.3194,0.37016,0.77625,3,4,2,0.3565,0.74571,-1.509079053,0.6253347071,0.1053802123,27,6
CHEMBL123693,CCCCCC(C)N,14,7.85,F,CHEMBL1132386,antagonist,antagonist,Antagonistic activity towards Opioid receptor mu 1,1,Scientific Literature,J Med Chem,1999,115.22,1.91,active,2,115.219,1.8296,-2.011,1,1,26.02,-13.49,0.526,0.59725,1,4,0,0.36717,0.82296,-1.948912461,2.090640093,0.2839707713,0,0
CHEMBL1237044,COc1cccc(C2(O)CCCCC2CN(C)C)c1,1300,5.89,F,CHEMBL2046316,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 1 hr by HTRF assay,1,Scientific Literature,ACS Med Chem Lett,2012,263.38,2.63,inactive,0,263.38,2.2768,-2.182,3,1,32.7,-1.5557,0.53082,0.77625,3,4,1,0.46081,0.78518,-1.504855518,1.772509923,0.2875778301,10,2
CHEMBL1254685,C[C@H]1CN(CCC(=O)Nc2ccccc2)[C@@H]2Cc3ccc(O)cc3[C@]1(C)C2,4.8,8.32,F,CHEMBL1250436,agonist,agonist,Agonist activity at mu opioid expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation,1,Scientific Literature,Bioorg Med Chem,2010,364.49,3.95,highly_active,3,364.487,3.7567,-4.12,4,2,52.57,4.733,0.39735,0.88315,4,4,2,0.34301,0.72579,-1.159251461,0.2940509964,-0.03492308284,1,1
CHEMBL1255595,Cc1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)o1,10854,4.96,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,340.42,3.26,inactive,0,340.422,2.5389,-4.125,5,1,68.7,0.94067,0.39541,0.83144,5,5,2,0.33342,0.71642,-0.9259016913,0.5034773149,-0.1212323043,7,1
CHEMBL1257347,Cc1ccc([C@@H](C)N2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)s1,2698,5.57,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,370.52,4.29,inactive,0,370.515,3.5317,-4.61,4,1,83.8,3.5645,0.39006,0.82315,5,5,2,0.37152,0.72409,-0.9829852356,0.01835827279,-0.1077793908,7,4
CHEMBL1257348,COc1cccc([C@@H](C)N2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)c1,1046,5.98,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,380.49,3.93,inactive,0,380.486,3.169,-4.164,5,1,64.79,1.6707,0.42973,0.84517,5,6,2,0.41216,0.7132,-0.9031017924,0.3196422936,0.07159740808,27,8
CHEMBL1257458,Cc1ccc([C@@H](C)N2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)cn1,1896,5.72,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,365.48,3.62,inactive,0,365.475,2.636,-3.719,5,1,68.45,1.5939,0.41426,0.85157,5,5,2,0.37682,0.72009,-0.9180011184,0.7018838528,-0.003622225078,27,3
CHEMBL1257459,C[C@H](c1ccnc(Cl)c1)N1[C@@H]2CC[C@H]1C[C@H](Oc1cccc(C(N)=O)c1)C2,22931,4.64,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,385.89,3.97,inactive,0,385.894,2.9415,-3.85,5,1,68.45,1.6606,0.41426,0.82887,6,5,2,0.33295,0.72182,-0.857195323,0.5503791796,7.17E-05,27,2
CHEMBL1257577,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2cccs2)c1,9359,5.03,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,342.46,3.42,inactive,0,342.462,2.8189,-4.085,4,1,83.8,3.9559,0.38772,0.79048,5,5,2,0.35355,0.72795,-0.9674590989,0.4777365937,-0.08671814101,7,4
CHEMBL1257578,Cc1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)s1,722,6.14,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,356.49,3.73,intermediate,1,356.489,3.245,-4.539,4,1,83.8,3.7242,0.39266,0.79656,5,5,2,0.34834,0.7141,-0.9745292812,0.123189454,-0.1340257423,7,4
CHEMBL1257579,C[C@H](c1ccc(Cl)nc1)N1[C@@H]2CC[C@H]1C[C@H](Oc1cccc(C(N)=O)c1)C2,1944,5.71,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,385.89,3.97,inactive,0,385.894,2.9415,-3.85,5,1,68.45,1.6606,0.41426,0.82757,6,5,2,0.39273,0.71734,-0.857195323,0.5503791796,7.17E-05,27,3
CHEMBL1257698,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3CCc2ccccc2)c1,424,6.37,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,350.46,3.4,intermediate,1,350.46,3.3824,-4.187,4,1,55.56,2.1327,0.41384,0.7971,4,6,2,0.35211,0.72292,-1.12232335,0.2960293521,0.12144802,3,1
CHEMBL1257820,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3CCCc2ccccc2)c1,659,6.18,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,364.49,3.79,intermediate,1,364.487,3.8368,-4.457,4,1,55.56,2.3181,0.442,0.79548,4,7,2,0.30041,0.69475,-1.095812522,0.03212853099,0.2228860465,1,1
CHEMBL1257821,Cc1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)cc1,482,6.32,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,350.46,3.67,intermediate,1,350.46,3.2962,-4.419,4,1,55.56,1.7982,0.40439,0.80899,4,5,2,0.33858,0.71558,-1.146951215,0.1871470713,-0.04740689214,27,8
CHEMBL1257937,Cc1cccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)c1,2648,5.58,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,350.46,3.67,inactive,0,350.46,3.2962,-4.419,4,1,55.56,1.7982,0.40439,0.81483,4,5,2,0.37086,0.71659,-1.146951215,0.1871470713,-0.04740689214,27,8
CHEMBL1257938,Cc1ccccc1CN1[C@@H]2CC[C@H]1C[C@H](Oc1cccc(C(N)=O)c1)C2,17554,4.76,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,350.46,3.67,inactive,0,350.46,3.2962,-4.419,4,1,55.56,1.7982,0.3966,0.8227,4,5,2,0.3893,0.73191,-1.146951215,0.1871470713,-0.04740689214,27,8
CHEMBL1258047,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccncc2)c1,7854,5.11,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,337.42,2.75,inactive,0,337.422,1.9514,-3.28,5,1,68.45,1.8402,0.3986,0.80497,5,5,2,0.34971,0.72725,-0.9018029,1.105727804,4.75E-04,27,2
CHEMBL1258048,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2cccnc2)c1,2894,5.54,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,337.42,2.75,inactive,0,337.422,1.9514,-3.28,5,1,68.45,1.8402,0.3986,0.81812,5,5,2,0.33538,0.72672,-0.9018029,1.105727804,4.75E-04,27,3
CHEMBL1258164,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccn2)c1,19001,4.72,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,337.42,2.75,inactive,0,337.422,2.0054,-3.304,5,1,68.45,1.8402,0.3958,0.8267,5,5,2,0.35483,0.72565,-0.9069889107,1.082236459,0.002406407932,27,1
CHEMBL1258279,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3CC2CCCCC2)c1,1826,5.74,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,342.48,3.74,inactive,0,342.481,3.2846,-4.378,4,1,55.56,-1.7132,0.41184,0.80188,4,5,1,0.3281,0.72875,-1.159816225,0.2208909788,-0.04029739046,27,1
CHEMBL1258280,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccc3c(c2)OCO3)c1,307,6.51,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,380.44,3.09,intermediate,1,380.443,3.0637,-4.786,6,1,74.02,1.8077,0.38497,0.84479,6,5,2,0.36016,0.71205,-0.7586036752,-0.01392883382,-0.224758681,1,1
CHEMBL1258391,CS(=O)(=O)Cc1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)cc1,576,6.24,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,428.55,2.9,intermediate,1,428.551,1.9336,-4.61,6,1,98.08,-0.95531,0.46212,0.80949,7,7,2,0.32255,0.69078,-0.3321492482,0.2169222142,-0.1832107841,27,8
CHEMBL1258392,Cn1cc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)cn1,9432,5.03,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,340.43,2.09,inactive,0,340.426,1.0146,-2.842,6,1,73.38,5.1885,0.3793,0.82801,6,5,2,0.3671,0.71686,-0.6732974584,1.523944224,-0.0506245293,7,1
CHEMBL1258502,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3CC(=O)N2CCCC2)c1,21090,4.68,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,357.45,1.78,inactive,0,357.452,1.6754,-2.843,6,1,75.87,4.7196,0.42916,0.82043,6,5,1,0.34837,0.72182,-0.7157330677,1.393153123,0.04381399262,1,1
CHEMBL1258503,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3CC(=O)Nc2ccccc2)c1,253,6.6,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,379.46,2.8,intermediate,1,379.459,2.3266,-4.026,6,2,84.66,3.0746,0.43305,0.81997,6,6,2,0.29113,0.69664,-0.5403253859,0.5633310243,-0.09453239288,1,1
CHEMBL1258615,CC(c1ccccc1)N1[C@@H]2CC[C@H]1C[C@H](Oc1cccc(C(N)=O)c1)C2,19837,4.7,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,350.46,3.92,inactive,0,350.46,3.239,-4.146,4,1,55.56,1.5939,0.39605,0.8267,4,5,2,0.36051,0.73894,-1.152849371,0.3578364979,0.01111465921,27,8
CHEMBL1258616,Cc1ccc(C(C)N2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)s1,8504,5.07,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,370.52,4.29,inactive,0,370.515,3.5317,-4.61,4,1,83.8,3.5645,0.40383,0.82315,5,5,2,0.39481,0.7203,-0.9829852356,0.01835827279,-0.1077793908,7,4
CHEMBL1258724,Cc1ccccc1C(C)N1[C@@H]2CC[C@H]1C[C@H](Oc1cccc(C(N)=O)c1)C2,16785,4.78,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,364.49,4.23,inactive,0,364.487,3.5829,-4.49,4,1,55.56,1.5939,0.40087,0.84822,4,5,2,0.40314,0.73367,-1.155405636,0.08231521321,-0.02116026693,27,8
CHEMBL1258725,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3C2CCCc3ccccc32)c1,22696,4.64,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,376.5,4.24,inactive,0,376.498,3.9804,-4.735,4,1,55.56,-1.0988,0.35759,0.89007,4,4,2,0.40698,0.73406,-1.217219844,-0.1294602368,-0.1214276423,1,1
CHEMBL1258845,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCC2)c1,9410,5.03,F,CHEMBL1255514,antagonist,antagonist,Antagonist activity at human mu opioid receptor assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2010,328.46,3.49,inactive,0,328.454,3.0899,-4.326,4,1,55.56,-3.6129,0.37082,0.81096,4,4,1,0.39998,0.75047,-1.206548124,0.3114042086,-0.1575406821,1,1
CHEMBL1306479,COc1ccc2c(c1)C=C(CN1CCC(CO)(CCc3ccccc3)CC1)CO2,85928,4.07,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,393.53,4.18,inactive,0,393.525,4.4307,-3.844,4,1,41.93,1.8681,0.48302,0.78763,4,7,2,0.33518,0.69514,-1.193121164,0.259926659,0.4821259214,1,1
CHEMBL1307063,Cc1cccc(NC(S)=NCC(c2cccnc2)N(C)C)c1C,2749,5.56,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,328.49,3.7,inactive,0,328.483,2.5692,-3.514,4,1,79.32,1.1635,0.47931,0.71581,5,5,2,0.41895,0.71994,-1.000969455,0.8696918143,0.02093079808,7,5
CHEMBL1308389,Cc1ccccc1NC(S)=NCC(c1cccnc1)N(C)C,12489,4.9,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,314.46,3.39,inactive,0,314.456,2.2253,-3.17,4,1,79.32,1.1635,0.48525,0.68393,5,5,2,0.46955,0.75391,-0.998413191,1.145213099,0.05320572422,7,5
CHEMBL1315401,CC(C)n1ncc2c(C(=O)Nc3cccc(C#N)c3)cc(C3CC3)nc21,17999,4.75,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,345.41,4.01,inactive,0,345.405,3.2121,-5.12,6,1,83.6,0.72129,0.38984,0.87927,6,4,3,0.34875,0.68231,-0.8285259267,-0.1883226125,-0.4034364858,1,1
CHEMBL1331866,Cc1ccc(C2(O)C[N+](c3ccccc3C)=C3SCCN32)cc1.[Br-],2829,5.55,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,405.36,3.21,inactive,0,405.359,3.4058,-3.58,3,1,51.78,2.5701,0.32042,0.89693,4,2,2,0.43245,0.74579,-1.321819346,0.6459327883,-0.1065111109,3,3
CHEMBL1345947,Brc1ccc(NC2=Nc3ccccc3CC2)cc1,52124,4.28,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,301.19,4.54,inactive,0,301.186,3.5204,-4.329,2,1,24.39,-2.8193,0.32081,0.71096,3,1,2,0.22881,0.7489,-1.715729763,0.291613427,-0.3345363746,1,1
CHEMBL1356740,CN1CCN(c2ccc(NC(=O)c3ccc(-c4ccccc4F)o3)cc2)CC1,26278,4.58,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,379.44,4.09,inactive,0,379.434,3.6252,-4.507,5,1,48.72,7.2739,0.41657,0.80135,6,4,3,0.18986,0.67011,-1.026774692,0.0600414894,-0.1351144527,1,1
CHEMBL1369123,Oc1c(C=Nc2cccc3cccnc23)sc2ccccc12,897,6.05,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2478, AID488842]",7,PubChem BioAssays,,,304.37,4.91,intermediate,1,304.372,3.9249,-4.917,3,1,73.72,1.4125,0.10394,0.81096,4,2,4,0.25074,0.74963,-1.40471938,-0.1310505502,-0.4048064811,1,1
CHEMBL13786,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O,620,6.21,F,CHEMBL1139195,agonist,agonist,Agonist activity at human cloned mu opioid receptor assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,573.67,-0.46,intermediate,1,573.669,-2.796,-2.849,12,7,225.25,-10.148,0.62858,0.76856,13,16,2,0.31845,0.62281,2.431735389,1.914641096,0.004533236425,14,14
CHEMBL1380599,Cc1ccc(C)c(NC(S)=NCC(c2ccccc2)N(C)C)c1,4154,5.38,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,327.5,4.3,inactive,0,327.495,3.5701,-4.309,3,1,66.43,1.1635,0.47931,0.68629,4,5,2,0.50623,0.73039,-1.243559974,0.2266315482,0.005324233125,7,2
CHEMBL1385823,CCOC(=O)C1(CCOc2ccccc2)CCN(Cc2cccn2-c2cccnc2)CC1,17520,4.76,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,433.55,4.49,inactive,0,433.55,3.2853,-5.088,6,0,56.59,5.5966,0.47274,0.79924,6,10,3,0.46692,0.68568,-0.607613708,-0.3599170086,0.2979852963,1,1
CHEMBL1388222,CN(C)C(CNC(=O)c1cnc(Cl)c(Cl)c1)c1ccccc1,4670,5.33,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,338.24,3.42,inactive,0,338.237,2.4052,-2.578,4,1,45.23,3.9145,0.5769,0.71292,6,5,2,0.40318,0.73844,-1.063081079,1.431339984,0.2634900323,2,2
CHEMBL1393837,CCOC(=O)C1(CC2CCCCO2)CCN(Cc2c(C)cc(C)cc2-n2cccn2)CC1,15497,4.81,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,439.6,4.59,inactive,0,439.598,3.1207,-3.674,6,0,56.59,1.3852,0.47747,0.87401,6,8,2,0.51317,0.70134,-0.7348422105,0.5212250986,0.4217808422,1,1
CHEMBL1400,CN(C)C[C@H]1CCCC[C@]1(O)c1cccc(O)c1,120,6.92,F,CHEMBL2046316,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 1 hr by HTRF assay,1,Scientific Literature,ACS Med Chem Lett,2012,249.35,2.33,intermediate,1,249.353,2.0011,-1.868,3,2,43.7,-1.5335,0.41844,0.78295,3,3,1,0.48442,0.80168,-1.429462703,2.045256003,0.1735471038,10,2
CHEMBL1403842,COc1ccc(-n2cc(CNCc3cccnc3)c(-c3cccc(F)c3)n2)cc1,70524,4.15,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,388.45,4.37,inactive,0,388.445,2.383,-3.865,5,1,51.97,2.1405,0.45671,0.82844,6,7,4,0.32725,0.67817,-0.7509773516,0.6070164065,0.1382674774,1,1
CHEMBL1407554,CN(C)CCCN(C(=O)c1ccc(S(=O)(=O)N(C)Cc2ccccc2)cc1)c1nc2c(F)cccc2s1.Cl,26183,4.58,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,577.15,4.85,inactive,0,577.143,4.7506,-4.54,7,0,110.44,7.3978,0.56765,0.87464,10,9,4,0.35879,0.66293,-0.1548713183,-0.4103755418,0.4404883394,2,2
CHEMBL1412340,CCC1(C)CC(CCNCc2ccc(N(C)C)cc2)(c2ccc(F)cc2)CCO1,29206,4.54,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,398.57,5.29,inactive,0,398.564,4.3782,-4.968,3,1,24.5,1.0886,0.587,0.77309,4,8,2,0.35533,0.69551,-1.199317418,-0.4157999115,0.3291166104,6,6
CHEMBL1416425,CN(C)C(CN=C(S)Nc1cccc(Cl)c1)c1ccccc1,4641,5.33,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,333.89,4.34,inactive,0,333.886,3.4883,-4.357,3,1,66.43,1.282,0.51386,0.66485,5,5,2,0.47004,0.74464,-1.163134873,0.2044589649,-0.02882943106,7,2
CHEMBL1422217,Cc1ccc(Cn2c(=N)n(CC(O)COc3ccccc3)c3ccccc32)cc1.Cl,35107,4.46,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,423.94,3.72,inactive,0,423.942,3.4885,-4.478,5,2,59.79,3.9594,0.469,0.84784,5,7,3,0.37777,0.69811,-0.7412143639,0.03595705156,0.1204089062,1,1
CHEMBL1423609,Cc1cc(C)cc(C(=O)N(CCc2ccccc2)C2=CC3CCC(C2)N3C)c1.Cl,43874,4.36,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,410.99,4.74,inactive,0,410.987,4.8351,-4.513,3,0,23.55,4.0969,0.5247,0.83313,3,5,2,0.45331,0.74246,-1.540838264,-0.2102959414,0.256270861,2,2
CHEMBL1423927,CC(=O)CSc1ccc(-c2nc3cc(C)c(C)cc3[nH]2)cn1,44830,4.35,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,311.41,3.92,inactive,0,311.408,3.0621,-4.63,4,1,83.94,0.58006,0.37593,0.80949,5,4,3,0.18696,0.70689,-1.063583058,0.1569994316,-0.2895859986,1,1
CHEMBL1425453,Cc1ccccc1[N+]1=C2SCCN2C(O)(c2ccccc2)C1.[Br-],18742,4.73,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,391.33,2.9,inactive,0,391.332,3.0619,-3.236,3,1,51.78,2.5701,0.31488,0.89258,4,2,2,0.48416,0.7608,-1.319263054,0.9214541142,-0.07423621917,3,3
CHEMBL1426979,COc1ccc2c(Cl)c(-c3nnc(SCC(=O)c4ccccc4)n3C)sc2c1,10277,4.99,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,429.95,5.33,inactive,0,429.951,4.5893,-6.553,5,0,110.55,4.4204,0.39536,0.87115,8,6,4,0.24161,0.67859,-0.643961714,-1.389149955,-0.3643063023,1,1
CHEMBL1429212,COC(=O)NCC(c1ccc2c(c1)OCO2)N1CCN(c2ccccc2)CC1,17286,4.76,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,383.45,2.63,inactive,0,383.447,2.5411,-3.408,7,1,63.27,-0.24295,0.46008,0.78175,7,6,2,0.36532,0.70589,-0.6277850653,0.8701997331,0.135372381,1,1
CHEMBL1437660,CCN(Cc1ccccc1)S(=O)(=O)c1ccc(C(=O)N(CCCN(C)C)c2nc3c(C)c(C)ccc3s2)cc1.Cl,56283,4.25,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,601.24,5.72,inactive,0,601.234,5.7439,-5.214,7,0,110.44,8.5873,0.57091,0.8923,9,10,4,0.35027,0.65456,-0.2158070074,-1.013153698,0.5341199114,2,2
CHEMBL1440652,Cn1c(CN2CCN(c3cccc(Cl)c3)CC2)nc2ccccc21,15708,4.8,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,340.86,3.55,inactive,0,340.857,3.084,-2.438,4,0,24.3,6.9705,0.41863,0.78531,5,3,3,0.30111,0.71061,-1.45142347,1.405444762,0.2715059663,1,1
CHEMBL1448229,CCn1cc(CNCc2cn(-c3ccccc3C)nc2-c2ccc(OC)c(F)c2)cn1,18886,4.72,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,419.5,4.5,inactive,0,419.502,2.0461,-3.776,6,1,56.9,3.4357,0.45616,0.86659,7,8,4,0.38489,0.65868,-0.4876009702,0.6762565478,0.1924921141,3,3
CHEMBL1449023,O=C(Nc1nc2ccccc2n1CCN1CCCC1)c1ccc(Cl)cc1,6100,5.21,F,CHEMBL3393059,agonist,agonist,Agonist activity at human mu opioid receptor expressed in COS7 cells after 60 mins IP1 assay,1,Scientific Literature,Bioorg Med Chem Lett,2015,368.87,4.04,inactive,0,368.867,3.8555,-3.823,5,1,50.16,4.4653,0.35623,0.81435,6,5,3,0.34311,0.70624,-1.05132639,0.4204829107,0.1614921313,8,6
CHEMBL1450071,O=c1c2ccc(Cl)cc2[nH]c(=S)n1Cc1cccnc1,65621,4.18,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,303.77,3.16,inactive,0,303.772,2.1486,-3.489,4,1,77.32,2.6685,0.38528,0.82757,6,2,2,0.40283,0.76373,-1.075102695,1.016837674,-0.3453220221,1,1
CHEMBL1455766,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)C)cc2)cc1,14000,4.85,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,479.65,4.11,inactive,0,479.643,3.8693,-4.265,6,2,86.89,-3.0787,0.62308,0.72855,7,10,3,0.34816,0.65619,-0.3067053579,0.007177860057,0.4694302957,12,12
CHEMBL1458051,OCC1(CCc2ccccc2)CCN(Cc2ccccc2Cl)CC1,67574,4.17,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,343.9,4.55,inactive,0,343.896,4.5919,-4.057,2,1,23.47,1.7965,0.49897,0.69426,3,6,2,0.34544,0.73618,-1.563366625,0.1612726661,0.3929886676,14,2
CHEMBL146054,CC(c1ccccc1Cl)N1CCC(n2c(O)nc3ccccc32)CC1,31,7.51,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,355.87,4.79,active,2,355.868,4.5158,-3.024,4,1,41.29,6.2794,0.36631,0.84166,5,3,3,0.42323,0.73413,-1.423620645,0.8130361462,0.2798851029,2,2
CHEMBL1460676,Cc1ccc2nc(N(CCCN(C)C)C(=O)c3ccc(S(=O)(=O)N4CCc5ccccc5C4)cc3)sc2c1.Cl,10199,4.99,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,585.2,4.95,inactive,0,585.191,4.9447,-4.919,7,0,110.44,7.0221,0.51062,0.89932,9,7,4,0.37837,0.65786,-0.2971062768,-0.6472400206,0.1893752895,3,3
CHEMBL1461661,O=C(NC(NC(=S)Nc1c(Cl)cccc1Cl)C(Cl)(Cl)Cl)OCc1ccccc1,8430,5.07,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2478, AID488842]",7,PubChem BioAssays,,,501.65,5.9,inactive,0,501.648,5.4758,-6.92,5,3,94.48,-13.864,0.5758,0.72768,11,7,2,0.38457,0.71538,-0.1847996853,-1.813890729,-0.3293222157,1,1
CHEMBL1463894,Cc1ccc(-n2cc(CNC(C)c3cnn(C)c3)c(-c3ccc(F)cc3)n2)cc1,2417,5.62,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,389.48,4.57,inactive,0,389.477,2.1468,-3.824,5,1,47.67,5.7653,0.41506,0.8293,6,6,4,0.34177,0.67099,-0.7832302113,0.6830736358,0.02065696247,3,3
CHEMBL1473706,COCCN(C(=O)C1CC(=O)N(Cc2ccccc2)C1)c1nc(-c2ccc([N+](=O)[O-])cc2)cs1,22850,4.64,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,480.55,3.75,inactive,0,480.544,2.7735,-4.8,9,0,136.8,1.0251,0.47296,0.8444,10,9,3,0.40612,0.65921,0.1445105395,-0.1201993627,0.02967919975,1,1
CHEMBL147511,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3,1.3,8.89,F,CHEMBL1154777,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,789.16,11.04,highly_active,3,789.154,11.257,-10.944,6,0,59.08,-8.9909,0.40332,1.0372,6,17,2,0.32441,0.59198,-0.3916728203,-5.617376212,0.7667850375,5,3
CHEMBL1481328,COc1ccc(Nc2nc(-c3sc(C)nc3C)cs2)c(OC)c1,19000,4.72,F,CHEMBL4390642,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells coexpressing Galpha15 assessed as increase in intracellular calcium flux in presence of mu opioid receptor antagonist naloxone and incubated for 1 hr measured for 90 secs at 1.5 sec interval by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2019,347.47,4.64,inactive,0,347.462,4.2365,-4.504,5,1,112.75,3.3925,0.43032,0.807,7,5,3,0.25837,0.69822,-0.8329430183,-0.01588519365,-0.05189807924,16,13
CHEMBL1482107,CN1C2C=C(N(CCc3ccccc3)C(=O)c3ccc(Cl)cc3)CC1CC2.Cl,67281,4.17,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,417.38,4.78,inactive,0,417.378,4.7533,-4.561,3,0,23.55,4.1892,0.52369,0.84047,4,5,2,0.35445,0.74665,-1.460413164,-0.2324685247,0.2221171969,2,2
CHEMBL1488893,Cc1ccc(C(=O)Nc2nc3ccccc3n2CCN2CCCC2)cc1,39000,4.41,F,CHEMBL3393059,agonist,agonist,Agonist activity at human mu opioid receptor expressed in COS7 cells after 60 mins IP1 assay,1,Scientific Literature,Bioorg Med Chem Lett,2015,348.45,3.69,inactive,0,348.449,3.5934,-3.431,5,1,50.16,4.3702,0.35623,0.8024,5,5,3,0.33409,0.70833,-1.129195237,0.7181769191,0.22792078,8,6
CHEMBL1490069,COc1ccc(-n2c3c(cc(C(=O)NNc4ccccc4C)c2=O)C(=O)CC(C)(C)C3)cc1,14489,4.84,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,445.52,4.07,inactive,0,445.517,4.326,-4.651,7,2,87.74,3.4808,0.37919,0.92528,7,5,2,0.32106,0.67148,-0.5589265708,-0.2007810297,-0.06864349941,1,1
CHEMBL1511139,CC(=O)c1ccc(S(=O)(=O)NCc2ccc(C(=O)NCC(c3ccccc3)N(C)C)cc2)cc1,1920,5.72,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2478, AID488842]",7,PubChem BioAssays,,,479.6,3.4,inactive,0,479.599,2.5114,-3.698,7,2,103.96,1.6369,0.60005,0.75973,8,9,3,0.34506,0.65907,-0.04523969534,0.5924425034,0.2720645386,1,1
CHEMBL1513567,CCOC(=O)C1(c2ccccc2)CCN(CCC(=O)Nc2cccc(Br)c2)CC1.Cl,40636,4.39,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,495.85,4.37,inactive,0,495.843,4.0437,-4.566,5,1,58.64,5.0728,0.48892,0.78935,6,8,2,0.27948,0.67621,-0.6789496337,-0.2072132924,0.3138774318,1,1
CHEMBL1522542,CN(C)CCCN(C(=O)c1ccc(S(=O)(=O)N(C)C2CCCCC2)cc1)c1nc2ccc(F)cc2s1.Cl,4846,5.32,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,569.17,4.99,inactive,0,569.164,4.8882,-4.791,7,0,110.44,-0.99422,0.55408,0.86986,10,8,3,0.35712,0.67738,-0.2170245385,-0.5616396602,0.2980796185,1,1
CHEMBL1531675,Cc1ccc(C)c(-n2cc(CNCCCn3cccn3)c(-c3ccccc3)n2)c1,10097,5,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,385.52,4.53,inactive,0,385.513,2.4842,-3.667,5,1,47.67,5.0226,0.47184,0.81387,5,8,4,0.37333,0.65998,-0.8040067186,0.6972156561,0.3180738354,1,1
CHEMBL1533638,CCOC(=O)C1(CCCc2ccccc2)CCN(Cc2cnn(C)c2)CC1,42974,4.37,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,369.51,3.59,inactive,0,369.507,2.9872,-2.768,5,0,47.36,4.938,0.51705,0.72141,5,9,2,0.35955,0.68297,-0.9729670045,1.130124664,0.7421682675,1,1
CHEMBL1548987,Cc1ccc(C2(O)C[N+](c3ccccc3)=C3SCCN32)cc1.[Br-],48163,4.32,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,391.33,2.9,inactive,0,391.332,3.0619,-3.236,3,1,51.78,2.5701,0.31695,0.87805,4,2,2,0.42369,0.74096,-1.319263054,0.9214541142,-0.07423621917,3,3
CHEMBL1558215,OCC1(CCc2ccccc2)CCN(Cc2cccn2-c2cccnc2)CC1,52643,4.28,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,375.52,4.08,inactive,0,375.514,3.2239,-4.863,4,1,41.29,2.2893,0.47118,0.78295,4,7,3,0.40976,0.72556,-1.035593943,-0.1140773782,0.05653498694,1,1
CHEMBL1566963,CN(C)CCCN(C(=O)c1ccc(S(=O)(=O)N2CCCCCC2)cc1)c1nc2c(F)cc(F)cc2s1.Cl,33448,4.48,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,573.13,4.74,inactive,0,573.127,4.7635,-4.757,7,0,110.44,1.9254,0.54061,0.88047,11,7,3,0.34177,0.67547,-0.1844708198,-0.5129648668,0.1777662993,1,1
CHEMBL1581275,Cn1c(-c2c(N)n(CCc3ccccc3)c3nc4ccccc4nc23)nc2ccccc21,24758,4.61,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,418.5,4.96,inactive,0,418.503,4.4222,-6.11,6,1,74.55,4.0805,0.29598,0.96824,6,4,6,0.33398,0.68735,-0.8407205852,-1.052347125,-0.4468019404,1,1
CHEMBL1581674,CN(C)CCCN(C(=O)c1ccc(S(=O)(=O)N2CCc3ccccc3C2)cc1)c1nc2ccc(F)cc2s1.Cl,3284,5.48,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,589.16,4.78,inactive,0,589.154,4.7016,-4.889,7,0,110.44,6.7716,0.51062,0.89932,10,7,4,0.36381,0.66606,-0.2052326651,-0.5932172644,0.150617178,3,3
CHEMBL1584594,CCc1ccc(NC(=O)Nc2ccc3c(c2)N(C)C(=O)CS3)cc1,36748,4.43,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,341.44,3.96,inactive,0,341.434,2.4028,-5.091,5,2,86.74,3.1699,0.45686,0.78472,6,3,2,0.19408,0.69678,-0.7480315615,-0.003895119621,-0.6468913131,1,1
CHEMBL1586285,Cc1nc(N2CCN(c3ccccn3)CC2)c2c(C)c(C(=O)N3CCN(c4ccc(F)cc4)CC3)sc2n1,10799,4.97,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,531.66,4.13,inactive,0,531.658,4.1465,-5.736,8,0,96.94,6.2352,0.41121,0.93277,10,4,4,0.23893,0.64774,-0.310966112,-0.9035837935,-0.4308733167,1,1
CHEMBL1587149,COc1ccc(CN2CN=C(Nc3nc(C)cc(C)n3)N(Cc3ccc(OC)cc3)C2)cc1,74430,4.13,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,446.56,3.81,inactive,0,446.553,3.8071,-5.143,8,1,75.11,2.8241,0.45797,0.79383,8,7,3,0.42538,0.6526,-0.3949668242,-0.4416294347,-0.02960583006,1,1
CHEMBL1587574,CCNS(=O)(=O)c1ccc(NC(=O)Nc2ccc3c(c2)OCO3)cc1,42765,4.37,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,363.4,2.36,inactive,0,363.393,2.4441,-4.208,8,3,114.14,0.34995,0.48954,0.75181,9,4,2,0.29165,0.6943,-0.1794842433,0.4918748775,-0.4433137234,1,1
CHEMBL1588202,Cc1ccc(-n2cc(CNC(C)c3cnn(C)c3C)c(-c3ccc(F)cc3)n2)cc1,12955,4.89,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,403.51,4.88,inactive,0,403.503,2.5447,-4.192,5,1,47.67,6.0767,0.41877,0.84401,6,6,4,0.35716,0.67735,-0.7909740315,0.3840618234,-0.009686590835,3,3
CHEMBL1594497,CCC(=NNc1ccnc2cc(Cl)ccc12)c1ccc(O)cc1,25300,4.6,F,CHEMBL1201862,agonist,agonist,"PUBCHEM_BIOASSAY: SAR Analysis of Agonists of the MOR Receptor using an Image-Based Assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2492, AID488822]",7,PubChem BioAssays,,,325.8,4.82,inactive,0,325.798,5.8095,-4.925,4,2,57.51,1.11,0.2128,0.77245,5,4,3,0.21726,0.71183,-1.346074965,-0.4999803666,0.04028617275,1,1
CHEMBL1606743,COc1ccc(CNCCc2c[nH]c3ccccc23)c(OC)c1C.O=C(O)C(=O)O,59509,4.22,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,414.46,3.83,inactive,0,414.456,3.1075,-3.832,4,2,46.28,0.61264,0.51434,0.77872,4,7,3,0.34472,0.70782,-0.9043036344,0.4889578242,0.2571812103,1,1
CHEMBL1609119,CN(C)CCCN(C(=O)c1ccc(S(=O)(=O)N2CCc3ccccc3C2)cc1)c1nc2c(F)cc(F)cc2s1.Cl,5100,5.29,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,607.15,4.92,inactive,0,607.144,4.8024,-5.203,7,0,110.44,6.7768,0.50907,0.91289,11,7,4,0.37514,0.66024,-0.1159153151,-0.8147160033,0.0795839844,3,3
CHEMBL1612697,CCOC(=O)C1(CCc2ccccc2)CCN(Cc2ccc(NC(C)=O)cc2)CC1,8300,5.08,F,CHEMBL4406853,antagonist,antagonist,Inhibition of mu opioid receptor (unknown origin) expressed in human UO5S cells assessed as increase in beta arrestin recruitment,1,Scientific Literature,Eur J Med Chem,2019,408.54,4.42,inactive,0,408.54,4.1742,-4.073,5,1,58.64,5.0031,0.52287,0.72413,5,9,2,0.3507,0.66892,-0.8652104397,0.1327237601,0.5509540957,14,2
CHEMBL1627325,CSCC[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)C(C)(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)[C@@H](C)O,10.96,7.96,F,CHEMBL1136992,antagonist,antagonist,Antagonist activity at human recombinant mu opioid receptor expressed in CHO cells coexpressing alphaqi5 assessed as inhibition of dermorphin-induced intracellular calcium mobilization,1,Scientific Literature,J Med Chem,2009,2243.63,None,active,2,2243.62,-20.752,-5.127,59,37,1030.7,-16.37,0.64035,1.0271,60,78,2,0.32417,0.42536,20.90330057,1.804408301,0.3794792739,1,1
CHEMBL1650842,OCC1(N2CCC(n3c(-c4ccc(F)c(Cl)c4)nc4ccccc43)CC2)CCCCCCC1,1219,5.91,F,CHEMBL1649335,agonist,agonist,Agonist activity at human MOP receptor expressed in CHO-K1 cells assessed as induction of [35S]GTPgammaS binding after 30 mins by liquid scintillation counting,1,Scientific Literature,Bioorg Med Chem,2010,470.03,6.61,inactive,0,470.03,6.9541,-5.83,4,1,41.29,-4.398,0.4009,0.88979,6,4,3,0.35769,0.71839,-1.297974497,-1.385381989,0.05161920616,11,5
CHEMBL1650844,OCC1(N2CCC(n3c(N4CC5CNCC5C4)nc4ccccc43)CC2)CCCCCCC1,3500,5.46,F,CHEMBL1649335,agonist,agonist,Agonist activity at human MOP receptor expressed in CHO-K1 cells assessed as induction of [35S]GTPgammaS binding after 30 mins by liquid scintillation counting,1,Scientific Literature,Bioorg Med Chem,2010,451.66,3.8,inactive,0,451.657,4.7447,-3.279,6,2,56.56,-1.8691,0.36311,0.89063,6,4,2,0.33151,0.72907,-0.9278428766,0.5356751078,0.2886267093,1,1
CHEMBL1650848,CC1CN(c2nc3ccccc3n2C2CCN(C3(CO)CCCCCCC3)CC2)CCN1,1772,5.75,F,CHEMBL1649335,agonist,agonist,Agonist activity at human MOP receptor expressed in CHO-K1 cells assessed as induction of [35S]GTPgammaS binding after 30 mins by liquid scintillation counting,1,Scientific Literature,Bioorg Med Chem,2010,439.65,3.95,inactive,0,439.646,4.824,-3.251,6,2,56.56,0.054824,0.39868,0.88345,6,4,2,0.36839,0.74585,-0.9569289617,0.5498458748,0.3050618341,11,2
CHEMBL1650851,O=c1[nH]c2ccccc2n1C1CCN(C2(CO)CCCCCCC2)CC1,144,6.84,F,CHEMBL1649335,agonist,agonist,Agonist activity at human MOP receptor expressed in CHO-K1 cells assessed as induction of [35S]GTPgammaS binding after 30 mins by liquid scintillation counting,1,Scientific Literature,Bioorg Med Chem,2010,357.5,3.44,intermediate,1,357.496,3.8338,-4.437,5,2,55.81,-1.9386,0.42063,0.79273,5,3,1,0.34904,0.75726,-1.080456209,0.1139213897,-0.2230728868,4,1
CHEMBL1685,C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N,38,7.42,F,CHEMBL1152717,agonist,agonist,Agonist activity at human cloned mu opioid receptor by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2009,245.37,3.11,active,2,245.365,3.2359,-3.802,2,2,46.25,-7.0946,0.24145,0.85805,2,0,1,0.50179,0.84089,-1.73681739,0.7352151197,-0.4077429656,1,1
CHEMBL1698780,CCN(CCNC(=O)c1ccc(CNS(=O)(=O)c2ccccc2)cc1)Cc1ccccc1,2030,5.69,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,451.59,3.42,inactive,0,451.589,3.1661,-3.543,6,2,86.89,-2.6007,0.61866,0.70997,7,10,3,0.32201,0.66013,-0.3013633424,0.5809126135,0.5400726839,12,12
CHEMBL1698790,CC(C)OC(=O)C1(N(Cc2ccco2)C(=O)c2ccccn2)CCCCC1,15000,4.82,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,370.45,3.97,inactive,0,370.447,2.7957,-3.457,6,0,72.64,-2.6596,0.48022,0.83186,6,7,2,0.56825,0.76189,-0.8064230172,0.7870788772,0.2951879904,1,1
CHEMBL1698841,CN(C)C(CN=C(S)Nc1cccc(Cl)c1)c1cccnc1,7495,5.12,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,334.88,3.74,inactive,0,334.874,2.4874,-3.562,4,1,79.32,1.282,0.51386,0.69536,6,5,2,0.43804,0.73779,-0.9205443436,0.8475190906,-0.01322292443,7,5
CHEMBL1699035,CCN(CCNC(=O)c1ccc(CNS(=O)(=O)c2ccc(OC)cc2)cc1)Cc1ccccc1,12600,4.9,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,481.62,3.43,inactive,0,481.615,3.0961,-3.561,7,2,96.12,4.8574,0.62343,0.73114,8,11,3,0.31426,0.64726,-0.05161577864,0.5427183687,0.6005554619,12,12
CHEMBL1699195,Cc1ccc(Cl)cc1N1CCN(CCNC(=O)Cn2c(=O)c3cccn3c3cccnc32)CC1,3980,5.4,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,478.98,2.55,inactive,0,478.982,2.0347,-5.769,8,1,73.71,8.2838,0.5017,0.92104,9,6,3,0.32781,0.67101,-0.1007227898,-0.5234807514,-0.5430885949,2,2
CHEMBL1700772,CC(C)c1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)C)cc2)cc1,660,6.18,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,507.7,4.93,intermediate,1,507.697,4.7124,-4.792,6,2,86.89,1.4572,0.63102,0.74025,7,11,3,0.33497,0.65499,-0.2919724805,-0.4887703664,0.5663506528,12,12
CHEMBL1700847,CN(C)C(CN=C(S)Nc1ccccc1Cl)c1cccnc1,3637,5.44,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,334.88,3.74,inactive,0,334.874,2.4874,-3.562,4,1,79.32,1.282,0.48525,0.70181,6,5,2,0.4252,0.73789,-0.9205443436,0.8475190906,-0.01322292443,7,5
CHEMBL1702166,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN3CCC(c4ccccc4)CC3)cc2)cc1,3880,5.41,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,491.66,4.08,inactive,0,491.654,4.563,-4.453,6,2,86.89,-0.15106,0.5648,0.74654,7,8,3,0.28197,0.64249,-0.450989517,-0.2095411864,0.3262657462,1,1
CHEMBL1702620,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4c(C)ccnc43)CC2)c(OC)c1,30900,4.51,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,518.62,2.3,inactive,0,518.616,1.7431,-5.339,10,1,92.17,9.8316,0.50872,0.95583,10,9,3,0.29074,0.63673,0.3499706072,-0.2905546385,-0.2219813811,7,7
CHEMBL1702752,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4cc(Br)cnc43)CC2)c(OC)c1,10200,4.99,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,583.49,2.76,inactive,0,583.485,2.1244,-5.829,10,1,92.17,8.0931,0.50547,0.93277,11,9,3,0.2948,0.63603,0.4871523596,-0.7088886557,-0.2882265132,7,7
CHEMBL1703982,COc1ccccc1N1CCN(C(c2cccs2)C(C)NC(=O)c2ccco2)CC1,50331,4.3,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,425.55,4.03,inactive,0,425.551,3.0149,-3.64,6,1,86.19,8.0693,0.47155,0.82844,7,7,3,0.40677,0.69937,-0.5464491216,0.6013214929,0.2263808162,1,1
CHEMBL1704988,Cc1ccnc2c1n1cccc1c(=O)n2CC(=O)NCCCN1CCN(c2ccc3c(c2)OCO3)CC1,17200,4.76,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,502.58,2.01,inactive,0,502.573,1.9945,-6.014,10,1,92.17,9.7615,0.48178,0.95566,10,7,3,0.27954,0.64514,0.2362651841,-0.6907626718,-0.5525739121,1,1
CHEMBL1705302,CC[C@@H](C)[C@@H]1CN([C@@H](CN2CCC[C@H]2CN2C(N)=NC[C@H]2C(C)C)C(C)C)C(=N)N1CCc1ccc(Cl)c(Cl)c1,10948,4.96,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,592.7,5.65,inactive,0,592.701,5.5553,-5.19,7,2,75.19,5.2336,0.51987,0.89586,9,12,1,0.53417,0.68596,-0.05609751426,-0.9673590739,0.6918365989,1,1
CHEMBL1707988,O=C(Cn1c(=O)c2cccn2c2cc(Br)cnc21)NCCCN1CCN(c2ccc(Cl)cc2)CC1,5320,5.27,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,557.88,3.39,inactive,0,557.878,2.8704,-6.529,8,1,73.71,8.1603,0.49451,0.91169,10,7,3,0.32331,0.64512,0.06296982345,-1.205715639,-0.5078956785,7,7
CHEMBL1709988,COc1ccc(C(CNC(=O)c2cncc(Br)c2)N(C)C)cc1,18532,4.73,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,378.27,2.89,inactive,0,378.269,1.751,-2.195,5,1,54.46,2.0509,0.58684,0.70181,6,6,2,0.47738,0.73006,-0.8070825149,1.723022298,0.3508059811,2,2
CHEMBL1711929,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4cc(Br)cnc43)CC2)cc1,10300,4.99,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,553.46,2.75,inactive,0,553.459,2.1944,-5.811,9,1,82.94,8.0931,0.50165,0.91361,10,8,3,0.29766,0.63554,0.2374047931,-0.6706944507,-0.3487092673,7,7
CHEMBL1712885,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCCN3CCN(c4ccccc4)CC3)cc2)cc1,469,6.33,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,506.67,3.42,intermediate,1,506.669,3.7136,-3.948,7,2,90.13,1.2988,0.56376,0.74654,8,9,3,0.26527,0.62582,-0.1773976981,0.2084207424,0.408049426,1,1
CHEMBL1713166,CN(C)C(CNC(=O)CSC(=S)N1CCCC1)c1ccccc1,17060,4.77,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,351.54,2.52,inactive,0,351.538,1.7546,-2.15,4,1,92.97,5.1252,0.60681,0.62953,6,7,1,0.35303,0.71705,-0.738853826,1.767289666,0.4092491721,1,1
CHEMBL1713635,COc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)C)cc2)cc1,9600,5.02,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,495.65,3.81,inactive,0,495.642,3.4554,-3.939,7,2,96.12,3.5719,0.62676,0.73618,8,11,3,0.35576,0.6483,-0.05440154087,0.2445050403,0.5621880582,12,12
CHEMBL1713943,COc1ccc(CN(CCNC(=O)c2ccc(CNS(=O)(=O)c3ccccc3)cc2)C(C)C)cc1,14300,4.84,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,495.65,3.81,inactive,0,495.642,3.4554,-3.939,7,2,96.12,-4.1455,0.63064,0.72942,8,11,3,0.3531,0.65627,-0.05440154087,0.2445050403,0.5621880582,12,12
CHEMBL1713967,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)(C)C)cc2)cc1,1390,5.86,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,493.67,4.5,inactive,0,493.67,4.2499,-4.374,6,2,86.89,-4.3363,0.58917,0.73199,7,10,3,0.37233,0.6613,-0.3243494351,-0.1363046073,0.4999489097,12,12
CHEMBL1714715,Cc1cccc(N2CCN(CCNC(=O)Cn3c(=O)c4cccn4c4cccnc43)CC2)c1C,6330,5.2,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,458.57,2.2,inactive,0,458.564,1.7726,-5.377,8,1,73.71,8.2595,0.5017,0.9294,8,6,3,0.28783,0.66505,-0.178591662,-0.2257866233,-0.4766598707,2,2
CHEMBL1717312,Cc1ccnc2c1n1cccc1c(=O)n2CC(=O)NCCCN1CCN(c2ccccc2)CC1,22500,4.65,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,458.57,2.29,inactive,0,458.564,1.8831,-5.303,8,1,73.71,9.8754,0.49442,0.93587,8,7,3,0.29494,0.65697,-0.1495245563,-0.214166139,-0.3429469353,7,7
CHEMBL1717557,COc1ccc(C(CNC(=O)CCc2ccsc2)N(C)C)cc1,1420,5.85,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,332.47,3.11,inactive,0,332.467,2.2636,-2.291,4,1,69.81,3.5392,0.59787,0.65353,5,8,2,0.39357,0.71806,-0.9107092411,1.59880186,0.5887221673,1,1
CHEMBL1717720,CC(C)N(CCNC(=O)c1ccc(CNS(=O)(=O)c2ccc(C3CCCCC3)cc2)cc1)Cc1ccccc1,2470,5.61,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,547.77,5.85,inactive,0,547.762,5.6622,-5.688,6,2,86.89,-0.5925,0.59889,0.76182,7,11,3,0.35234,0.63566,-0.2994738183,-1.21913164,0.4906478364,1,1
CHEMBL1718184,Cc1ccc(S(=O)(=O)N2CCc3ccc(C(=O)NCCN(Cc4ccccc4)C(C)C)cc3C2)cc1,2890,5.54,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,505.68,4.38,inactive,0,505.681,3.9135,-4.2,6,1,78.1,-0.070427,0.54647,0.84517,7,8,3,0.42402,0.66649,-0.4827780252,0.02520323813,0.3426056046,1,1
CHEMBL1719053,CCN(CCNC(=O)c1ccc(CNS(=O)(=O)c2ccc(Br)cc2)cc1)Cc1ccccc1,8460,5.07,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,530.49,4.18,inactive,0,530.485,3.8913,-4.377,6,2,86.89,2.8815,0.61943,0.72502,8,10,3,0.35011,0.65298,-0.1667378101,-0.1129428785,0.4415525894,12,12
CHEMBL1719184,Cc1cccc(NC(S)=NCC(c2cccnc2)N(C)C)c1,15641,4.81,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,314.46,3.39,inactive,0,314.456,2.2253,-3.17,4,1,79.32,1.1635,0.51386,0.6766,5,5,2,0.39789,0.71259,-0.998413191,1.145213099,0.05320572422,7,5
CHEMBL1720091,CCC(=O)C(CCN1CCOCC1)(c1ccccc1)c1ccccc1,12037,4.92,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,337.46,3.67,inactive,0,337.461,3.1296,-2.541,3,0,29.54,3.9696,0.51103,0.71863,3,7,2,0.67445,0.75979,-1.436149607,1.292076969,0.6717557163,1,1
CHEMBL1720462,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NC3CCCN(Cc4ccccc4)C3)cc2)cc1,6750,5.17,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,477.63,3.87,inactive,0,477.627,3.905,-4.351,6,2,86.89,-3.8593,0.51768,0.76856,7,7,3,0.37327,0.65598,-0.44605356,-0.009300600933,0.1543081359,1,1
CHEMBL1721558,Cc1cccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)C)cc2)c1,7990,5.1,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,479.65,4.11,inactive,0,479.643,3.8693,-4.265,6,2,86.89,-0.45598,0.62308,0.74264,7,10,3,0.37155,0.65711,-0.3067053579,0.007177860057,0.4694302957,12,12
CHEMBL1721727,CCc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(CC)Cc3ccccc3)cc2)cc1,19500,4.71,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,479.65,3.98,inactive,0,479.643,3.9256,-4.046,6,2,86.89,4.8501,0.62601,0.73114,7,11,3,0.33835,0.65152,-0.2779963741,0.1135848053,0.6307842609,12,12
CHEMBL1725537,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C3CCCC3)cc2)cc1,3310,5.48,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,505.68,4.65,inactive,0,505.681,4.3174,-4.891,6,2,86.89,-5.9843,0.58803,0.74882,7,10,3,0.3711,0.65158,-0.2898639888,-0.4638989963,0.385097189,1,1
CHEMBL1725847,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4cccnc43)CC2)c(OC)c1,10800,4.97,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,504.59,1.99,inactive,0,504.589,1.3992,-4.995,10,1,92.17,9.8831,0.50567,0.93505,10,9,3,0.3073,0.64349,0.3525268163,-0.01503302331,-0.1897063603,7,7
CHEMBL1726077,CC(C)N(CCNC(=O)c1ccc(CNS(=O)(=O)c2ccc(Br)cc2)cc1)Cc1ccccc1,3220,5.49,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,544.52,4.57,inactive,0,544.512,4.2506,-4.755,6,2,86.89,1.5517,0.62308,0.73028,8,10,3,0.36026,0.66127,-0.1695235032,-0.4111565167,0.4031850738,12,12
CHEMBL1726155,Cc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4cccnc43)CC2)cc1,18800,4.73,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,458.57,2.29,inactive,0,458.564,1.8831,-5.303,8,1,73.71,9.8754,0.4954,0.91432,8,7,3,0.28718,0.65444,-0.1495245563,-0.214166139,-0.3429469353,7,7
CHEMBL1728022,CN(CCNC(=O)c1ccc(CNS(=O)(=O)c2ccc([N+](=O)[O-])cc2)cc1)Cc1ccccc1,1690,5.77,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,482.56,2.94,inactive,0,482.559,1.8382,-3.703,9,2,132.71,-4.4825,0.62224,0.73783,10,10,3,0.33437,0.65924,0.4151902773,0.6958392227,0.2007292492,12,12
CHEMBL1728158,CN1C2C=C(N(CCc3c[nH]c4ccccc34)C(=O)c3ccc(Cl)cc3)CC1CC2.Cl,47876,4.32,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,456.42,5.26,inactive,0,456.415,4.7927,-5.086,4,1,39.34,4.3236,0.48612,0.87682,5,5,3,0.37091,0.71856,-1.121347757,-0.5709418785,0.03312548973,1,1
CHEMBL1729698,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccccc4)C(C)C)ccc3C2)cc1,15100,4.82,F,CHEMBL1201862,antagonist,antagonist,"PUBCHEM_BIOASSAY: SAR Analysis of Antagonists of the MOR Receptor using an Image-Based Assay - Set 3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2420]",7,PubChem BioAssays,,,505.68,4.38,inactive,0,505.681,3.9135,-4.2,6,1,78.1,-0.070427,0.54647,0.83521,7,8,3,0.35455,0.65568,-0.4827780252,0.02520323813,0.3426056046,1,1
CHEMBL1732484,COc1ccc(C(CNC(=O)c2ccc3c(c2)CCC3)N(C)C)cc1,502.9,6.3,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,338.45,3.22,intermediate,1,338.449,2.8415,-2.978,4,1,41.57,0.81967,0.54332,0.75032,4,6,2,0.37371,0.70919,-1.179480638,1.110431127,0.3566126654,1,1
CHEMBL1743604,Cc1cc(O)cc(C)c1C[C@@H](C(=O)N1Cc2ccccc2C[C@H]1C(=O)OC1=C2O[C@H]3[C@@H](O)C=C[C@H]4[C@H]5CC(C=C1)C2[C@]43CCN5C)N(C)C.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,13,7.89,F,CHEMBL1667791,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Eur J Med Chem,2011,893.87,4.03,active,2,893.872,3.2895,-5.02,9,2,102.78,8.1289,0.42431,1.0635,9,7,2,0.4561,0.69062,0.6491170056,-0.6878651966,-0.09336564515,1,1
CHEMBL1743605,Cc1cc(O)cc(C)c1C[C@@H](C(=O)N1Cc2ccccc2C[C@H]1C(=O)NCCC(=O)OC1=C2O[C@H]3[C@@H](O)C=C[C@H]4[C@H]5CC(C=C1)C2[C@]43CCN5C)N(C)C.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,29,7.54,F,CHEMBL1667791,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,Eur J Med Chem,2011,964.95,3.54,active,2,964.951,2.8276,-5.057,11,3,131.88,7.7224,0.48869,1.0629,11,10,2,0.44444,0.66723,1.372100151,-0.7185361824,0.03352454156,1,1
CHEMBL1766022,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CCCF,130,6.89,F,CHEMBL1765082,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting,1,Scientific Literature,J Med Chem,2011,359.51,4.3,intermediate,1,359.511,4.0066,-5.186,3,1,70.39,-3.0022,0.2287,0.9553,5,3,2,0.36708,0.76086,-1.223442114,-0.371534491,-0.3575291763,3,3
CHEMBL1766023,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1C[C@@H]1CCCO1,71,7.15,F,CHEMBL1765082,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting,1,Scientific Literature,J Med Chem,2011,383.56,4.12,active,2,383.558,3.6713,-5.226,4,1,79.62,-2.2815,0.22273,0.96577,5,2,2,0.3608,0.74939,-1.100517075,-0.3434018255,-0.529393719,1,1
CHEMBL1766024,CNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1,47,7.33,F,CHEMBL1765082,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting,1,Scientific Literature,J Med Chem,2011,367.56,4.81,active,2,367.559,4.4202,-5.341,3,1,56.4,0.20185,0.18851,0.96055,4,3,2,0.32871,0.73989,-1.356841662,-0.5429017126,-0.3034127629,4,4
CHEMBL1766025,CCNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1,420,6.38,F,CHEMBL1765082,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting,1,Scientific Literature,J Med Chem,2011,381.59,5.2,intermediate,1,381.586,4.8265,-5.641,3,1,56.4,0.16916,0.20459,0.96225,4,4,2,0.32463,0.72858,-1.323347469,-0.8161355054,-0.216264294,4,4
CHEMBL1766036,CN(C)c1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1,140,6.85,F,CHEMBL1765082,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting,1,Scientific Literature,J Med Chem,2011,381.59,4.83,intermediate,1,381.586,4.6696,-5.317,3,0,47.61,0.51423,0.2104,0.96225,4,3,2,0.32361,0.72711,-1.482803715,-0.5987832678,-0.2132052335,4,4
CHEMBL1766041,CNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CCCF,29,7.54,F,CHEMBL1765082,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting,1,Scientific Literature,J Med Chem,2011,373.54,4.76,active,2,373.538,4.3309,-5.17,3,1,56.4,-2.501,0.23463,0.95865,5,4,2,0.34601,0.74558,-1.240912355,-0.4472203594,-0.1854957555,3,3
CHEMBL1766043,CCNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CCCF,240,6.62,F,CHEMBL1765082,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting,1,Scientific Literature,J Med Chem,2011,387.57,5.15,intermediate,1,387.565,4.7372,-5.47,3,1,56.4,-2.5191,0.24833,0.96038,5,5,2,0.31573,0.72734,-1.207418107,-0.7204540695,-0.0983473555,3,3
CHEMBL1773091,CO[C@@]12CCCC[C@@]13CCN(CC1CCC1)[C@@H]2Cc1ccc(OC(=O)CCCCCCCCC(=O)OCc2ccccc2)cc13,1.7,8.77,F,CHEMBL1772956,agonist,agonist,Agonist activity at human mu-opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,Bioorg Med Chem,2011,615.86,8.08,highly_active,3,615.852,8.1089,-7.648,6,0,65.07,-9.098,0.42545,1.015,6,17,2,0.2814,0.62227,-0.4247285656,-2.964781034,1.082870448,1,1
CHEMBL1774946,CO[C@@]12CCCC[C@@]13CCN(CC1CCC1)[C@@H]2Cc1ccc(O)cc13,3.6,8.44,F,CHEMBL1772956,agonist,agonist,Agonist activity at human mu-opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,Bioorg Med Chem,2011,341.5,4.02,highly_active,3,341.493,3.5716,-3.966,3,1,32.7,-1.5557,0.242,0.99311,3,3,1,0.43336,0.79544,-1.498235651,0.4360296142,-0.04922069116,10,4
CHEMBL1774947,CO[C@@]12CCCC[C@@]13CCN(CC1CCC1)[C@@H]2Cc1ccc(OC(=O)CCCCCCCCC(=O)Oc2ccc4c(c2)[C@@]25CCCC[C@@]2(OC)[C@@H](C4)N(CC2CCC2)CC5)cc13,1.8,8.74,F,CHEMBL1772956,agonist,agonist,Agonist activity at human mu-opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,Bioorg Med Chem,2011,849.21,10.57,highly_active,3,849.205,10.466,-10.3,8,0,77.54,-9.0299,0.40095,1.111,8,19,2,0.34302,0.5953,0.152365914,-5.180486541,0.960036984,5,1
CHEMBL1774948,C=CCN1CC[C@]23c4c5ccc(OC(=O)CCCCCCCCC(=O)Oc6ccc7c(c6)[C@@]68CCCC[C@@]6(OC)[C@@H](C7)N(CC6CCC6)CC8)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,10,8,F,CHEMBL1772956,agonist,agonist,Agonist activity at human mu-opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,Bioorg Med Chem,2011,835.09,7.86,highly_active,3,835.091,8.422,-9.219,10,1,114.84,-10.202,0.37954,1.1502,10,18,2,0.2818,0.59764,0.7221286236,-4.144704931,0.7085770516,3,3
CHEMBL1774949,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3,1.2,8.92,F,CHEMBL1772956,agonist,agonist,Agonist activity at human mu-opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,Bioorg Med Chem,2011,805.16,10.15,highly_active,3,805.153,10.434,-10.494,7,1,79.31,-8.0534,0.40173,1.067,7,17,2,0.33046,0.59425,-0.01801894183,-5.209422868,0.681942259,5,1
CHEMBL1774950,C=CCN1CC[C@]23c4c5ccc(OC(=O)CCCCCCCCC(=O)Oc6ccc7c(c6)[C@@]68CCCC[C@@]6(O)[C@@H](C7)N(CC6CCC6)CC8)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,2,8.7,F,CHEMBL1772956,agonist,agonist,Agonist activity at human mu-opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,Bioorg Med Chem,2011,821.07,7.2,highly_active,3,821.064,7.9941,-9.091,10,2,125.84,-10.037,0.3787,1.1432,10,17,2,0.27437,0.60536,0.8238089736,-3.955126354,0.5270505258,3,3
CHEMBL1774951,O=C(CCCCCCCCC(=O)Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1)Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1,130,6.89,F,CHEMBL1772956,agonist,agonist,Agonist activity at human mu-opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,Bioorg Med Chem,2011,873.29,11.54,intermediate,1,873.284,11.612,-12.422,8,2,146.94,-2.6738,0.31837,1.0664,10,15,4,0.19958,0.55965,0.4952301541,-6.567266892,0.02433584315,1,1
CHEMBL1774952,c1c2c(cc3sc(NCCCCCCCCCCNc4nc5cc6c(cc5s4)C[C@@H]4[C@@H]5CCCC[C@]65CCN4CC4CC4)nc13)C[C@@H]1[C@@H]3CCCC[C@]23CCN1CC1CC1,22,7.66,F,CHEMBL1772956,agonist,agonist,Agonist activity at human mu-opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,Bioorg Med Chem,2011,845.32,12.49,active,2,845.318,12.311,-12.458,6,2,112.8,0.17488,0.36596,1.0628,8,17,4,0.24707,0.56403,0.1133578928,-6.715003962,0.3918802707,1,1
CHEMBL1824509,Cl.O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccnc(Cl)c1,0.83,9.08,F,CHEMBL1821548,agonist,agonist,Agonist activity against mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2011,518.44,2.8,highly_active,3,518.439,2.5898,-4.289,7,3,94.92,5.5429,0.26864,1.0864,8,4,2,0.38718,0.72526,-0.1349946424,0.2678703553,-0.3746924346,7,6
CHEMBL1824510,Cl.O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccnc(Br)c1,1.19,8.92,F,CHEMBL1821548,agonist,agonist,Agonist activity against mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2011,562.89,2.91,highly_active,3,562.89,2.709,-4.387,7,3,94.92,3.7116,0.26864,1.0864,8,4,2,0.36803,0.72267,-0.07568172097,0.147230115,-0.3745089198,7,6
CHEMBL1824511,Cl.O=C(CCc1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,1.46,8.84,F,CHEMBL1821548,agonist,agonist,Agonist activity against mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2011,512.05,2.47,highly_active,3,512.048,2.3389,-4.025,7,3,94.92,5.4832,0.30695,1.0827,7,6,2,0.34868,0.7143,-0.09591559417,0.4492762352,-0.13648644,9,1
CHEMBL1824512,Cc1cc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)ccn1.Cl,1.13,8.95,F,CHEMBL1821548,agonist,agonist,Agonist activity against mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2011,498.02,2.46,highly_active,3,498.021,2.2843,-4.158,7,3,94.92,5.4639,0.26864,1.0845,7,4,2,0.37346,0.7268,-0.1957989675,0.4193741989,-0.3783861618,7,6
CHEMBL1824513,Cl.O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1Br,1.31,8.88,F,CHEMBL1821548,agonist,agonist,Agonist activity against mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2011,562.89,2.91,highly_active,3,562.89,2.6116,-4.624,7,3,94.92,3.7116,0.27269,1.087,8,4,2,0.38416,0.73892,-0.05343108526,0.02453134888,-0.4465629481,7,6
CHEMBL1824514,Cl.O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1Cl,2.32,8.63,F,CHEMBL1821548,agonist,agonist,Agonist activity against mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2011,518.44,2.8,highly_active,3,518.439,2.4924,-4.526,7,3,94.92,5.5429,0.27269,1.087,8,4,2,0.41574,0.74258,-0.1127440345,0.1451715479,-0.4467464284,7,6
CHEMBL1824515,Cc1cnccc1C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5.Cl,1.52,8.82,F,CHEMBL1821548,agonist,agonist,Agonist activity against mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2011,498.02,2.46,highly_active,3,498.021,2.2303,-4.134,7,3,94.92,5.4639,0.27269,1.0851,7,4,2,0.39244,0.74443,-0.19061294,0.4428657256,-0.3803177262,7,6
CHEMBL1824516,Cl.O=C(Cc1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,2.32,8.63,F,CHEMBL1821548,agonist,agonist,Agonist activity against mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2011,498.02,2.08,highly_active,3,498.021,1.8845,-3.755,7,3,94.92,5.5412,0.31291,1.0827,7,5,2,0.39192,0.7498,-0.1224263746,0.7131770272,-0.2379244618,1,1
CHEMBL1824517,Cl.O=C(CNC(=O)c1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,2.84,8.55,F,CHEMBL1821548,agonist,agonist,Agonist activity against mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2011,541.05,1.27,highly_active,3,541.046,0.9701,-3.557,9,4,124.02,5.9163,0.34482,1.0838,9,6,2,0.32907,0.69781,0.5084156934,0.9516169162,-0.3225905528,1,1
CHEMBL1824518,CN1CCC(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)CC1.Cl,5.08,8.29,F,CHEMBL1821548,agonist,agonist,Agonist activity against mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2011,504.07,1.78,highly_active,3,504.069,1.733,-3.354,7,3,85.27,9.282,0.23631,1.0834,7,4,1,0.40063,0.74287,-0.1909409563,0.9807456873,-0.2470135066,7,1
CHEMBL1834247,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](C)C(=O)N[C@H]1Cc2ccccc2CN(CC(N)=O)C1=O,0.0832,10.08,F,CHEMBL2150869,agonist,agonist,Agonist activity at human MOR expressed in HEK293 cell membrane assessed as inhibition of forskolin-induced cAMP accumulation by by liquid scintillation counting,1,Scientific Literature,J Med Chem,2011,495.58,-0.06,highly_active,3,495.578,-0.6936,-3.076,10,5,167.85,3.7243,0.50109,0.85231,10,8,2,0.36791,0.65917,1.051836852,1.560988945,-0.3644061922,2,2
CHEMBL1834249,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NC1Cc2ccccc2CN(CC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(N)=O)C1=O,11,7.96,F,CHEMBL1833812,agonist,agonist,Agonist activity at Mu-type opioid receptor,1,Scientific Literature,J Med Chem,2011,814.9,-1.78,active,2,814.894,-2.2663,-3.179,18,9,286.82,5.2146,0.52731,0.92262,18,16,3,0.42974,0.60202,3.79083217,1.435648509,-0.2027924413,1,1
CHEMBL1834250,C[C@H](C(=O)NC1Cc2ccccc2CN(CC(N)=O)C1=O)N1Cc2cc(O)ccc2CC(N)C1=O,20.8,7.68,F,CHEMBL1833812,agonist,agonist,Agonist activity at Mu-type opioid receptor,1,Scientific Literature,J Med Chem,2011,479.54,-0.45,active,2,479.535,-1.6085,-2.263,10,4,159.06,4.435,0.4366,0.90627,10,5,2,0.44408,0.69094,0.8426996048,2.238555181,-0.5530357127,2,1
CHEMBL1834409,CCC(C)(C)[C@](C)(O)[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5,6,8.22,F,CHEMBL1833948,partial agonist,agonist,Partial agonist activity at human MOP receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2011,481.68,4.8,highly_active,3,481.674,4.7961,-5.108,5,2,62.16,4.3598,0.31889,1.1215,5,6,1,0.43172,0.78232,-0.8128885632,-0.6032674984,0.06130474897,4,1
CHEMBL1834410,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)CC(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,2.6,8.59,F,CHEMBL1833948,partial agonist,agonist,Partial agonist activity at human MOP receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2011,481.68,4.8,highly_active,3,481.674,4.7961,-5.108,5,2,62.16,1.4411,0.27966,1.1138,5,6,1,0.41949,0.75752,-0.8128885632,-0.6032674984,0.06130474897,4,2
CHEMBL1834413,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)CC1CC4CCC1C4)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,6.1,8.21,F,CHEMBL1833948,partial agonist,agonist,Partial agonist activity at human MOP receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2011,519.73,5.19,highly_active,3,519.723,4.8051,-5.963,5,2,62.16,4.876,0.2472,1.1182,5,6,1,0.37809,0.7502,-0.7158006788,-1.144543821,-0.1406270587,1,1
CHEMBL19019,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,0.59,9.23,F,CHEMBL1145844,agonist,agonist,Effective concentration agonistic activity towards Opioid receptor mu 1,1,Scientific Literature,J Med Chem,2003,341.41,1.53,highly_active,3,341.406,1.5768,-3.192,5,2,70,4.6068,0.18707,1.0736,5,2,1,0.50278,0.81063,-0.8984028516,1.269145705,-0.3664878788,4,3
CHEMBL1902708,COc1ccc(-c2nc(CN3CCC(C(=O)NC4CCCc5ccccc54)CC3)c(C)o2)cc1OC,20825,4.68,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,489.62,5.07,inactive,0,489.614,4.3357,-5.718,7,1,76.83,1.7118,0.33475,0.86425,7,7,3,0.35352,0.63976,-0.47658097,-0.9122882705,-0.07305573459,1,1
CHEMBL1927270,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1,2.042,8.69,F,CHEMBL3758180,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells assessed as calcium mobilization by Fluo-4 AM based fluorescence analysis,1,Scientific Literature,Eur J Med Chem,2016,699.81,-0.14,highly_active,3,699.806,0.014,-4.564,14,8,234.84,-1.5231,0.41926,0.85376,14,9,3,0.44298,0.67729,2.359504632,0.4027130788,-0.7554509724,12,12
CHEMBL200204,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CCCC[C@@]1(O)c1ccccc1)CC2,2700,5.57,F,CHEMBL1147765,antagonist,antagonist,Inhibitory activity at human mu opioid receptor in BHK cells by GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2006,405.54,3.25,inactive,0,405.54,3.3401,-4.395,5,2,55.81,5.0099,0.36781,0.88256,5,3,2,0.52048,0.74322,-0.9506377802,0.1785175698,-0.2766428508,2,1
CHEMBL200371,O=C1NCN(c2ccccc2)C12CCN([C@H]1CCCC[C@@]1(O)c1ccccc1)CC2,1600,5.8,F,CHEMBL1147765,antagonist,antagonist,Inhibitory activity at human mu opioid receptor in BHK cells by GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2006,405.54,3.25,inactive,0,405.54,3.3401,-4.395,5,2,55.81,5.0099,0.36783,0.88256,5,3,2,0.47685,0.76053,-0.9506377802,0.1785175698,-0.2766428508,2,1
CHEMBL201296,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1Cc1ccccc1,170,6.77,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,337.51,5.36,intermediate,1,337.505,5.089,-4.39,2,1,23.47,1.6625,0.42856,0.82449,2,5,2,0.45169,0.74618,-1.719982176,-0.100086838,0.2943025796,1,1
CHEMBL201434,C[C@H]1CN(CCc2ccccc2)[C@H](CCc2ccccc2)C[C@@]1(C)c1cccc(O)c1,210,6.68,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,413.61,6.24,intermediate,1,413.603,6.5066,-5.367,2,1,23.47,2.7469,0.4294,0.83059,2,7,3,0.39152,0.70654,-1.631880732,-1.019102226,0.4712862412,1,1
CHEMBL201530,C[C@H]1CN(CCc2ccccc2)[C@H](CCN)C[C@@]1(C)c1cccc(O)c1,390,6.41,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,352.52,3.95,intermediate,1,352.52,3.7402,-3.801,3,2,49.49,3.8982,0.45135,0.81812,3,6,2,0.39381,0.73354,-1.228623588,0.4701043023,0.2589355667,8,8
CHEMBL201661,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCCc1ccccc1,16,7.8,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,365.56,5.79,active,2,365.559,5.9735,-4.772,2,1,23.47,1.0631,0.47466,0.81578,2,7,2,0.38898,0.71751,-1.671399716,-0.5306268321,0.5323204018,14,8
CHEMBL201845,C[C@H]1CN(CCc2ccccc2)[C@H](CCNC(=O)c2ccccc2)C[C@@]1(C)c1cccc(O)c1,130,6.89,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,456.63,5.42,intermediate,1,456.628,5.5922,-5.169,4,2,52.57,4.7108,0.44984,0.8267,4,8,3,0.36903,0.67731,-1.001038687,-0.7806624374,0.3866200759,1,1
CHEMBL202139,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCC,320,6.5,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,289.46,4.57,intermediate,1,289.461,4.5316,-3.637,2,1,23.47,2.3448,0.44635,0.80497,2,5,1,0.45772,0.77037,-1.763940342,0.4856498112,0.3904784663,10,8
CHEMBL202150,CCCCN1C[C@H](C)[C@](C)(c2cccc(O)c2)C[C@H]1CCC,290,6.54,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,303.49,4.96,intermediate,1,303.488,4.986,-3.907,2,1,23.47,2.4944,0.45534,0.8075,2,6,1,0.41721,0.75281,-1.737429514,0.2217489901,0.4919164928,10,8
CHEMBL202200,CCCCCN1C[C@H](C)[C@](C)(c2cccc(O)c2)C[C@H]1CCC,210,6.68,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,317.52,5.35,intermediate,1,317.515,5.4404,-4.177,2,1,23.47,-1.1569,0.4633,0.80949,2,7,1,0.40328,0.73439,-1.710918687,-0.04215183096,0.5933545193,10,8
CHEMBL202327,CCCCCCN1C[C@H](C)[C@](C)(c2cccc(O)c2)C[C@H]1CCC,39,7.41,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,331.54,5.74,active,2,331.542,5.8948,-4.447,2,1,23.47,-5.5769,0.4702,0.81047,2,8,1,0.37789,0.71913,-1.684407906,-0.306052623,0.694792541,10,8
CHEMBL202352,CCCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1,120,6.92,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,365.56,5.79,intermediate,1,365.559,5.9735,-4.772,2,1,23.47,-1.6224,0.44257,0.82225,2,7,2,0.38919,0.71831,-1.671399716,-0.5306268321,0.5323204018,8,8
CHEMBL202461,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1C,170,6.77,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,261.41,3.79,intermediate,1,261.407,3.6709,-3.067,2,1,23.47,2.6064,0.41635,0.79273,2,3,1,0.40699,0.79771,-1.823945365,1.022784636,0.2018921267,10,8
CHEMBL202462,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CC,100,7,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,275.44,4.18,active,2,275.434,4.0772,-3.367,2,1,23.47,2.6382,0.42952,0.80083,2,4,1,0.53626,0.77468,-1.79045117,0.7495506323,0.2890404398,10,8
CHEMBL203150,C[C@H]1CN(CCc2ccccc2)[C@H](Cc2ccccc2)C[C@@]1(C)c1cccc(O)c1,280,6.55,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,399.58,5.85,intermediate,1,399.576,6.0522,-5.097,2,1,23.47,3.7969,0.42529,0.83186,2,6,3,0.52378,0.71528,-1.65839156,-0.7552014046,0.3698482147,1,1
CHEMBL203307,C[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1,50,7.3,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,323.48,4.62,active,2,323.478,4.6103,-3.962,2,1,23.47,5.0119,0.44805,0.79328,2,4,2,0.34144,0.74859,-1.750932207,0.2610755195,0.2280063959,8,8
CHEMBL2048761,COc1cccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)c1,3.8,8.42,F,CHEMBL2046406,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2012,430.64,6.17,highly_active,3,430.634,5.3079,-5.985,3,1,24.5,-1.1655,0.38936,0.94342,3,6,2,0.36133,0.69949,-1.360764092,-1.178709273,0.03196377728,6,6
CHEMBL2048762,COc1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1,7.8,8.11,F,CHEMBL2046406,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2012,430.64,6.17,highly_active,3,430.634,5.3079,-5.985,3,1,24.5,-1.1655,0.38936,0.94068,3,6,2,0.33714,0.69946,-1.360764092,-1.178709273,0.03196377728,6,6
CHEMBL2048764,c1cc2c(cc1CNc1ccc3c(c1)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)OCO2,3.6,8.44,F,CHEMBL2046406,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2012,444.62,5.89,highly_active,3,444.617,5.4893,-6.678,4,1,33.73,-1.2675,0.36734,0.95333,4,5,2,0.33375,0.69822,-1.224721889,-1.61711154,-0.238146,1,1
CHEMBL2048765,COc1cccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)c1,2,8.7,F,CHEMBL2046406,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-induced [33S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2012,416.61,5.78,highly_active,3,416.607,4.9659,-5.715,3,1,24.5,-0.41062,0.38374,0.94225,3,6,2,0.33867,0.69961,-1.355024287,-0.9470979106,0.04640988236,5,5
CHEMBL2048766,c1cc2c(cc1CNc1ccc3c(c1)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CC1)CC4)OCO2,0.21,9.68,F,CHEMBL2046406,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-induced [33S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2012,430.59,5.5,highly_active,3,430.59,5.1473,-6.408,4,1,33.73,-0.50877,0.36189,0.95224,4,5,2,0.34249,0.70214,-1.218982084,-1.385500177,-0.223699895,1,1
CHEMBL2048767,O=[N+]([O-])c1cccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)c1,1.1,8.96,F,CHEMBL2046406,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2012,445.61,6.07,highly_active,3,445.605,4.4563,-6.427,5,1,61.09,-6.2647,0.40155,0.94648,5,6,2,0.34567,0.69798,-0.8604638312,-1.298822332,-0.2807140368,6,6
CHEMBL2048768,Oc1ccccc1CNc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3,38,7.42,F,CHEMBL2046406,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2012,416.61,5.86,active,2,416.607,5.0322,-5.671,3,2,35.5,-1.1096,0.36614,0.94225,3,5,2,0.39088,0.72789,-1.28537126,-0.9059630117,-0.08206692513,6,6
CHEMBL2048769,Oc1cccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)c1,4.8,8.32,F,CHEMBL2046406,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-induced [33S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2012,416.61,5.86,highly_active,3,416.607,5.0322,-5.671,3,2,35.5,-1.1096,0.37179,0.94147,3,5,2,0.30701,0.70098,-1.28537126,-0.9059630117,-0.08206692513,6,6
CHEMBL2048770,Oc1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1,3.6,8.44,F,CHEMBL2046406,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2012,416.61,5.86,highly_active,3,416.607,5.0322,-5.671,3,2,35.5,-1.1096,0.37179,0.9395,3,5,2,0.32465,0.70716,-1.28537126,-0.9059630117,-0.08206692513,6,6
CHEMBL2048771,Oc1ccccc1CNc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3,8.8,8.06,F,CHEMBL2046406,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2012,402.58,5.47,highly_active,3,402.58,4.6902,-5.401,3,2,35.5,-0.3455,0.35808,0.94108,3,5,2,0.36496,0.71948,-1.279631455,-0.6743516491,-0.06762082005,5,5
CHEMBL2048772,Oc1cccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)c1,3.5,8.46,F,CHEMBL2046406,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-induced [33S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2012,402.58,5.47,highly_active,3,402.58,4.6902,-5.401,3,2,35.5,-0.3455,0.3642,0.94029,3,5,2,0.35005,0.71028,-1.279631455,-0.6743516491,-0.06762082005,5,5
CHEMBL2048773,Oc1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1,7.6,8.12,F,CHEMBL2046406,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-induced [33S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2012,402.58,5.47,highly_active,3,402.58,4.6902,-5.401,3,2,35.5,-0.3455,0.3642,0.9383,3,5,2,0.36174,0.71683,-1.279631455,-0.6743516491,-0.06762082005,5,5
CHEMBL2048774,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(NCc2cccc(O)c2)cc13,6.5,8.19,F,CHEMBL2046406,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2012,362.52,4.69,highly_active,3,362.515,3.9658,-4.585,3,2,35.5,-0.07305,0.37945,0.92876,3,3,2,0.40024,0.74108,-1.385392836,-0.004536646654,-0.1782040126,1,1
CHEMBL2048782,COc1ccccc1CNc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341,210,6.68,F,CHEMBL2046406,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2012,404.51,3.11,intermediate,1,404.508,2.5975,-4.244,5,2,53.96,5.3599,0.32602,1.046,5,4,2,0.46315,0.74628,-0.8334130799,0.3839266426,-0.2449567389,2,2
CHEMBL2048786,CN1CC[C@]23c4c5ccc(NCc6cccc(O)c6)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,550,6.26,F,CHEMBL2046406,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2012,390.48,2.81,intermediate,1,390.481,2.3218,-3.93,5,3,64.96,5.3146,0.32285,1.0437,5,3,2,0.45137,0.7488,-0.7580202371,0.6566727637,-0.3589874996,2,2
CHEMBL205049,Cc1cc(C(N)=O)cc(C)c1C[C@H](N)C(=O)N1CCCC[C@H]1c1nc(-c2ccccc2)c[nH]1,9,8.05,F,CHEMBL2157906,agonist,agonist,Agonist activity at mu opioid receptor expressed in CHO-hg cells by [35S]-GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2012,445.57,3.42,highly_active,3,445.565,2.622,-3.875,7,3,118.1,-0.91506,0.50082,0.87115,7,6,3,0.37171,0.67641,-0.1623507251,0.5563583781,-0.1014429386,2,2
CHEMBL208454,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1c1nc(-c2ccccc2)c[nH]1,27,7.57,F,CHEMBL2157906,agonist,agonist,Agonist activity at mu opioid receptor expressed in CHO-hg cells by [35S]-GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2012,466.59,4.6,active,2,466.583,3.5699,-4.206,6,3,95.24,0.96188,0.41505,0.8972,6,5,4,0.41811,0.68851,-0.4642206644,0.1856631176,-0.0935592981,3,3
CHEMBL210005,C[C@H]1[C@H]2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cc4)cc3[C@]1(C)CCN2CC1CC1,3,8.52,F,CHEMBL1146899,antagonist,antagonist,Antagonist activity against human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2006,478.68,6.26,highly_active,3,478.678,6.5262,-7.214,3,1,32.34,5.5451,0.43911,0.91503,3,7,3,0.24661,0.65269,-1.300781454,-2.170561705,0.003593607931,15,2
CHEMBL2113275,C=CCN1CC[C@]23c4c5ccc(OC(=O)CCCCCCCCC(=O)Oc6ccc7c(c6)[C@@]68CCCCC6[C@@H](C7)N(CC6CCC6)CC8)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,2,8.7,F,CHEMBL1147138,agonist,agonist,Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,805.07,8.09,highly_active,3,805.065,8.8175,-9.541,9,1,105.61,-10.202,0.38549,1.1258,9,17,2,0.26925,0.59599,0.4501085364,-4.363149582,0.6119508802,3,3
CHEMBL2113294,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccccc4)[C@@H](C2)N(C)CC[C@]315,160,6.8,F,CHEMBL1148829,agonist,agonist,Agonist activity at human delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,500.64,3.97,intermediate,1,500.637,3.698,-5.056,6,1,60.03,3.7825,0.25283,1.1236,6,6,2,0.45027,0.71322,-0.634968181,-0.4127235719,-0.06133668813,13,7
CHEMBL2113295,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccccc4C)[C@@H](C2)N(C)CC[C@]315,15.1,7.82,F,CHEMBL1148829,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,514.67,4.28,active,2,514.664,4.0419,-5.4,6,1,60.03,3.7586,0.24082,1.1247,6,6,2,0.37191,0.68302,-0.637524473,-0.6882448979,-0.09361157982,13,7
CHEMBL2113296,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccccc4Cl)[C@@H](C2)N(C)CC[C@]315,106,6.97,F,CHEMBL1148829,agonist,agonist,Agonist activity at human delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,535.08,4.62,intermediate,1,535.082,4.304,-5.792,6,1,60.03,3.8336,0.24082,1.1244,7,6,2,0.51639,0.70698,-0.559655656,-0.9859386955,-0.1600402094,13,6
CHEMBL2113299,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccc([N+](=O)[O-])cc4)[C@@H](C2)N(C)CC[C@]315,26,7.58,F,CHEMBL1148829,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,545.64,3.88,active,2,545.634,2.7764,-5.516,9,1,105.85,-1.2118,0.27889,1.1244,9,7,2,0.26495,0.68541,0.1150795344,-0.5710306082,-0.3135315726,13,6
CHEMBL2113300,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccccc4[N+](=O)[O-])[C@@H](C2)N(C)CC[C@]315,216,6.67,F,CHEMBL1148829,agonist,agonist,Agonist activity at human delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,545.64,3.88,intermediate,1,545.634,2.7764,-5.516,9,1,105.85,-1.2118,0.26521,1.1264,9,7,2,0.31796,0.69055,0.1150795344,-0.5710306082,-0.3135315726,13,6
CHEMBL2113301,COc1ccccc1/C=C/C(=O)NC[C@H]1C[C@@]23CC[C@@]1(OC)[C@@H]1Oc4c(OC)ccc5c4[C@@]12CCN(C)[C@@H]3C5,11.7,7.93,F,CHEMBL1148829,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,530.67,3.98,active,2,530.663,3.628,-5.074,7,1,69.26,3.7825,0.24379,1.1256,7,7,2,0.48259,0.69178,-0.385220592,-0.4509175649,-8.54E-04,13,7
CHEMBL2113302,COc1ccc(/C=C/C(=O)NC[C@H]2C[C@@]34CC[C@@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(C)[C@@H]4C6)cc1,74.2,7.13,F,CHEMBL1148829,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,530.67,3.98,active,2,530.663,3.628,-5.074,7,1,69.26,3.7825,0.27092,1.1244,7,7,2,0.49518,0.68025,-0.385220592,-0.4509175649,-8.54E-04,13,7
CHEMBL2113303,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5,3.12,8.51,F,CHEMBL1148829,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,486.61,3.67,highly_active,3,486.61,3.4223,-4.742,6,2,71.03,3.7996,0.25615,1.1205,6,5,2,0.37608,0.7018,-0.559575377,-0.1399773517,-0.1753673561,13,7
CHEMBL2113304,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccccc1C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5,7.23,8.14,F,CHEMBL1148829,agonist,agonist,Agonist activity at human delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,500.64,3.97,highly_active,3,500.637,3.7662,-5.086,6,2,71.03,3.7776,0.24373,1.1216,6,5,2,0.4965,0.69972,-0.5621316412,-0.4154986364,-0.2076422822,13,7
CHEMBL2113305,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccccc1Cl)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5,3.36,8.47,F,CHEMBL1148829,agonist,agonist,Agonist activity at human delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,521.06,4.32,highly_active,3,521.055,4.0283,-5.478,6,2,71.03,3.8518,0.24373,1.1213,7,5,2,0.45287,0.71387,-0.4842627551,-0.7131927438,-0.2740710237,13,6
CHEMBL2113306,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccc(C)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5,15.9,7.8,F,CHEMBL1148829,agonist,agonist,Agonist activity at human delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,500.64,3.97,active,2,500.637,3.7662,-5.086,6,2,71.03,3.7776,0.26163,1.1209,6,5,2,0.42274,0.70463,-0.5621316412,-0.4154986364,-0.2076422822,13,7
CHEMBL2113307,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccc(Cl)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5,35.4,7.45,F,CHEMBL1148829,agonist,agonist,Agonist activity at human delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,521.06,4.32,active,2,521.055,4.0283,-5.478,6,2,71.03,3.8518,0.26163,1.1204,7,5,2,0.31997,0.7047,-0.4842627551,-0.7131927438,-0.2740710237,13,6
CHEMBL2113308,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccc([N+](=O)[O-])cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5,11.3,7.95,F,CHEMBL1148829,agonist,agonist,Agonist activity at human delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,531.61,3.57,active,2,531.607,2.5007,-5.202,9,2,116.85,-1.1898,0.28226,1.1213,9,6,2,0.39674,0.69812,0.1904724353,-0.2982846565,-0.4275623869,13,6
CHEMBL2113309,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC/C=C/c4ccccc4)[C@@H](C2)N(C)CC[C@]315,139,6.86,F,CHEMBL1148829,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,486.66,4.44,intermediate,1,486.654,4.0476,-5.074,5,1,42.96,4.3954,0.2849,1.1058,5,7,2,0.42469,0.72312,-0.8259159981,-0.4866091774,0.1224501119,4,2
CHEMBL2113310,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC/C=C/c4ccc(Cl)cc4)[C@@H](C2)N(C)CC[C@]315,149,6.83,F,CHEMBL1148829,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,521.1,5.1,intermediate,1,521.099,4.6536,-5.81,5,1,42.96,4.4427,0.29323,1.1223,6,7,2,0.45473,0.70827,-0.7506034595,-1.059824694,0.02374654765,4,2
CHEMBL2113311,CO[C@@]12CC[C@@]3(C[C@@H]1CNC/C=C/c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5,26.2,7.58,F,CHEMBL1148829,agonist,agonist,Agonist activity at human delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,472.63,4.14,active,2,472.627,3.7719,-4.76,5,2,53.96,4.4052,0.28905,1.1035,5,6,2,0.42798,0.72289,-0.750523125,-0.2138632671,0.008419332022,4,2
CHEMBL2113312,CO[C@@]12CC[C@@]3(C[C@@H]1CNC/C=C/c1ccc(Cl)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5,5.37,8.27,F,CHEMBL1148829,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,507.07,4.79,highly_active,3,507.072,4.3779,-5.496,5,2,53.96,4.454,0.29736,1.1191,6,6,2,0.40424,0.70553,-0.6752106277,-0.787078432,-0.09028415476,4,2
CHEMBL2113313,CO[C@@]12C=C[C@@]3([C@@H]4CN(C(=O)/C=C/c5ccccc5C)C[C@@H]41)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5,1.8,8.74,F,CHEMBL1148829,agonist,agonist,Agonist activity at human delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,510.63,3.7,highly_active,3,510.632,3.7273,-4.502,6,1,62.24,5.6896,0.22854,1.1569,6,3,2,0.50925,0.71079,-0.7771951327,-0.0621634194,-0.2220090704,2,2
CHEMBL2113314,CO[C@@]12C=C[C@@]3([C@@H]4CN(C(=O)/C=C/c5ccc(C)cc5)C[C@@H]41)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5,3.1,8.51,F,CHEMBL1148829,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,510.63,3.7,highly_active,3,510.632,3.7273,-4.502,6,1,62.24,5.6896,0.24667,1.1563,6,3,2,0.47974,0.69965,-0.7771951327,-0.0621634194,-0.2220090704,2,2
CHEMBL2151247,CNC(=O)COCC(=O)NCCCCCNC(=O)COCC(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,92.1,7.04,F,CHEMBL4715781,antagonist,antagonist,Antagonist activity at human MOR transfected in CHO cells co-transfected with Gqi5 assessed as inhibition of DAMGO-induced calcium mobilization incubated for 15 mins prior to DAMGO addition and measured for 90 secs by Fluo-4AM dye based fluorescence analysis,1,Scientific Literature,Bioorg Med Chem,2016,671.79,-0.38,active,2,671.789,-0.5335,-3.068,14,6,187.79,1.5852,0.47409,1.0842,14,17,1,0.31858,0.60714,2.342090932,1.270020678,0.4573309077,6,6
CHEMBL2151734,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N(C)[C@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N(C)CC(N)=O,0.079,10.1,F,CHEMBL2150869,agonist,agonist,Agonist activity at human MOR expressed in HEK293 cell membrane assessed as inhibition of forskolin-induced cAMP accumulation by by liquid scintillation counting,1,Scientific Literature,J Med Chem,2011,511.62,0.4,highly_active,3,511.621,0.0665,-2.477,10,4,159.06,5.9901,0.6461,0.81387,10,11,2,0.45248,0.68726,0.9790747425,1.714892196,0.2395069877,3,3
CHEMBL2158957,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O,12,7.92,F,CHEMBL2157899,agonist,agonist,Agonist activity at MOP receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins,1,Scientific Literature,Bioorg Med Chem,2012,1059.3,None,active,2,1059.3,1.8882,-7.257,19,10,325.34,5.0179,0.51599,0.95279,20,27,5,0.47568,0.55564,4.763666631,-2.042100947,0.4185868316,2,2
CHEMBL2158958,CCCCCCCCC(N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O,45,7.35,F,CHEMBL2157899,agonist,agonist,Agonist activity at MOP receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins,1,Scientific Literature,Bioorg Med Chem,2012,1228.57,None,active,2,1228.57,4.512,-9.292,21,11,354.44,-13.6,0.52651,0.97225,22,36,5,0.39568,0.52931,5.642931884,-3.954391916,1.11573803,2,2
CHEMBL2158990,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CCC(=O)N[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O,590.2,6.23,F,CHEMBL2157939,agonist,agonist,Agonist activity at mu-opioid receptor in human SH-SY5Y cells assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by immunoassay,1,Scientific Literature,J Med Chem,2012,1034.09,None,intermediate,1,1034.08,-2.8048,-4.052,24,14,385.12,0.29694,0.44805,1.0004,24,21,4,0.36138,0.56943,5.93731085,0.8192863599,-0.3668420569,1,1
CHEMBL2159120,Cc1cc(C(N)=O)cc(C)c1C[C@H](N)C(=O)N(Cc1cccc(C(=O)O)c1)[C@@H](C)c1nc(-c2ccccc2)c[nH]1,61,7.21,F,CHEMBL2157906,agonist,agonist,Agonist activity at mu opioid receptor expressed in CHO-hg cells by [35S]-GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2012,539.64,4.15,active,2,539.634,0.6836,-4.555,9,4,155.4,1.9439,0.54762,0.87713,9,10,4,0.42439,0.66509,0.8700291236,0.3697976549,-0.2533679984,2,1
CHEMBL2159122,COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@@H](C)c2ncc(-c3ccccc3)[nH]2)cc1C(=O)O,1,9,F,CHEMBL2157906,agonist,agonist,Agonist activity at mu opioid receptor expressed in CHO-hg cells by [35S]-GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2012,569.66,4.16,highly_active,3,569.66,0.6136,-4.573,10,4,164.63,2.0141,0.54446,0.89477,10,11,4,0.45183,0.65788,1.119776719,0.3316034219,-0.1928852396,2,1
CHEMBL215926,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NCCCCc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314,1.45,8.84,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,521.1,5.1,highly_active,3,521.099,5.1692,-6.209,5,1,50.8,2.5564,0.35358,1.0919,6,9,2,0.31562,0.68921,-0.675852557,-1.408228138,0.1890363105,6,2
CHEMBL216365,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)C/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314,1.27,8.9,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,533.07,4.71,highly_active,3,533.066,4.6963,-6.326,6,1,67.87,4.1873,0.30026,1.0959,7,7,2,0.30365,0.69162,-0.5127893893,-1.377752517,-0.14555055,5,2
CHEMBL2163910,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccc(F)cc1,7.35,8.13,F,CHEMBL2163332,agonist,agonist,Agonist activity at mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by liquid scintillation counter,1,Scientific Literature,J Med Chem,2012,640.72,2.5,highly_active,3,640.714,1.7763,-4.803,11,6,183.64,-1.0691,0.46651,0.92172,12,12,4,0.43376,0.64951,1.567225919,-0.06067937111,-0.0927180792,6,6
CHEMBL2163911,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccc(Cl)cc1,12,7.92,F,CHEMBL2163332,agonist,agonist,Agonist activity at mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by liquid scintillation counter,1,Scientific Literature,J Med Chem,2012,657.17,3.01,active,2,657.169,2.2815,-5.225,11,6,183.64,0.30808,0.46651,0.92172,12,12,4,0.43873,0.64764,1.553221135,-0.4123961069,-0.1203884843,6,6
CHEMBL2163912,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1cccc(Cl)c1,0.72,9.14,F,CHEMBL2163332,agonist,agonist,Agonist activity at mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by liquid scintillation counter,1,Scientific Literature,J Med Chem,2012,657.17,3.01,highly_active,3,657.169,2.2815,-5.225,11,6,183.64,0.30808,0.46651,0.92768,12,12,4,0.40242,0.63957,1.553221135,-0.4123961069,-0.1203884843,6,6
CHEMBL2163913,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccccc1Cl,0.84,9.08,F,CHEMBL2163332,agonist,agonist,Agonist activity at mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by liquid scintillation counter,1,Scientific Literature,J Med Chem,2012,657.17,3.01,highly_active,3,657.169,2.2815,-5.225,11,6,183.64,0.30808,0.46087,0.93298,12,12,4,0.4392,0.66206,1.553221135,-0.4123961069,-0.1203884843,6,6
CHEMBL2163914,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccc(OC)cc1,10.91,7.96,F,CHEMBL2163332,agonist,agonist,Agonist activity at mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by liquid scintillation counter,1,Scientific Literature,J Med Chem,2012,652.75,2.37,active,2,652.75,1.6055,-4.507,12,6,192.87,0.2914,0.46883,0.91096,12,13,4,0.46864,0.64398,1.727656107,0.1226251215,0.03879790297,6,6
CHEMBL2163915,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccc2c(c1)OCO2,10.7,7.97,F,CHEMBL2163332,agonist,agonist,Agonist activity at mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by liquid scintillation counter,1,Scientific Literature,J Med Chem,2012,666.74,2.09,active,2,666.733,1.7869,-5.2,13,6,202.1,0.22663,0.44378,0.93173,13,12,4,0.45136,0.64416,1.863698273,-0.3157771551,-0.2313118606,1,1
CHEMBL2163916,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,0.0334,10.48,F,CHEMBL2163332,agonist,agonist,Agonist activity at mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by liquid scintillation counter,1,Scientific Literature,J Med Chem,2012,612.69,1.95,highly_active,3,612.685,0.8642,-4.171,12,6,196.78,0.22195,0.46829,0.9183,12,12,4,0.41104,0.6526,1.704142557,0.5006417538,-0.09744208952,4,1
CHEMBL2163917,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccoc1,0.0342,10.47,F,CHEMBL2163332,agonist,agonist,Agonist activity at mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by liquid scintillation counter,1,Scientific Literature,J Med Chem,2012,612.69,1.95,highly_active,3,612.685,0.8102,-4.147,12,6,196.78,0.0304,0.46785,0.9183,12,12,4,0.36962,0.65739,1.709328571,0.5241332599,-0.09937363668,4,1
CHEMBL2163918,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1cccc2ccccc12,72.3,7.14,F,CHEMBL2163332,agonist,agonist,Agonist activity at mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by liquid scintillation counter,1,Scientific Literature,J Med Chem,2012,672.79,3.51,active,2,672.784,2.8699,-6.095,11,6,183.64,0.27087,0.4311,0.9279,11,12,5,0.42982,0.64349,1.490027772,-1.039570256,-0.2341786722,1,1
CHEMBL2163919,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccc2ccccc2c1,70.34,7.15,F,CHEMBL2163332,agonist,agonist,Agonist activity at mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by liquid scintillation counter,1,Scientific Literature,J Med Chem,2012,672.79,3.51,active,2,672.784,2.8699,-6.095,11,6,183.64,0.27087,0.43829,0.92104,11,12,5,0.41377,0.63829,1.490027772,-1.039570256,-0.2341786722,1,1
CHEMBL2163920,C=C(C(=O)N[C@@H](Cc1ccccc1)C(N)=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccccc1,36.5,7.44,F,CHEMBL2163332,agonist,agonist,Agonist activity at mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by liquid scintillation counter,1,Scientific Literature,J Med Chem,2012,583.69,1.88,active,2,583.687,1.6361,-3.964,10,5,167.85,0.48308,0.4918,0.86592,10,12,3,0.41324,0.64841,1.138843273,0.499292595,0.1673067229,1,1
CHEMBL2163921,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccccc1,0.16,9.8,F,CHEMBL2163332,agonist,agonist,Agonist activity at mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by liquid scintillation counter,1,Scientific Literature,J Med Chem,2012,622.73,2.36,highly_active,3,622.724,1.6755,-4.489,11,6,183.64,0.27087,0.46726,0.90602,11,12,4,0.42697,0.65159,1.477908555,0.1608193472,-0.02168486842,6,6
CHEMBL2163922,C=C(C(N)=O)[C@@H](NC(=O)C(=C)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccccc1)c1ccccc1,45.09,7.35,F,CHEMBL2163332,agonist,agonist,Agonist activity at mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by liquid scintillation counter,1,Scientific Literature,J Med Chem,2012,595.7,2.57,active,2,595.698,2.0087,-3.878,10,5,167.85,-0.073567,0.46715,0.87957,10,12,3,0.41085,0.64588,1.110043505,0.4739548149,0.2440597697,1,1
CHEMBL216558,O=C1CC[C@@]2(NC/C=C/Cc3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,1.21,8.92,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,505.06,4.58,highly_active,3,505.056,4.6413,-5.667,5,2,61.8,3.0076,0.37463,1.088,6,7,2,0.34495,0.70202,-0.6300314589,-0.9427749342,-0.005615867328,6,2
CHEMBL217102,O=C1CC[C@@]2(NCCCCc3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,0.29,9.54,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,507.07,4.8,highly_active,3,507.072,4.8935,-5.895,5,2,61.8,2.5218,0.3589,1.088,6,8,2,0.35465,0.70222,-0.6004597252,-1.135481876,0.07500560808,6,2
CHEMBL217395,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)CCc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314,0.03,10.52,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,521.06,4.24,highly_active,3,521.055,4.3652,-5.921,6,1,67.87,5.4117,0.30432,1.096,7,7,2,0.32112,0.69605,-0.5114155769,-1.07044143,-0.09618840467,5,2
CHEMBL217479,O=C(CCCc1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5,0.87,9.06,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,521.06,4.33,highly_active,3,521.055,4.5439,-5.877,6,2,78.87,2.0675,0.31753,1.0921,7,7,2,0.35624,0.70053,-0.4095119175,-1.061595989,-0.1087810806,5,2
CHEMBL217658,O=C1CC[C@@]2(NCCc3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,1.56,8.81,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,479.02,4.02,highly_active,3,479.018,3.9847,-5.355,5,2,61.8,4.2438,0.32,1.088,6,6,2,0.3895,0.72915,-0.653481361,-0.6076803046,-0.1278704057,2,2
CHEMBL217710,O=C(C/C=C/c1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5,1.84,8.73,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,519.04,4.41,highly_active,3,519.039,4.4206,-6.012,6,2,78.87,4.1472,0.30442,1.0921,7,6,2,0.31894,0.70087,-0.4373965103,-1.105006285,-0.2595812476,5,2
CHEMBL217790,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/Cc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314,12.1,7.92,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,533.07,4.4,active,2,533.066,4.5674,-5.963,6,1,67.87,2.7191,0.28388,1.0959,7,7,2,0.34278,0.68621,-0.5144764746,-1.141635197,-0.07537192722,5,1
CHEMBL2178731,NC(=O)[C@H]1CC(=O)NCCC(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1,37,7.43,F,CHEMBL2177066,agonist,agonist,Agonist activity at human MOR expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 15 mins by cAMP EIA,1,Scientific Literature,J Med Chem,2012,518.57,-0.2,active,2,518.572,-0.4294,-3.618,11,6,175.28,6.1219,0.39514,0.85805,11,5,3,0.36853,0.70873,1.17720162,1.225594159,-0.8148937613,1,1
CHEMBL2178733,CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(N)=O,200,6.7,F,CHEMBL2177066,partial agonist,agonist,Partial agonist activity at human MOR expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 15 mins by cAMP EIA,1,Scientific Literature,J Med Chem,2012,449.51,0.54,intermediate,1,449.509,0.196,-3.387,9,5,146.18,2.0638,0.53535,0.81625,9,10,3,0.47571,0.69058,0.792112059,1.237766478,-0.07324434778,1,1
CHEMBL217950,C[C@H]1CN2CCN(Cc3ccoc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,6.1,8.21,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,340.47,3.47,highly_active,3,340.465,2.8073,-2.777,4,1,39.85,3.71,0.34644,0.83603,4,3,2,0.60883,0.83466,-1.32331383,1.270913808,0.1046192785,4,1
CHEMBL2179652,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314,1.74,8.76,F,CHEMBL2177065,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting analysis,1,Scientific Literature,J Med Chem,2012,605.18,7.46,highly_active,3,605.176,7.2245,-7.833,5,1,54.82,0.63462,0.26204,1.1216,6,8,4,0.35973,0.6656,-0.7427556164,-2.787136576,-0.003380215183,25,19
CHEMBL2179653,CO[C@@]12Cc3cc(-c4ccc(Cl)cc4)cnc3[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5,379,6.42,F,CHEMBL2177065,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting analysis,1,Scientific Literature,J Med Chem,2012,460.96,4.68,intermediate,1,460.96,4.1975,-5.312,5,1,54.82,4.8413,0.19451,1.1114,6,2,3,0.35613,0.73726,-1.001061198,-0.5639106135,-0.4443914921,1,1
CHEMBL2179654,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OCc2ccccc2)[C@H]1C5,301,6.52,F,CHEMBL2177065,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting analysis,1,Scientific Literature,J Med Chem,2012,537.06,6.25,intermediate,1,537.057,5.6156,-6.635,5,1,54.82,4.7813,0.22566,1.1183,6,4,4,0.38433,0.69536,-0.8970994676,-1.686781398,-0.3519813427,1,1
CHEMBL2179655,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OC/C=C/c2ccccc2)[C@H]1C5,4.27,8.37,F,CHEMBL2177065,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting analysis,1,Scientific Literature,J Med Chem,2012,563.1,6.76,highly_active,3,563.095,6.3768,-7.152,5,1,54.82,4.875,0.24701,1.1179,6,5,4,0.36475,0.69359,-0.8764017257,-2.16073146,-0.2647635068,2,1
CHEMBL2179656,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OCCCc2ccccc2)[C@H]1C5,2.15,8.67,F,CHEMBL2177065,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting analysis,1,Scientific Literature,J Med Chem,2012,565.11,6.68,highly_active,3,565.111,6.5001,-7.017,5,1,54.82,0.90897,0.26504,1.1179,6,6,4,0.39383,0.68287,-0.8485170166,-2.117321504,-0.1139634469,2,1
CHEMBL2179660,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OC(=O)c2ccccc2)[C@H]1C5,4623,5.33,F,CHEMBL2177065,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting analysis,1,Scientific Literature,J Med Chem,2012,551.04,5.89,inactive,0,551.04,5.698,-6.764,6,1,71.89,4.8053,0.20223,1.1246,7,4,4,0.37155,0.69433,-0.7043665869,-1.78713756,-0.4096641186,1,1
CHEMBL2179661,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OC(=O)Cc2ccccc2)[C@H]1C5,87,7.06,F,CHEMBL2177065,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting analysis,1,Scientific Literature,J Med Chem,2012,565.07,5.82,active,2,565.067,5.6961,-6.729,6,1,71.89,3.5293,0.25178,1.124,7,5,4,0.38279,0.7119,-0.6387362664,-1.792347613,-0.2995457411,1,1
CHEMBL2179662,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OC(=O)CCc2ccccc2)[C@H]1C5,48,7.32,F,CHEMBL2177065,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting analysis,1,Scientific Literature,J Med Chem,2012,579.1,6.21,active,2,579.094,6.1505,-6.999,6,1,71.89,1.3342,0.26721,1.1238,7,6,4,0.41184,0.67965,-0.6122254304,-2.056248323,-0.1981077883,1,1
CHEMBL217998,Cc1cccc(CN2CCN3C[C@H](C)[C@](C)(c4cccc(O)c4)C[C@@H]3C2)c1,1.5,8.82,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,364.53,4.18,highly_active,3,364.531,4.0165,-3.463,3,1,26.71,3.9084,0.38065,0.84632,3,3,2,0.53387,0.77999,-1.557290085,0.632078491,0.150033045,16,12
CHEMBL217999,Cc1ccc(CN2CCN3C[C@H](C)[C@](C)(c4cccc(O)c4)C[C@@H]3C2)cc1,9.5,8.02,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,364.53,4.18,highly_active,3,364.531,4.0165,-3.463,3,1,26.71,3.9084,0.38065,0.84245,3,3,2,0.56192,0.80182,-1.557290085,0.632078491,0.150033045,16,12
CHEMBL218135,C[C@H]1CN2CCN(C(=O)Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,6.7,8.17,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,378.52,3.45,highly_active,3,378.514,3.7531,-3.213,4,1,43.78,4.7983,0.43923,0.84206,4,3,2,0.30405,0.71517,-1.341714374,0.8148464186,0.1351011227,2,1
CHEMBL218136,C[C@H]1CN2CCN(Cc3ccc4ccccc4c3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,74,7.13,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,400.57,5.03,active,2,400.564,4.867,-4.725,3,1,26.71,3.9084,0.36319,0.86084,3,3,3,0.39847,0.72619,-1.542614628,-0.2927897073,-0.03018575705,1,1
CHEMBL218242,C[C@H]1CN2CCN(Cc3ccccc3O)C[C@H]2C[C@@]1(C)c1cccc(O)c1,1.6,8.8,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,366.51,3.58,highly_active,3,366.503,3.3269,-2.823,4,2,46.94,3.9084,0.3724,0.8467,4,3,2,0.45921,0.76587,-1.229593448,1.142151932,0.1287601104,16,12
CHEMBL218506,C[C@H]1CN2C[C@@H](c3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1,52,7.28,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,336.48,3.7,active,2,336.477,3.5178,-3.252,3,2,35.5,3.7655,0.33811,0.85083,3,2,2,0.46601,0.77485,-1.480119983,0.8957087256,-0.02053806369,10,1
CHEMBL218705,C[C@H]1CN2CCN(Cc3ccc(Cl)cc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,42,7.38,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,384.95,4.53,active,2,384.949,4.2786,-3.855,3,1,26.71,3.9512,0.38065,0.84008,4,3,2,0.55984,0.79682,-1.479421265,0.3343844413,0.08360443082,16,12
CHEMBL218706,CC(=O)N1C[C@H]2C[C@@](C)(c3cccc(O)c3)[C@@H](C)CN2C[C@@H]1c1ccccc1,220,6.66,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,378.52,3.96,intermediate,1,378.514,3.8274,-3.172,4,1,43.78,4.6033,0.34176,0.87495,4,2,2,0.42947,0.74274,-1.397599636,0.8389307259,0.05622529276,10,2
CHEMBL218909,C[C@H]1CN2CCN(Cc3cccc(O)c3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,4.5,8.35,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,366.51,3.58,highly_active,3,366.503,3.3269,-2.823,4,2,46.94,3.9084,0.38065,0.84632,4,3,2,0.60186,0.81134,-1.229593448,1.142151932,0.1287601104,16,12
CHEMBL218980,C[C@H]1CN2C[C@@H](Cc3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1,22,7.66,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,350.51,3.57,active,2,350.504,3.7682,-3.671,3,2,35.5,3.7655,0.37539,0.84708,3,3,2,0.35203,0.74876,-1.422990029,0.5794065689,0.01497068805,1,1
CHEMBL219012,C[C@H]1[C@@H]2CCCCN2CC[C@@]1(C)c1cccc(O)c1,1000,6,F,CHEMBL1137299,antagonist,antagonist,Antagonist activity against human cloned mu opioid receptor expressed in CHO cells assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,259.39,3.54,intermediate,1,259.392,3.3091,-3.183,2,1,23.47,0.90232,0.36973,0.82626,2,1,1,0.39331,0.80399,-1.870264284,1.044703132,-0.07836519418,2,1
CHEMBL219044,COC(=O)c1cccc(CN2CCN3C[C@H](C)[C@](C)(c4cccc(O)c4)C[C@@H]3C2)c1,6.9,8.16,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,408.54,3.66,highly_active,3,408.54,3.5856,-3.26,5,1,53.01,1.6281,0.41586,0.85734,5,5,2,0.52504,0.73778,-1.033931213,0.763655301,0.274043114,16,12
CHEMBL219097,CC(C)[C@H]1CN2C[C@H](C)[C@](C)(c3cccc(O)c3)C[C@@H]2CN1,66,7.18,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,302.46,2.99,active,2,302.46,2.999,-2.966,3,2,35.5,3.4528,0.36618,0.83685,3,2,1,0.35185,0.76056,-1.485411512,1.186388075,-0.03084341933,2,1
CHEMBL219099,C[C@H]1CN2CCN(Cc3cccnc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,7.5,8.12,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,351.49,3.27,highly_active,3,351.492,2.6717,-2.324,4,1,39.6,3.9084,0.37305,0.84632,4,3,2,0.59085,0.81986,-1.312143313,1.550660182,0.1979145944,16,1
CHEMBL219152,C[C@H]1CN2CCN(Cc3ccncc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,18,7.75,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,351.49,3.27,active,2,351.492,2.6717,-2.324,4,1,39.6,3.9084,0.37305,0.83928,4,3,2,0.51596,0.80195,-1.312143313,1.550660182,0.1979145944,16,1
CHEMBL219154,C[C@H]1CN2CCN(Cc3cccc(Oc4ccccc4)c3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,9.7,8.01,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,442.6,5.67,highly_active,3,442.601,5.0682,-5.416,4,1,35.94,3.8554,0.44628,0.85304,4,5,3,0.51745,0.72144,-1.229588357,-0.798561272,0.006358242586,1,1
CHEMBL219317,C[C@H]1CN2CCN(C(=O)Nc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,16,7.8,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,379.5,3.91,active,2,379.502,3.7489,-3.764,5,2,55.81,5.1213,0.40975,0.84206,5,2,2,0.28444,0.70869,-1.112870738,0.5168686356,-0.1669075841,2,1
CHEMBL219318,C[C@H]1CN2CCN(Cc3ccccc3Cl)C[C@H]2C[C@@]1(C)c1cccc(O)c1,1.8,8.74,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,384.95,4.53,highly_active,3,384.949,4.2786,-3.855,3,1,26.71,3.9512,0.3724,0.8467,4,3,2,0.57778,0.83104,-1.479421265,0.3343844413,0.08360443082,16,12
CHEMBL219337,C[C@H]1CN2CCN(Cc3ccc(N(C)C)cc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,190,6.72,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,393.58,3.94,intermediate,1,393.573,3.569,-3.155,4,1,29.95,4.6707,0.41893,0.84708,4,4,2,0.37196,0.72002,-1.299774566,0.8510413988,2.44E-01,16,12
CHEMBL219466,C[C@H]1CN2CCN(Cc3ccccn3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,13,7.89,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,351.49,3.27,active,2,351.492,2.7257,-2.348,4,1,39.6,3.9084,0.37007,0.85009,4,3,2,0.51419,0.8101,-1.317329313,1.527168697,2.00E-01,16,1
CHEMBL219495,C[C@H]1CN2CCN(CCc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,2,8.7,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,364.53,3.92,highly_active,3,364.531,4.1027,-3.231,3,1,26.71,4.1814,0.39163,0.83766,3,4,2,0.45909,0.76611,-1.532662236,0.7409605901,0.3188879333,1,1
CHEMBL219554,C[C@H]1CN2CCN(Cc3ccsc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,1.4,8.85,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,356.54,3.94,highly_active,3,356.532,3.457,-3.019,3,1,54.95,4.3721,0.34644,0.83603,4,3,2,0.49251,0.77055,-1.373285568,1.001694727,0.1257542214,4,1
CHEMBL219599,Cc1ccccc1CN1CCN2C[C@H](C)[C@](C)(c3cccc(O)c3)C[C@@H]2C1,1.8,8.74,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,364.53,4.18,highly_active,3,364.531,4.0165,-3.463,3,1,26.71,3.9084,0.3724,0.85009,3,3,2,0.59164,0.82075,-1.557290085,0.632078491,0.150033045,16,12
CHEMBL220248,C[C@H]1CN2CCN(c3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,54,7.27,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,336.48,3.88,active,2,336.477,3.7497,-3.641,3,1,26.71,3.9084,0.34816,0.8467,3,2,2,0.32068,0.73803,-1.606716252,0.6129705561,-0.03608390685,1,1
CHEMBL2204031,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@]2(CC[C@@]3(O)[C@H]1C5)O[C@H]1N3[C@H](OC1(C)C)C(C)(C)O[C@@H]32,6,8.22,F,CHEMBL2203184,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 2 hrs by liquid scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2012,470.57,1.84,highly_active,3,470.564,1.6638,-3.002,8,2,83.86,2.4939,0.086,1.1515,8,0,1,0.5772,0.82243,-0.4067640798,1.270968481,-0.5553415295,1,1
CHEMBL2208347,C[C@H]1[C@H]2Cc3ccc(C(=O)NCCc4ccc(-c5ccc(O)cc5)cc4)cc3[C@]1(C)CCN2CC1CC1,0.5,9.3,F,CHEMBL2203245,partial agonist,agonist,Partial agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2012,494.68,5.97,highly_active,3,494.677,6.1805,-6.918,4,2,52.57,5.5536,0.44689,0.91761,4,7,3,0.24473,0.64805,-0.9756410987,-1.93600973,-0.04995427671,15,2
CHEMBL2208349,CC1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5O)cc4)cc3C1(C)CCN2CC1CC1,1.5,8.82,F,CHEMBL2203245,partial agonist,agonist,Partial agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2012,494.68,5.97,highly_active,3,494.677,6.1805,-6.918,4,2,52.57,5.5536,0.46709,0.90627,4,7,3,0.26019,0.64939,-0.9756410987,-1.93600973,-0.04995427671,15,5
CHEMBL2208350,COc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)cc1OC,1.6,8.8,F,CHEMBL2203245,partial agonist,agonist,Partial agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2012,538.73,6.28,highly_active,3,538.729,6.3862,-7.25,5,1,50.8,5.5737,0.47604,0.91784,5,9,3,0.22313,0.62856,-0.8012879296,-2.246948958,0.1245591341,15,5
CHEMBL2208351,CC1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccc6c(c5)OCO6)cc4)cc3C1(C)CCN2CC1CC1,0.15,9.82,F,CHEMBL2203245,partial agonist,agonist,Partial agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2012,522.69,5.99,highly_active,3,522.687,6.6376,-7.925,5,1,50.8,5.496,0.45263,0.92217,5,7,3,0.24943,0.6423,-0.9149917274,-2.647158259,-0.2060333516,1,1
CHEMBL2208352,COc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)cc1C,0.6,9.22,F,CHEMBL2203245,partial agonist,agonist,Partial agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2012,522.73,6.58,highly_active,3,522.73,6.8001,-7.576,4,1,41.57,5.5737,0.47435,0.91193,4,8,3,0.26418,0.63885,-1.05359177,-2.484276249,0.03180130325,15,5
CHEMBL2208354,COc1ccc2cc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)ccc2c1,45,7.35,F,CHEMBL2203245,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2012,482.67,5.76,active,2,482.666,5.9914,-6.752,4,1,41.57,5.5737,0.44869,0.909,4,7,3,0.2697,0.65861,-1.10455608,-1.807955815,0.01063657225,1,1
CHEMBL2208358,COc1cccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)c1,0.22,9.66,F,CHEMBL2203245,partial agonist,agonist,Partial agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2012,508.71,6.27,highly_active,3,508.704,6.4562,-7.232,4,1,41.57,5.5737,0.47661,0.90752,4,8,3,0.26474,0.64859,-1.051033952,-2.208755711,0.06407654235,15,5
CHEMBL2208361,CC(C)Oc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)cc1,2.3,8.64,F,CHEMBL2203245,partial agonist,agonist,Partial agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2012,536.76,7.05,highly_active,3,536.757,7.2218,-7.91,4,1,41.57,5.2199,0.48663,0.90399,4,9,3,0.22791,0.63151,-1.020327028,-2.780202114,0.1128572993,15,5
CHEMBL224014,O=C(CCCCCCCCC(=O)Oc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3,4.4,8.36,F,CHEMBL1147138,agonist,agonist,Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,819.1,8.31,highly_active,3,819.092,8.8667,-9.848,9,1,105.61,-6.7975,0.37571,1.1268,9,17,2,0.2363,0.59549,0.4801784813,-4.565814573,0.5461439105,1,1
CHEMBL224671,O=C(CCCCCCCCC(=O)Oc1ccc2c3c1O[C@H]1[C@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3,18,7.75,F,CHEMBL1147138,agonist,agonist,Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as inhibition of DAGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2007,835.14,8.49,active,2,835.135,9.065,-10.067,9,2,108.77,-7.9134,0.37238,1.1204,9,17,2,0.33604,0.59079,0.5909257433,-4.732058242,0.4854324717,1,1
CHEMBL226113,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1Cc1c([nH]c2ccccc12)C3,1.7,8.77,F,CHEMBL1143667,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO membrane assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2007,398.55,4.87,highly_active,3,398.548,4.7586,-5.439,3,1,28.26,5.0672,0.17788,1.0055,3,3,3,0.40889,0.7356,-1.495156419,-0.6922787326,-0.2229897044,2,2
CHEMBL226166,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1Cc1c([nH]c2ccccc12)C3,92,7.04,F,CHEMBL1143667,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO membrane assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2007,384.52,4.57,active,2,384.521,4.4829,-5.125,3,2,39.26,5.1207,0.16303,1.0036,3,2,3,0.42012,0.74541,-1.419763594,-0.4195324714,-0.3370204041,2,2
CHEMBL226167,CN1CC[C@]23Cc4nc(N)sc4C[C@H]2[C@H]1Cc1ccc(O)cc13,140,6.85,F,CHEMBL1143667,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO membrane assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2007,327.45,2.34,intermediate,1,327.451,2.7493,-3.703,4,2,90.62,6.28,0.12941,0.97874,5,0,2,0.47433,0.79362,-1.115835864,0.8061786775,-0.5472505401,1,1
CHEMBL226217,Nc1nc2c(s1)C[C@H]1[C@H]3Cc4ccc(O)cc4[C@@]1(CCN3CC1CC1)C2,0.4,9.4,F,CHEMBL1143667,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO membrane assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2007,367.52,3.12,highly_active,3,367.516,3.4737,-4.519,4,2,90.62,6.0312,0.18613,0.98697,5,2,2,0.39051,0.76312,-1.010074464,0.1363636048,-0.4366673084,7,7
CHEMBL229440,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1C/C=C/C[C@H](C(=O)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O,2.65,8.58,F,CHEMBL1145383,agonist,agonist,Agonist activity at human mu opioid receptor by [35S]GTP-gamma-S binding assay,1,Scientific Literature,J Med Chem,2007,551.6,-0.49,highly_active,3,551.598,-2.4521,-2.98,12,7,199.95,-11.296,0.4665,0.8024,12,7,2,0.2953,0.67643,1.813545351,1.911209367,-0.831324614,3,1
CHEMBL2334768,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H]1CCN(C(=O)[C@@H](N)Cc2ccc(O)cc2)C1)c1ccccc1,0.057,10.24,F,CHEMBL2331515,agonist,agonist,Agonist activity at FLAG-tagged mu-type opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by liquid scintillation counting analysis,1,Scientific Literature,J Med Chem,2013,622.73,2.22,highly_active,3,622.724,1.6201,-4.271,11,6,183.64,0.16831,0.43875,0.8945,11,12,4,0.31941,0.62774,1.474331388,0.2988055897,0.02364147426,2,1
CHEMBL2334769,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H]1CCN(C(=O)[C@@H](N)Cc2ccc(O)cc2)C1)c1ccco1,0.0933,10.03,F,CHEMBL2331515,agonist,agonist,Agonist activity at FLAG-tagged mu-type opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by liquid scintillation counting analysis,1,Scientific Literature,J Med Chem,2013,612.69,1.81,highly_active,3,612.685,0.8088,-3.953,12,6,196.78,0.10338,0.43853,0.90777,12,12,4,0.32177,0.63052,1.70056539,0.6386279964,-0.05211574684,1,1
CHEMBL2334770,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCN(C(=O)[C@@H](N)Cc2ccc(O)cc2)C1)c1ccccc1,0.0397,10.4,F,CHEMBL2331515,agonist,agonist,Agonist activity at FLAG-tagged mu-type opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by liquid scintillation counting analysis,1,Scientific Literature,J Med Chem,2013,622.73,2.22,highly_active,3,622.724,1.6201,-4.271,11,6,183.64,0.16831,0.43875,0.8945,11,12,4,0.33801,0.62623,1.474331388,0.2988055897,0.02364147426,2,1
CHEMBL2347235,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccncc5)cc4)cc3[C@@]1(C)CCN2CC1CC1,2.2,8.66,F,CHEMBL2346652,partial agonist,agonist,Partial agonist activity at human mu opioid receptor expressed in CHO cell membrane assessed as stimulation of [35S]GTPgammaS binding after 60 mins by liquid scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2013,479.67,5.66,highly_active,3,479.666,5.5253,-6.419,4,1,45.23,5.5451,0.45382,0.91503,4,7,3,0.31825,0.65573,-1.05819101,-1.527501451,0.01920020257,15,1
CHEMBL2347236,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5cccnc5)cc4)cc3[C@@]1(C)CCN2CC1CC1,0.85,9.07,F,CHEMBL2346652,partial agonist,agonist,Partial agonist activity at human mu opioid receptor expressed in CHO cell membrane assessed as stimulation of [35S]GTPgammaS binding after 60 mins by liquid scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2013,479.67,5.66,highly_active,3,479.666,5.5253,-6.419,4,1,45.23,5.5451,0.45382,0.92082,4,7,3,0.27162,0.65641,-1.05819101,-1.527501451,0.01920020257,15,1
CHEMBL2347237,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccn5)cc4)cc3[C@@]1(C)CCN2CC1CC1,1.7,8.77,F,CHEMBL2346652,partial agonist,agonist,Partial agonist activity at human mu opioid receptor expressed in CHO cell membrane assessed as stimulation of [35S]GTPgammaS binding after 60 mins by liquid scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2013,479.67,5.66,highly_active,3,479.666,5.6163,-6.111,4,1,45.23,5.5451,0.45091,0.9224,4,7,3,0.26831,0.65946,-1.082962953,-1.361879638,0.1076989157,15,1
CHEMBL2347238,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)nc4)cc3[C@@]1(C)CCN2CC1CC1,4.5,8.35,F,CHEMBL2346652,partial agonist,agonist,Partial agonist activity at human mu opioid receptor expressed in CHO cell membrane assessed as stimulation of [35S]GTPgammaS binding after 60 mins by liquid scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2013,479.67,5.66,highly_active,3,479.666,5.6163,-6.111,4,1,45.23,5.5451,0.45091,0.92059,4,7,3,0.27293,0.65171,-1.082962953,-1.361879638,0.1076989157,15,1
CHEMBL2347239,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cn4)cc3[C@@]1(C)CCN2CC1CC1,19,7.72,F,CHEMBL2346652,partial agonist,agonist,Partial agonist activity at human mu opioid receptor expressed in CHO cell membrane assessed as stimulation of [35S]GTPgammaS binding after 60 mins by liquid scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2013,479.67,5.66,active,2,479.666,5.5793,-6.443,4,1,45.23,5.5451,0.45123,0.92104,4,7,3,0.32947,0.64935,-1.063377032,-1.550992656,0.02113184916,15,1
CHEMBL235239,CO[C@]12CC(O)[C@@]3(C[C@@H]1[C@@H](C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5,12,7.92,F,CHEMBL1149641,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO membrane by [35S]GTP-gamma-S binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2007,387.48,1.19,active,2,387.474,1.1461,-2.907,6,3,82.39,4.1635,0.20992,1.1206,6,2,1,0.57732,0.81472,-0.5421553757,1.481806372,-0.4194315745,4,4
CHEMBL238017,CO[C@]12C(O)C[C@@]3(C[C@@H]1[C@H](C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5,15,7.82,F,CHEMBL1149641,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO membrane by [35S]GTP-gamma-S binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2007,387.48,1.19,active,2,387.474,1.1461,-2.907,6,3,82.39,4.2111,0.21879,1.1157,6,2,1,0.53354,0.81161,-0.5421553757,1.481806372,-0.4194315745,4,4
CHEMBL2387187,CC(C)C1CCC(N2CCC(N3C(=O)Cc4ccccc43)CC2)CC1,73.5,7.13,F,CHEMBL2385080,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem Lett,2013,340.51,4.25,active,2,340.509,4.126,-4.334,3,0,23.55,3.0234,0.41124,0.78413,3,3,1,0.34294,0.73989,-1.666068901,0.1106408726,-0.01268169461,5,5
CHEMBL2387188,CCC[C@H]1CC[C@@H](N2CCC(N3C(=O)Cc4ccccc43)CC2)CC1,595,6.22,F,CHEMBL2385080,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem Lett,2013,340.51,4.4,intermediate,1,340.509,4.3621,-4.444,3,0,23.55,3.4355,0.38261,0.79438,3,4,1,0.34111,0.72619,-1.643166459,-0.007865322439,0.0941666422,5,5
CHEMBL2387189,CCC(C)(C)[C@H]1CC[C@@H](N2CCC(N3C(=O)Cc4ccccc43)CC2)CC1,189,6.72,F,CHEMBL2385080,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem Lett,2013,368.57,5.04,intermediate,1,368.563,5.1462,-4.781,3,0,23.55,4.0009,0.41529,0.80343,3,4,1,0.33608,0.75048,-1.675646833,-0.3688809114,0.12940071,5,5
CHEMBL2387191,CC(C1CCCCC1)N1CCC(N2C(=O)Cc3ccccc32)CC1,28,7.55,F,CHEMBL2385080,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem Lett,2013,326.48,4.01,active,2,326.482,3.738,-4.174,3,0,23.55,1.0186,0.41521,0.78648,3,3,1,0.33063,0.74181,-1.649909418,0.2854410792,-0.03179291649,45,1
CHEMBL2387192,CC(c1ccccc1)N1CCC(N2C(=O)Cc3ccccc32)CC1,50.6,7.3,F,CHEMBL2385080,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem Lett,2013,320.44,3.8,active,2,320.435,3.3331,-3.564,3,0,23.55,7.125,0.4047,0.78648,3,3,2,0.38047,0.73654,-1.640155257,0.7205991094,0.0579867523,45,2
CHEMBL2387193,O=C1Cc2ccccc2N1C1CCN(C2CC[C@H]3CCCc4cccc2c43)CC1,129,6.89,F,CHEMBL2385080,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem Lett,2013,386.54,5,intermediate,1,386.537,5.1853,-5.11,3,0,23.55,3.557,0.34679,0.91876,3,2,2,0.47239,0.72936,-1.72797636,-0.5608803654,-0.1419171683,5,1
CHEMBL2387194,CC1C(=O)N(C2CCN([C@H]3CC[C@@H](C(C)C)CC3)CC2)c2ccccc21,119.6,6.92,F,CHEMBL2385080,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem Lett,2013,354.54,4.82,intermediate,1,354.536,4.805,-4.702,3,0,23.55,3.9713,0.38083,0.82626,3,3,1,0.36347,0.73345,-1.706555676,-0.237080811,-0.002406365846,5,5
CHEMBL2387195,CC1C(=O)N(C2CCN(C3CCCCCCC3)CC2)c2ccccc21,94,7.03,F,CHEMBL2385080,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem Lett,2013,340.51,4.71,active,2,340.509,5.2765,-4.652,3,0,23.55,2.077,0.37272,0.81435,3,2,1,0.30643,0.73436,-1.83079934,-0.2631840116,-0.02387337849,4,3
CHEMBL2387196,CCC1C(=O)N(C2CCN([C@H]3CC[C@@H](C(C)C)CC3)CC2)c2ccccc21,4.7,8.33,F,CHEMBL2385080,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem Lett,2013,368.57,5.21,highly_active,3,368.563,5.2594,-4.972,3,0,23.55,4.446,0.38869,0.84323,3,4,1,0.3667,0.72404,-1.680044896,-0.5009816031,0.09903165591,5,5
CHEMBL2387197,CCC1C(=O)N(C2CCN(C3CCCCCCC3)CC2)c2ccccc21,37.3,7.43,F,CHEMBL2385080,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem Lett,2013,354.54,5.1,active,2,354.536,5.7309,-4.922,3,0,23.55,2.562,0.38155,0.83271,3,3,1,0.31222,0.72516,-1.804288457,-0.5270847501,0.07756457912,4,3
CHEMBL2387198,CC(C)C1CCC(N2CCC(N3C(=O)CCc4ccccc43)CC2)CC1,68,7.17,F,CHEMBL2385080,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem Lett,2013,354.54,4.65,active,2,354.536,4.468,-4.604,3,0,23.55,2.9434,0.41829,0.79602,3,3,1,0.28735,0.72834,-1.671808706,-0.12097049,-0.02712779968,1,1
CHEMBL2387200,CC1CC(=O)N(C2CCN(C3CCCCCCC3)CC2)c2ccccc21,58,7.24,F,CHEMBL2385080,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem Lett,2013,354.54,5.1,active,2,354.536,5.6185,-4.922,3,0,23.55,-0.58059,0.38132,0.81905,3,2,1,0.31682,0.73603,-1.836539145,-0.4947953742,-0.03831948356,1,1
CHEMBL241824,CNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CC1)CC3,14,7.85,F,CHEMBL1144610,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,354.49,3.87,active,2,354.492,3.6865,-4.793,4,1,41.57,-3.3122,0.30458,0.90271,4,4,1,0.39072,0.75015,-1.260297615,-0.09452729403,-0.1620902549,4,2
CHEMBL2418738,COc1ccc2c3c1O[C@H]1[C@@H](O)[C@H](C)C[C@H]4[C@@H](C2)N(C)CC[C@@]341,2000,5.7,F,CHEMBL2417445,agonist,agonist,Agonist activity at human MOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2013,315.41,1.97,inactive,0,315.412,2.0771,-3.249,4,1,41.93,5.7044,0.095973,1.0381,4,1,1,0.5143,0.80772,-1.339103125,1.169328122,-0.3224456744,12,8
CHEMBL2418739,C[C@@H]1C[C@H]2[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@@H](O5)[C@H]1O,20,7.7,F,CHEMBL2417445,agonist,agonist,Agonist activity at human MOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2013,301.39,1.67,active,2,301.385,1.8014,-2.935,4,2,52.93,5.6515,0.095695,1.0344,4,0,1,0.66713,0.84413,-1.263710246,1.442074355,-0.4364763721,12,8
CHEMBL2418740,COc1ccc2c3c1O[C@H]1[C@@H](O)[C@H](OC)C[C@H]4[C@@H](C2)N(C)CC[C@@]341,16000,4.8,F,CHEMBL2417445,agonist,agonist,Agonist activity at human MOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2013,331.41,1.35,inactive,0,331.41,1.3836,-2.818,5,1,51.16,5.0786,0.11187,1.0482,5,2,1,0.51735,0.78897,-1.059062268,1.516942831,-0.2444028003,12,8
CHEMBL2418741,COc1ccc2c3c1O[C@H]1[C@@H](O)[C@H](O)C[C@H]4[C@@H](C2)N(C)CC[C@@]341,16000,4.8,F,CHEMBL2417445,agonist,agonist,Agonist activity at human MOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2013,317.39,0.7,inactive,0,317.384,0.9557,-2.69,5,2,62.16,5.0596,0.097896,1.0439,5,1,1,0.5281,0.81171,-0.957380377,1.70652037,-0.425929258,12,8
CHEMBL2418742,COc1ccc2c3c1O[C@H]1[C@@H](O)[C@H](F)C[C@H]4[C@@H](C2)N(C)CC[C@@]341,40000,4.4,F,CHEMBL2417445,agonist,agonist,Agonist activity at human MOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2013,319.38,1.67,inactive,0,319.375,1.6568,-3.272,4,1,41.93,3.6867,0.096956,1.0475,5,1,1,0.52071,0.81332,-1.224149342,1.222842709,-0.3997750817,12,8
CHEMBL2418743,COc1ccc2c3c1O[C@H]1[C@@H](OC)[C@H](C)C[C@H]4[C@@H](C2)N(C)CC[C@@]341,3200,5.5,F,CHEMBL2417445,agonist,agonist,Agonist activity at human MOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2013,329.44,2.63,inactive,0,329.438,2.505,-3.377,4,0,30.93,5.2413,0.1101,1.0435,4,2,1,0.5353,0.81478,-1.440785023,0.9797505725,-0.1409192082,12,8
CHEMBL2418744,COc1cc(C)c2c3c1O[C@H]1[C@@H](O)[C@H](C)C[C@H]4[C@@H](C2)N(C)CC[C@@]341,5000,5.3,F,CHEMBL2417445,agonist,agonist,Agonist activity at human MOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2013,329.44,2.28,inactive,0,329.438,2.421,-3.593,4,1,41.93,5.7044,0.093919,1.0509,4,1,1,0.53848,0.79449,-1.341660946,0.8938077953,-0.3547207577,12,8
CHEMBL2418745,COc1cc(C)c2c3c1O[C@H]1[C@H](F)[C@H](C)C[C@H]4[C@@H](C2)N(C)CC[C@@]341,3200,5.5,F,CHEMBL2417445,agonist,agonist,Agonist activity at human MOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2013,331.43,3.26,inactive,0,331.429,3.1221,-4.175,3,0,21.7,3.7917,0.13602,1.0584,4,1,1,0.61615,0.78914,-1.608429907,0.4101299835,-0.3285666312,12,8
CHEMBL2419121,COc1c(C(=O)N[C@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)nc(Cl)c2ccccc12,23.7,7.62,F,CHEMBL3400112,antagonist,antagonist,Antagonist activity at human MOR expressed in CHO cells assessed as inhibition of DAMGO-induced increase in intracellular Ca2+ level incubated for 15 mins prior to DAMGO addition by microplate reader analysis,1,Scientific Literature,Bioorg Med Chem,2015,562.07,3.97,active,2,562.064,3.7682,-5.937,8,3,104.15,5.5824,0.22318,1.1053,9,5,3,0.39039,0.74476,0.06534379182,-0.9595325416,-0.530459384,3,2
CHEMBL242046,CNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CCC1)CC3,11,7.96,F,CHEMBL1144610,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,368.52,4.26,active,2,368.519,4.0285,-5.063,4,1,41.57,-4.0232,0.32705,0.90425,4,4,1,0.39107,0.74237,-1.26603742,-0.3261386566,-0.17653636,10,2
CHEMBL242047,CCNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CCC1)CC3,39,7.41,F,CHEMBL1144610,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,382.55,4.65,active,2,382.546,4.4348,-5.363,4,1,41.57,-9.3324,0.34163,0.90501,4,5,1,0.41811,0.72982,-1.232543274,-0.5993724203,-0.08938789588,10,2
CHEMBL242048,O=C(Nc1ccccc1)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CCC1)CC3,1.3,8.89,F,CHEMBL1144610,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,430.59,6.16,highly_active,3,430.59,5.7372,-6.57,4,1,41.57,-9.8512,0.34179,0.9095,4,5,2,0.28312,0.69484,-1.254478543,-1.581576479,-0.1889788517,1,1
CHEMBL242756,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1,73,7.14,F,CHEMBL1149134,agonist,agonist,Agonistic activity against Opioid receptor mu 1 in Chinese hamster ovary membranes,1,Scientific Literature,J Med Chem,2004,353.54,4.35,active,2,353.532,4.0959,-5.357,3,1,70.39,-0.25281,0.18044,0.95725,4,2,2,0.34816,0.75643,-1.339371429,-0.4672159559,-0.4754461101,4,4
CHEMBL242968,NC(=O)Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3,31,7.51,F,CHEMBL1147995,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding after 60 mins,1,Scientific Literature,Bioorg Med Chem,2007,339.48,3.65,active,2,339.481,3.052,-4.919,4,2,58.36,0.20202,0.2651,0.93381,4,3,1,0.3918,0.76552,-1.105356415,-0.01665825944,-0.4438030009,4,1
CHEMBL2440150,CC(C)(NCC[C@@]1(c2ccc(F)cc2)CCOC2(CCCC2)C1)c1ccccc1,3162.28,5.5,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,395.56,6.1,inactive,0,395.56,5.2914,-5.773,2,1,21.26,-0.255,0.49123,0.82315,3,6,2,0.4798,0.73311,-1.493321016,-1.02010456,0.08539105987,20,4
CHEMBL2443253,c1ccc([C@]2(CCNCc3ccc4ccccc4c3)CCOC3(CCCC3)C2)nc1,158.49,6.8,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,400.57,5.78,intermediate,1,400.564,4.5649,-5.809,3,1,34.15,-2.0895,0.47693,0.84708,3,6,3,0.4032,0.7042,-1.297065029,-0.9158107336,-0.05043376367,2,1
CHEMBL2443254,c1ccc([C@]2(CCNCC3CCCC3)CCOC3(CCCC3)C2)nc1,31.62,7.5,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,342.53,4.61,active,2,342.525,3.3608,-4.236,3,1,34.15,-1.4062,0.4592,0.82225,3,6,1,0.44564,0.73569,-1.318865707,0.274412553,0.1513406213,15,1
CHEMBL2443255,Cc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1,6.31,8.2,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,370.56,4.99,highly_active,3,370.559,3.581,-4.557,3,1,62.39,-0.26231,0.46937,0.84972,4,6,2,0.47188,0.73438,-1.134806266,0.02412650657,0.05819868296,15,6
CHEMBL2443257,Cc1ccc(CNCC[C@@]2(c3ccccn3)CCOC3(CCCC3)C2)s1,15.85,7.8,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,370.56,4.99,active,2,370.559,3.6632,-4.667,3,1,62.39,0.19749,0.47984,0.84897,4,6,2,0.44807,0.71899,-1.139320206,-0.05489906762,0.04316612446,15,6
CHEMBL2443258,Cc1ccc(CNCC[C@@]2(c3ccccn3)CCOC3(CCCC3)C2)o1,50.12,7.3,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,354.49,4.52,active,2,354.492,2.9571,-4.253,4,1,47.29,-2.642,0.48186,0.83016,4,6,2,0.46762,0.71717,-1.090692544,0.3253887658,0.05595955667,15,2
CHEMBL2443259,Cc1cc(C)c(CNCC[C@@]2(c3ccccn3)CCOC3(CCCC3)C2)s1,25.12,7.6,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,384.59,5.3,active,2,384.586,4.0071,-5.011,3,1,62.39,0.3073,0.47716,0.85628,4,6,2,0.43603,0.72783,-1.141876476,-0.3304206744,0.01089111611,15,6
CHEMBL2443260,Cc1cc(CNCC[C@@]2(c3ccccn3)CCOC3(CCCC3)C2)sc1C,5.012,8.3,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,384.59,5.3,highly_active,3,384.586,4.0071,-5.011,3,1,62.39,-1.6212,0.48849,0.85557,4,6,2,0.44523,0.70365,-1.141876476,-0.3304206744,0.01089111611,15,6
CHEMBL2443261,Cc1cc(CNCC[C@@]2(c3ccccn3)CCOC3(CCCC3)C2)oc1C,31.62,7.5,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,368.52,4.83,active,2,368.519,3.301,-4.597,4,1,47.29,-5.3454,0.49067,0.83766,4,6,2,0.44675,0.71902,-1.093248814,0.04986715896,0.02368454832,15,2
CHEMBL2443262,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1,12,7.92,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as beta arrestin-2 recruitment incubated for 3 days by PathHunter assay,1,Scientific Literature,Eur J Med Chem,2022,386.56,4.69,active,2,386.558,3.1671,-4.231,4,1,71.62,-0.59069,0.47494,0.85413,5,7,2,0.44248,0.71711,-0.882502385,0.2614538396,0.1509564741,15,6
CHEMBL2443263,Fc1ccc([C@]2(CCNCc3ccccc3)CCOC3(CCCC3)C2)cc1,31.62,7.5,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,367.51,5.37,active,2,367.506,4.4182,-5.288,2,1,21.26,-3.4295,0.48131,0.81243,3,6,2,0.45992,0.73111,-1.45727136,-0.5564886593,0.07348874185,20,4
CHEMBL2443266,C[C@H](NCC[C@@]1(c2ccc(F)cc2)CCOC2(CCCC2)C1)c1ccccc1,501.19,6.3,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,381.54,5.93,intermediate,1,381.533,4.7049,-5.359,2,1,21.26,-0.41823,0.45817,0.81905,3,6,2,0.51123,0.72243,-1.465725778,-0.6613207279,0.09973521119,20,4
CHEMBL2443267,C[C@@H](NCC[C@@]1(c2ccc(F)cc2)CCOC2(CCCC2)C1)c1ccccc1,1000,6,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,381.54,5.93,intermediate,1,381.533,4.7049,-5.359,2,1,21.26,-0.41823,0.46346,0.81905,3,6,2,0.51021,0.73174,-1.465725778,-0.6613207279,0.09973521119,20,4
CHEMBL2443268,c1ccc(CNCCC2(c3ccccn3)CCOC3(CCCC3)C2)cc1,50.12,7.3,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,350.51,4.62,active,2,350.504,3.3705,-4.203,3,1,34.15,-2.0895,0.4815,0.81194,3,6,2,0.44204,0.72625,-1.30918426,0.2845788484,0.1620600573,20,1
CHEMBL2443269,c1ccc(CNCC[C@@]2(c3ccccn3)CCOC3(CCCC3)C2)cc1,12.59,7.9,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,350.51,4.62,active,2,350.504,3.3705,-4.203,3,1,34.15,-2.0895,0.48185,0.8236,3,6,2,0.43908,0.72852,-1.30918426,0.2845788484,0.1620600573,20,2
CHEMBL2443271,Clc1ccccc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1,10,8,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,384.95,5.28,highly_active,3,384.949,3.9765,-4.939,3,1,34.15,-1.9968,0.48569,0.85376,4,6,2,0.45233,0.72752,-1.233871666,-0.2886365851,0.0633564242,20,2
CHEMBL2443273,c1ccc(CNCC[C@@]2(c3ccccn3)CCOC3(CCCC3)C2)nc1,158.49,6.8,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,351.49,4.02,intermediate,1,351.492,2.4236,-3.432,4,1,47.04,-2.0895,0.47977,0.82844,4,6,2,0.4099,0.72458,-1.071779752,0.9041477695,0.1795982105,20,1
CHEMBL2443274,c1ccc([C@]2(CCNCc3cccnc3)CCOC3(CCCC3)C2)nc1,199.53,6.7,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,351.49,4.02,intermediate,1,351.492,2.3696,-3.408,4,1,47.04,-2.0895,0.48185,0.82714,4,6,2,0.45314,0.73104,-1.066593742,0.9276391145,0.1776666223,20,1
CHEMBL2443275,c1ccc([C@]2(CCNCc3ccncc3)CCOC3(CCCC3)C2)nc1,1258.93,5.9,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,351.49,4.02,inactive,0,351.492,2.3696,-3.408,4,1,47.04,-2.0895,0.48185,0.8236,4,6,2,0.46576,0.74054,-1.066593742,0.9276391145,0.1776666223,20,1
CHEMBL2443276,c1ccc([C@]2(CCNCc3cnccn3)CCOC3(CCCC3)C2)nc1,630.96,6.2,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,352.48,3.41,intermediate,1,352.48,1.4227,-2.637,5,1,59.93,-2.0895,0.47977,0.82844,5,6,2,0.45411,0.73513,-0.8291892366,1.547207875,0.1952047344,20,1
CHEMBL2443277,c1ccc([C@]2(CCNCc3ccncn3)CCOC3(CCCC3)C2)nc1,794.33,6.1,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,352.48,3.41,intermediate,1,352.48,1.8613,-3.223,5,1,59.93,-2.0895,0.47977,0.82844,5,6,2,0.49326,0.72978,-0.8533175823,1.126094887,0.1152227798,20,1
CHEMBL2443278,c1ccc([C@]2(CCNCc3cccs3)CCOC3(CCCC3)C2)nc1,15.85,7.8,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,356.54,4.68,active,2,356.532,3.2371,-4.213,3,1,62.39,0.14253,0.46985,0.84517,4,6,2,0.44288,0.73296,-1.132249949,0.2996480844,0.09047369607,15,6
CHEMBL2443279,c1ccc([C@]2(CCNCc3ccsc3)CCOC3(CCCC3)C2)nc1,12.59,7.9,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,356.54,4.68,active,2,356.532,3.1549,-4.103,3,1,62.39,-0.88795,0.46101,0.84517,4,6,2,0.47103,0.73865,-1.127736009,0.3786736586,0.1055062546,15,1
CHEMBL2443281,Cc1ccc(C2(CCNCc3ccccc3O)CCOCC2)cc1,10000,5,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,325.45,3.93,inactive,0,325.45,3.3021,-3.909,3,2,41.49,-3.3603,0.55773,0.72591,3,6,2,0.37596,0.74189,-1.240743102,0.5065761677,0.1760960895,6,6
CHEMBL2443282,CC[C@]1(C)CC(CCNCc2ccccc2O)(c2ccc(F)cc2)CCO1,39.81,7.4,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,371.5,4.93,active,2,371.494,4.1361,-4.636,3,2,41.49,0.25623,0.55413,0.78295,4,7,2,0.411,0.72999,-1.12913625,-0.1246894766,0.2139917303,6,6
CHEMBL2443283,CC1(C)CC(CCNCc2ccccc2)(c2ccc(F)cc2)CCO1,1584.89,5.8,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,341.47,4.83,inactive,0,341.468,4.0274,-4.662,2,1,21.26,-2.9854,0.54275,0.73618,3,6,2,0.44042,0.74207,-1.480787494,-0.09534071319,0.16610166,6,6
CHEMBL2443284,CCC1(CC)CC(CCNCc2ccccc2)(c2ccc(F)cc2)CCO1,251.19,6.6,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,369.52,5.61,intermediate,1,369.522,4.9362,-5.202,2,1,21.26,0.057922,0.54963,0.76387,3,8,2,0.4341,0.73326,-1.427765839,-0.6231423553,0.368977713,6,6
CHEMBL2443285,Fc1ccc(C2(CCNCc3ccccc3)CCOC3(CCCC3)C2)cc1,79.43,7.1,F,CHEMBL2440083,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation by fluorescence assay,1,Scientific Literature,J Med Chem,2013,367.51,5.37,active,2,367.506,4.4182,-5.288,2,1,21.26,-3.4295,0.48096,0.77872,3,6,2,0.44288,0.73362,-1.45727136,-0.5564886593,0.07348874185,20,1
CHEMBL245049,CNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(C)CC3,50,7.3,F,CHEMBL1144610,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,314.43,3.09,active,2,314.427,2.9621,-3.977,4,1,41.57,-3.2274,0.28722,0.88979,4,2,1,0.47823,0.7874,-1.366059026,0.5752879192,-0.2726734283,1,1
CHEMBL246572,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc2nc(N)sc2c1)C(=O)O,350,6.46,F,CHEMBL1139195,agonist,agonist,Agonist activity at human cloned mu opioid receptor assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,643.79,0.42,intermediate,1,643.788,-2.1363,-4.566,13,7,272.17,-9.8569,0.59517,0.84284,15,16,3,0.37776,0.61421,2.873943618,0.7295417633,-0.4025024264,1,1
CHEMBL246739,Cc1cc(C(N)=O)cc(C)c1C[C@H](N)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)O,180,6.75,F,CHEMBL1139195,agonist,agonist,Agonist activity at human cloned mu opioid receptor assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,610.71,-0.15,intermediate,1,610.709,-2.1517,-3.977,13,7,222.81,-12.004,0.63688,0.8218,13,16,2,0.28602,0.6241,2.517679703,1.104801357,-0.1740736511,14,14
CHEMBL246956,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(C(N)=O)cc1)C(N)=O,270,6.57,F,CHEMBL1139195,agonist,agonist,Agonist activity at human cloned mu opioid receptor assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,599.71,-1.66,intermediate,1,599.711,-2.034,-3.31,13,7,253.9,2.658,0.64078,0.78055,14,17,2,0.33931,0.61735,2.662614292,1.479005642,0.04927408837,14,14
CHEMBL247368,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O,630,6.2,F,CHEMBL1139195,agonist,agonist,Agonist activity at human cloned mu opioid receptor assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,572.69,-1.05,intermediate,1,572.685,-1.467,-2.925,12,7,231.04,2.6816,0.62805,0.76856,13,16,2,0.3682,0.63555,2.297928645,1.641672811,0.1697860512,14,14
CHEMBL247758,Cc1cc(C(N)=O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)O,49,7.31,F,CHEMBL1139195,agonist,agonist,Agonist activity at human cloned mu opioid receptor assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,624.74,0.24,active,2,624.736,-1.7924,-4.355,13,7,222.81,-12.167,0.62068,0.83186,13,16,2,0.37832,0.61613,2.514893985,0.8065878389,-0.2124410911,14,14
CHEMBL247760,Cc1cc(C(N)=O)cc(C)c1C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)O)[C@@H](C)O,250,6.6,F,CHEMBL1139195,agonist,agonist,Agonist activity at human cloned mu opioid receptor assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,741.84,-1.93,intermediate,1,741.84,-3.8435,-3.864,17,10,292.37,-5.6414,0.61902,0.86692,17,20,2,0.40186,0.59981,4.062704094,1.336748238,-0.2362045295,14,14
CHEMBL249567,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(Br)cc4)cc3[C@@]1(C)CCN2CC1CC1,16,7.8,F,CHEMBL1140563,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membrane by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2007,481.48,5.36,active,2,481.476,5.5922,-5.962,3,1,32.34,3.7551,0.43595,0.90702,4,6,2,0.32904,0.67694,-1.231797273,-1.263227649,0.06412746187,2,2
CHEMBL249985,COc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)[C@@]3(C)CCN(CC5CC5)C(C4)[C@@H]3C)cc2)cc1,11,7.96,F,CHEMBL1140563,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membrane by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2007,508.71,6.27,active,2,508.704,6.4562,-7.232,4,1,41.57,5.5737,0.47208,0.91945,4,8,3,0.27308,0.63517,-1.051033952,-2.208755711,0.06407654235,15,3
CHEMBL250993,C[C@H]1C2Cc3ccc(C(=O)NCCc4cccc(Br)c4)cc3[C@@]1(C)CCN2CC1CC1,5.6,8.25,F,CHEMBL1140563,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membrane by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2007,481.48,5.36,highly_active,3,481.476,5.5922,-5.962,3,1,32.34,3.7551,0.43595,0.9095,4,6,2,0.32096,0.67416,-1.231797273,-1.263227649,0.06412746187,2,2
CHEMBL255354,C[C@@H](NC(=O)[C@@H](Cc1ccccc1)CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)C(=O)O,3,8.52,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,438.57,3.44,highly_active,3,438.566,2.1985,-3.634,6,3,89.87,2.0508,0.53774,0.807,6,8,2,0.37552,0.71494,-0.2556995944,0.7473099593,0.150222824,14,8
CHEMBL255555,C[C@H]1CN(CCC(=O)N(Cc2ccccc2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,25,7.6,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,514.67,5.11,active,2,514.664,3.6648,-4.435,6,2,81.08,2.6645,0.54728,0.84087,6,10,3,0.377,0.68297,-0.298850668,-0.08995360377,0.423410363,2,2
CHEMBL256010,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](CCc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,9.9,8,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,528.69,5.05,highly_active,3,528.691,4.0948,-5.039,6,3,89.87,-6.3041,0.49315,0.82714,6,11,3,0.36936,0.67183,-0.1366482049,-0.5328676578,0.3935027574,1,1
CHEMBL256834,C[C@H]1CN(CCC(=O)N(C)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,14,7.85,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,438.57,3.54,active,2,438.566,2.2467,-3.112,6,2,81.08,3.5537,0.57942,0.8085,6,8,2,0.36628,0.69635,-0.4028138851,1.032917828,0.3309999446,5,4
CHEMBL257895,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,13,7.89,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,496.6,3.28,active,2,496.602,1.831,-3.649,8,4,127.17,-6.2954,0.5322,0.8227,8,11,2,0.38414,0.69152,0.4620682689,0.7272601827,0.2827141755,14,8
CHEMBL257906,CO[C@@H]1CN(C[C@H]2Cc3ccc(Br)cc3C2)CC[C@H]1n1c(C(C)(C)O)nc2cc(C)ccc21,24900,4.6,F,CHEMBL1141625,agonist,agonist,Agonist activity at mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2008,512.49,5.01,inactive,0,512.49,5.1643,-3.393,5,1,50.52,1.5018,0.37585,0.9389,6,5,3,0.31135,0.69343,-1.000449387,0.3104285754,0.4777120298,1,1
CHEMBL258115,CC(C)CN(C(=O)CCN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)[C@@H](Cc1ccccc1)C(=O)O,43,7.37,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,480.65,4.56,active,2,480.647,3.3257,-3.842,6,2,81.08,-2.9131,0.58771,0.8236,6,10,2,0.40859,0.69246,-0.3392005267,0.3503886175,0.5141761249,5,4
CHEMBL258294,C[C@H]1CN(CCC(=O)N(CC2CC2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,16,7.8,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,478.63,4.32,active,2,478.631,2.9711,-3.928,6,2,81.08,3.4704,0.55431,0.83016,6,10,2,0.4075,0.69318,-0.2970524849,0.3631027556,0.4415831763,1,1
CHEMBL259299,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccc(Br)cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,4890,5.31,F,CHEMBL1144846,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay,1,Scientific Literature,J Med Chem,2008,573.44,5.06,inactive,0,573.434,4.0085,-5.671,8,0,109.11,-3.4851,0.26313,0.99474,9,6,2,0.37322,0.68984,-0.1614552729,-0.902338949,-0.2344233902,12,5
CHEMBL259658,COC(=O)[C@@H]1C[C@H](NC(=O)c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,360,6.44,F,CHEMBL1144846,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay,1,Scientific Literature,J Med Chem,2008,493.56,3.87,intermediate,1,493.554,2.8091,-4.701,8,1,111.91,1.041,0.30473,1.0122,8,5,2,0.38576,0.7033,-0.1961686273,-0.02019285789,-0.3087414209,12,2
CHEMBL260120,C[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N(C)CC(N)=O)N(C)C(=O)[C@@H](N)Cc1ccc(O)cc1,3.28,8.48,F,CHEMBL2150869,agonist,agonist,Agonist activity at human MOR expressed in HEK293 cell membrane assessed as inhibition of forskolin-induced cAMP accumulation by by liquid scintillation counting,1,Scientific Literature,J Med Chem,2011,483.57,-0.22,highly_active,3,483.567,-0.6213,-1.789,10,4,159.06,5.9901,0.64824,0.78763,10,11,2,0.39029,0.69067,0.9841872661,2.265934914,0.3040568907,3,3
CHEMBL260121,COC(=O)[C@@H]1C[C@H](OC(=O)c2cc3ccccc3o2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,1680,5.78,F,CHEMBL1144846,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay,1,Scientific Literature,J Med Chem,2008,534.56,5.04,inactive,0,534.559,3.7889,-6.02,9,0,122.25,-1.4228,0.23929,1.0253,9,6,3,0.34074,0.68185,-0.07682846934,-1.028439651,-0.3807658875,1,1
CHEMBL260286,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccc(OC)cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,830,6.08,F,CHEMBL1144846,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay,1,Scientific Literature,J Med Chem,2008,524.57,4.3,intermediate,1,524.564,3.2133,-4.855,9,0,118.34,-1.6951,0.27537,1.0143,9,7,2,0.35297,0.68418,-0.04633324977,-0.2466775216,-0.07542048325,12,5
CHEMBL260485,COC(=O)[C@@H]1C[C@H](OC(=O)c2cccc(OC)c2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,1670,5.78,F,CHEMBL1144846,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay,1,Scientific Literature,J Med Chem,2008,524.57,4.3,inactive,0,524.564,3.2133,-4.855,9,0,118.34,-1.6951,0.27537,1.0166,9,7,2,0.35546,0.68635,-0.04633324977,-0.2466775216,-0.07542048325,12,5
CHEMBL262420,C[C@H]1[C@H]2CC[C@@H](c3ccccc3)CN2CC[C@@]1(C)c1cccc(O)c1,120,6.92,F,CHEMBL1137299,antagonist,antagonist,Antagonist activity against human cloned mu opioid receptor expressed in CHO cells assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,335.49,4.94,intermediate,1,335.489,5.0535,-4.416,2,1,23.47,2.7318,0.34288,0.86049,2,2,2,0.38354,0.75991,-1.853797185,-0.06889204152,-0.01642952888,10,2
CHEMBL263096,O=C(NCc1ccccc1)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CC1)CC3,2.2,8.66,F,CHEMBL1144610,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,430.59,5.44,highly_active,3,430.59,5.1046,-6.116,4,1,41.57,-12.324,0.35875,0.90777,4,6,2,0.29904,0.69214,-1.156334397,-1.217398726,-0.06967983653,1,1
CHEMBL263482,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)CCCc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314,4.91,8.31,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,535.08,4.63,highly_active,3,535.082,4.8196,-6.191,6,1,67.87,2.1017,0.31312,1.0959,7,8,2,0.30456,0.69109,-0.4849047965,-1.334342222,0.005249617082,5,2
CHEMBL264967,COC(=O)[C@@H]1C[C@H](OC(=O)c2cccs2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,1150,5.94,F,CHEMBL1144846,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay,1,Scientific Literature,J Med Chem,2008,500.57,4.36,inactive,0,500.566,3.1499,-4.847,8,0,137.35,0.3911,0.25893,0.9927,9,6,2,0.36576,0.70942,-0.1191465051,-0.1934143309,-0.2074897307,2,1
CHEMBL265195,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccc([N+](=O)[O-])cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,1370,5.86,F,CHEMBL1144846,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay,1,Scientific Literature,J Med Chem,2008,539.54,4.2,inactive,0,539.535,2.3617,-5.297,11,0,154.93,-6.6325,0.2823,0.99715,11,7,2,0.37093,0.68557,0.4539668766,-0.3667905648,-0.3880982671,12,5
CHEMBL267027,O=C(CCc1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5,0.028,10.55,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,507.03,3.94,highly_active,3,507.028,4.0895,-5.607,6,2,78.87,5.3775,0.30886,1.0923,7,6,2,0.35264,0.71645,-0.4360226979,-0.7976951972,-0.2102191023,5,2
CHEMBL267495,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,0.72,9.14,F,CHEMBL3351376,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2014,476.57,3.09,highly_active,3,476.571,2.6177,-4.251,7,2,86.38,4.4373,0.27341,1.0887,7,5,2,0.37317,0.73471,-0.3348189064,0.3010053771,-0.2109025206,5,2
CHEMBL270187,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,6.2,8.21,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,564.73,5.82,highly_active,3,564.724,4.8348,-6.375,6,3,89.87,-5.2541,0.46195,0.85231,6,10,4,0.34526,0.66803,-0.1510397539,-1.469356448,0.07957091465,1,1
CHEMBL270190,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1,1.7,8.77,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,424.54,3.05,highly_active,3,424.539,1.8392,-3.256,6,3,89.87,0.59744,0.5394,0.79818,6,8,2,0.37576,0.71782,-0.2529138431,1.045523428,0.1885902861,14,8
CHEMBL270401,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](CC2CCCCC2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,5.3,8.28,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,520.71,5.39,highly_active,3,520.711,3.997,-5.23,6,3,89.87,-10.332,0.49199,0.8293,6,10,2,0.37975,0.69222,-0.1741425897,-0.6080051024,0.2317571946,2,1
CHEMBL270833,C[C@H]1CN(CCC(=O)N(Cc2ccc(-c3ccccc3)cc2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,36,7.44,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,590.76,6.77,active,2,590.761,5.324,-6.521,6,2,81.08,2.6645,0.51865,0.8591,6,11,4,0.40039,0.66177,-0.2332108842,-1.691142054,0.2643563158,1,1
CHEMBL271662,C[C@H]1CN(CCC(=O)N(Cc2cccc(Cl)c2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,6.8,8.17,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,549.11,5.76,highly_active,3,549.109,4.2708,-5.171,6,2,81.08,2.7254,0.54711,0.85699,7,10,3,0.43055,0.67859,-0.2235381016,-0.6631690785,0.3247067643,2,2
CHEMBL277530,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)Cc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314,8.84,8.05,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,507.03,3.85,highly_active,3,507.028,3.9108,-5.651,6,1,67.87,5.4117,0.3116,1.0964,7,6,2,0.35555,0.71776,-0.5379263573,-0.8065406377,-0.1976264264,2,2
CHEMBL278789,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,2.4,8.62,F,CHEMBL1833812,agonist,agonist,Agonist activity at Mu-type opioid receptor,1,Scientific Literature,J Med Chem,2011,802.89,-2,highly_active,3,802.883,-2.0392,-3.304,18,10,295.61,5.1532,0.56765,0.88951,18,19,3,0.41255,0.59592,4.005081903,1.309124979,0.05038701111,2,2
CHEMBL285479,C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,3.981,8.4,F,CHEMBL3763121,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells by calcium mobilization assay,1,Scientific Literature,Bioorg Med Chem,2016,802.89,-2,highly_active,3,802.883,-2.0392,-3.304,18,10,295.61,5.1532,0.56725,0.88951,18,19,3,0.35213,0.59545,4.005081903,1.309124979,0.05038701111,2,2
CHEMBL299031,CC[C@@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,339,6.47,F,CHEMBL4376854,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of cAMP accumulation by HTRF assay,1,Scientific Literature,J Med Chem,2020,398.5,3.83,intermediate,1,398.501,3.2432,-3.205,6,1,63.79,2.1076,0.27555,0.95369,6,6,2,0.44205,0.7063,-0.8126290373,0.854059777,0.3046208993,10,4
CHEMBL300616,Oc1nc2ccccc2n1C1CCN(Cc2ccccc2)CC1,2183,5.66,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,307.4,3.58,inactive,0,307.396,3.6231,-2.217,4,1,41.29,6.6931,0.37308,0.77994,4,3,3,0.31873,0.74588,-1.490478829,1.491083578,0.3523421691,2,2
CHEMBL301160,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3,1.6,8.8,F,CHEMBL1154777,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,311.47,4.25,highly_active,3,311.467,3.9671,-4.288,2,1,23.47,-1.3172,0.25072,0.92833,2,2,1,0.43251,0.78865,-1.770255751,0.2175852838,-0.1458467724,10,4
CHEMBL3084526,NC(=O)[C@@]1(Cc2ccc(F)cc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl,540,6.27,F,CHEMBL1138605,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,497.44,6.56,intermediate,1,497.439,6.1689,-6.997,3,1,46.33,0.54472,0.30828,0.91023,6,6,3,0.62396,0.77356,-1.063085217,-1.98911933,-0.1458560083,2,1
CHEMBL3084529,NC(=O)[C@]1(c2ccc(F)cn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl,733,6.13,F,CHEMBL1138605,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,484.4,5.67,intermediate,1,484.401,4.6957,-6.276,4,1,59.22,0.54472,0.26057,0.95022,7,5,3,0.5475,0.75325,-0.8290908573,-1.281649135,-0.3184300889,16,6
CHEMBL3084530,NC(=O)[C@]1(c2ccc(Cl)cn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl,368,6.43,F,CHEMBL1138605,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,500.86,6.18,intermediate,1,500.856,5.2009,-6.698,4,1,59.22,1.8847,0.26057,0.95022,7,5,3,0.52928,0.73134,-0.8430956603,-1.6333658,-0.3461005332,16,6
CHEMBL3084531,NC(=O)[C@]1(c2ccc(Br)cn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl,421,6.38,F,CHEMBL1138605,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,545.31,6.29,intermediate,1,545.307,5.3201,-6.796,4,1,59.22,0.094721,0.26057,0.92638,7,5,3,0.51839,0.72859,-0.7837826362,-1.754005987,-0.3459170826,16,6
CHEMBL3084549,CC(=O)N[C@]1(c2ccccn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl,1933,5.71,F,CHEMBL1138605,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,480.44,6.14,inactive,0,480.437,5.495,-5.894,4,1,45.23,0.0062171,0.25352,0.95188,6,5,3,0.60226,0.74008,-1.050689587,-1.192172465,-0.07908217652,16,6
CHEMBL3084551,COC(=O)N[C@]1(c2ccccn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl,3777,5.42,F,CHEMBL1138605,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,496.44,6.36,inactive,0,496.436,5.6982,-6.209,5,1,54.46,-8.1795,0.26611,0.95601,7,6,3,0.66648,0.73761,-0.8407764517,-1.439279891,-0.05396845716,16,6
CHEMBL3084558,COC(=O)N[C@]1(Cc2ccc(Cl)cc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl,1563,5.81,F,CHEMBL1138605,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,543.92,7.7,inactive,0,543.92,7.4069,-7.83,4,1,41.57,-8.1795,0.30297,0.92572,7,7,3,0.54926,0.70992,-0.9487523489,-2.75235047,-0.0737557402,2,1
CHEMBL3084634,Clc1ccccc1C(c1ccccc1Cl)N1[C@@H]2CC[C@H]1C[C@@H](c1ccccn1)C2,2193,5.66,F,CHEMBL1152437,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as increase in SCH-221510-stimulated [35S]GTPgammaS binding in presence of GDP,1,Scientific Literature,J Med Chem,2009,423.39,6.89,inactive,0,423.386,6.497,-6.122,2,0,16.13,0.11851,0.22562,0.88374,4,4,3,0.43703,0.74834,-1.712029654,-1.450121696,0.008714951459,16,6
CHEMBL3086303,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1Cc1sc(N)nc1C3,39,7.41,F,CHEMBL3085732,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,1,Scientific Literature,J Med Chem,2013,381.55,3.43,active,2,381.542,3.7494,-4.833,4,1,79.62,6.0087,0.20352,0.99118,5,3,2,0.39763,0.75666,-1.085468824,-0.1363816578,-0.3226367976,7,7
CHEMBL3086304,Br.Nc1nc2c(s1)C[C@H]1[C@H]3Cc4ccc(O)cc4[C@@]1(CCN3CC1CC1)C2,1.8,8.74,F,CHEMBL3085732,antagonist,antagonist,Antagonist activity at human mu opioid receptor transfected in CHO cells assessed as inhibition of U50488-induced [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,1,Scientific Literature,J Med Chem,2013,448.43,3.12,highly_active,3,448.427,3.4737,-4.519,4,2,90.62,6.0312,0.18613,0.98697,5,2,2,0.39748,0.7648,-0.8850446083,0.05942219047,-0.4240459192,7,7
CHEMBL3086305,CC(=O)Nc1nc2c(s1)C[C@H]1[C@H]3Cc4ccc(O)cc4[C@@]1(CCN3CC1CC1)C2,0.52,9.28,F,CHEMBL3085732,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,1,Scientific Literature,J Med Chem,2013,409.56,3.5,highly_active,3,409.552,3.8547,-4.785,5,2,93.7,6.8229,0.19561,0.99434,6,3,2,0.31889,0.72484,-0.803104243,-0.1386691312,-0.3612723175,7,7
CHEMBL3086306,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1Cc1sc(NC(C)=O)nc1C3,80,7.1,F,CHEMBL3085732,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,1,Scientific Literature,J Med Chem,2013,423.58,3.8,active,2,423.579,4.1304,-5.099,5,1,82.7,6.8271,0.20989,0.99834,6,4,2,0.33943,0.71505,-0.8784970748,-0.4114153928,-0.2472416151,7,7
CHEMBL3086307,CNc1nc2c(s1)C[C@H]1[C@H]3Cc4ccc(OC)cc4[C@@]1(CCN3CC1CC1)C2,51,7.29,F,CHEMBL3085732,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,1,Scientific Literature,J Med Chem,2013,395.57,3.89,active,2,395.569,4.0737,-4.817,4,1,65.63,6.4158,0.20973,0.99406,5,4,2,0.36695,0.73972,-1.102939085,-0.2120672055,-0.150603284,7,7
CHEMBL3086308,Br.CNc1nc2c(s1)C[C@H]1[C@H]3Cc4ccc(O)cc4[C@@]1(CCN3CC1CC1)C2,0.52,9.28,F,CHEMBL3085732,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,1,Scientific Literature,J Med Chem,2013,462.46,3.58,highly_active,3,462.454,3.798,-4.503,4,2,76.63,6.4433,0.19381,0.98993,5,3,2,0.34958,0.74791,-0.9025148689,-0.01626335727,-0.2520124056,7,7
CHEMBL3086465,C[C@H]1CN(CCCc2ccccc2)[C@@H]2C[C@@H](N)C[C@@]1(c1cccc(O)c1)C2,20.6,7.69,F,CHEMBL3085655,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2013,364.53,4.09,active,2,364.531,3.8636,-4.265,3,2,49.49,2.892,0.42808,0.8591,3,5,2,0.34862,0.73688,-1.248432106,0.1768496309,0.06548485557,7,1
CHEMBL31421,CC1(C)SSC(C)(C)[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H]1C(=O)O,1.6,8.8,F,CHEMBL4428100,agonist,agonist,Agonist activity at human MOR expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation by EIA method,1,Scientific Literature,J Med Chem,2016,645.8,1.11,highly_active,3,645.8,-1.0217,-4.188,12,7,250.55,-11.798,0.42427,0.85009,14,7,2,0.35417,0.68005,2.131988252,0.8683323958,-0.9989068346,3,1
CHEMBL3145240,Cc1ccc(-n2[nH]c(C)c(C=Nc3ccc(Cl)c4cccnc34)c2=O)cc1,2730,5.56,F,CHEMBL1201862,agonist,agonist,"PUBCHEM_BIOASSAY: SAR Analysis of Agonists of the MOR Receptor using an Image-Based Assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1777, AID1785, AID1786, AID1966, AID2133, AID2136, AID2284, AID2285, AID2492, AID488822]",7,PubChem BioAssays,,,376.85,4.73,inactive,0,376.846,2.5718,-4.83,5,1,57.59,4.0029,0.29457,0.8584,6,3,3,0.2732,0.70614,-0.9093980625,0.06937535388,-0.4787124317,1,1
CHEMBL316446,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1,14.4,7.84,F,CHEMBL3627650,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) transfected in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production,1,Scientific Literature,Bioorg Med Chem Lett,2015,610.72,1.67,active,2,610.713,1.3029,-4.575,11,6,183.64,4.593,0.4911,0.88374,11,12,4,0.43311,0.66757,1.50670835,0.1861571686,-0.09843794975,7,7
CHEMBL3184427,COc1ccccc1C1CCN(Cc2ccc3c(c2)CCC(C)(C)O3)CC1,7400,5.13,F,CHEMBL1201862,antagonist,antagonist,"PubChem BioAssay. Late-stage results from the probe development effort to identify antagonists of OPRK1: luminescence-based cell-based dose response OPRM1 counterscreen, Set 2.   (Class of assay: confirmatory)",7,PubChem BioAssays,,,365.52,5.18,inactive,0,365.515,5.2804,-4.461,3,0,21.7,1.5047,0.37782,0.79924,3,4,2,0.33702,0.70493,-1.716792894,-0.2011443455,0.2291710218,1,1
CHEMBL3185265,CN(C)c1cccc2c1c(NC(=O)Nc1ccc(OCc3ccccc3)cc1)nn2C,42900,4.37,F,CHEMBL1201862,antagonist,antagonist,"PubChem BioAssay. Late-stage results from the probe development effort to identify antagonists of OPRK1: luminescence-based cell-based dose response OPRM1 counterscreen, Set 2.   (Class of assay: confirmatory)",7,PubChem BioAssays,,,415.5,4.86,inactive,0,415.496,3.7761,-5.814,7,2,71.42,3.315,0.44717,0.8267,7,6,4,0.34659,0.67358,-0.4960396037,-0.7779064204,-0.314997869,1,1
CHEMBL319536,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(O)c1,1.1,8.96,F,CHEMBL1137299,antagonist,antagonist,Antagonist activity against human cloned mu opioid receptor expressed in CHO cells assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,309.45,4.23,highly_active,3,309.451,4.2856,-3.584,2,1,23.47,3.3964,0.45535,0.75255,2,4,2,0.36363,0.74119,-1.752176899,0.5532933688,0.2713734741,8,8
CHEMBL320874,O=C1Cc2ccccc2N1C1CCN(Cc2ccccc2)CC1,1981,5.7,F,CHEMBL2385080,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem Lett,2013,306.41,3.24,inactive,0,306.408,3.0464,-3.493,3,0,23.55,7.4761,0.39368,0.77117,3,3,2,0.31787,0.74275,-1.631700848,0.8254311079,0.03174018542,45,2
CHEMBL3213958,Cc1ccc(CSCC(=O)N/N=C/c2sccc2C)cc1,42819,4.37,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,318.47,3.75,inactive,0,318.464,3.9456,-5.205,3,1,95,5.5219,0.56463,0.58491,5,6,2,0.27245,0.6943,-1.061981596,-0.3667001531,-0.1126428581,1,1
CHEMBL3215667,CCOc1ccc(Cc2nc3cc(NC(=N)c4ccco4)ccc3n2CCN(CC)CC)cc1.Cl.Cl,400,6.4,F,CHEMBL2046316,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 1 hr by HTRF assay,1,Scientific Literature,ACS Med Chem Lett,2012,532.52,5.4,intermediate,1,532.514,3.733,-2.905,7,2,79.31,5.1011,0.48838,0.85083,7,11,4,0.34619,0.64349,-0.1913934558,0.7689741967,0.895942467,5,1
CHEMBL3215668,CCOc1ccc(Cc2nc3cc(NC(=N)N[N+](=O)[O-])ccc3n2CCN(CC)CC)cc1.Cl.Cl,52,7.28,F,CHEMBL2046316,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 1 hr by HTRF assay,1,Scientific Literature,ACS Med Chem Lett,2012,526.47,3.5,active,2,526.467,1.8599,-3.125,10,3,124.02,2.9578,0.55314,0.84087,10,10,3,0.40856,0.65913,0.5738304656,1.002557257,0.3253609386,2,2
CHEMBL3215960,CCCN[C@H]1C[C@H]2C[C@@](c3cccc(O)c3)(C1)[C@H](C)CN2CCCc1ccccc1.Cl.Cl,18,7.75,F,CHEMBL3085655,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2013,479.54,5.14,active,2,479.534,5.0758,-4.751,3,2,35.5,3.5571,0.43108,0.87115,3,8,2,0.39724,0.7065,-1.099509943,-0.469981198,0.4580457643,7,6
CHEMBL3216476,Cl.Cl.O=C(O)CN[C@H]1CC[C@@]2(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,0.69,9.16,F,CHEMBL1671784,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins,1,Scientific Literature,J Med Chem,2011,591.58,3.66,highly_active,3,591.574,0.9297,-4.741,7,3,91.26,-2.0071,0.31767,1.1008,7,10,2,0.38784,0.69857,0.3934189124,0.1441902056,-0.09921971272,2,2
CHEMBL3216560,CCOc1ccc(Cc2nc3cc(NC(=N)c4ccoc4)ccc3n2CCN(CC)CC)cc1.Cl.Cl,590,6.23,F,CHEMBL2046316,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 1 hr by HTRF assay,1,Scientific Literature,ACS Med Chem Lett,2012,532.52,5.4,intermediate,1,532.514,3.679,-2.881,7,2,79.31,5.101,0.48838,0.85083,7,11,4,0.36955,0.6578,-0.1862074173,0.792465583,0.8940108443,5,1
CHEMBL3216611,C[C@@H]1CN(CCCc2ccccc2)[C@H]2C[C@H](N)C[C@]1(c1cccc(O)c1)C2.Cl.Cl,19.5,7.71,F,CHEMBL3085655,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2013,437.46,4.09,active,2,437.453,3.8636,-4.265,3,2,49.49,2.892,0.42645,0.8591,3,5,2,0.3494,0.73217,-1.135747483,0.1075052791,0.07686003059,7,6
CHEMBL3216613,C[C@@H]1CN(CCCc2ccccc2)[C@H]2C[C@H](N(C)C)C[C@]1(c1cccc(O)c1)C2.Cl.Cl,6.5,8.19,F,CHEMBL3085655,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2013,465.51,4.7,highly_active,3,465.507,4.4816,-3.819,3,1,26.71,4.6017,0.42925,0.86954,3,6,2,0.38484,0.72731,-1.303020891,0.2073669398,0.4448261958,7,6
CHEMBL3216780,CCOc1ccc(Cc2nc3cc(NC(=N)c4cccs4)ccc3n2CCC2CCCN2C)cc1.Cl.Cl,2200,5.66,F,CHEMBL2046316,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 1 hr by HTRF assay,1,Scientific Literature,ACS Med Chem Lett,2012,560.6,6.01,inactive,0,560.592,4.7621,-3.667,6,2,94.41,5.4842,0.42343,0.86015,7,9,4,0.34238,0.6416,-0.3337615774,0.1419734765,0.6472761828,1,1
CHEMBL3216936,Cl.Cl.O=C(O)CN[C@@H]1CC[C@@]2(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,4.24,8.37,F,CHEMBL1671784,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins,1,Scientific Literature,J Med Chem,2011,591.58,3.66,highly_active,3,591.574,0.9297,-4.741,7,3,91.26,-2.0071,0.31814,1.1008,7,10,2,0.43353,0.7112,0.3934189124,0.1441902056,-0.09921971272,2,2
CHEMBL3216999,CCOc1ccc(Cc2nc3cc(NC(=N)c4cccs4)ccc3n2CCN(CC)CC)cc1.Cl.Cl,340,6.47,F,CHEMBL2046316,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 1 hr by HTRF assay,1,Scientific Literature,ACS Med Chem Lett,2012,548.58,5.87,intermediate,1,548.581,4.4109,-3.233,6,2,94.41,6.6388,0.48838,0.85083,7,11,4,0.37412,0.64816,-0.2406931274,0.4442207054,0.9001132341,5,2
CHEMBL3217000,CCOc1ccc(Cc2nc3cc(NC(=N)c4cccs4)ccc3n2CCN(C)C)cc1.Cl.Cl,1500,5.82,F,CHEMBL2046316,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 1 hr by HTRF assay,1,Scientific Literature,ACS Med Chem Lett,2012,520.53,5.09,inactive,0,520.527,3.5983,-2.633,6,2,94.41,5.6109,0.46793,0.84784,7,9,4,0.34427,0.65549,-0.3076815459,0.9906887122,0.7258164713,5,2
CHEMBL3217001,CCOc1ccc(Cc2nc3ccc(NC(=N)c4cccs4)cc3n2CCN(CC)CC)cc1.Cl.Cl,170,6.77,F,CHEMBL2046316,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 1 hr by HTRF assay,1,Scientific Literature,ACS Med Chem Lett,2012,548.58,5.87,intermediate,1,548.581,4.4109,-3.233,6,2,94.41,6.6388,0.48838,0.85413,7,11,4,0.39174,0.64552,-0.2406931274,0.4442207054,0.9001132341,5,1
CHEMBL3217050,CCN(C)[C@H]1C[C@H]2C[C@@](c3cccc(O)c3)(C1)[C@H](C)CN2CCCc1ccccc1.Cl.Cl,60,7.22,F,CHEMBL3085655,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2013,479.54,5.09,active,2,479.534,4.8879,-4.119,3,1,26.71,4.5896,0.4358,0.87433,3,7,2,0.38139,0.71406,-1.269526687,-0.06586699339,0.5319746064,7,6
CHEMBL3217051,CCN[C@H]1C[C@H]2C[C@@](c3cccc(O)c3)(C1)[C@H](C)CN2CCCc1ccccc1.Cl.Cl,33,7.48,F,CHEMBL3085655,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2013,465.51,4.75,active,2,465.507,4.6214,-4.481,3,2,35.5,3.5539,0.42663,0.86954,3,7,2,0.38746,0.72529,-1.126020771,-0.2060803769,0.3566077378,7,6
CHEMBL3217211,CCOc1ccc(Cc2nc3cc(NC(C)=N)ccc3n2CCN(CC)CC)cc1.Cl.Cl,940,6.03,F,CHEMBL2046316,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 1 hr by HTRF assay,1,Scientific Literature,ACS Med Chem Lett,2012,480.48,4.78,intermediate,1,480.482,3.1005,-2.053,6,2,66.17,5.655,0.5359,0.84284,6,10,3,0.40686,0.66984,-0.4445377659,1.440218632,0.9399761148,2,2
CHEMBL3217271,C[C@@H]1CN(CCCc2ccccc2)[C@H]2C[C@H](N(C)CC3CC3)C[C@]1(c1cccc(O)c1)C2.Cl.Cl,2.7,8.57,F,CHEMBL3085655,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2013,505.57,5.48,highly_active,3,505.571,5.206,-4.635,3,1,26.71,5.7117,0.41997,0.88077,3,8,2,0.37027,0.69939,-1.197260989,-0.4624473448,0.5554092169,2,2
CHEMBL3217272,CN[C@H]1C[C@H]2C[C@@](c3cccc(O)c3)(C1)[C@H](C)CN2CCCc1ccccc1.Cl.Cl,15,7.82,F,CHEMBL3085655,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2013,451.48,4.36,active,2,451.48,4.2151,-4.181,3,2,35.5,3.7876,0.42737,0.86625,3,6,2,0.34274,0.7238,-1.159514916,0.06715338686,0.2694592737,7,6
CHEMBL3217273,C[C@@H]1CN(CCCc2ccccc2)[C@H]2C[C@H](NCC3CC3)C[C@]1(c1cccc(O)c1)C2.Cl.Cl,130,6.89,F,CHEMBL3085655,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2013,491.55,5.14,intermediate,1,491.545,4.9395,-4.997,3,2,35.5,4.2218,0.40423,0.8737,3,8,2,0.37054,0.70004,-1.053753516,-0.6026616859,0.3800425054,2,2
CHEMBL3219777,Cc1nnc(C(C)C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccc(NC(=O)COCC(=O)NCCCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1,40,7.4,F,CHEMBL3638635,antagonist,antagonist,"Flux Assay: As Ca2+ flux is associated with the activation of the MOR, the functional activity of bivalent ligand 1, monovalent ligand 2, and naltrexone was then evaluated in a Ca2+ mobilization assay in hMORCHO cells transfected with chimeric Ca2+ following a published protocol.23 No agonism was observed for any of the tested compounds (data not shown). Thus, they were further assessed for their antagonist properties as the ability to inhibit DAMGO (a MOR agonist) induced Ca2+ flux.",37,BindingDB Database,,2015,1197.48,None,active,2,1197.47,5.1682,-6.987,20,7,250.84,-6.9442,0.48863,1.1124,22,28,3,0.3862,0.51532,4.294903432,-2.64771868,1.256864227,2,1
CHEMBL3219778,CNC(=O)COCC(=O)NCCCCCCCNC(=O)COCC(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,37.8,7.42,F,CHEMBL3217593,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in Gqi5 transfected CHO cells assessed as inhibition of DAMGO-stimulated Ca2+ influx preincubated for 15 mins followed by DAMGO challenge,1,Scientific Literature,Medchemcomm,2013,699.85,0.4,active,2,699.843,0.3753,-3.608,14,6,187.79,-0.74478,0.4775,1.0843,14,19,1,0.29368,0.5906,2.395112601,0.7422190567,0.6602069435,6,6
CHEMBL322875,CC(C)=CC[C@@]12Cc3c([nH]c4ccccc34)[C@]3(C)Oc4c(O)ccc5c4[C@]13CCN(C)C2C5,1201,5.92,F,CHEMBL1145844,agonist,agonist,Effective concentration agonistic activity towards Opioid receptor mu 1,1,Scientific Literature,J Med Chem,2003,440.59,5.58,inactive,0,440.585,5.8096,-5.429,4,2,48.49,5.2112,0.22616,1.1277,4,2,3,0.58203,0.75188,-1.324661991,-0.880127701,-0.2402635001,1,1
CHEMBL3262088,CC[C@](O)([C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5)C(C)(C)C,50.2,7.3,F,CHEMBL3259633,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by beta-plate liquid scintillation counting analysis,1,Scientific Literature,J Med Chem,2014,481.68,4.8,active,2,481.674,4.7961,-5.108,5,2,62.16,1.604,0.31312,1.1162,5,6,1,0.51488,0.77856,-0.8128885632,-0.6032674984,0.06130474897,4,2
CHEMBL3262090,CO[C@]12CC[C@@]3(C[C@@H]1[C@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,10.4,7.98,F,CHEMBL3259633,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by beta-plate liquid scintillation counting analysis,1,Scientific Literature,J Med Chem,2014,473.61,4.35,active,2,473.611,3.6618,-4.838,5,2,62.16,3.6333,0.277,1.1106,5,5,2,0.44,0.75357,-0.750983822,-0.2272252075,-0.137447967,5,3
CHEMBL3262091,CC[C@@](O)(c1ccccc1)[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5,18.4,7.74,F,CHEMBL3259633,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by beta-plate liquid scintillation counting analysis,1,Scientific Literature,J Med Chem,2014,501.67,4.91,active,2,501.665,4.7027,-5.522,5,2,62.16,3.9075,0.30541,1.1224,5,6,2,0.45168,0.75113,-0.7520682102,-0.8499101413,-0.05035420845,5,3
CHEMBL3262092,CO[C@]12CC[C@@]3(C[C@@H]1[C@@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1.55,8.81,F,CHEMBL3259633,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by beta-plate liquid scintillation counting analysis,1,Scientific Literature,J Med Chem,2014,473.61,4.35,highly_active,3,473.611,3.6618,-4.838,5,2,62.16,3.6333,0.22882,1.1106,5,5,2,0.40658,0.74653,-0.750983822,-0.2272252075,-0.137447967,5,3
CHEMBL3262093,CO[C@]12C=C[C@@]3(C[C@@H]1[C@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,2.75,8.56,F,CHEMBL3259633,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by beta-plate liquid scintillation counting analysis,1,Scientific Literature,J Med Chem,2014,471.6,4.13,highly_active,3,471.595,3.3864,-4.61,5,2,62.16,4.8595,0.29556,1.1268,5,5,2,0.49102,0.75631,-0.7325092199,-0.04331122824,-0.1217795639,5,2
CHEMBL3262361,CC[C@@](O)(c1ccccc1)[C@H]1C[C@@]23C=C[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5,31.8,7.5,F,CHEMBL3259633,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by beta-plate liquid scintillation counting analysis,1,Scientific Literature,J Med Chem,2014,499.65,4.69,active,2,499.649,4.4273,-5.294,5,2,62.16,5.1308,0.32276,1.1374,5,6,2,0.42085,0.74934,-0.7335936275,-0.6659960917,-0.03468584462,5,2
CHEMBL3262362,CC[C@](O)([C@H]1C[C@@]23C=C[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5)C(C)(C)C,238,6.62,F,CHEMBL3259633,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by beta-plate liquid scintillation counting analysis,1,Scientific Literature,J Med Chem,2014,479.66,4.58,intermediate,1,479.659,4.5207,-4.88,5,2,62.16,2.8219,0.33341,1.1318,5,6,1,0.56462,0.77148,-0.7944124243,-0.4193544065,0.0769732699,4,1
CHEMBL3262542,O=C1Cc2ccccc2N1C1CCN([C@H]2CC[C@@H]3CCCc4cccc2c43)CC1,409,6.39,F,CHEMBL3259735,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem,2014,386.54,5,intermediate,1,386.537,5.1853,-5.11,3,0,23.55,3.557,0.32476,0.91876,3,2,2,0.38485,0.72777,-1.72797636,-0.5608803654,-0.1419171683,5,2
CHEMBL3262543,O=C1Cc2ccccc2N1C1CCN([C@@H]2CC[C@@H]3CCCc4cccc2c43)CC1,745,6.13,F,CHEMBL3259735,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem,2014,386.54,5,intermediate,1,386.537,5.1853,-5.11,3,0,23.55,3.557,0.32259,0.91876,3,2,2,0.39108,0.73299,-1.72797636,-0.5608803654,-0.1419171683,5,2
CHEMBL3262544,CCC1C(=O)N(C2CCN([C@H]3CC[C@@H]4CCCc5cccc3c54)CC2)c2ccccc21,56.9,7.25,F,CHEMBL3259735,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem,2014,414.59,5.95,active,2,414.591,6.3187,-5.748,3,0,23.55,4.892,0.33665,0.94128,3,3,2,0.41118,0.71607,-1.741952307,-1.17250287,-0.03020381304,5,2
CHEMBL3262545,CCC1C(=O)N(C2CCN([C@@H]3CC[C@@H]4CCCc5cccc3c54)CC2)c2ccccc21,81.4,7.09,F,CHEMBL3259735,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem,2014,414.59,5.95,active,2,414.591,6.3187,-5.748,3,0,23.55,4.892,0.33469,0.94128,3,3,2,0.43892,0.71364,-1.741952307,-1.17250287,-0.03020381304,5,2
CHEMBL3262546,CCC1C(=O)N(C2CCN(C3CCCc4ccccc43)CC2)c2ccccc21,28.7,7.54,F,CHEMBL3259735,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem,2014,374.53,5.07,active,2,374.526,5.2079,-4.791,3,0,23.55,4.892,0.36217,0.88608,3,3,2,0.41488,0.72641,-1.718503244,-0.3783190318,0.0371577073,1,1
CHEMBL3262547,CCC1C(=O)N(C2CCN(C3CCc4ccccc4C3)CC2)c2ccccc21,22.3,7.65,F,CHEMBL3259735,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem,2014,374.53,4.55,active,2,374.526,5.0818,-4.94,3,0,23.55,6.772,0.35528,0.86986,3,3,2,0.28051,0.71356,-1.696958467,-0.4442190217,-0.0175151148,1,1
CHEMBL3262548,CCC1C(=O)N(C2CCN(Cc3cccc4[nH]ccc34)CC2)c2ccccc21,23.4,7.63,F,CHEMBL3259735,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem,2014,373.5,4.67,active,2,373.498,4.2192,-4.656,4,1,39.34,8.8323,0.37664,0.87713,4,4,3,0.3159,0.71878,-1.306613048,-0.1246638465,-0.04553825938,1,1
CHEMBL3262549,CCC1C(=O)N(C2CCN(CCC(c3ccccc3)c3ccccc3)CC2)c2ccccc21,39.5,7.4,F,CHEMBL3259735,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem,2014,438.62,6.21,active,2,438.613,6.5919,-5.662,3,0,23.55,9.4046,0.42569,0.83847,3,7,3,0.37445,0.69795,-1.559237817,-1.243289697,0.4326293164,1,1
CHEMBL3262551,CCC1C(=O)N(C2CCN(CCCc3ccccc3)CC2)c2ccccc21,673,6.17,F,CHEMBL3259735,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem,2014,362.52,4.62,intermediate,1,362.515,5.0643,-4.513,3,0,23.55,8.9365,0.44375,0.82538,3,6,2,0.32038,0.70577,-1.5970959,-0.2167305449,0.3814712794,2,1
CHEMBL3262552,CCC1C(=O)N(C2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21,2110,5.68,F,CHEMBL3259735,agonist,agonist,Agonist activity at human mu opioid receptor transfected in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,1,Scientific Literature,Bioorg Med Chem,2014,360.5,4.7,inactive,0,360.499,4.941,-4.648,3,0,23.55,8.7197,0.4187,0.82538,3,5,2,0.31944,0.69769,-1.624980562,-0.2601405303,0.2306712242,2,1
CHEMBL326684,CO[C@@]12CCC(=O)[C@]3(C)Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5,3.28,8.48,F,CHEMBL4028881,agonist,agonist,Agonist activity at recombinant human MOR expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2017,329.4,1.79,highly_active,3,329.395,1.5783,-2.613,5,1,59,4.4831,0.17656,1.108,5,1,1,0.57843,0.84471,-1.113866899,1.620212871,-0.2769614517,7,1
CHEMBL3287467,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)C[C@@]1(C2)Cc1cc2ccccc2nc1C3,197,6.71,F,CHEMBL3286318,agonist,agonist,Agonist activity at mu-opioid receptor (unknown origin) by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2014,396.53,4.64,intermediate,1,396.532,4.7663,-5.105,3,1,36.36,4.3749,0.1536,1.0165,3,2,3,0.34989,0.73517,-1.533260524,-0.4805812783,-0.251372313,1,1
CHEMBL3309506,CN1C(=O)CCC2=C1[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(C)[C@H](C4)[C@]3(O)C2,80,7.1,F,CHEMBL3352469,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2014,368.43,1.29,active,2,368.432,1.1726,-2.549,6,2,73.24,5.3296,0.12965,1.102,6,0,1,0.54399,0.79827,-0.8004917641,1.71825233,-0.4836664329,3,3
CHEMBL3309507,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C2=C(CCC(=O)N2Cc2ccccc2)C[C@@]3(O)[C@H]1C5,4.97,8.3,F,CHEMBL3352469,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2014,444.53,2.86,highly_active,3,444.529,2.5907,-3.872,6,2,73.24,5.9712,0.24641,1.109,6,2,2,0.58528,0.7713,-0.6965301032,0.5953818551,-0.3912561716,2,2
CHEMBL3309508,CN1C(=O)[C@H](CCO)CC2=C1[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(C)[C@H](C4)[C@]3(O)C2,163,6.79,F,CHEMBL3352469,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2014,412.49,0.9,intermediate,1,412.484,0.9696,-2.472,7,3,93.47,5.1097,0.17851,1.1085,7,2,1,0.49054,0.79543,-0.3478603006,1.746799577,-0.3665096956,3,3
CHEMBL3309509,CN1C(=O)[C@@H](CCO)CC2=C1[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(C)[C@H](C4)[C@]3(O)C2,709,6.15,F,CHEMBL3352469,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2014,412.49,0.9,intermediate,1,412.484,0.9696,-2.472,7,3,93.47,5.1097,0.17688,1.1085,7,2,1,0.4936,0.77992,-0.3478603006,1.746799577,-0.3665096956,3,3
CHEMBL3309510,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C2=C(C[C@H](CCO)C(=O)N2Cc2ccccc2)C[C@@]3(O)[C@H]1C5,94.9,7.02,F,CHEMBL3352469,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2014,488.58,2.47,active,2,488.582,2.3877,-3.795,7,3,93.47,5.8097,0.25878,1.1152,7,4,2,0.58014,0.7599,-0.2438970933,0.623927973,-0.2740993097,2,2
CHEMBL331325,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,1.66,8.78,F,CHEMBL4396910,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells co-expressing C-terminally modified Galphaqi5 assessed as induction of calcium mobilization by Fluo-4AM dye-based fluorescence assay,1,Scientific Literature,Eur J Med Chem,2019,599.73,1.81,highly_active,3,599.73,1.9513,-4.738,10,5,167.85,4.4461,0.52118,0.85805,10,12,3,0.38907,0.6691,1.162530443,-0.02641225593,0.02600373863,6,6
CHEMBL3325696,Cc1nn(-c2ccccc2Cl)c2c1C(=O)CC(C)(C)C2,2280,5.64,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,288.78,3.99,inactive,0,288.777,3.0931,-4.089,3,0,34.89,2.6031,0.27914,0.89313,4,1,2,0.45548,0.77547,-1.631570316,0.5089667921,-0.3366880234,21,21
CHEMBL3325699,Cc1nn(-c2ccc(Cl)cc2)c2c1C(=O)CC(C)(C)C2,13600,4.87,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,288.78,3.99,inactive,0,288.777,3.0931,-4.089,3,0,34.89,2.6031,0.31172,0.87527,4,1,2,0.36951,0.75944,-1.631570316,0.5089667921,-0.3366880234,21,21
CHEMBL3325700,Cc1nn(-c2ccccc2Br)c2c1C(=O)CC(C)(C)C2,1120,5.95,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,333.23,4.1,inactive,0,333.228,3.2123,-4.187,3,0,34.89,0.7486,0.27914,0.89313,4,1,2,0.47032,0.77489,-1.572257388,0.388326874,-0.3365044264,21,21
CHEMBL3325701,Cc1nn(-c2ccc(Br)cc2)c2c1C(=O)CC(C)(C)C2,9910,5,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,333.23,4.1,inactive,0,333.228,3.2123,-4.187,3,0,34.89,0.7486,0.31172,0.87527,4,1,2,0.36462,0.75643,-1.572257388,0.388326874,-0.3365044264,21,21
CHEMBL3325702,Cc1ccccc1-n1nc(C)c2c1CC(C)(C)CC2=O,4720,5.33,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,268.36,3.64,inactive,0,268.359,2.831,-3.697,3,0,34.89,2.5386,0.27914,0.87083,3,1,2,0.51258,0.7755,-1.709439174,0.8066609409,-0.2702593164,21,21
CHEMBL3325703,CCc1ccccc1-n1nc(C)c2c1CC(C)(C)CC2=O,19000,4.72,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,282.39,3.9,inactive,0,282.386,3.2466,-3.856,3,0,34.89,2.4013,0.32377,0.88107,3,2,2,0.58078,0.76868,-1.683515972,0.6148546281,-0.1472727941,21,21
CHEMBL3325704,COc1ccc(-n2nc(C)c3c2CC(C)(C)CC3=O)cc1,18400,4.74,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,284.36,3.34,inactive,0,284.358,2.4171,-3.371,4,0,44.12,2.6181,0.35007,0.85521,4,2,2,0.32528,0.74895,-1.457135342,1.043988162,-0.1775015831,21,21
CHEMBL3325705,CCOC(=O)c1ccccc1-n1nc(C)c2c1CC(C)(C)CC2=O,30200,4.52,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,326.4,3.51,inactive,0,326.395,2.8064,-3.794,5,0,61.19,-1.0977,0.36089,0.9045,5,4,2,0.63635,0.73848,-1.152586146,0.6650038467,-0.05910084168,21,21
CHEMBL3325706,COC(=O)c1ccc(-n2nc(C)c3c2CC(C)(C)CC3=O)cc1,10000,5,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,312.37,3.12,inactive,0,312.368,2.4001,-3.494,5,0,61.19,0.33934,0.38293,0.86289,5,3,2,0.29516,0.72814,-1.186080302,0.9382377508,-0.1462492475,21,21
CHEMBL3325707,Cc1ccc(-n2nc(C)c3c2CC(C)(C)CC3=O)c(C)c1,370,6.43,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,282.39,3.95,intermediate,1,282.386,3.1749,-4.041,3,0,34.89,2.5386,0.29052,0.87805,3,1,2,0.45644,0.75803,-1.711995485,0.5311396852,-0.3025342473,21,21
CHEMBL3325708,Cc1cccc(-n2nc(C)c3c2CC(C)(C)CC3=O)c1C,8900,5.05,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,282.39,3.95,inactive,0,282.386,3.1749,-4.041,3,0,34.89,2.5386,0.29052,0.88579,3,1,2,0.48835,0.77214,-1.711995485,0.5311396852,-0.3025342473,21,21
CHEMBL3325709,Cc1ccc(C)c(-n2nc(C)c3c2CC(C)(C)CC3=O)c1,10000,5,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,282.39,3.95,inactive,0,282.386,3.1749,-4.041,3,0,34.89,2.5386,0.29052,0.88404,3,1,2,0.55284,0.75891,-1.711995485,0.5311396852,-0.3025342473,21,21
CHEMBL3325710,Cc1cc(Cl)ccc1-n1nc(C)c2c1CC(C)(C)CC2=O,370,6.43,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,302.8,4.3,intermediate,1,302.804,3.437,-4.433,3,0,34.89,2.6031,0.29052,0.8972,4,1,2,0.47504,0.76304,-1.634126627,0.2334455365,-0.3689629543,21,21
CHEMBL3325711,Cc1nn(-c2ccc(F)cc2F)c2c1C(=O)CC(C)(C)C2,10300,4.99,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,290.31,3.61,inactive,0,290.312,2.6887,-3.981,3,0,34.89,1.1986,0.29052,0.90142,5,1,2,0.41768,0.76981,-1.528248157,0.6391850408,-0.3800506904,21,21
CHEMBL3325712,Cc1nn(-c2cc(Cl)ccc2Cl)c2c1C(=O)CC(C)(C)C2,2890,5.54,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,323.22,4.64,inactive,0,323.222,3.6991,-4.825,3,0,34.89,2.6031,0.29052,0.90348,5,1,2,0.49308,0.76104,-1.556257791,-0.06424833149,-0.4353915446,21,21
CHEMBL3325713,Cc1nn(-c2ccc(Cl)cc2Cl)c2c1C(=O)CC(C)(C)C2,150,6.82,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,323.22,4.64,intermediate,1,323.222,3.6991,-4.825,3,0,34.89,2.6031,0.29052,0.90142,5,1,2,0.42353,0.76015,-1.556257791,-0.06424833149,-0.4353915446,21,21
CHEMBL3325714,Cc1nn(-c2ccc(Br)cc2Br)c2c1C(=O)CC(C)(C)C2,730,6.14,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP production after 30 mins by HTRF assay,1,Scientific Literature,Bioorg Med Chem,2014,412.12,4.86,intermediate,1,412.124,3.9375,-5.021,3,0,34.89,0.7486,0.29052,0.90142,5,1,2,0.42289,0.75805,-1.437631845,-0.3055287585,-0.4350245793,21,21
CHEMBL3325715,Cc1nn(-c2ccc(Cl)cc2Br)c2c1C(=O)CC(C)(C)C2,41,7.39,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,367.67,4.75,active,2,367.673,3.8183,-4.923,3,0,34.89,0.81306,0.29052,0.90219,5,1,2,0.4285,0.76472,-1.496944794,-0.1848885595,-0.4352080596,21,21
CHEMBL3325716,Cc1ccc(-n2nc(C)c3c2CC(C)(C)CC3=O)c(Br)c1,6000,5.22,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP production after 30 mins by HTRF assay,1,Scientific Literature,Bioorg Med Chem,2014,347.26,4.41,inactive,0,347.255,3.5562,-4.531,3,0,34.89,0.7486,0.29052,0.90219,4,1,2,0.40796,0.76482,-1.574813631,0.1128053085,-0.3687794692,21,21
CHEMBL3325717,Cc1nn(-c2ccc(Cl)cc2Cl)c2c1C(=O)CCC2,13600,4.87,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,295.17,4.01,inactive,0,295.168,3.0983,-4.488,3,0,34.89,-0.16107,0.31058,0.88752,5,1,2,0.4003,0.7604,-1.545129471,0.265004815,-0.4441390264,21,21
CHEMBL3325718,CC1(C)CC(=O)c2c(C(F)(F)F)nn(-c3ccc(Cl)cc3Cl)c2C1,1540,5.81,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,377.19,5.35,inactive,0,377.192,4.2035,-5.259,3,0,34.89,-9.5217,0.33995,0.92217,8,2,2,0.4188,0.74489,-1.289866222,-0.4773835224,-0.3953824853,21,21
CHEMBL3325719,CC1(C)CC(=O)c2c(C3CC3)nn(-c3ccc(Cl)cc3Cl)c2C1,370,6.43,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,349.26,5.21,intermediate,1,349.26,4.466,-5.438,3,0,34.89,2.6359,0.2874,0.92746,5,2,2,0.42064,0.74173,-1.531806788,-0.5957237726,-0.370835684,1,1
CHEMBL3325841,Cc1nn(-c2ccc(Br)cc2Br)c2c1C(O)CC(C)(C)C2,100,7,F,CHEMBL3351626,agonist,agonist,Agonist activity at human mu opioid receptor expressed CHO-K1 cells coexpressing Galpha15 assessed as induction of intracellular calcium release by FLIPR calcium assay,1,Scientific Literature,Bioorg Med Chem,2014,414.14,4.71,active,2,414.14,3.7623,-4.292,3,1,38.05,0.62015,0.30474,0.90142,5,1,2,0.40984,0.75688,-1.348671481,0.1645917458,-0.3199751109,1,1
CHEMBL3325881,CN(C)[C@]1(c2ccccc2)CC[C@@H](NC(=O)NCCCc2ccccc2)CC1.Cl,12000,4.92,F,CHEMBL3351750,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-K1 cells assessed as stimulation of [35S]-GTPgammaS binding by scintillation proximity assay,1,Scientific Literature,ACS Med Chem Lett,2014,416.01,4.32,inactive,0,416.007,4.1941,-4.27,4,2,44.37,1.7991,0.53063,0.75547,4,7,2,0.35563,0.69062,-1.014605602,0.04086915323,0.3099358086,1,1
CHEMBL3325957,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12.O=C(O)CC(O)(CC(=O)O)C(=O)O,1.2,8.92,F,CHEMBL3352090,agonist,agonist,Agonist activity at human recombinant MOP receptor expressed in CHO-K1 cells assessed as stimulation of [35S]GTPgammaS binding by scintillation proximity assay,1,Scientific Literature,ACS Med Chem Lett,2014,570.61,5.11,highly_active,3,570.612,4.375,-4.582,3,1,28.26,0.11275,0.26471,0.95777,4,2,3,0.30859,0.74146,-1.210549353,-0.2739064014,-0.1531525298,5,4
CHEMBL3325959,CN[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12.O=C(O)CC(O)(CC(=O)O)C(=O)O,2.6,8.59,F,CHEMBL3352090,agonist,agonist,Agonist activity at human recombinant MOP receptor expressed in CHO-K1 cells assessed as stimulation of [35S]GTPgammaS binding by scintillation proximity assay,1,Scientific Literature,ACS Med Chem Lett,2014,556.59,4.76,highly_active,3,556.585,4.1085,-4.944,3,2,37.05,-0.88807,0.25839,0.95405,4,2,3,0.28262,0.73846,-1.067043395,-0.4141198143,-0.328519391,5,4
CHEMBL3325961,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(O)ccc3[nH]c12.O=C(O)CC(O)(CC(=O)O)C(=O)O,1.2,8.92,F,CHEMBL3352090,agonist,agonist,Agonist activity at human recombinant MOP receptor expressed in CHO-K1 cells assessed as stimulation of [35S]GTPgammaS binding by scintillation proximity assay,1,Scientific Literature,ACS Med Chem Lett,2014,568.62,4.67,highly_active,3,568.621,3.9285,-3.972,4,2,48.49,1.4781,0.26471,0.92329,4,2,3,0.29723,0.7386,-0.9747263494,0.1821442425,-0.1356673211,5,4
CHEMBL3326222,CN(C)[C@]1(c2ccccc2)CC[C@@H](NCCc2c[nH]c3ccccc23)CC1.Cl.Cl,51000,4.29,F,CHEMBL3351750,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-K1 cells assessed as stimulation of [35S]-GTPgammaS binding by scintillation proximity assay,1,Scientific Literature,ACS Med Chem Lett,2014,434.46,4.7,inactive,0,434.453,3.9934,-4.064,3,2,31.06,2.3756,0.44084,0.80548,3,6,3,0.39852,0.71141,-1.179976176,0.1897891825,0.2695564715,1,1
CHEMBL3326226,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3ccccc3[nH]c12.O=C(O)CC(O)(CC(=O)O)C(=O)O,1000,6,F,CHEMBL3351750,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-K1 cells assessed as stimulation of [35S]-GTPgammaS binding by scintillation proximity assay,1,Scientific Literature,ACS Med Chem Lett,2014,552.62,4.97,intermediate,1,552.622,4.2742,-4.268,3,1,28.26,1.4527,0.26918,0.91313,3,2,3,0.33034,0.75008,-1.299866681,-0.05240794326,-0.08211945289,5,4
CHEMBL3326228,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)NCCc1c3ccccc3[nH]c12.Cl,0.2,9.7,F,CHEMBL3352090,agonist,agonist,Agonist activity at human recombinant MOP receptor expressed in CHO-K1 cells assessed as stimulation of [35S]GTPgammaS binding by scintillation proximity assay,1,Scientific Literature,ACS Med Chem Lett,2014,395.98,4.54,highly_active,3,395.976,4.1307,-4.132,3,2,31.06,2.5815,0.2584,0.94186,3,2,3,0.30584,0.7483,-1.433673764,0.2137913161,-0.1318110258,5,1
CHEMBL332947,CN1CCC23c4c5ccc(O)c4OC2c2nc(N)ncc2CC3(O)C1C5,75.2,7.12,F,CHEMBL1131901,agonist,agonist,Agonistic activity against human opioid Mu receptor transfected into Chinese hamster ovary (CHO) cells using [3H]-DAMGO as radioligand,1,Scientific Literature,Bioorg Med Chem Lett,1999,352.39,0.68,active,2,352.393,0.6343,-2.5,7,3,104.73,5.4396,0.17524,1.0791,7,0,2,0.46715,0.7943,-0.4540537987,1.87340195,-0.6461052344,3,3
CHEMBL333357,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1,5.754,8.24,F,CHEMBL4396910,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells co-expressing C-terminally modified Galphaqi5 assessed as induction of calcium mobilization by Fluo-4AM dye-based fluorescence assay,1,Scientific Literature,Eur J Med Chem,2019,571.68,1.19,highly_active,3,571.676,1.2635,-4.05,10,5,167.85,4.4795,0.52212,0.83928,10,12,3,0.40209,0.67501,1.16764308,0.5246302761,0.09055358321,6,6
CHEMBL3338874,C[C@@]1(c2ccccc2O)O[C@@H]2N3[C@H](CO[C@H]31)O[C@]2(C)c1ccccc1O,57.6,7.24,F,CHEMBL3352005,agonist,agonist,Agonist activity at human MOR expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2014,355.39,2.6,active,2,355.389,2.6803,-2.495,6,2,71.39,0.91107,0.26662,0.99132,6,2,2,0.57743,0.7883,-0.9141512071,1.475213058,-0.05277511186,1,1
CHEMBL3339378,O=C(NCc1ccccc1)C1=N[C@@]23CC[C@]1(O)C1Oc4c(O)ccc5c4C12CCN(CC1CC1)C3C5,0.4,9.4,F,CHEMBL3351376,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2014,485.58,2.47,highly_active,3,485.582,1.7775,-4.371,7,3,94.39,6.4093,0.35227,1.1143,7,5,2,0.43851,0.73056,-0.1025825277,0.3806617539,-0.4052886825,1,1
CHEMBL3339379,O=C(NCCc1ccccc1)C1=N[C@@]23CC[C@]1(O)C1Oc4c(O)ccc5c4C12CCN(CC1CC1)C3C5,1.09,8.96,F,CHEMBL3351376,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2014,499.61,2.51,highly_active,3,499.609,2.2076,-4.483,7,3,94.39,6.3273,0.36495,1.1143,7,6,2,0.39891,0.71137,-0.08051091818,0.2140224486,-0.268708796,1,1
CHEMBL3357966,CCOC(=O)Cc1c2c(n(Cc3ccccc3)c1O)[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(C)[C@H](C4)[C@]3(O)C2,70.5,7.15,F,CHEMBL3352469,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2014,516.59,2.97,active,2,516.592,3.0412,-3.269,8,3,104.39,-3.8323,0.29794,1.1224,8,6,3,0.6006,0.73747,-0.05567579331,0.7701815563,0.1209941043,1,1
CHEMBL3393881,O=C(Nc1nc2ccccc2n1CCN1CCCC1)c1ccc(F)cc1,2400,5.62,F,CHEMBL3393059,agonist,agonist,Agonist activity at human mu opioid receptor expressed in COS7 cells after 60 mins IP1 assay,1,Scientific Literature,Bioorg Med Chem Lett,2015,352.41,3.52,inactive,0,352.412,3.3503,-3.401,5,1,50.16,3.1031,0.35623,0.81435,6,5,3,0.33597,0.71467,-1.037321634,0.7721996052,0.1891625709,8,6
CHEMBL3393885,N#Cc1cccc(C(=O)Nc2nc3ccccc3n2CCN2CCCC2)c1,7800,5.11,F,CHEMBL3393059,agonist,agonist,Agonist activity at human mu opioid receptor expressed in COS7 cells after 60 mins IP1 assay,1,Scientific Literature,Bioorg Med Chem Lett,2015,359.43,3.26,inactive,0,359.432,3.0851,-3.86,6,1,73.95,0.16306,0.35303,0.81625,6,5,3,0.39322,0.70292,-0.8364011607,0.5476777812,0.001690295264,8,6
CHEMBL3393991,O=C(Nc1nc2ccccc2n1CCN1CCCC1)c1ccc(Cl)c(Cl)c1,1800,5.75,F,CHEMBL3393059,agonist,agonist,Agonist activity at human mu opioid receptor expressed in COS7 cells after 60 mins IP1 assay,1,Scientific Literature,Bioorg Med Chem Lett,2015,403.31,4.69,inactive,0,403.312,4.4615,-4.559,5,1,50.16,4.4653,0.35545,0.83479,7,5,3,0.33161,0.69754,-0.9760138235,-0.1527325641,0.06278853263,8,6
CHEMBL3393993,Cc1ccc(C(=O)Nc2nc3ccccc3n2CCN2CCCC2)nc1,100000,4,F,CHEMBL3393059,agonist,agonist,Agonist activity at human mu opioid receptor expressed in COS7 cells after 60 mins IP1 assay,1,Scientific Literature,Bioorg Med Chem Lett,2015,349.44,3.09,inactive,0,349.437,2.6465,-2.66,6,1,63.05,4.3702,0.27983,0.82134,6,5,3,0.33909,0.70888,-0.8917907462,1.337745658,0.2454589093,8,1
CHEMBL3393998,O=C(Nc1nc2ccccc2n1CCN1CCCC1)c1cc2ccccc2s1,3300,5.48,F,CHEMBL3393059,agonist,agonist,Agonist activity at human mu opioid receptor expressed in COS7 cells after 60 mins IP1 assay,1,Scientific Literature,Bioorg Med Chem Lett,2015,390.51,4.6,inactive,0,390.51,4.1707,-4.436,5,1,78.4,5.7077,0.29061,0.85521,6,5,4,0.29685,0.70137,-0.9335857028,-0.01015361978,0.02123357832,3,1
CHEMBL3393999,O=C(Nc1nc2ccccc2n1CCN1CCCC1)c1nc2ccccc2s1,100000,4,F,CHEMBL3393059,agonist,agonist,Agonist activity at human mu opioid receptor expressed in COS7 cells after 60 mins IP1 assay,1,Scientific Literature,Bioorg Med Chem Lett,2015,391.5,3.99,inactive,0,391.498,3.2567,-3.351,6,1,91.29,5.9315,0.32019,0.85231,7,5,4,0.29238,0.69748,-0.7144613395,0.7886380076,0.1203427758,3,1
CHEMBL3394000,O=C(Nc1nc2ccccc2n1CCN1CCCC1)c1ccc[nH]1,6800,5.17,F,CHEMBL3393059,agonist,agonist,Agonist activity at human mu opioid receptor expressed in COS7 cells after 60 mins IP1 assay,1,Scientific Literature,Bioorg Med Chem Lett,2015,323.4,2.71,inactive,0,323.399,2.026,-2.135,6,2,65.95,5.4784,0.3449,0.807,6,5,3,0.372,0.73504,-0.7857780203,1.791512374,0.2422411095,4,3
CHEMBL3394003,CSc1c[nH]c(C(=O)Nc2nc3ccccc3n2CCN2CCCC2)c1,255,6.59,F,CHEMBL3393059,agonist,agonist,Agonist activity at human mu opioid receptor expressed in COS7 cells after 60 mins IP1 assay,1,Scientific Literature,Bioorg Med Chem Lett,2015,369.49,3.43,intermediate,1,369.492,2.5032,-2.983,6,2,91.25,5.798,0.35016,0.82315,7,6,3,0.33891,0.70351,-0.5438196019,1.155761412,0.1638521234,4,3
CHEMBL3394004,CS(=O)(=O)c1c[nH]c(C(=O)Nc2nc3ccccc3n2CCN2CCCC2)c1,3800,5.42,F,CHEMBL3393059,agonist,agonist,Agonist activity at human mu opioid receptor expressed in COS7 cells after 60 mins IP1 assay,1,Scientific Literature,Bioorg Med Chem Lett,2015,401.49,2.12,inactive,0,401.49,1.028,-2.552,8,2,108.47,6.2642,0.36816,0.84897,9,6,3,0.33493,0.70515,-0.04839235428,1.637824504,0.004190451251,4,3
CHEMBL3394005,O=C(Nc1nc2ccccc2n1CCN1CCCC1)c1cc2ccccc2[nH]1,150,6.82,F,CHEMBL3393059,agonist,agonist,Agonist activity at human mu opioid receptor expressed in COS7 cells after 60 mins IP1 assay,1,Scientific Literature,Bioorg Med Chem Lett,2015,373.46,3.87,intermediate,1,373.459,3.3429,-3.636,6,2,65.95,5.4355,0.30326,0.84708,6,5,4,0.32478,0.70523,-0.7927596562,0.631733562,0.07313571976,3,1
CHEMBL3394006,O=C(Nc1nc2ccccc2n1CCN1CC[C@H](O)C1)c1ccc(Cl)cc1,1750,5.76,F,CHEMBL3393059,agonist,agonist,Agonist activity at human mu opioid receptor expressed in COS7 cells after 60 mins IP1 assay,1,Scientific Literature,Bioorg Med Chem Lett,2015,384.87,3.01,inactive,0,384.866,3.0034,-3.424,6,2,70.39,6.0005,0.3687,0.81951,7,5,3,0.33812,0.70381,-0.671936188,0.8034433886,0.05996779222,8,6
CHEMBL3394007,O=C(Nc1nc2cccnc2n1CCN1CCCC1)c1ccc(Cl)cc1,52500,4.28,F,CHEMBL3393059,agonist,agonist,Agonist activity at human mu opioid receptor expressed in COS7 cells after 60 mins IP1 assay,1,Scientific Literature,Bioorg Med Chem Lett,2015,369.86,3.43,inactive,0,369.855,3.1375,-3.873,6,1,63.05,4.4653,0.35623,0.83968,7,5,3,0.34144,0.70926,-0.8028101652,0.516877079,0.01125635237,8,1
CHEMBL3394008,CS(=O)(=O)c1c[nH]c(C(=O)Nc2nc3cccnc3n2CCN2CCCC2)c1,34500,4.46,F,CHEMBL3393059,agonist,agonist,Agonist activity at human mu opioid receptor expressed in COS7 cells after 60 mins IP1 assay,1,Scientific Literature,Bioorg Med Chem Lett,2015,402.48,1.51,inactive,0,402.478,0.31,-2.602,9,2,121.36,6.3717,0.36816,0.86921,10,6,3,0.32892,0.70127,0.2001238773,1.734218683,-0.1460453363,4,1
CHEMBL3401554,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cc2cc([N+](=O)[O-])ccc2cn1,2728,5.56,F,CHEMBL3400112,antagonist,antagonist,Antagonist activity at human MOR expressed in CHO cells assessed as inhibition of DAMGO-induced increase in intracellular Ca2+ level incubated for 15 mins prior to DAMGO addition by microplate reader analysis,1,Scientific Literature,Bioorg Med Chem,2015,542.59,3.21,inactive,0,542.59,2.2132,-5.88,10,3,140.74,0.47345,0.21532,1.0956,10,5,3,0.40645,0.73718,0.5125820734,-0.6291292962,-0.8164876463,3,2
CHEMBL3408737,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(N)=O)C1=O,0.1,10,F,CHEMBL4699489,agonist,agonist,Agonist activity at human MOR stably expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,594.72,-0.43,highly_active,3,594.714,-1.2682,-3.096,13,8,229.75,3.9912,0.51373,0.87019,13,13,2,0.45722,0.62147,2.324880704,1.537300123,-0.1758435778,2,2
CHEMBL3580743,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(F)cc2F)C(=O)N1,6.31,8.2,F,CHEMBL3580572,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells co-expressing C-terminally modified GGalphaqi5 assessed as stimulation of calcium release by Fluo-4 AM dye-based fluorescence assay,1,Scientific Literature,ACS Med Chem Lett,2015,735.79,0.14,highly_active,3,735.786,0.2156,-5.192,14,8,234.84,-2.8631,0.41744,0.88922,16,9,3,0.51248,0.68236,2.538139319,-0.04028410495,-0.8975172539,12,12
CHEMBL3580744,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(C(F)(F)F)cc2)C(=O)N1,5.248,8.28,F,CHEMBL3580572,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells co-expressing C-terminally modified GGalphaqi5 assessed as stimulation of calcium release by Fluo-4 AM dye-based fluorescence assay,1,Scientific Literature,ACS Med Chem Lett,2015,767.81,0.88,highly_active,3,767.803,0.8623,-5.342,14,8,234.84,-8.7131,0.43618,0.88286,17,10,3,0.30316,0.63363,2.623339814,-0.2859433797,-0.7477168146,12,12
CHEMBL3580745,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCCCNC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(F)cc2)NC1=O,2.512,8.6,F,CHEMBL3580572,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells co-expressing C-terminally modified GGalphaqi5 assessed as stimulation of calcium release by Fluo-4 AM dye-based fluorescence assay,1,Scientific Literature,ACS Med Chem Lett,2015,745.85,0.62,highly_active,3,745.85,0.8026,-5.566,14,8,234.84,-2.8877,0.4203,0.88665,15,9,3,0.71451,0.65019,2.443709353,-0.3698281814,-0.8910340194,12,12
CHEMBL3580746,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCCCNC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(F)cc2F)NC1=O,5.129,8.29,F,CHEMBL3580572,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells co-expressing C-terminally modified GGalphaqi5 assessed as stimulation of calcium release by Fluo-4 AM dye-based fluorescence assay,1,Scientific Literature,ACS Med Chem Lett,2015,763.84,0.76,highly_active,3,763.84,0.9034,-5.88,14,8,234.84,-2.8877,0.41705,0.90037,16,9,3,0.44887,0.67158,2.533026804,-0.591326968,-0.962067212,12,12
CHEMBL3580748,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCCCNC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc2ccccc2)NC1=O,2.754,8.56,F,CHEMBL3580572,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells co-expressing C-terminally modified GGalphaqi5 assessed as stimulation of calcium release by Fluo-4 AM dye-based fluorescence assay,1,Scientific Literature,ACS Med Chem Lett,2015,745.85,0.62,highly_active,3,745.85,0.8026,-5.566,14,8,234.84,-2.8877,0.4203,0.88894,15,9,3,0.60463,0.65613,2.443709353,-0.3698281814,-0.8910340194,12,12
CHEMBL3580749,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCCCNC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](Cc2ccc(F)cc2F)NC(=O)[C@H](Cc2ccccc2)NC1=O,1.66,8.78,F,CHEMBL3580572,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells co-expressing C-terminally modified GGalphaqi5 assessed as stimulation of calcium release by Fluo-4 AM dye-based fluorescence assay,1,Scientific Literature,ACS Med Chem Lett,2015,763.84,0.76,highly_active,3,763.84,0.9034,-5.88,14,8,234.84,-2.8877,0.41705,0.90245,16,9,3,0.48466,0.66413,2.533026804,-0.591326968,-0.962067212,12,12
CHEMBL3580750,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCCCNC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](Cc2ccc(C(F)(F)F)cc2)NC(=O)[C@H](Cc2ccccc2)NC1=O,6.761,8.17,F,CHEMBL3580572,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells co-expressing C-terminally modified GGalphaqi5 assessed as stimulation of calcium release by Fluo-4 AM dye-based fluorescence assay,1,Scientific Literature,ACS Med Chem Lett,2015,795.86,1.5,highly_active,3,795.857,1.5501,-6.03,14,8,234.84,-8.7377,0.43487,0.89666,17,10,3,0.61967,0.67418,2.618227301,-0.8369862402,-0.8122667749,12,12
CHEMBL3582484,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1,2.57,8.59,F,CHEMBL3580572,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells co-expressing C-terminally modified GGalphaqi5 assessed as stimulation of calcium release by Fluo-4 AM dye-based fluorescence assay,1,Scientific Literature,ACS Med Chem Lett,2015,717.8,0,highly_active,3,717.796,0.1148,-4.878,14,8,234.84,-2.8631,0.42087,0.87179,15,9,3,0.50835,0.66865,2.448821965,0.1812146275,-0.8264840549,12,12
CHEMBL3582485,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccc(F)cc2F)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1,4.074,8.39,F,CHEMBL3580572,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells co-expressing C-terminally modified GGalphaqi5 assessed as stimulation of calcium release by Fluo-4 AM dye-based fluorescence assay,1,Scientific Literature,ACS Med Chem Lett,2015,735.79,0.14,highly_active,3,735.786,0.2156,-5.192,14,8,234.84,-2.8631,0.41744,0.88694,16,9,3,0.50392,0.65783,2.538139319,-0.04028410495,-0.8975172539,12,12
CHEMBL3582487,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N1,3.236,8.49,F,CHEMBL3580572,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells co-expressing C-terminally modified GGalphaqi5 assessed as stimulation of calcium release by Fluo-4 AM dye-based fluorescence assay,1,Scientific Literature,ACS Med Chem Lett,2015,717.8,0,highly_active,3,717.796,0.1148,-4.878,14,8,234.84,-2.8631,0.42087,0.87433,15,9,3,0.49884,0.6613,2.448821965,0.1812146275,-0.8264840549,12,12
CHEMBL35838,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O,26.1,7.58,F,CHEMBL1149874,agonist,agonist,Agonist activity at mu opioid receptor assessed as inhibition of forskolin-induced cAMP production in human SH-SY5Y cells pretreated for 24 hrs with DMEM medium after 15 mins,1,Scientific Literature,Bioorg Med Chem,2008,554.65,-0.76,active,2,554.646,-0.9435,-2.98,12,7,205.74,2.9188,0.62647,0.75761,12,15,2,0.34004,0.62926,2.024301475,1.545541956,0.1762411865,14,14
CHEMBL361274,N[C@@H](Cc1ccc(O)cc1)C(=O)N1Cc2ccccc2C[C@H]1c1nc(-c2ccccc2)c[nH]1,2445,5.61,F,CHEMBL2157906,agonist,agonist,Agonist activity at mu opioid receptor expressed in CHO-hg cells by [35S]-GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2012,438.53,3.98,inactive,0,438.529,2.8821,-3.518,6,3,95.24,0.99219,0.41518,0.88345,6,5,4,0.42367,0.68782,-0.4591081468,0.7367058273,-2.90E-02,3,3
CHEMBL3627737,C=C(C(N)=O)[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccsc1,0.0643,10.19,F,CHEMBL3627650,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) transfected in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production,1,Scientific Literature,Bioorg Med Chem Lett,2015,628.75,2.42,highly_active,3,628.752,1.4599,-4.389,11,6,211.88,0.51736,0.4694,0.9183,12,12,4,0.4939,0.65337,1.659356831,0.2549141588,-7.82E-02,4,1
CHEMBL3629337,C=C(C(N)=O)[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1cccs1,0.0629,10.2,F,CHEMBL3627650,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) transfected in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production,1,Scientific Literature,Bioorg Med Chem Lett,2015,628.75,2.42,highly_active,3,628.752,1.5421,-4.499,11,6,211.88,1.484,0.46847,0.9183,12,12,4,0.46318,0.66818,1.654842899,0.1758882832,-0.0932713397,4,1
CHEMBL362991,NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1,741.31,6.13,F,CHEMBL3763121,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells by calcium mobilization assay,1,Scientific Literature,Bioorg Med Chem,2016,521.62,0.46,intermediate,1,521.616,0.4382,-2.939,10,4,159.06,4.4795,0.52132,0.85267,10,9,2,0.40411,0.69654,0.8817914271,1.394519859,-0.01753221999,4,4
CHEMBL3697625,Cc1nnc(C(C)C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1cccc(NC(=O)COCC(=O)NCCCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)c1,37.8,7.42,F,CHEMBL3638635,antagonist,antagonist,"Flux Assay: As Ca2+ flux is associated with the activation of the MOR, the functional activity of bivalent ligand 1, monovalent ligand 2, and naltrexone was then evaluated in a Ca2+ mobilization assay in hMORCHO cells transfected with chimeric Ca2+ following a published protocol.23 No agonism was observed for any of the tested compounds (data not shown). Thus, they were further assessed for their antagonist properties as the ability to inhibit DAMGO (a MOR agonist) induced Ca2+ flux.",37,BindingDB Database,,2015,1197.48,None,active,2,1197.47,5.1682,-6.987,20,7,250.84,-6.9442,0.48863,1.1144,22,28,3,0.33722,0.53013,4.294903432,-2.64771868,1.256864227,2,1
CHEMBL371970,CC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1,90,7.05,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,337.51,5.01,active,2,337.505,5.0647,-4.232,2,1,23.47,4.3419,0.44732,0.80949,2,5,2,0.41754,0.73736,-1.72442138,-0.002825301597,0.3294444224,8,8
CHEMBL373446,C[C@H]1CN2CCN(Cc3cccs3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,0.63,9.2,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,356.54,3.94,highly_active,3,356.532,3.5392,-3.129,3,1,54.95,5.8519,0.35917,0.83603,4,3,2,0.50221,0.78192,-1.377799524,0.9226689711,0.1107216391,4,1
CHEMBL373641,C[C@H]1CN2CCN(Cc3cccc(Cl)c3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,1.8,8.74,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,384.95,4.53,highly_active,3,384.949,4.2786,-3.855,3,1,26.71,3.9512,0.38065,0.8444,4,3,2,0.49789,0.76537,-1.479421265,0.3343844413,0.08360443082,16,12
CHEMBL373707,C[C@H]1CN2C[C@H](c3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(C(N)=O)c1,1.5,8.82,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,363.51,3.1,highly_active,3,363.503,2.9508,-3.637,4,2,58.36,4.2263,0.37897,0.86084,4,3,2,0.32129,0.7208,-1.115434308,0.7330415984,-0.141050061,10,2
CHEMBL373709,C[C@H]1CN2CCN(Cc3ccnc4ccccc34)C[C@H]2C[C@@]1(C)c1cccc(O)c1,80,7.1,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,401.55,4.42,active,2,401.552,3.9886,-3.825,4,1,39.6,3.9084,0.35405,0.87927,4,3,3,0.53812,0.78156,-1.319124985,0.3908812593,0.02880914158,2,1
CHEMBL373925,C[C@H]1CN2C[C@H](c3ccccc3)N(Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(C(N)=O)c1,28,7.55,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,453.63,5.01,active,2,453.628,4.6218,-4.598,4,1,49.57,3.9795,0.36554,0.89063,4,5,3,0.36957,0.71581,-1.153392799,-0.2472598692,0.1247620555,2,2
CHEMBL373984,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C(=O)NCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3,8.9,8.05,F,CHEMBL1146900,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,732.97,5.8,highly_active,3,732.963,5.4389,-7.55,9,3,125.2,-3.413,0.45737,1.0026,9,11,3,0.36577,0.61961,0.6101507496,-2.432387951,-0.09328773886,1,1
CHEMBL374324,C[C@H]1CN2CCN(S(=O)(=O)c3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,140,6.85,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,400.54,3.06,intermediate,1,400.541,3.1235,-2.744,5,1,69.23,-2.3125,0.39143,0.86153,6,2,2,0.40064,0.73773,-1.040119259,1.194862116,-7.83E-04,1,1
CHEMBL374455,C[C@H]1CN2CCN(Cc3ccco3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,7.2,8.14,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,340.47,3.47,highly_active,3,340.465,2.8613,-2.801,4,1,39.85,3.9715,0.36179,0.83603,4,3,2,0.59807,0.83357,-1.328499829,1.247422323,0.1065508084,4,1
CHEMBL374559,C[C@H]1CN2C[C@@H](c3ccccc3)CC[C@H]2C[C@@]1(C)c1cccc(O)c1,110,6.96,F,CHEMBL1137299,antagonist,antagonist,Antagonist activity against human cloned mu opioid receptor expressed in CHO cells assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,335.49,4.94,intermediate,1,335.489,5.0535,-4.416,2,1,23.47,2.4657,0.33315,0.84632,2,2,2,0.41958,0.76337,-1.853797185,-0.06889204152,-0.01642952888,10,2
CHEMBL374678,C[C@H]1CN2CCCN(Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,15,7.82,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,364.53,4.27,active,2,364.531,4.0146,-3.389,3,1,26.71,4.109,0.36563,0.84556,3,3,2,0.37611,0.72796,-1.560473609,0.6759885948,0.16786189,1,1
CHEMBL375025,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1C/C=C\C[C@H](C(=O)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O,2.35,8.63,F,CHEMBL1145383,agonist,agonist,Agonist activity at human mu opioid receptor by [35S]GTP-gamma-S binding assay,1,Scientific Literature,J Med Chem,2007,551.6,-0.49,highly_active,3,551.598,-2.4521,-2.98,12,7,199.95,-11.296,0.4665,0.8024,12,7,2,0.3893,0.70851,1.813545351,1.911209367,-0.831324614,3,1
CHEMBL375119,C[C@H]1CN2C[C@H](C3CCCCC3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1,1.3,8.89,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,342.53,3.91,highly_active,3,342.525,3.6704,-3.862,3,2,35.5,-0.73777,0.34555,0.85083,3,2,1,0.33782,0.74426,-1.460482905,0.5042681956,-0.1467747224,10,1
CHEMBL375165,C[C@H]1CN2CCN(CCCc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,13,7.89,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,378.56,4.31,active,2,378.558,4.5571,-3.501,3,1,26.71,3.3001,0.42317,0.83726,3,5,2,0.47814,0.77611,-1.506151353,0.4770598516,0.4203258909,1,1
CHEMBL375504,Oc1ccc2c(c1)[C@]13CCN(CC4CCC4)[C@H](C2)[C@@H]1Cc1c([nH]c2ccccc12)C3,110,6.96,F,CHEMBL1143667,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO membrane assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2007,398.55,4.96,intermediate,1,398.548,4.8249,-5.395,3,2,39.26,3.3265,0.19246,1.0044,3,2,3,0.39358,0.73691,-1.425503399,-0.651143834,-0.3514665092,1,1
CHEMBL375633,C[C@H]1CN2CCN(Cc3cccc4ccccc34)C[C@H]2C[C@@]1(C)c1cccc(O)c1,16,7.8,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,400.57,5.03,active,2,400.564,4.867,-4.725,3,1,26.71,3.9084,0.35405,0.86692,3,3,3,0.52427,0.76884,-1.542614628,-0.2927897073,-0.03018575705,2,1
CHEMBL375803,C[C@H]1CN2CCN(Cc3ccc(O)cc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,5.7,8.24,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,366.51,3.58,highly_active,3,366.503,3.3269,-2.823,4,2,46.94,3.9084,0.38065,0.84245,4,3,2,0.46252,0.76685,-1.229593448,1.142151932,0.1287601104,16,12
CHEMBL3758969,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCCCNC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2cccc3ccccc23)NC1=O,19.95,7.7,F,CHEMBL3758180,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells assessed as calcium mobilization by Fluo-4 AM based fluorescence analysis,1,Scientific Literature,Eur J Med Chem,2016,777.92,1.63,active,2,777.92,1.8962,-6.858,14,8,234.84,-1.5477,0.39238,0.89175,14,9,4,0.4214,0.64713,2.36651122,-1.348719045,-1.03249463,1,1
CHEMBL3759167,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCCCNC(=O)C[C@@H](C(N)=O)NC(=O)[C@@H](Cc2cccc3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC1=O,5.62,8.25,F,CHEMBL5126521,agonist,agonist,Agonist activity at human recombinant MOP expressed in CHO cells by calcium mobilization assay,1,Scientific Literature,J Med Chem,2022,777.92,1.63,highly_active,3,777.92,1.8962,-6.858,14,8,234.84,-1.5477,0.39238,0.8934,14,9,4,0.51279,0.64885,2.36651122,-1.348719045,-1.03249463,1,1
CHEMBL3759179,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCCCNC(=O)C[C@@H](C(N)=O)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2ccccc2)NC1=O,3.631,8.44,F,CHEMBL3758180,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells assessed as calcium mobilization by Fluo-4 AM based fluorescence analysis,1,Scientific Literature,Eur J Med Chem,2016,777.92,1.63,highly_active,3,777.92,1.8962,-6.858,14,8,234.84,-1.5477,0.39773,0.88809,14,9,4,0.61764,0.67794,2.36651122,-1.348719045,-1.03249463,1,1
CHEMBL3759489,CN1CC[C@]23c4c5ccc(O)c4O[C@@]2(C)c2[nH]c4ccccc4c2C[C@@]3(CCCc2ccccc2)[C@H]1C5,45.1,7.35,F,CHEMBL3758122,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as [35S]GTPgammaS binding by cell based assay,1,Scientific Literature,Eur J Med Chem,2016,490.65,6.24,active,2,490.645,6.4429,-6.398,4,2,48.49,2.7481,0.27564,1.1254,4,4,4,0.5122,0.736,-1.185803837,-1.633767782,-0.1787149338,2,1
CHEMBL3759981,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCCCNC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC1=O,11.48,7.94,F,CHEMBL3758180,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells assessed as calcium mobilization by Fluo-4 AM based fluorescence analysis,1,Scientific Literature,Eur J Med Chem,2016,777.92,1.63,active,2,777.92,1.8962,-6.858,14,8,234.84,-1.5477,0.39773,0.88637,14,9,4,0.52328,0.63714,2.36651122,-1.348719045,-1.03249463,1,1
CHEMBL376355,Nc1nc2c(s1)C[C@H]1[C@H]3Cc4ccc(O)cc4[C@@]1(CCN3CC1CCC1)C2,2.6,8.59,F,CHEMBL1143667,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO membrane assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2007,381.55,3.51,highly_active,3,381.542,3.8157,-4.789,4,2,90.62,4.3041,0.22057,0.98782,5,2,2,0.37933,0.76368,-1.015815825,-0.09524680014,-0.4511135706,1,1
CHEMBL3764033,NC(=O)[C@@H]1CC(F)(F)CN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CC(F)(F)CN1C(=O)[C@@H](N)Cc1ccc(O)cc1,398.11,6.4,F,CHEMBL3763121,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells by calcium mobilization assay,1,Scientific Literature,Bioorg Med Chem,2016,593.58,0.95,intermediate,1,593.576,0.7166,-3.835,10,4,159.06,-3.4404,0.51316,0.91922,14,9,2,0.47021,0.68637,1.237034192,0.7421649933,-0.2316278649,4,4
CHEMBL376413,C[C@H]1CN2CCN(CC3CCCCC3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,1.1,8.96,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,356.55,4.26,highly_active,3,356.552,4.0049,-3.422,3,1,26.71,-1.1746,0.38787,0.83928,3,3,1,0.61896,0.82985,-1.570155084,0.6658222581,0.1571424884,16,1
CHEMBL3764219,NC(=O)[C@H]1CC(F)(F)CN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1,20.42,7.69,F,CHEMBL3763121,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells by calcium mobilization assay,1,Scientific Literature,Bioorg Med Chem,2016,557.6,0.7,active,2,557.596,0.5774,-3.387,10,4,159.06,-2.5776,0.52124,0.90826,12,9,2,0.47575,0.70272,1.059412812,1.068342351,-0.1245800673,4,4
CHEMBL3765406,NC(=O)[C@H]1CC(F)(F)CN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CC(F)(F)CN1C(=O)[C@@H](N)Cc1ccc(O)cc1,4.677,8.33,F,CHEMBL3763121,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells by calcium mobilization assay,1,Scientific Literature,Bioorg Med Chem,2016,593.58,0.95,highly_active,3,593.576,0.7166,-3.835,10,4,159.06,-3.4404,0.51333,0.91922,14,9,2,0.46053,0.69014,1.237034192,0.7421649933,-0.2316278649,4,4
CHEMBL376690,C[C@H]1CN2CCN(Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,0.73,9.14,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,350.51,3.88,highly_active,3,350.504,3.6726,-3.119,3,1,26.71,3.9084,0.37305,0.83928,3,3,2,0.62013,0.81327,-1.554733832,0.9075999161,0.1823080295,16,12
CHEMBL377069,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCCC[C@H]1c1nc(-c2ccccc2)c[nH]1,2,8.7,F,CHEMBL2157906,agonist,agonist,Agonist activity at mu opioid receptor expressed in CHO-hg cells by [35S]-GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2012,418.54,4.02,highly_active,3,418.539,3.189,-3.49,6,3,95.24,-1.2806,0.47854,0.85009,6,5,3,0.41221,0.70383,-0.5270363722,0.7190255466,0.0190690243,2,2
CHEMBL377789,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1,150,6.82,F,CHEMBL1146899,antagonist,antagonist,Antagonist activity against human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2006,478.68,6.26,intermediate,1,478.678,6.5262,-7.214,3,1,32.34,5.5451,0.45382,0.91503,3,7,3,0.27581,0.6481,-1.300781454,-2.170561705,0.003593607931,15,3
CHEMBL3785265,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)C/C1=C/c1ccccc1,54.6,7.26,F,CHEMBL3785070,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2016,415.53,3.85,active,2,415.531,3.8405,-4.614,4,2,60.77,5.953,0.22594,1.0239,4,3,2,0.35836,0.75023,-1.085801549,-0.04550870735,-0.2467335725,1,1
CHEMBL3786083,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)CC/C1=C/c1ccccc1,19.2,7.72,F,CHEMBL3785070,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2016,429.56,4.24,active,2,429.558,4.1825,-4.884,4,2,60.77,4.9533,0.22642,1.0189,4,3,2,0.41836,0.76178,-1.091541327,-0.2771200286,-0.261179712,1,1
CHEMBL3787016,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCc1c([nH]c2ccccc12)C3,6.23,8.21,F,CHEMBL3785070,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2016,414.55,4.07,highly_active,3,414.547,4.0015,-4.945,4,3,59.49,4.6139,0.16047,1.0386,4,2,3,0.35506,0.7477,-1.05180294,-0.2431211362,-0.4363671123,1,1
CHEMBL3787663,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCc1cc2ccccc2nc1C3,11.6,7.94,F,CHEMBL3785070,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2016,426.56,4.14,active,2,426.558,4.2781,-5.126,4,2,56.59,4.2029,0.14827,1.0371,4,2,3,0.33544,0.74064,-1.155259408,-0.4213662452,-0.4008742989,1,1
CHEMBL382919,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1,15,7.82,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,351.53,5.4,active,2,351.532,5.5191,-4.502,2,1,23.47,1.9392,0.44455,0.81812,2,6,2,0.38695,0.7282,-1.697910552,-0.2667261227,0.4308824489,8,8
CHEMBL383044,C[C@H]1CN(CCc2ccccc2)[C@H](CCCc2ccccc2)C[C@@]1(C)c1cccc(O)c1,360,6.44,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,427.63,6.63,intermediate,1,427.63,6.961,-5.637,2,1,23.47,0.86691,0.42927,0.82973,2,8,3,0.38275,0.69395,-1.605369904,-1.283003047,0.5727242677,1,1
CHEMBL383094,CCCCCCCN1C[C@H](C)[C@](C)(c2cccc(O)c2)C[C@H]1CCC,9,8.05,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,345.57,6.13,highly_active,3,345.569,6.3492,-4.717,2,1,23.47,-10.717,0.47612,0.81096,2,9,1,0.36042,0.70437,-1.657897023,-0.5699533615,0.7962304987,10,8
CHEMBL383320,O=C(O)CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3,3,8.52,F,CHEMBL1147138,agonist,agonist,Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,495.7,6.66,highly_active,3,495.701,5.7319,-6.519,5,1,66.84,-11.548,0.41489,0.93668,5,13,1,0.29902,0.65035,-0.5911063121,-1.710232004,0.5784288005,10,4
CHEMBL383491,CC(=O)NCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1,130,6.89,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,394.56,4.13,intermediate,1,394.557,4.1484,-3.999,4,2,52.57,5.5642,0.46348,0.81578,4,7,2,0.34566,0.69914,-1.027949006,0.2304045449,0.3548965609,8,8
CHEMBL383896,O=C1CC[C@@]2(NCC/C=C/c3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,0.24,9.62,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,505.06,4.88,highly_active,3,505.056,4.7702,-6.03,5,2,61.8,3.0076,0.34638,1.088,6,7,2,0.37269,0.7055,-0.628344318,-1.178892172,-0.07579455901,6,2
CHEMBL384118,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC/C=C/Cc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314,4.98,8.3,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,519.09,4.88,highly_active,3,519.083,4.917,-5.981,5,1,50.8,3.0491,0.36902,1.0919,6,8,2,0.36588,0.68787,-0.7054242351,-1.215521113,0.1084147662,6,2
CHEMBL384336,C[C@H]1CN2CCN(C(=O)CCc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,78,7.11,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,392.54,3.84,active,2,392.541,4.2075,-3.483,4,1,43.78,3.6813,0.42494,0.84127,4,4,2,0.3013,0.70035,-1.315203594,0.5509456266,0.2365391444,1,1
CHEMBL384497,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NCCCc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314,0.12,9.92,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,507.07,4.71,highly_active,3,507.072,4.7148,-5.939,5,1,50.8,4.4364,0.34452,1.0918,6,8,2,0.30446,0.69952,-0.7023633846,-1.144327317,0.08759828397,2,2
CHEMBL384895,C[C@H]1CN2CCN(Cc3cccc(OCc4ccccc4)c3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,22,7.66,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,456.63,5.46,active,2,456.628,5.0207,-4.46,4,1,35.94,3.6578,0.4348,0.85628,4,6,3,0.47148,0.74297,-1.201023063,-0.2534657616,0.3352012312,1,1
CHEMBL385280,C[C@H]1[C@H]2CC[C@H](c3ccccc3)CN2CC[C@@]1(C)c1cccc(O)c1,190,6.72,F,CHEMBL1137299,antagonist,antagonist,Antagonist activity against human cloned mu opioid receptor expressed in CHO cells assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,335.49,4.94,intermediate,1,335.489,5.0535,-4.416,2,1,23.47,2.7318,0.34293,0.86049,2,2,2,0.32319,0.74162,-1.853797185,-0.06889204152,-0.01642952888,10,1
CHEMBL385392,C[C@H]1[C@@H]2CC[C@H](c3ccccc3)CN2CC[C@@]1(C)c1cccc(O)c1,150,6.82,F,CHEMBL1137299,antagonist,antagonist,Antagonist activity against human cloned mu opioid receptor expressed in CHO cells assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,335.49,4.94,intermediate,1,335.489,5.0535,-4.416,2,1,23.47,2.7318,0.34304,0.86049,2,2,2,0.33466,0.7456,-1.853797185,-0.06889204152,-0.01642952888,10,2
CHEMBL386272,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314,17.8,7.75,F,CHEMBL1152801,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,519.04,4.32,active,2,519.039,4.2419,-6.056,6,1,67.87,4.0518,0.23462,1.096,7,6,2,0.2982,0.69478,-0.5393001697,-1.113851725,-0.2469885718,5,2
CHEMBL386492,O=C(/C=C/c1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5,0.53,9.28,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,505.01,4.02,highly_active,3,505.012,3.9662,-5.742,6,2,78.87,4.0115,0.23766,1.0923,7,5,2,0.31777,0.70894,-0.4639073656,-0.8411055047,-0.3610192397,5,2
CHEMBL387016,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314,96.3,7.02,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,355.43,1.83,active,2,355.433,1.8525,-3.506,5,1,59,4.6558,0.18352,1.0778,5,3,1,0.50469,0.79518,-0.9737956695,0.9963994646,-0.2524571936,4,3
CHEMBL387101,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NCCc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314,3.73,8.43,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,493.05,4.32,highly_active,3,493.045,4.2604,-5.669,5,1,50.8,4.2784,0.31473,1.0919,6,7,2,0.37366,0.71526,-0.728874165,-0.8804265248,-0.01383973778,2,2
CHEMBL387248,C[C@H]1CN2C[C@H](c3ccccc3)CC[C@@H]2C[C@@]1(C)c1cccc(O)c1,210,6.68,F,CHEMBL1137299,antagonist,antagonist,Antagonist activity against human cloned mu opioid receptor expressed in CHO cells assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,335.49,4.94,intermediate,1,335.489,5.0535,-4.416,2,1,23.47,2.4657,0.33358,0.84632,2,2,2,0.38501,0.75434,-1.853797185,-0.06889204152,-0.01642952888,10,2
CHEMBL38874,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO,1,9,F,CHEMBL1147037,agonist,agonist,Activation of human mu opioid receptor expressed in HEK293a cells by [35S]GTP-gamma-S binding assay,1,Scientific Literature,J Biol Chem,2007,513.6,-0.94,highly_active,3,513.593,-1.0567,-1.86,11,6,174.09,2.7582,0.6621,0.77625,11,13,2,0.43824,0.65359,1.52053085,2.27162741,0.3225549697,14,14
CHEMBL390866,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CCC1,85,7.07,F,CHEMBL1765082,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding by scintillation counting,1,Scientific Literature,J Med Chem,2011,367.56,4.74,active,2,367.559,4.4379,-5.627,3,1,70.39,-1.0015,0.21698,0.9583,4,2,2,0.35522,0.75236,-1.345111282,-0.6988272895,-0.4898922199,1,1
CHEMBL391580,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(C(N)=O)cc1)C(=O)O,140,6.85,F,CHEMBL1139195,agonist,agonist,Agonist activity at human cloned mu opioid receptor assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,600.7,-1.06,intermediate,1,600.695,-3.363,-3.234,13,7,248.11,-9.7703,0.64126,0.78055,14,17,2,0.3371,0.62161,2.796421036,1.751973928,-0.1159787264,14,14
CHEMBL392269,CO[C@]12CC(O)[C@@]3(C[C@@H]1[C@H](C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5,89,7.05,F,CHEMBL1149641,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO membrane by [35S]GTP-gamma-S binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2007,387.48,1.19,active,2,387.474,1.1461,-2.907,6,3,82.39,4.1635,0.21839,1.1206,6,2,1,0.5802,0.81479,-0.5421553757,1.481806372,-0.4194315745,4,4
CHEMBL394573,NC(=O)Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3,63,7.2,F,CHEMBL1147995,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding after 60 mins,1,Scientific Literature,Bioorg Med Chem,2007,353.51,4.04,active,2,353.508,3.394,-5.189,4,2,58.36,-0.5144,0.29223,0.93505,4,3,1,0.33869,0.75062,-1.11109622,-0.248269622,-0.458249106,10,4
CHEMBL394624,O=C(NCc1ccccc1)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CCC1)CC3,7.1,8.15,F,CHEMBL1144610,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,444.62,5.83,highly_active,3,444.617,5.4466,-6.386,4,1,41.57,-13.051,0.36646,0.90925,4,6,2,0.29551,0.68904,-1.162074203,-1.449010089,-0.08412594161,1,1
CHEMBL397035,O=C(Nc1ccccc1)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CC1)CC3,0.44,9.36,F,CHEMBL1144610,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,416.57,5.77,highly_active,3,416.563,5.3952,-6.3,4,1,41.57,-9.1108,0.33123,0.90802,4,5,2,0.30752,0.7069,-1.248738738,-1.349965116,-0.1745327466,1,1
CHEMBL398707,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,2.6,8.59,F,CHEMBL1153960,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,285.34,1.63,highly_active,3,285.342,1.6758,-2.826,4,1,49.77,4.2337,0.10554,1.0296,4,0,1,0.61657,0.82993,-1.377864687,1.530937941,-0.392170571,7,2
CHEMBL399465,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccccc4-c4ccccc4)cc3[C@@]1(C)CCN2CC1CC1,12,7.92,F,CHEMBL1140563,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membrane by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2007,478.68,6.26,active,2,478.678,6.5262,-7.214,3,1,32.34,5.5451,0.44424,0.9244,3,7,3,0.35366,0.66488,-1.300781454,-2.170561705,0.003593607931,1,1
CHEMBL401245,CO[C@]12C(O)C[C@@]3(C[C@@H]1[C@@H](C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5,43,7.37,F,CHEMBL1149641,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO membrane by [35S]GTP-gamma-S binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2007,387.48,1.19,active,2,387.474,1.1461,-2.907,6,3,82.39,4.2111,0.21033,1.1157,6,2,1,0.52603,0.81593,-0.5421553757,1.481806372,-0.4194315745,4,4
CHEMBL401278,C[C@H]1C2Cc3ccc(C(=O)NCCc4cccc(-c5ccccc5)c4)cc3[C@@]1(C)CCN2CC1CC1,6.8,8.17,F,CHEMBL1140563,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membrane by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2007,478.68,6.26,highly_active,3,478.678,6.5262,-7.214,3,1,32.34,5.5451,0.45382,0.91991,3,7,3,0.31854,0.65146,-1.300781454,-2.170561705,0.003593607931,1,1
CHEMBL401508,C[C@H]1CN(CCC(=O)N[C@@H](CC2CCCCC2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,5.5,8.26,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,430.59,3.92,highly_active,3,430.587,2.3368,-3.935,6,3,89.87,-10.853,0.52437,0.79105,6,8,1,0.3587,0.70075,-0.2702900167,0.5536652505,0.09532569207,5,1
CHEMBL401615,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](CCCCN)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,1.2,8.92,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,495.66,3.55,highly_active,3,495.662,0.5104,-4.013,7,4,115.89,-8.4556,0.52558,0.82043,7,12,2,0.36116,0.68452,0.5207804269,0.7277565591,0.134506919,14,8
CHEMBL401716,C[C@H]1CN(CCC(=O)N[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,7.8,8.11,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,424.54,3.19,highly_active,3,424.539,1.9802,-3.474,6,3,89.87,-5.784,0.52764,0.79105,6,8,2,0.34026,0.69144,-0.2593079686,0.8927044449,0.155633076,5,4
CHEMBL401789,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](CC(=O)O)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,3.8,8.42,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,482.58,2.89,highly_active,3,482.575,1.3766,-3.379,8,4,127.17,-4.7335,0.53628,0.8218,8,10,2,0.38826,0.70473,0.4355574746,0.9911609541,0.181276171,14,8
CHEMBL402964,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(-c3ccccc3)cc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,21,7.68,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,590.76,6.33,active,2,590.761,5.2996,-6.855,6,3,89.87,-5.2541,0.47175,0.84897,6,11,4,0.34949,0.65745,-0.09751922937,-1.870155357,0.1330107229,1,1
CHEMBL403190,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,1.5,8.82,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,514.67,4.66,highly_active,3,514.664,3.6404,-4.769,6,3,89.87,-5.2541,0.49245,0.8293,6,10,3,0.40281,0.69109,-0.1631589854,-0.2689668657,0.2920647356,2,1
CHEMBL403191,C[C@H]1CN(CCC(=O)N(CCc2ccccc2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,63,7.2,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,528.69,5.15,active,2,528.691,4.0949,-4.547,6,2,81.08,2.6645,0.5434,0.83271,6,11,3,0.46657,0.66325,-0.2767791195,-0.2565929008,0.559990262,1,1
CHEMBL403324,CCN(C(=O)CCN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)[C@@H](Cc1ccccc1)C(=O)O,110,6.96,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,452.6,3.93,intermediate,1,452.593,2.653,-3.412,6,2,81.08,3.5725,0.58143,0.81625,6,9,2,0.36993,0.69133,-0.3693197285,0.7596839242,0.4181483504,5,4
CHEMBL403325,C[C@H]1CN(CCC(=O)N[C@@H](CCc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,10,8,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,438.57,3.58,highly_active,3,438.566,2.4346,-3.744,6,3,89.87,-6.834,0.53075,0.78821,6,9,2,0.30225,0.67111,-0.232797141,0.6288036238,0.2570711025,1,1
CHEMBL403633,C[C@H](NC(=O)[C@@H](Cc1ccccc1)CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)C(=O)O,1.2,8.92,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,438.57,3.44,highly_active,3,438.566,2.1985,-3.634,6,3,89.87,2.0508,0.53616,0.807,6,8,2,0.3764,0.72014,-0.2556995944,0.7473099593,0.150222824,14,8
CHEMBL404303,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,7.9,8.1,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,564.73,5.82,highly_active,3,564.724,4.8348,-6.375,6,3,89.87,-5.2541,0.4549,0.8591,6,10,4,0.36803,0.67504,-0.1510397539,-1.469356448,0.07957091465,1,1
CHEMBL404583,C[C@H]1CN(CCC(=O)N(c2ccccc2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,70,7.16,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,500.64,5.11,active,2,500.637,3.9383,-4.957,6,2,81.08,2.4758,0.52615,0.85231,6,9,3,0.42963,0.6819,-0.3737111453,-0.4186149325,0.2333981137,1,1
CHEMBL405618,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O,213.8,6.67,F,CHEMBL3758180,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells assessed as calcium mobilization by Fluo-4 AM based fluorescence analysis,1,Scientific Literature,Eur J Med Chem,2016,1603.99,None,intermediate,1,1603.98,-8.5737,-5.496,39,25,661.7,-7.27,0.61989,0.98423,39,54,2,0.41053,0.48048,12.7165812,0.1846381658,0.8187651056,1,1
CHEMBL4061477,O=C(NCC1NCCc2ccccc21)c1ccccc1OC(F)(F)F,3310,5.48,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,350.34,3.2,inactive,0,350.339,3.5862,-3.872,4,2,50.36,-5.7628,0.51401,0.80291,7,5,2,0.45516,0.7578,-0.9581468667,0.4638516268,0.0668514435,31,24
CHEMBL4061620,Cc1ccc(C(=O)NCC2c3ccccc3CCN2CCCl)cc1,30,7.52,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,342.87,3.56,active,2,342.869,3.7196,-3.532,3,1,32.34,4.682,0.47825,0.78878,4,5,2,0.38403,0.73329,-1.385002034,0.6369734722,0.2667506732,31,24
CHEMBL4062124,O=C(NCC1NCCc2ccccc21)c1ccc(F)cc1,540,6.27,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,284.33,2.44,intermediate,1,284.333,2.588,-3.163,3,2,41.13,0.96088,0.46722,0.74343,4,3,2,0.43519,0.75788,-1.333823969,1.145122514,-0.06101810799,31,24
CHEMBL4063074,Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1,29.4,7.53,F,CHEMBL4619756,antagonist,antagonist,Antagonist activity at human mu opiod receptor expressed in CHO cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding incubated for 4 hrs by microbeta liquid scintillation counting method,1,Scientific Literature,Bioorg Med Chem Lett,2020,418.51,5.67,active,2,418.51,4.8612,-6.298,4,1,55.56,2.089,0.52783,0.8075,5,6,3,0.39341,0.68686,-1.033485499,-1.270158618,-0.1822752671,3,3
CHEMBL4063837,CC(C)(C)C[C@@H]1COCc2nc(OCc3ccccn3)cc(=O)n21,10000,5,F,CHEMBL4017502,agonist,agonist,Agonist activity at human mu-type opioid receptor expressed in CHO-K1 cells assessed as cAMP accumulation by HTRF assay,1,Scientific Literature,J Med Chem,2017,329.4,2.72,inactive,0,329.399,1.863,-3.46,6,0,64.02,-3.7358,0.45368,0.8153,6,5,1,0.28188,0.7292,-0.8800843198,1.009887752,-0.03403787474,1,1
CHEMBL4064752,O=C(NCC1NCCc2ccccc21)C1CCCC1,8910,5.05,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,258.37,2.18,inactive,0,258.364,2.0455,-2.735,3,2,41.13,1.0688,0.39986,0.71675,3,3,1,0.35297,0.75722,-1.3892641,1.5178844,-0.02716582323,2,1
CHEMBL4064781,CN(C(=O)/C=C/c1ccncc1)[C@@H]1CC[C@@]2(O)[C@H]3[C@@H](O)c4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,12100,4.92,F,CHEMBL4052747,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-dhfr(-) cells assessed as inhibition of forskolin-induced cAMP accumulation by TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,503.6,2.38,inactive,0,503.597,1.7561,-3.25,8,3,106.36,4.648,0.30776,1.1074,8,5,2,0.4074,0.72688,0.03419702578,1.029612129,-0.1644588072,9,1
CHEMBL4065490,CO[C@@]12CCC[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5,1.37,8.86,F,CHEMBL4028881,agonist,agonist,Agonist activity at recombinant human MOR expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2017,301.39,2.22,highly_active,3,301.385,1.9887,-2.852,4,1,41.93,1.8674,0.14158,1.069,4,1,1,0.53737,0.85237,-1.368747879,1.431789814,-0.2402852136,12,2
CHEMBL4065924,O=C(NCC1NCCc2ccccc21)c1ccc(Cl)c(Cl)c1,250,6.6,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,335.23,3.61,intermediate,1,335.233,3.6992,-4.321,3,2,41.13,2.3498,0.47067,0.77499,5,3,2,0.34373,0.73726,-1.272516178,0.220190415,-0.1873921854,31,24
CHEMBL4066058,CN(C(=O)/C=C/c1ccsc1)[C@@H]1CC[C@@]2(O)[C@H]3[C@@H](O)c4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,110,6.96,F,CHEMBL4052747,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-dhfr(-) cells assessed as inhibition of forskolin-induced cAMP accumulation by TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,508.64,3.05,intermediate,1,508.637,2.5414,-3.945,7,3,121.71,4.9927,0.27991,1.1078,8,5,2,0.41631,0.72991,-0.02694523864,0.4806468339,-0.2366191338,5,1
CHEMBL4066436,O=C(NCC1NCCc2ccccc21)c1cccc(Cl)c1,380,6.42,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,300.79,2.96,intermediate,1,300.788,3.0932,-3.585,3,2,41.13,2.3498,0.46722,0.75619,4,3,2,0.3927,0.74647,-1.347828773,0.7934058485,-0.08868855232,31,24
CHEMBL4067629,Oc1ccc2c(c1)C13CCN(CC4CC4)C(C2)C12CCC1C3[C@@H](CN1c1ccccc1)C2,10,8,F,CHEMBL4033739,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells assessed as cAMP accumulation,1,Scientific Literature,Bioorg Med Chem Lett,2017,426.6,4.98,highly_active,3,426.602,4.6741,-5.523,3,1,26.71,3.6779,0.24809,1.0077,3,3,2,0.35982,0.73634,-1.443191022,-0.7540900641,-0.2492210166,1,1
CHEMBL4069608,CN(C(=O)C#Cc1ccccc1)[C@@H]1CC[C@@]2(O)[C@H]3[C@@H](O)c4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,904,6.04,F,CHEMBL4052747,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-dhfr(-) cells assessed as inhibition of forskolin-induced cAMP accumulation by TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,500.6,2.33,intermediate,1,500.593,2.6877,-4.432,7,3,93.47,-1.3759,0.31051,1.1074,7,4,2,0.38557,0.71855,-0.2309734425,0.1853743665,-0.3847119351,9,1
CHEMBL4070138,O=C(NCC1NCCc2ccccc21)c1ccccc1,750,6.12,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,266.34,2.3,intermediate,1,266.343,2.4872,-2.849,3,2,41.13,2.3009,0.46326,0.72141,3,3,2,0.37348,0.7601,-1.423141367,1.366621282,0.0100150808,31,24
CHEMBL4070288,CCc1ccc(C(=O)NCC2c3ccccc3CCN2C)cc1,10,8,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,308.43,3.21,highly_active,3,308.424,3.4996,-2.99,3,1,32.34,5.399,0.48833,0.76251,3,4,2,0.29144,0.73288,-1.541696078,1.04186348,0.2741283215,31,24
CHEMBL4070613,O=C(NCC1NCCc2ccccc21)C1CCC1,6800,5.17,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,244.34,1.79,inactive,0,244.337,1.7035,-2.465,3,2,41.13,2.8328,0.4026,0.71096,3,3,1,0.3459,0.76958,-1.383524294,1.749495762,-0.01271971815,1,1
CHEMBL4070750,Cc1ccc(C(=O)NCC2NCCc3ccccc32)cc1,140,6.85,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,280.37,2.61,intermediate,1,280.37,2.8311,-3.193,3,2,41.13,2.2342,0.46722,0.73028,3,3,2,0.30413,0.74032,-1.42569762,1.091099857,-0.02225990367,31,24
CHEMBL4071332,Cc1ccc(C(=O)NCC2c3ccccc3CCN2C)cc1C,10,8,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,308.43,3.26,highly_active,3,308.424,3.4279,-3.175,3,1,32.34,5.598,0.47071,0.77811,3,3,2,0.36969,0.74804,-1.570175592,0.9581485367,0.1188668683,31,24
CHEMBL4072327,CN(C(=O)CCCc1ccccc1)[C@@H]1CC[C@@]2(O)[C@H]3[C@@H](O)c4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,12900,4.89,F,CHEMBL4052747,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-dhfr(-) cells assessed as inhibition of forskolin-induced cAMP accumulation by TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,518.65,3.3,inactive,0,518.652,3.3347,-4.18,7,3,93.47,2.4985,0.372,1.1074,7,7,2,0.36375,0.71203,-0.1539980585,0.1660613575,0.07217280422,1,1
CHEMBL4072866,O=C(NCC1NCCc2ccccc21)c1cccc(F)c1,780,6.11,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,284.33,2.44,intermediate,1,284.333,2.588,-3.163,3,2,41.13,0.96088,0.46722,0.75619,4,3,2,0.35957,0.75515,-1.333823969,1.145122514,-0.06101810799,31,24
CHEMBL4073340,COC1CCC(C(=O)NCC2NCCc3ccccc32)CC1,6600,5.18,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,302.42,2.19,inactive,0,302.416,1.9633,-2.734,4,2,50.36,2.7596,0.43911,0.73701,4,4,1,0.34737,0.74735,-1.11729562,1.479656035,3.84E-02,31,4
CHEMBL4074110,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2CCC[C@@]3(O)[C@H]1C5,8.99,8.05,F,CHEMBL4028881,agonist,agonist,Agonist activity at recombinant human MOR expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2017,287.36,1.57,highly_active,3,287.358,1.5608,-2.724,4,2,52.93,2.5263,0.12685,1.0543,4,0,1,0.63632,0.86347,-1.267067537,1.621368321,-4.22E-01,12,2
CHEMBL4074409,O=C(NCC1NCCc2ccccc21)C1CCCCC1,6380,5.2,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,272.39,2.57,inactive,0,272.391,2.3875,-3.005,3,2,41.13,-1.4075,0.4174,0.72141,3,3,1,0.37213,0.76576,-1.395003941,1.286272926,-0.0416119914,31,4
CHEMBL4075084,CC(C)C(NC(=O)/C(=C/c1ccccc1)CN1CCC(C)(c2cccc(O)c2)C(C)C1)C(=O)O,660.69,6.18,F,CHEMBL4038325,antagonist,antagonist,Antagonist activity at recombinant human MOR expressed in HEK293T cells assessed as reduction in DAMGO-induced inhibition of forskolin-stimulated cAMP level preincubated for 15 to 20 mins followed by DAMGO and forskolin addition by GloSensor assay,1,Scientific Literature,J Med Chem,2017,464.61,4.3,intermediate,1,464.604,3.136,-4.163,6,3,89.87,-3.9762,0.54785,0.8075,6,8,2,0.44563,0.70145,-0.3003301034,0.2485561345,0.1603376977,14,6
CHEMBL4076303,CN1CCC23c4cc(O)ccc4CC1C21CCC2C3[C@@H](CN2C(=O)c2ccccc2)O1,5.9,8.23,F,CHEMBL4033703,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by Eu-cAMP tracer based TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,416.52,2.96,highly_active,3,416.519,2.8683,-3.793,5,1,53.01,5.7062,0.28458,1.0609,5,1,2,0.41723,0.75116,-1.094896188,0.6177131933,-0.3573245008,2,2
CHEMBL4076673,COCCCN1CCC23c4cc(O)ccc4CC1C21CCC2C3[C@@H](CN2C(=O)c2ccccc2)O1,22,7.66,F,CHEMBL4033703,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by Eu-cAMP tracer based TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,474.6,3.37,active,2,474.599,3.2302,-3.984,6,1,62.24,3.3623,0.32414,1.0655,6,5,2,0.37836,0.7134,-0.708116857,0.3376787087,0.02654813234,2,2
CHEMBL4077552,CN(C(=O)/C=C/c1ccccn1)[C@@H]1CC[C@@]2(O)[C@H]3[C@@H](O)c4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,2880,5.54,F,CHEMBL4052747,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-dhfr(-) cells assessed as inhibition of forskolin-induced cAMP accumulation by TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,503.6,2.38,inactive,0,503.597,1.8101,-3.274,8,3,106.36,4.648,0.29774,1.1082,8,5,2,0.38351,0.7271,0.02901101508,1.006120784,-0.1625272189,9,1
CHEMBL4080324,CN(C(=O)/C=C/c1ccc(Cl)cc1)[C@@H]1CC[C@@]2(O)[C@H]3[C@@H](O)c4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,48.8,7.31,F,CHEMBL4052747,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-dhfr(-) cells assessed as inhibition of forskolin-induced cAMP accumulation by TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,537.06,3.64,active,2,537.054,3.363,-4.781,7,3,93.47,4.6959,0.31418,1.1085,8,5,2,0.39021,0.71836,-0.1330808376,-0.1866635791,-0.2787690177,9,3
CHEMBL4080799,O=C(NCC1NCCc2ccccc21)N1CCOCC1,8080,5.09,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,275.35,0.92,inactive,0,275.351,1.0079,-1.563,5,2,53.6,3.8275,0.52547,0.72141,5,2,1,0.36008,0.75605,-1.063056554,2.386666341,-0.03770387376,31,1
CHEMBL4081344,Cc1ccc(C(=O)NCC2NCCc3ccccc32)c(C)c1,660,6.18,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,294.4,2.92,intermediate,1,294.397,3.175,-3.537,3,2,41.13,2.2342,0.4773,0.76043,3,3,2,0.34428,0.73623,-1.428253884,0.8155785721,-0.05453482981,31,24
CHEMBL4081523,CCCC(NC(=O)/C(=C/c1ccccc1)CN1CCC(C)(c2cccc(O)c2)C(C)C1)C(=O)O,2344.23,5.63,F,CHEMBL4038325,antagonist,antagonist,Antagonist activity at recombinant human MOR expressed in HEK293T cells assessed as reduction in DAMGO-induced inhibition of forskolin-stimulated cAMP level preincubated for 15 to 20 mins followed by DAMGO and forskolin addition by GloSensor assay,1,Scientific Literature,J Med Chem,2017,464.61,4.44,inactive,0,464.604,3.3721,-4.273,6,3,89.87,-6.4316,0.54529,0.8075,6,9,2,0.45198,0.69214,-0.277427661,0.1300499395,0.2671860345,14,6
CHEMBL4081855,CCC(C)C(NC(=O)/C(=C/c1ccccc1)CN1CCC(C)(c2cccc(O)c2)C(C)C1)C(=O)O,1621.81,5.79,F,CHEMBL4038325,antagonist,antagonist,Antagonist activity at recombinant human MOR expressed in HEK293T cells assessed as reduction in DAMGO-induced inhibition of forskolin-stimulated cAMP level preincubated for 15 to 20 mins followed by DAMGO and forskolin addition by GloSensor assay,1,Scientific Literature,J Med Chem,2017,478.63,4.69,inactive,0,478.631,3.5904,-4.433,6,3,89.87,-1.2256,0.55346,0.81435,6,9,2,0.44072,0.69341,-0.2738192758,-0.01534468655,0.2617757242,14,6
CHEMBL4081856,O=S(=O)(c1ccccc1)N1C[C@H]2OC34CCC1C2C31CCN(CC2CC2)C4Cc2ccc(O)cc21,2.5,8.6,F,CHEMBL4033703,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by Eu-cAMP tracer based TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,492.64,3.29,highly_active,3,492.638,2.9612,-4.105,6,1,78.46,-2.7855,0.28454,1.0722,7,3,2,0.40358,0.72659,-0.6219093562,0.322703875,-0.2725067796,1,1
CHEMBL4082299,O=C(NCC1NCCc2ccccc21)c1ccc(OC(F)(F)F)cc1,370,6.43,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,350.34,3.2,intermediate,1,350.339,3.5862,-3.872,4,2,50.36,-5.7628,0.52684,0.76182,7,5,2,0.30627,0.72454,-0.9581468667,0.4638516268,0.0668514435,31,24
CHEMBL4082823,CN(C(=O)/C=C/c1ccccc1)[C@@H]1CC[C@@]2(O)[C@H]3[C@@H](O)c4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,209,6.68,F,CHEMBL4052747,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-dhfr(-) cells assessed as inhibition of forskolin-induced cAMP accumulation by TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,502.61,2.99,intermediate,1,502.609,2.757,-4.045,7,3,93.47,4.648,0.30776,1.1074,7,5,2,0.42054,0.72991,-0.2083934317,0.3865518543,-0.1800653846,9,3
CHEMBL4083309,O=C(NCC1NCCc2ccccc21)c1ccccc1F,3280,5.48,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,284.33,2.44,inactive,0,284.333,2.588,-3.163,3,2,41.13,0.96088,0.47344,0.76113,4,3,2,0.3538,0.74884,-1.333823969,1.145122514,-0.06101810799,31,24
CHEMBL4086255,CN(C(=O)/C=C/c1cccnc1)[C@@H]1CC[C@@]2(O)[C@H]3[C@@H](O)c4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,3760,5.42,F,CHEMBL4052747,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-dhfr(-) cells assessed as inhibition of forskolin-induced cAMP accumulation by TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,503.6,2.38,inactive,0,503.597,1.7561,-3.25,8,3,106.36,4.648,0.30776,1.108,8,5,2,0.42039,0.7315,0.03419702578,1.029612129,-0.1644588072,9,1
CHEMBL4087151,CN(C(=O)/C=C/c1cccs1)[C@@H]1CC[C@@]2(O)[C@H]3[C@@H](O)c4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,4870,5.31,F,CHEMBL4052747,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-dhfr(-) cells assessed as inhibition of forskolin-induced cAMP accumulation by TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,508.64,3.05,inactive,0,508.637,2.6236,-4.055,7,3,121.71,6.0475,0.28991,1.1078,8,5,2,0.42327,0.73287,-0.03145919535,0.401621078,-0.2516517162,5,1
CHEMBL4087761,Cc1cccc(C(=O)NCC2NCCc3ccccc32)c1,370,6.43,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,280.37,2.61,intermediate,1,280.37,2.8311,-3.193,3,2,41.13,2.2342,0.46722,0.73945,3,3,2,0.41919,0.74753,-1.42569762,1.091099857,-0.02225990367,31,24
CHEMBL4088589,CO[C@@]12CCC[C@]3(C)Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5,2.95,8.53,F,CHEMBL4028881,agonist,agonist,Agonist activity at recombinant human MOR expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2017,315.41,2.61,highly_active,3,315.412,2.2867,-2.961,4,1,41.93,2.2823,0.17795,1.0941,4,1,1,0.58964,0.8516,-1.376770185,1.302620414,-0.2217021781,12,1
CHEMBL4089738,Cc1ccc(C(=O)NCC2c3ccccc3CCN2CC(C)C)cc1,110,6.96,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,336.48,3.98,intermediate,1,336.477,4.163,-3.561,3,1,32.34,-1.5026,0.48564,0.77499,3,5,2,0.36524,0.72304,-1.504007525,0.5511415682,0.3343178177,31,24
CHEMBL4090064,Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)c(Cl)c2)c1,144.2,6.84,F,CHEMBL4049389,antagonist,antagonist,Antagonist activity at recombinant human mu-opioid receptor expressed in CHO cell membranes assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding after 4 hrs by microbeta scintillation counting method,1,Scientific Literature,Eur J Med Chem,2017,452.96,6.32,intermediate,1,452.955,5.4672,-7.034,4,1,55.56,2.1305,0.50035,0.82844,6,6,3,0.41143,0.68811,-0.9581729518,-1.843374022,-0.280978905,3,3
CHEMBL4090148,O=C(NCC1NCCc2ccccc21)c1ccc(Cl)cc1,230,6.64,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,300.79,2.96,intermediate,1,300.788,3.0932,-3.585,3,2,41.13,2.3498,0.46722,0.74343,4,3,2,0.32793,0.74141,-1.347828773,0.7934058485,-0.08868855232,31,24
CHEMBL4090628,Cc1ccc(/C=C/C(=O)N(C)[C@@H]2CC[C@@]3(O)[C@H]4[C@@H](O)c5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1,308,6.51,F,CHEMBL4052747,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-dhfr(-) cells assessed as inhibition of forskolin-induced cAMP accumulation by TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,516.64,3.3,intermediate,1,516.636,3.1009,-4.389,7,3,93.47,4.6238,0.31418,1.1078,7,5,2,0.40256,0.71334,-0.2109497432,0.1110305987,-0.2123403155,9,3
CHEMBL4091098,COc1ccccc1C(=O)NCC1NCCc2ccccc21,3310,5.48,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,296.37,2.31,inactive,0,296.369,2.4172,-2.867,4,2,50.36,2.3008,0.47354,0.76113,4,4,2,0.41308,0.74865,-1.173393815,1.328427036,0.07049786412,31,24
CHEMBL4091515,O=C(NCC1NCCc2ccccc21)N1CCCCC1,3310,5.48,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,273.38,2.07,inactive,0,273.379,2.1719,-2.452,4,2,44.37,2.6872,0.52453,0.71956,4,2,1,0.40929,0.77003,-1.309813373,1.661643294,-0.05797484498,31,1
CHEMBL4092125,CN1CCc2ccccc2C1CNC(=O)c1ccc(Cl)c(Cl)c1,10,8,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,349.26,3.95,highly_active,3,349.26,3.9521,-3.959,3,1,32.34,5.6932,0.47071,0.79493,5,3,2,0.35007,0.74702,-1.414437886,0.3627603796,-0.01399048729,31,24
CHEMBL409225,C[C@H](C(=O)N[C@H]1Cc2ccccc2CN(CC(N)=O)C1=O)N1Cc2cc(O)ccc2C[C@H](N)C1=O,5.17,8.29,F,CHEMBL2150869,agonist,agonist,Agonist activity at human MOR expressed in HEK293 cell membrane assessed as inhibition of forskolin-induced cAMP accumulation by by liquid scintillation counting,1,Scientific Literature,J Med Chem,2011,479.54,-0.45,highly_active,3,479.535,-1.6085,-2.263,10,4,159.06,4.435,0.41569,0.90627,10,5,2,0.35956,0.68716,0.8426996048,2.238555181,-0.5530357127,2,1
CHEMBL4092452,CC1CCCCC1C(=O)NCC1NCCc2ccccc21,10000,5,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,286.42,2.82,inactive,0,286.417,2.6568,-3.165,3,2,41.13,-0.75845,0.44651,0.73783,3,3,1,0.35919,0.76767,-1.397337987,1.132042256,-0.03965286678,31,1
CHEMBL4093524,CCCCN1CCc2ccccc2C1CNC(=O)c1ccc(C)cc1,160,6.8,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,336.48,4.12,intermediate,1,336.477,4.3991,-3.671,3,1,32.34,2.3646,0.47648,0.77499,3,6,2,0.38495,0.72128,-1.481105016,0.4326353154,0.4411660273,31,24
CHEMBL4093632,CN(C(=O)/C=C/c1ccco1)[C@@H]1CC[C@@]2(O)[C@H]3[C@@H](O)c4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,14200,4.85,F,CHEMBL4052747,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-dhfr(-) cells assessed as inhibition of forskolin-induced cAMP accumulation by TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,492.57,2.58,inactive,0,492.57,1.9457,-3.727,8,3,106.61,4.6131,0.28652,1.1078,8,5,2,0.43696,0.74078,0.01784054561,0.7263743807,-0.2558225302,5,1
CHEMBL4094890,CC1CCC(C(=O)NCC2NCCc3ccccc32)CC1,1530,5.82,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,286.42,2.82,inactive,0,286.417,2.6568,-3.165,3,2,41.13,2.606,0.43895,0.7268,3,3,1,0.39678,0.75967,-1.397337987,1.132042256,-0.03965286678,31,4
CHEMBL4096255,CC1CN(C/C(=C\c2ccccc2)C(=O)NCC(=O)O)CCC1(C)c1cccc(O)c1,1288.25,5.89,F,CHEMBL4038325,antagonist,antagonist,Antagonist activity at recombinant human MOR expressed in HEK293T cells assessed as reduction in DAMGO-induced inhibition of forskolin-stimulated cAMP level preincubated for 15 to 20 mins followed by DAMGO and forskolin addition by GloSensor assay,1,Scientific Literature,J Med Chem,2017,422.53,3.28,inactive,0,422.523,2.104,-3.355,6,3,89.87,0.92261,0.54359,0.78935,6,7,2,0.44769,0.71333,-0.3276635068,0.956064881,0.10267739,14,6
CHEMBL4096314,O=C(c1ccccc1)N1C[C@H]2OC34CCC1C2C31CCN(CCc2ccccc2)C4Cc2ccc(O)cc21,5.3,8.28,F,CHEMBL4033703,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by Eu-cAMP tracer based TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,506.65,4.58,highly_active,3,506.644,4.7165,-5.228,5,1,53.01,3.6495,0.31568,1.0667,5,4,3,0.36811,0.69427,-0.9688613368,-0.671797664,-0.1283342714,1,1
CHEMBL4097466,Cc1ccc(C(=O)NCC2c3ccccc3CCN2C)cc1,40,7.4,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,294.4,2.95,active,2,294.397,3.084,-2.831,3,1,32.34,5.598,0.46727,0.7569,3,3,2,0.35467,0.75391,-1.567619328,1.233669821,0.1511417945,31,24
CHEMBL4097865,CCc1ccc(C(=O)NCC2NCCc3ccccc32)cc1,60,7.22,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,294.4,2.87,active,2,294.397,3.2467,-3.352,3,2,41.13,2.0197,0.48901,0.73701,3,4,2,0.30588,0.72837,-1.399774398,0.8992934737,0.1007266578,31,24
CHEMBL4098662,Oc1ccc2c(c1)C13CCN(CC4CC4)C(C2)C12CCC1C3[C@@H](CN1CC1CCCCC1)C2,21,7.68,F,CHEMBL4033739,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells assessed as cAMP accumulation,1,Scientific Literature,Bioorg Med Chem Lett,2017,446.68,5.35,active,2,446.676,4.9293,-5.304,3,1,26.71,-0.4135,0.28949,1,3,4,1,0.35193,0.7306,-1.4066314,-0.7012375448,-0.05599483684,1,1
CHEMBL4098842,O=C(NCC1NCCc2ccccc21)N1CCCC1,4020,5.4,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,259.35,1.68,inactive,0,259.352,1.8299,-2.182,4,2,44.37,4.1727,0.49979,0.71485,4,2,1,0.3402,0.75739,-1.304073568,1.893254656,-0.04352873991,2,1
CHEMBL4099273,CN(C(=O)CCc1ccccc1)[C@@H]1CC[C@@]2(O)[C@H]3[C@@H](O)c4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,18300,4.74,F,CHEMBL4052747,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-dhfr(-) cells assessed as inhibition of forskolin-induced cAMP accumulation by TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,504.63,2.91,inactive,0,504.625,2.8803,-3.91,7,3,93.47,5.8085,0.36282,1.1074,7,6,2,0.44742,0.73868,-0.180508828,0.4299620091,-0.02926527585,9,1
CHEMBL4099423,CN[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CCCCNC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@H](Cc2ccccc2)NC1=O,10.23,7.99,F,CHEMBL4007500,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells assessed as calcium mobilization by Fluo-4 AM based fluorescence analysis,1,Scientific Literature,Bioorg Med Chem Lett,2017,727.86,0.47,active,2,727.86,0.632,-4.118,14,7,212.06,3.6622,0.42914,0.88017,14,10,3,0.65942,0.69354,2.192231151,0.5025748687,-0.3874847247,12,12
CHEMBL4099749,COc1cccc(C(=O)NCC2NCCc3ccccc32)c1,860,6.07,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,296.37,2.31,intermediate,1,296.369,2.4172,-2.867,4,2,50.36,2.3008,0.48203,0.75181,4,4,2,0.34087,0.73747,-1.173393815,1.328427036,0.07049786412,31,24
CHEMBL4100195,CCC1CCC(C(=O)NCC2NCCc3ccccc32)CC1,1120,5.95,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,300.45,3.21,inactive,0,300.444,3.1112,-3.435,3,2,41.13,2.6839,0.44993,0.73114,3,4,1,0.31916,0.74153,-1.370827159,0.8681414347,0.06178515973,31,4
CHEMBL4100317,COc1ccc(C(=O)NCC2NCCc3ccccc32)cc1,370,6.43,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,296.37,2.31,intermediate,1,296.369,2.4172,-2.867,4,2,50.36,2.3008,0.48203,0.73701,4,4,2,0.33198,0.72959,-1.173393815,1.328427036,0.07049786412,31,24
CHEMBL4100902,CC1(c2cccc(O)c2)CCN(C/C(=C\c2ccccc2)C(=O)O)CC1,18,7.75,F,CHEMBL4038325,antagonist,antagonist,Antagonist activity at recombinant human MOR expressed in HEK293T cells assessed as reduction in DAMGO-induced inhibition of forskolin-stimulated cAMP level preincubated for 15 to 20 mins followed by DAMGO and forskolin addition by GloSensor assay,1,Scientific Literature,J Med Chem,2017,351.45,3.91,active,2,351.445,2.751,-3.428,4,2,60.77,6.8262,0.50242,0.73369,4,5,2,0.3721,0.73089,-1.021801786,0.8770657865,0.07526606063,14,6
CHEMBL4102638,O=C(NCC1c2ccccc2CCN1S(=O)(=O)c1ccc(Br)cc1OC(F)(F)F)C1CCCCC1,1120,5.95,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,575.45,5.33,inactive,0,575.444,5.3336,-5.448,6,1,84.09,-11.054,0.45284,0.89639,11,6,2,0.43889,0.71339,-0.3187294077,-1.003390533,-5.74E-04,1,1
CHEMBL4103044,O=C(c1ccoc1)N1C[C@H]2CC34CCC1C2C31CCN(CC2CC2)C4Cc2ccc(O)cc21,155,6.81,F,CHEMBL4033739,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells assessed as cAMP accumulation,1,Scientific Literature,Bioorg Med Chem Lett,2017,444.58,4.2,intermediate,1,444.573,3.8141,-4.788,5,1,56.92,4.7597,0.27581,1.046,5,3,2,0.37767,0.73817,-1.01239945,-0.1836906485,-0.2658431586,1,1
CHEMBL4103328,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2CCC[C@@]3(OCc2ccccc2)[C@H]1C5,0.13,9.89,F,CHEMBL4028881,agonist,agonist,Agonist activity at recombinant human MOR expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2017,377.48,3.79,highly_active,3,377.482,3.4068,-4.175,4,1,41.93,1.8114,0.24133,1.0787,4,3,2,0.41154,0.78897,-1.264786221,0.3089191782,-0.1478749934,1,1
CHEMBL4103819,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3[C@@H](O)c4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,1100,5.96,F,CHEMBL4052747,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-dhfr(-) cells assessed as inhibition of forskolin-induced cAMP accumulation by TR-FRET assay,1,Scientific Literature,Bioorg Med Chem Lett,2017,492.57,2.58,inactive,0,492.57,1.8917,-3.703,8,3,106.61,4.4881,0.27991,1.1078,8,5,2,0.40824,0.73049,0.0230265702,0.7498657464,-0.2577541356,5,2
CHEMBL410436,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccsc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,690,6.16,F,CHEMBL1144846,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay,1,Scientific Literature,J Med Chem,2008,500.57,4.36,intermediate,1,500.566,3.0677,-4.737,8,0,137.35,-1.146,0.26889,0.9927,9,6,2,0.38068,0.7101,-0.1146325593,-0.1143884345,-0.19245709,2,1
CHEMBL4104814,CC(C)CC(NC(=O)/C(=C/c1ccccc1)CN1CCC(C)(c2cccc(O)c2)C(C)C1)C(=O)O,780,6.11,F,CHEMBL4038325,antagonist,antagonist,Antagonist activity at recombinant human MOR expressed in HEK293T cells assessed as reduction in DAMGO-induced inhibition of forskolin-stimulated cAMP level preincubated for 15 to 20 mins followed by DAMGO and forskolin addition by GloSensor assay,1,Scientific Literature,J Med Chem,2017,478.63,4.69,intermediate,1,478.631,3.5904,-4.433,6,3,89.87,-7.2399,0.55177,0.81047,6,9,2,0.42319,0.70297,-0.2738192758,-0.01534468655,0.2617757242,14,6
CHEMBL4105599,Cc1ccc(C(=O)NCC2NCCc3ccccc32)cc1C,120,6.92,F,CHEMBL3992491,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells co-expressing Galpha 15 assessed as increase in intracellular calcium release incubated for 1 measured every 1.52 secs for 90 secs by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2017,294.4,2.92,intermediate,1,294.397,3.175,-3.537,3,2,41.13,2.2342,0.47067,0.75547,3,3,2,0.37835,0.73547,-1.428253884,0.8155785721,-0.05453482981,31,24
CHEMBL411089,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NCC/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314,1.64,8.79,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,519.09,5.18,highly_active,3,519.083,5.0459,-6.344,5,1,50.8,3.0491,0.34129,1.0919,6,8,2,0.33581,0.68836,-0.7037371717,-1.451638152,0.03823626005,6,2
CHEMBL411557,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O,213.8,6.67,F,CHEMBL3580572,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells co-expressing C-terminally modified GGalphaqi5 assessed as stimulation of calcium release by Fluo-4 AM dye-based fluorescence assay,1,Scientific Literature,ACS Med Chem Lett,2015,2147.52,None,intermediate,1,2147.51,-12.127,-7.393,54,33,917.37,-6.0672,0.60045,1.0414,54,71,4,0.41357,0.44789,18.15785592,-0.9099377933,0.7460578829,1,1
CHEMBL4126803,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O,112.2,6.95,F,CHEMBL4118237,agonist,agonist,Agonist activity at MOR (unknown origin) expressed in HEK cells assessed as reduction in cAMP accumulation by split luciferase assay,1,Scientific Literature,Bioorg Med Chem,2018,1081.33,None,intermediate,1,1081.33,0.9514,-6.122,20,10,358.32,6.11,0.4159,0.91456,22,12,4,0.53904,0.58993,4.460340958,-1.035763536,-1.00420684,4,3
CHEMBL4128853,CC1(C)SSC(C)(C)[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H]1NC(=O)[C@@H](N)Cc1ccc(O)cc1,190.55,6.72,F,CHEMBL4118237,agonist,agonist,Agonist activity at MOR (unknown origin) expressed in HEK cells assessed as reduction in cAMP accumulation by split luciferase assay,1,Scientific Literature,Bioorg Med Chem,2018,1081.33,None,intermediate,1,1081.33,1.16,-5.502,20,10,358.32,0.65384,0.37824,0.91899,22,12,4,0.66617,0.64845,4.407514483,-0.7067732905,-0.8223871535,4,1
CHEMBL412923,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,0.1,10,F,CHEMBL4270665,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2018,638.77,2.29,highly_active,3,638.766,1.9907,-5.263,11,6,183.64,4.5624,0.49102,0.89773,11,12,4,0.48955,0.67365,1.501594227,-0.3648847155,-0.1629880633,7,7
CHEMBL4129668,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NCCSSCCNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O,87.1,7.06,F,CHEMBL4118237,agonist,agonist,Agonist activity at MOR (unknown origin) expressed in HEK cells assessed as reduction in cAMP accumulation by split luciferase assay,1,Scientific Literature,Bioorg Med Chem,2018,1091.37,None,active,2,1091.37,0.0758,-6.628,20,12,426.5,1.5882,0.43884,0.87083,24,12,4,0.5479,0.58712,5.120012216,-1.158673761,-1.438614746,2,2
CHEMBL412996,C[C@H]1CN2C[C@H](c3ccccc3)N(Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1,40,7.4,F,CHEMBL1137297,antagonist,antagonist,Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells,1,Scientific Literature,J Med Chem,2006,426.6,5.62,active,2,426.602,5.1888,-4.213,3,1,26.71,3.5157,0.34332,0.88256,3,4,3,0.3795,0.72031,-1.518078457,-0.08459256032,0.2452740767,2,2
CHEMBL4130069,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O,513,6.29,F,CHEMBL4118237,agonist,agonist,Agonist activity at MOR (unknown origin) expressed in HEK cells assessed as reduction in cAMP accumulation by split luciferase assay,1,Scientific Literature,Bioorg Med Chem,2018,1025.22,None,intermediate,1,1025.22,-0.4242,-4.746,20,10,358.32,6.1393,0.41651,0.88922,22,12,4,0.58411,0.59943,4.470562967,0.06632404274,-0.8751072241,4,3
CHEMBL4130303,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NCCSSCCNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O,3.467,8.46,F,CHEMBL4118237,agonist,agonist,Agonist activity at MOR (unknown origin) expressed in HEK cells assessed as reduction in cAMP accumulation by split luciferase assay,1,Scientific Literature,Bioorg Med Chem,2018,1147.48,None,highly_active,3,1147.47,1.4514,-8.004,20,12,426.5,1.5738,0.438,0.89932,24,12,4,0.58431,0.60619,5.10977471,-2.26075155,-1.567715799,2,2
CHEMBL415247,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1,120,6.92,F,CHEMBL1155455,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2010,465.64,3.55,intermediate,1,465.636,3.0866,-3.963,6,4,84.83,6.511,0.45409,0.85083,6,6,2,0.35848,0.69568,-0.3208402482,0.4102767137,-0.0239007955,9,2
CHEMBL4161204,CN(C)[C@H](CNC(=O)C1CCN(C(N)=O)CC1)c1cccs1,12300,4.91,F,CHEMBL4130639,agonist,agonist,Agonist activity at MOR (unknown origin) expressed in HEK293T assessed as intracellular cAMP accumulation after 15 mins by luciferase based GloSensor assay,1,Scientific Literature,J Med Chem,2018,324.45,1.26,inactive,0,324.448,0.2432,-1.462,6,2,106.91,8.7859,0.51856,0.68511,7,5,1,0.3174,0.73458,-0.4140269512,2.501873872,0.080966507,1,1
CHEMBL4165704,CN(C)[C@H](CNC(=O)Nc1ccc(C(N)=O)cc1)c1cccs1,5210,5.28,F,CHEMBL4130639,agonist,agonist,Agonist activity at MOR (unknown origin) expressed in HEK293T assessed as intracellular cAMP accumulation after 15 mins by luciferase based GloSensor assay,1,Scientific Literature,J Med Chem,2018,332.43,2.27,inactive,0,332.427,1.0445,-2.753,6,3,115.7,5.9001,0.5909,0.68273,7,6,2,0.31206,0.71348,-0.272811887,1.595777974,-0.06429994228,1,1
CHEMBL4169199,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)N1C(=O)O[C@H](CNC(=O)[C@@H](N)Cc2ccc(O)cc2)C1=O,0.016,10.8,F,CHEMBL4145618,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 assessed as inhibition forskolin-induced cAMP accumulation after 15 mins by EIA,1,Scientific Literature,J Med Chem,2018,626.67,1.03,highly_active,3,626.668,0.2778,-4.632,13,6,209.94,-0.76809,0.50353,0.91503,13,13,4,0.39292,0.64572,2.022551937,0.3070654071,-0.2279144348,1,1
CHEMBL4170683,FCC[C@@H]1Cc2ccccc2C2(CCC(N3CCN(C4CCCCC4)CC3)CC2)O1,1757,5.75,F,CHEMBL4152385,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as reduction in forskolin-induced intracellular cAMP increase after 45 mins by HTRF analysis,1,Scientific Literature,J Med Chem,2018,414.61,5.08,inactive,0,414.607,4.7843,-4.455,3,0,15.71,-1.8544,0.36409,0.84362,4,4,1,0.34499,0.72757,-1.544292537,-0.1615138098,0.16334106,1,1
CHEMBL4177061,N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)O,1,9,F,CHEMBL4145618,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 assessed as inhibition forskolin-induced cAMP accumulation after 15 mins by EIA,1,Scientific Literature,J Med Chem,2018,611.7,2.27,highly_active,3,611.697,-0.0261,-4.499,11,6,177.85,-8.2703,0.49161,0.88374,11,12,4,0.41899,0.66883,1.640515101,0.4591253069,-0.2636908172,7,7
CHEMBL4202891,COc1cccc(CN2CCC(n3c(=O)[nH]c4ccccc43)CC2)c1,1158,5.94,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,337.42,3.18,inactive,0,337.422,2.7588,-4.062,5,1,44.81,7.3562,0.41804,0.77872,5,4,2,0.32059,0.7263,-1.08290754,0.5134243,-0.1409794076,45,42
CHEMBL4202958,O=c1[nH]c2cc(Cl)ccc2n1C1CCN(Cc2ccc(Br)cc2F)CC1,355,6.45,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,438.73,4.72,intermediate,1,438.727,4.2608,-5.928,4,1,35.58,4.3123,0.3959,0.84323,7,3,2,0.30618,0.71692,-1.033399603,-0.9369512592,-0.4697191705,45,42
CHEMBL4203403,CC(c1ccc(Br)cc1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,4.8,8.32,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,400.32,4.49,highly_active,3,400.319,3.8407,-4.949,4,1,35.58,5.3409,0.41201,0.83059,5,3,2,0.38419,0.72318,-1.206483946,-0.2470692257,-0.2737358352,45,42
CHEMBL4203421,CC(=O)Nc1ccc(CN2CCC(n3c(=O)[nH]c4ccccc43)CC2)cc1,760,6.12,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,364.45,3.13,intermediate,1,364.448,2.5325,-4.386,6,2,64.68,7.726,0.44076,0.77687,6,4,2,0.27097,0.70264,-0.7272917635,0.3515932551,-0.3267312417,45,42
CHEMBL4203641,O=c1[nH]c2ccc(Cl)cc2n1C1CCN(Cc2ccccc2Cl)CC1,148,6.83,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,376.29,4.47,intermediate,1,376.286,4.0408,-5.516,4,1,35.58,7.4423,0.39075,0.8444,6,3,2,0.34222,0.7353,-1.18202993,-0.5948123626,-0.3988694227,45,42
CHEMBL4204767,O=c1[nH]c2ccc(Cl)cc2n1C1CCN(Cc2ccc(Br)cc2F)CC1,3459,5.46,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in human USOS-beta-arrestin-hMOR-PathHunter cells incubated for 90 mins by beta-arrestin-2 enzyme fragment complementation assay,1,Scientific Literature,J Med Chem,2018,438.73,4.72,inactive,0,438.727,4.2608,-5.928,4,1,35.58,4.3123,0.3959,0.84972,7,3,2,0.31559,0.71755,-1.033399603,-0.9369512592,-0.4697191705,45,42
CHEMBL4205200,O=c1[nH]c2cc(Cl)c(Cl)cc2n1[C@@H]1CCN(Cc2ccc(Br)cc2)C1,2975,5.53,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,441.16,4.85,inactive,0,441.155,4.424,-6.08,4,1,35.58,2.646,0.40379,0.86823,7,3,2,0.39247,0.70597,-1.041664554,-1.057056591,-0.4829435049,2,1
CHEMBL4205780,O=c1[nH]c2cc(OC(F)(F)F)ccc2n1C1CCN(Cc2ccccc2Cl)CC1,1236,5.91,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,425.84,4.72,inactive,0,425.837,4.5338,-5.803,5,1,44.81,-0.64857,0.4466,0.85046,9,5,2,0.32279,0.71415,-0.7923480135,-0.9243667247,-0.2433294853,45,42
CHEMBL4205961,O=c1[nH]c2cc(Cl)ccc2n1C1CCN(Cc2ccccc2Cl)CC1,184,6.74,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,376.29,4.47,intermediate,1,376.286,4.0408,-5.516,4,1,35.58,7.4423,0.39075,0.83766,6,3,2,0.32925,0.73259,-1.18202993,-0.5948123626,-0.3988694227,45,42
CHEMBL4206287,CC(c1ccccc1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,102,6.99,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,321.42,3.73,intermediate,1,321.423,3.1155,-4.115,4,1,35.58,7.1309,0.4047,0.77436,4,3,2,0.38078,0.73835,-1.341109489,0.4467864067,-0.1752156824,45,42
CHEMBL4207047,O=c1[nH]c2c(Cl)cccc2n1C1CCN(Cc2ccccc2Cl)CC1,1962,5.71,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in human USOS-beta-arrestin-hMOR-PathHunter cells incubated for 90 mins by beta-arrestin-2 enzyme fragment complementation assay,1,Scientific Literature,J Med Chem,2018,376.29,4.47,inactive,0,376.286,4.0408,-5.516,4,1,35.58,7.4423,0.39075,0.85304,6,3,2,0.3161,0.73445,-1.18202993,-0.5948123626,-0.3988694227,45,42
CHEMBL4207227,CC(C)Oc1ccc(C(C)N2CCC(n3c(=O)[nH]c4ccccc43)CC2)cc1,5413,5.27,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in human USOS-beta-arrestin-hMOR-PathHunter cells incubated for 90 mins by beta-arrestin-2 enzyme fragment complementation assay,1,Scientific Literature,J Med Chem,2018,379.5,4.51,inactive,0,379.502,3.8111,-4.811,5,1,44.81,6.6988,0.45073,0.79105,5,5,2,0.32056,0.69657,-1.060655041,-0.1628542832,-0.06595210766,45,42
CHEMBL4208784,O=c1[nH]c2cc(Br)ccc2n1C1CCN(Cc2ccccc2Cl)CC1,57,7.24,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,420.74,4.58,active,2,420.737,4.16,-5.614,4,1,35.58,5.6523,0.39075,0.82494,6,3,2,0.32871,0.73041,-1.122716953,-0.7154525203,-0.3986859769,45,42
CHEMBL4209504,COc1ccc2c(c1)[nH]c(=O)n2C1CCN(Cc2ccccc2Cl)CC1,2123,5.67,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,371.87,3.83,inactive,0,371.867,3.3648,-4.798,5,1,44.81,7.3776,0.40185,0.8444,6,4,2,0.34671,0.72686,-1.007594945,-0.05979113343,-0.2396830408,45,42
CHEMBL4209633,O=c1[nH]c2c(Cl)cc(Cl)cc2n1C1CCN(Cc2ccc(Br)cc2F)CC1,153,6.82,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,473.17,5.38,intermediate,1,473.172,4.8668,-6.664,4,1,35.58,4.3123,0.39506,0.86823,8,3,2,0.30625,0.70731,-0.9580870092,-1.510166693,-0.5684228036,45,42
CHEMBL4210060,O=c1[nH]c2cc(Cl)c(Cl)cc2n1C1CCN(Cc2ccc(Br)cc2F)CC1,91,7.04,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,473.17,5.38,active,2,473.172,4.8668,-6.664,4,1,35.58,4.3123,0.39506,0.86758,8,3,2,0.29278,0.70735,-0.9580870092,-1.510166693,-0.5684228036,45,42
CHEMBL4210229,O=c1[nH]c2ccccc2n1C1CCN(Cc2ccccc2Cl)CC1,4487,5.35,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in human USOS-beta-arrestin-hMOR-PathHunter cells incubated for 90 mins by beta-arrestin-2 enzyme fragment complementation assay,1,Scientific Literature,J Med Chem,2018,341.84,3.82,inactive,0,341.841,3.4348,-4.78,4,1,35.58,7.4423,0.39149,0.82225,5,3,2,0.32144,0.74685,-1.257342475,-0.0215971687,-0.3001659407,45,42
CHEMBL4210647,COc1ccc(C(C)N2CCC(n3c(=O)[nH]c4ccccc43)CC2)cc1,87,7.06,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in human USOS-beta-arrestin-hMOR-PathHunter cells incubated for 90 mins by beta-arrestin-2 enzyme fragment complementation assay,1,Scientific Literature,J Med Chem,2018,351.45,3.74,active,2,351.449,3.0455,-4.133,5,1,44.81,7.1033,0.42935,0.78589,5,4,2,0.36168,0.71662,-1.091361938,0.4085921611,-0.1147328991,45,42
CHEMBL4211156,O=c1[nH]c2ccccc2n1C1CCN(Cc2cccc(OC(F)(F)F)c2)CC1,9326,5.03,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in human USOS-beta-arrestin-hMOR-PathHunter cells incubated for 90 mins by beta-arrestin-2 enzyme fragment complementation assay,1,Scientific Literature,J Med Chem,2018,391.39,4.07,inactive,0,391.392,3.9278,-5.067,5,1,44.81,-0.66768,0.48016,0.83562,8,5,2,0.37543,0.73952,-0.8676605799,-0.3511512499,-0.1446258866,45,42
CHEMBL4211411,CC(c1ccc(Br)cc1F)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,18,7.75,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,418.31,4.63,active,2,418.309,3.9415,-5.263,4,1,35.58,4.0009,0.38965,0.84746,6,3,2,0.38236,0.72497,-1.117166596,-0.4685679647,-0.3447690288,45,42
CHEMBL4211596,O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(Br)cc2F)CC1,3357,5.47,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in human USOS-beta-arrestin-hMOR-PathHunter cells incubated for 90 mins by beta-arrestin-2 enzyme fragment complementation assay,1,Scientific Literature,J Med Chem,2018,404.28,4.07,inactive,0,404.282,3.6548,-5.192,4,1,35.58,4.3,0.39681,0.82844,6,3,2,0.31903,0.73044,-1.10871215,-0.3637358548,-0.3710155326,45,42
CHEMBL4211924,CC(c1ccc(Cl)cc1F)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,22,7.66,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,373.86,4.52,active,2,373.858,3.8223,-5.165,4,1,35.58,5.8175,0.38965,0.84746,6,3,2,0.39508,0.7252,-1.176479545,-0.3479277657,-0.3449525091,45,42
CHEMBL4211973,CC(c1ccc(F)cc1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,75,7.12,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,339.41,3.87,active,2,339.413,3.2163,-4.429,4,1,35.58,5.7909,0.41201,0.83059,5,3,2,0.39529,0.73469,-1.251792139,0.2252876678,-0.246248876,45,42
CHEMBL4212107,CC(c1ccc2c(c1)OCO2)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,407,6.39,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in human USOS-beta-arrestin-hMOR-PathHunter cells incubated for 90 mins by beta-arrestin-2 enzyme fragment complementation assay,1,Scientific Literature,J Med Chem,2018,365.43,3.46,intermediate,1,365.432,3.2269,-4.826,6,1,54.04,7.0255,0.3934,0.82887,6,3,2,0.3413,0.72146,-0.9553197405,-0.02981042763,-0.3848427586,1,1
CHEMBL4212298,CCC(c1ccc(Cl)cc1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,1593,5.8,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,369.9,4.77,inactive,0,369.895,4.1759,-5.121,4,1,35.58,6.783,0.41641,0.83968,5,4,2,0.37732,0.7221,-1.239286114,-0.3903298188,-0.1724812938,45,42
CHEMBL4212370,O=c1[nH]c2cc(F)ccc2n1C1CCN(Cc2ccccc2Cl)CC1,1644,5.78,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in human USOS-beta-arrestin-hMOR-PathHunter cells incubated for 90 mins by beta-arrestin-2 enzyme fragment complementation assay,1,Scientific Literature,J Med Chem,2018,359.83,3.96,inactive,0,359.831,3.5356,-5.094,4,1,35.58,6.1023,0.39075,0.83766,6,3,2,0.32255,0.74282,-1.168025147,-0.2430956268,-0.3711990176,45,42
CHEMBL4212478,O=c1[nH]c2cc(Cl)c(Cl)cc2n1C1CCCN(Cc2ccc(Br)cc2)CC1,1403,5.85,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,469.21,5.63,inactive,0,469.209,5.108,-6.62,4,1,35.58,1.3349,0.38846,0.86425,7,3,2,0.35328,0.70227,-1.053144165,-1.520279316,-0.5118357151,1,1
CHEMBL4212726,O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(Cl)cc2)CC1,7656,5.12,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in human USOS-beta-arrestin-hMOR-PathHunter cells incubated for 90 mins by beta-arrestin-2 enzyme fragment complementation assay,1,Scientific Literature,J Med Chem,2018,341.84,3.82,inactive,0,341.841,3.4348,-4.78,4,1,35.58,7.4423,0.40041,0.81483,5,3,2,0.29134,0.73198,-1.257342475,-0.0215971687,-0.3001659407,45,42
CHEMBL4212828,O=c1[nH]c2cccc(Cl)c2n1C1CCN(Cc2ccccc2Cl)CC1,3109,5.51,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,376.29,4.47,inactive,0,376.286,4.0408,-5.516,4,1,35.58,7.4423,0.39075,0.85945,6,3,2,0.33042,0.75068,-1.18202993,-0.5948123626,-0.3988694227,45,42
CHEMBL4213520,CS(=O)(=O)c1ccc2c(c1)[nH]c(=O)n2C1CCN(Cc2ccccc2Cl)CC1,7618,5.12,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,419.93,3.22,inactive,0,419.932,2.4368,-5.197,6,1,78.1,8.4992,0.41485,0.8584,8,4,2,0.32649,0.71277,-0.5199568586,-0.1752849201,-0.5382165129,45,42
CHEMBL4214930,O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(Cl)c(Cl)c2)CC1,6423,5.19,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,376.29,4.47,inactive,0,376.286,4.0408,-5.516,4,1,35.58,7.4423,0.40639,0.8293,6,3,2,0.31885,0.72293,-1.18202993,-0.5948123626,-0.3988694227,45,42
CHEMBL4214973,O=c1[nH]c2c(Cl)c(Cl)cc(Cl)c2n1C1CCN(Cc2ccc(Br)cc2F)CC1,1764,5.75,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,507.62,6.03,inactive,0,507.617,5.4728,-7.4,4,1,35.58,4.3123,0.39428,0.90999,9,3,2,0.2774,0.70596,-0.8827744151,-2.083382126,-0.6671264367,45,42
CHEMBL4215093,N#Cc1ccc(CN2CCC(n3c(=O)[nH]c4ccccc43)CC2)cc1,3424,5.46,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,332.41,3.04,inactive,0,332.406,2.6644,-4.817,5,1,59.37,3.15,0.40313,0.7679,5,3,2,0.29372,0.72944,-1.042417284,0.1055978009,-0.459967684,45,42
CHEMBL4215165,O=c1[nH]c2ccccc2n1C1CCN(Cc2cccc(Cl)c2)CC1,1354,5.87,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,341.84,3.82,inactive,0,341.841,3.4348,-4.78,4,1,35.58,7.4423,0.40041,0.81997,5,3,2,0.32178,0.73203,-1.257342475,-0.0215971687,-0.3001659407,45,42
CHEMBL4215250,O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(Br)cc2)CC1,367,6.43,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,386.29,3.93,intermediate,1,386.292,3.554,-4.878,4,1,35.58,5.64,0.40041,0.81483,5,3,2,0.30517,0.72804,-1.198029547,-0.1422370869,-0.2999823438,45,42
CHEMBL4215601,CCOc1ccc(C(C)N2CCC(n3c(=O)[nH]c4ccccc43)CC2)cc1,189,6.72,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,365.48,4.13,intermediate,1,365.475,3.4518,-4.433,5,1,44.81,5.7027,0.44096,0.78878,5,5,2,0.32432,0.70258,-1.057869279,0.1353590452,-0.02758470396,45,42
CHEMBL4215851,Cc1ccc2c(c1)[nH]c(=O)n2C1CCN(Cc2ccccc2Cl)CC1,224,6.65,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,355.87,4.13,intermediate,1,355.868,3.7787,-5.124,4,1,35.58,7.3713,0.39075,0.83766,5,3,2,0.33627,0.73498,-1.259898767,-0.2971184947,-0.3324408324,45,42
CHEMBL4216374,CC(c1ccc(OC(F)(F)F)cc1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,31,7.51,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,405.42,4.63,active,2,405.419,4.2145,-5.138,5,1,44.81,-0.93289,0.48996,0.84087,8,5,2,0.33643,0.71298,-0.8761149781,-0.4559833888,-0.118379378,45,42
CHEMBL4216570,Cc1cc(Cl)ccc1CN1CCC(n2c(=O)[nH]c3ccccc32)CC1,2880,5.54,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in human USOS-beta-arrestin-hMOR-PathHunter cells incubated for 90 mins by beta-arrestin-2 enzyme fragment complementation assay,1,Scientific Literature,J Med Chem,2018,355.87,4.13,inactive,0,355.868,3.7787,-5.124,4,1,35.58,7.3713,0.39681,0.82844,5,3,2,0.34764,0.7335,-1.259898767,-0.2971184947,-0.3324408324,45,42
CHEMBL4216907,O=c1[nH]c2cc(Cl)c(Cl)cc2n1[C@H]1CCN(Cc2ccc(Br)cc2)C1,373,6.43,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,441.16,4.85,intermediate,1,441.155,4.424,-6.08,4,1,35.58,2.646,0.40379,0.86823,7,3,2,0.37166,0.70725,-1.041664554,-1.057056591,-0.4829435049,2,1
CHEMBL4216968,O=c1[nH]c2c(Cl)cccc2n1C1CCN(Cc2ccc(Br)cc2F)CC1,55,7.26,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,438.73,4.72,active,2,438.727,4.2608,-5.928,4,1,35.58,4.3123,0.3959,0.85805,7,3,2,0.30093,0.71779,-1.033399603,-0.9369512592,-0.4697191705,45,42
CHEMBL4217435,O=c1[nH]c2cc(Cl)c(Cl)cc2n1C1CCN(Cc2ccc(Br)cc2)CC1,149,6.83,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,455.18,5.24,intermediate,1,455.182,4.766,-6.35,4,1,35.58,5.6523,0.39828,0.85734,7,3,2,0.29778,0.70786,-1.047404359,-1.288667954,-0.49738961,45,42
CHEMBL4217675,Cc1ccc(CN2CCC(n3c(=O)[nH]c4ccccc43)CC2)cc1,433,6.36,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by scintillation counting method,1,Scientific Literature,J Med Chem,2018,321.42,3.48,intermediate,1,321.423,3.1727,-4.388,4,1,35.58,7.3551,0.40041,0.76319,4,3,2,0.30275,0.72963,-1.335211333,0.2760969801,-0.2337372338,45,42
CHEMBL4218547,CC(c1ccc(Cl)cc1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,184,6.74,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in human USOS-beta-arrestin-hMOR-PathHunter cells incubated for 90 mins by beta-arrestin-2 enzyme fragment complementation assay,1,Scientific Literature,J Med Chem,2018,355.87,4.38,intermediate,1,355.868,3.7215,-4.851,4,1,35.58,7.1575,0.41201,0.83059,5,3,2,0.37567,0.72557,-1.265796895,-0.1264290268,-0.2739193155,45,42
CHEMBL4219000,COc1ccc(CN2CCC(n3c(=O)[nH]c4ccccc43)CC2)cc1,2254,5.65,F,CHEMBL4196199,agonist,agonist,Agonist activity at human mu opioid receptor expressed in human USOS-beta-arrestin-hMOR-PathHunter cells incubated for 90 mins by beta-arrestin-2 enzyme fragment complementation assay,1,Scientific Literature,J Med Chem,2018,337.42,3.18,inactive,0,337.422,2.7588,-4.062,5,1,44.81,7.3562,0.41804,0.7679,5,4,2,0.32195,0.73166,-1.08290754,0.5134243,-0.1409794076,45,42
CHEMBL425758,CC(C)[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1,620,6.21,F,CHEMBL1149448,antagonist,antagonist,Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor,1,Scientific Literature,Bioorg Med Chem Lett,2006,351.53,5.26,intermediate,1,351.532,5.283,-4.392,2,1,23.47,1.5018,0.45411,0.81812,2,5,2,0.50365,0.74778,-1.720812995,-0.1482199276,0.3240341121,8,8
CHEMBL427214,Cc1cc(C(N)=O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1c1nc(-c2ccccc2)c[nH]1,161,6.79,F,CHEMBL2157906,agonist,agonist,Agonist activity at mu opioid receptor expressed in CHO-hg cells by [35S]-GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2012,493.61,3.99,intermediate,1,493.609,3.0029,-4.591,7,3,118.1,1.3422,0.43825,0.91265,7,6,4,0.40984,0.67456,-0.09953497856,0.02299585004,-0.2140713537,3,3
CHEMBL4276875,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,0.19,9.72,F,CHEMBL4270665,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2018,658.8,0.57,highly_active,3,658.801,0.3057,-4.464,13,9,238.54,2.9656,0.55022,0.83521,13,17,3,0.60018,0.63291,2.60237454,0.3601869028,0.07937226604,3,3
CHEMBL427862,CCNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CC1)CC3,2.4,8.62,F,CHEMBL1144610,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2007,368.52,4.26,highly_active,3,368.519,4.0928,-5.093,4,1,41.57,-8.6278,0.32284,0.90348,4,5,1,0.32191,0.72468,-1.226803422,-0.3677610868,-0.07494178604,4,2
CHEMBL4280750,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)O,47.5,7.32,F,CHEMBL4270665,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2018,1063.23,None,active,2,1063.22,-2.2006,-6.14,23,14,406.23,-9.3547,0.5422,0.92681,23,31,4,0.4835,0.56659,6.412155303,-0.6665840623,0.1978173446,1,1
CHEMBL4284374,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O,51.1,7.29,F,CHEMBL4270665,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2018,1337.6,None,active,2,1337.59,-1.0874,-8.02,28,17,496.24,0.89471,0.53537,0.95297,28,41,5,0.46999,0.52938,8.401437675,-2.303653212,0.6287307489,1,1
CHEMBL4284813,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,0.1,10,F,CHEMBL4270665,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2018,630.79,1.43,highly_active,3,630.787,1.3734,-5.093,11,7,202.66,-1.2322,0.54136,0.83313,11,17,3,0.53134,0.64187,1.931170152,-0.1987966171,0.2260528149,3,3
CHEMBL4288649,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)O,0.28,9.55,F,CHEMBL4270665,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2018,787.92,-0.08,highly_active,3,787.916,-1.7632,-4.624,17,11,304.94,-9.3547,0.55439,0.87495,17,22,3,0.52153,0.60581,4.147136794,0.4734548182,0.03358351325,3,3
CHEMBL4290989,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)O,3.67,8.44,F,CHEMBL4270665,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2018,512.61,0.44,highly_active,3,512.609,-1.3258,-3.108,11,8,203.65,-9.8843,0.58084,0.79273,11,13,2,0.49984,0.66145,1.88211353,1.6134967,-0.1306507014,3,3
CHEMBL4296720,CN1CC[C@]23Cc4nc5ccccc5cc4C[C@@]2(O)[C@H]1Cc1ccc(O)cc13.Cl.Cl,232.5,6.63,F,CHEMBL3091434,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2013,445.39,2.97,intermediate,1,445.388,3.2117,-4.04,4,2,56.59,5.4869,0.11074,1.0375,4,0,3,0.41807,0.76257,-1.14259638,0.4107158385,-0.4856362505,6,6
CHEMBL4296726,Cl.Cl.Oc1ccc2c(c1)[C@]13CCN(Cc4ccco4)[C@H](C2)[C@]1(O)Cc1cc2ccccc2nc1C3,1.199,8.92,F,CHEMBL3091434,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2013,511.45,4.13,highly_active,3,511.447,3.8185,-5.045,5,2,69.73,3.7729,0.19179,1.035,5,2,4,0.33677,0.72401,-0.812399176,-0.3723332276,-0.4689830241,2,1
CHEMBL4296731,Cl.Cl.Oc1ccc2c(c1)[C@]13CCN(CCF)[C@H](C2)[C@]1(O)Cc1cc2ccccc2nc1C3,115.5,6.94,F,CHEMBL3091434,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2013,477.41,3.31,intermediate,1,477.405,3.3924,-4.415,4,2,56.59,2.4998,0.1628,1.0311,5,2,3,0.3697,0.74936,-0.9474164726,0.1004829813,-0.3585740723,6,6
CHEMBL4296732,C[C@H](O)CN1CC[C@]23Cc4nc5ccccc5cc4C[C@@]2(O)[C@H]1Cc1ccc(O)cc13.Cl.Cl,16.87,7.77,F,CHEMBL3091434,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2013,489.44,2.72,active,2,489.441,3.0506,-4.211,5,3,76.82,2.9439,0.17941,1.0451,5,2,3,0.36203,0.74012,-0.6834332792,0.2859471426,-0.4230956847,6,6
CHEMBL4296733,CCN1CC[C@]23Cc4nc5ccccc5cc4C[C@@]2(O)[C@H]1Cc1ccc(O)cc13.Cl.Cl,106.4,6.97,F,CHEMBL3091434,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2013,459.42,3.36,intermediate,1,459.415,3.618,-4.34,4,2,56.59,5.1211,0.13291,1.0401,4,1,3,0.38888,0.74919,-1.109102165,0.1374817649,-0.3984878983,6,6
CHEMBL4296735,Cl.Cl.OCCN1CC[C@]23Cc4nc5ccccc5cc4C[C@@]2(O)[C@H]1Cc1ccc(O)cc13,158,6.8,F,CHEMBL3091434,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2013,475.42,2.33,intermediate,1,475.414,2.6913,-3.833,5,3,76.82,4.0589,0.16703,1.0422,5,2,3,0.3738,0.74258,-0.6806475001,0.5841606527,-0.3847282571,6,6
CHEMBL4296736,CCOCCN1CC[C@]23Cc4nc5ccccc5cc4C[C@@]2(O)[C@H]1Cc1ccc(O)cc13.Cl.Cl,202.1,6.69,F,CHEMBL3091434,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2013,503.47,3.38,intermediate,1,503.468,3.5255,-4.261,5,2,65.82,2.6617,0.21571,1.0317,5,4,3,0.3479,0.71641,-0.7488336741,0.1213481007,-0.1160532864,6,6
CHEMBL4296737,Cl.Cl.Oc1ccc2c(c1)[C@]13CCN(C[C@@H]4CCCO4)[C@H](C2)[C@]1(O)Cc1cc2ccccc2nc1C3,15.29,7.82,F,CHEMBL3091434,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem,2013,515.48,3.52,active,2,515.479,3.5115,-4.725,5,2,65.82,2.1685,0.18795,1.0349,5,2,3,0.35266,0.72395,-0.7979806378,-0.1352851047,-0.4290006224,2,1
CHEMBL4299371,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1,39,7.41,F,CHEMBL3734657,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation by bioluminescent assay,1,Scientific Literature,J Med Chem,2015,1120.21,None,active,2,1120.2,4.8202,-8.453,17,8,248.16,-2.3451,0.56151,0.97737,23,24,5,0.38887,0.5513,4.061081521,-3.322325264,0.4103015668,1,1
CHEMBL430397,C[C@H]1C2Cc3ccc(C(=O)NCCCc4ccc5ccccc5c4)cc3[C@@]1(C)CCN2CC1CC1,24,7.62,F,CHEMBL1140563,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membrane by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2007,466.67,6.14,active,2,466.667,6.5158,-7.004,3,1,32.34,3.2404,0.45314,0.91714,3,7,3,0.33133,0.6568,-1.32779281,-2.033662713,0.05159173325,1,1
CHEMBL431074,Cc1ncc2c(n1)C1Oc3c(O)ccc4c3C13CCN(C)C(C4)C3(O)C2,71.95,7.14,F,CHEMBL1131901,agonist,agonist,Agonistic activity against human opioid Mu receptor transfected into Chinese hamster ovary (CHO) cells using [3H]-DAMGO as radioligand,1,Scientific Literature,Bioorg Med Chem Lett,1999,351.41,1.41,active,2,351.405,1.1755,-1.781,6,2,78.71,5.4143,0.17524,1.0791,6,0,2,0.48822,0.79786,-0.8445014169,2.187319217,-0.3056156551,3,3
CHEMBL437983,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](CCCN)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,1.4,8.85,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,481.64,3.16,highly_active,3,481.635,0.056,-3.743,7,4,115.89,-6.4919,0.5293,0.81859,7,11,2,0.3536,0.69001,0.4942696386,0.9916573395,0.03306890693,14,8
CHEMBL438821,C[C@H]1[C@@H]2CC[C@@H](c3ccccc3)CN2CC[C@@]1(C)c1cccc(O)c1,53,7.28,F,CHEMBL1137299,agonist,agonist,Agonist activity at human cloned mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,335.49,4.94,active,2,335.489,5.0535,-4.416,2,1,23.47,2.7318,0.34299,0.86049,2,2,2,0.67538,0.86455,-1.853797185,-0.06889204152,-0.01642952888,10,1
CHEMBL438871,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccc(Cl)cc5)cc4)cc3[C@@]1(C)CCN2CC1CC1,2.5,8.6,F,CHEMBL1140563,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membrane by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2007,513.13,6.91,highly_active,3,513.123,7.1322,-7.95,3,1,32.34,5.5911,0.46121,0.91968,4,7,3,0.32177,0.6438,-1.225468929,-2.743776829,-0.0951099133,15,3
CHEMBL441765,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1,4840,5.32,F,CHEMBL1144846,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay,1,Scientific Literature,J Med Chem,2008,369.34,4.4,inactive,0,369.334,4.2898,-4.187,3,0,23.55,1.3436,0.57252,0.78821,5,4,1,0.44912,0.74848,-1.484402735,0.124604996,0.1279126565,1,1
CHEMBL441899,C[C@H]1CN(CCC(=O)N[C@@H](Cc2ccc(-c3ccccc3)cc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1,28,7.55,F,CHEMBL1144033,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding,1,Scientific Literature,Bioorg Med Chem Lett,2008,500.64,4.86,active,2,500.637,3.6394,-5.56,6,3,89.87,-5.784,0.50995,0.81625,6,9,3,0.32864,0.64937,-0.1936666286,-0.7084849628,-0.00342081411,1,1
CHEMBL443311,O=C1CC[C@@]2(NCCCc3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,0.0125,10.9,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,493.05,4.41,highly_active,3,493.045,4.4391,-5.625,5,2,61.8,4.4018,0.35005,1.0879,6,7,2,0.34389,0.71642,-0.6269705056,-0.8715810843,-0.02643241368,2,2
CHEMBL4434948,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1C/C=C\C[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,19.6,7.71,F,CHEMBL4433209,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,ACS Med Chem Lett,2019,1161.08,-1.31,active,2,1161.08,-1.5966,-5.324,20,12,325.3,1.4627,0.41714,0.87743,20,12,4,0.5934,0.60867,4.794715508,-0.1791854882,-1.163504318,2,1
CHEMBL4435280,CC(C)[C@H]1CC[C@@H](N2CCC(n3ccc4ccccc43)CC2)CC1,232,6.63,F,CHEMBL4354845,agonist,agonist,Agonist activity at human MOP expressed in CHO cell membrane incubated for 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,324.51,5.49,intermediate,1,324.51,5.1187,-3.397,2,0,8.17,1.8452,0.32206,0.78055,2,3,2,0.33653,0.7438,-2.018775774,0.5028099675,0.3953603492,4,4
CHEMBL4436170,CC(C)C1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O,0.2,9.7,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,392.54,4.15,highly_active,3,392.541,3.9089,-3.94,4,0,32.78,8.7601,0.38593,0.81672,4,5,2,0.30019,0.70045,-1.338793843,0.306835875,0.2304123176,37,21
CHEMBL4437661,CCOc1ccc(CN2CC3CC3C2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F,990,6,F,CHEMBL4376894,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,551.61,3.05,intermediate,1,551.604,2.5451,-3.902,6,3,87.82,0.49288,0.53911,0.79328,6,9,2,0.33944,0.66587,-0.07046129544,0.4087084417,0.2548647571,1,1
CHEMBL4438550,O=C1N(c2ccccc2)CC2(CCN(CCc3ccccc3)CC2)OC12CC2,11,7.96,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,376.5,3.66,active,2,376.498,3.241,-3.705,4,0,32.78,9.1703,0.39009,0.82887,4,4,2,0.33418,0.70879,-1.341939545,0.5890365524,0.08924685808,2,1
CHEMBL4439285,COCC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O,32,7.5,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,394.52,3.14,active,2,394.513,2.7374,-3.131,5,0,42.01,8.6376,0.39562,0.81672,5,6,2,0.30225,0.68801,-1.042138663,0.9732313926,0.329670754,37,21
CHEMBL4439718,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cnccn2)C1=O,527,6.28,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,366.47,2.31,intermediate,1,366.463,1.5858,-2.445,6,0,58.56,8.8656,0.38511,0.83059,6,4,2,0.35523,0.72078,-0.9005093414,1.632173281,0.08793843477,37,1
CHEMBL4439811,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(/C=N/O)c4ccccc43)CC2)CC1,3199,5.5,F,CHEMBL4354845,agonist,agonist,Agonist activity at human MOP expressed in CHO cell membrane incubated for 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,367.54,5.3,inactive,0,367.535,5.6734,-4.096,4,1,40.76,2.1557,0.31207,0.8267,4,4,2,0.34666,0.70997,-1.506322814,-0.04089588486,0.2986889599,4,4
CHEMBL4439908,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1,523,6.28,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,350.46,3.13,intermediate,1,350.46,2.9115,-3.132,4,0,32.78,8.331,0.39613,0.76523,4,4,2,0.32048,0.71959,-1.370157673,1.008349184,0.1777516499,37,21
CHEMBL4440055,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cccnc2)C1=O,627,6.2,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,365.48,2.91,intermediate,1,365.475,2.2353,-2.715,5,0,45.67,8.8656,0.38465,0.81905,5,4,2,0.32773,0.70716,-1.126322479,1.359191419,0.1499911128,37,6
CHEMBL4440537,CCOc1ccc(CN2CCc3ccccc3C2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F,1.9,8.72,F,CHEMBL4376894,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,601.67,4.15,highly_active,3,601.664,3.3646,-4.752,6,3,87.82,0.021105,0.51662,0.83271,6,9,3,0.34315,0.64596,-0.04945594718,-0.2814880547,0.173146393,1,1
CHEMBL4441320,CCC(=O)N(c1ccccc1)C1CCN(CC(F)c2ccccc2F)CC1,5.495,8.26,F,CHEMBL4304817,agonist,agonist,Agonist activity at Gi-coupled mu opioid receptor (unknown origin) expressed in HEK293T cells assessed as inhibition of cAMP production at pH 6.5 measured after 15 mins by Glo-Sensor assay,1,Scientific Literature,ACS Med Chem Lett,2019,372.46,4.74,highly_active,3,372.457,4.1482,-4.174,3,0,23.55,7.0857,0.51787,0.77872,5,6,2,0.34466,0.72152,-1.372992867,0.1282021012,0.3104038708,14,12
CHEMBL4442534,N=C(N)NCCC[C@H](NC(=O)C12CC3CC(CC(C3)C1)C2)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O,1900,5.72,F,CHEMBL4330128,agonist,agonist,Agonist activity at mu-opioid receptor (unknown origin) expressed in HEK293A cells assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins,1,Scientific Literature,Bioorg Med Chem,2019,1165.45,None,inactive,0,1165.45,2.3494,-8.102,21,12,346.15,2.2858,0.50673,0.94458,21,30,4,0.44646,0.54559,5.473030075,-2.729841994,0.4758620398,2,2
CHEMBL4443716,CCOc1ccc(CN2Cc3ccccc3C2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F,8.4,8.08,F,CHEMBL4376894,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,587.64,4.11,highly_active,3,587.637,2.6391,-4.64,6,3,87.82,-0.227,0.51498,0.81047,6,9,3,0.31592,0.64834,0.008226519735,-0.07647482645,0.09352389965,1,1
CHEMBL4443759,CCOc1ccc(C(=O)N2Cc3ccccc3C2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F,15,7.82,F,CHEMBL4376894,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,601.62,3.75,active,2,601.62,2.7215,-4.769,7,3,104.89,0.30745,0.51755,0.82449,7,8,3,0.38392,0.6593,0.1556156398,-0.1640184522,-0.06380140847,1,1
CHEMBL4445578,CC1OC2(CCN(CCc3ccncc3)CC2)CN(c2ccccc2)C1=O,1424,5.85,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,365.48,2.91,inactive,0,365.475,2.2353,-2.715,5,0,45.67,8.8656,0.38465,0.79656,5,4,2,0.31818,0.71357,-1.126322479,1.359191419,0.1499911128,37,1
CHEMBL4446209,COC(=O)CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O,181,6.74,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,422.53,3.06,intermediate,1,422.523,2.8422,-3.383,6,0,59.08,3.2882,0.40452,0.83059,6,7,2,0.28974,0.68065,-0.7793362176,0.7704036828,0.346964473,37,21
CHEMBL4446292,O=C1COC2(CCN(Cc3ccccc3)CC2)CN1c1ccccc1,3044,5.52,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,336.44,3.08,inactive,0,336.434,2.4814,-3.02,4,0,32.78,7.6461,0.37763,0.76723,4,3,2,0.33008,0.7342,-1.39222774,1.174987511,0.04117193767,1,1
CHEMBL4448670,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ncccc2C(F)(F)F)C1=O,343,6.46,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,433.47,3.93,intermediate,1,433.472,3.435,-4.018,5,0,45.67,1.6756,0.42009,0.87115,8,5,2,0.31752,0.70954,-0.8792646186,0.3004564061,0.08006596238,37,5
CHEMBL4449152,CC(Cc1ccsc1)NC(=O)NCC(Cc1ccccc1)N(C)C,180,6.75,F,CHEMBL4406853,antagonist,antagonist,Inhibition of mu opioid receptor (unknown origin) assessed as reduction in intracellular cAMP accumulation,1,Scientific Literature,Eur J Med Chem,2019,345.51,3.15,intermediate,1,345.509,2.8765,-3.279,4,2,72.61,6.7108,0.64606,0.64904,5,8,2,0.40691,0.71718,-0.8186950819,0.9106128715,0.3998235883,2,2
CHEMBL4449491,N=C(N)NCCC[C@H](NC(=O)C12CC3CC(CC(C3)C1)C2)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O,1584.89,5.8,F,CHEMBL4330128,agonist,agonist,Agonist activity at mu-opioid receptor (unknown origin) expressed in HEK293A cells assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins,1,Scientific Literature,Bioorg Med Chem,2019,1165.45,None,inactive,0,1165.45,2.3494,-8.102,21,12,346.15,2.2858,0.50425,0.94611,21,30,4,0.4491,0.54245,5.473030075,-2.729841994,0.4758620398,2,2
CHEMBL4450665,C[C@H]1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O,16,7.8,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,364.49,3.52,active,2,364.487,3.2362,-3.51,4,0,32.78,8.8656,0.38458,0.79656,4,4,2,0.32554,0.70902,-1.368912998,0.7161311527,0.1343845478,37,21
CHEMBL4451073,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CCCN)c4ccccc43)CC2)CC1.Cl.Cl,1764,5.75,F,CHEMBL4354845,agonist,agonist,Agonist activity at human MOP expressed in CHO cell membrane incubated for 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,454.53,5.38,inactive,0,454.528,5.0081,-3.739,3,1,34.19,1.461,0.36493,0.84784,3,6,2,0.37619,0.696,-1.360415586,0.17516673,0.5283763357,4,4
CHEMBL4451128,CC(c1ccc2c(c1)OCCO2)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,106,6.97,F,CHEMBL4371007,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes after 1 hr by [35S]-GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2018,379.46,3.5,intermediate,1,379.459,3.0943,-4.297,6,1,54.04,-0.0012731,0.40177,0.83521,6,3,2,0.33928,0.71252,-0.9425381603,0.2913714025,-0.272400413,1,1
CHEMBL4451838,CC(=O)Nc1ccccc1CCN1CCC2(CC1)CN(c1ccccc1)C(=O)C(C)O2,342,6.47,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,421.54,3.47,intermediate,1,421.539,2.9399,-3.852,6,1,61.88,9.4319,0.40807,0.82887,6,5,2,0.42703,0.69432,-0.7635496523,0.5161061851,0.009115574029,37,21
CHEMBL4452042,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2Cl)C1=O,1,9,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,398.93,4.17,highly_active,3,398.932,3.8422,-4.246,4,0,32.78,8.8875,0.37625,0.83271,5,4,2,0.31047,0.71547,-1.293600415,0.1429158597,0.03568097303,37,21
CHEMBL4452384,O=c1[nH]c2cc(Cl)c(Cl)cc2n1C1CCN(Cc2ccc(Cl)cc2)CC1,97,7.01,F,CHEMBL4371007,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes after 1 hr by [35S]-GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2018,410.73,5.13,active,2,410.731,4.6468,-6.252,4,1,35.58,7.4423,0.39828,0.83354,7,3,2,0.30762,0.71115,-1.106717383,-1.168027767,-0.4975730606,45,42
CHEMBL445332,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,2860,5.54,F,CHEMBL1773062,agonist,agonist,Agonist activity at mu opioid receptor assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,J Nat Prod,2011,432.47,3,inactive,0,432.467,1.8395,-3.667,8,0,109.11,-1.1048,0.26595,1.0069,8,5,1,0.4748,0.73962,-0.3229911435,0.8025835957,-0.16762685,1,1
CHEMBL4453368,CCOc1ccc(Cc2ccccc2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C,72,7.14,F,CHEMBL4376894,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,432.56,4.18,active,2,432.562,4.0437,-5.277,5,3,84.58,-1.735,0.56255,0.78706,5,9,3,0.36939,0.66687,-0.4950529346,-0.5480045778,0.1374679323,3,1
CHEMBL4454089,Cc1cc(C)c(Nc2nc(-c3sc(C)nc3C)cs2)c(C)c1,6100,5.21,F,CHEMBL4390642,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells coexpressing Galpha15 assessed as increase in intracellular calcium flux in presence of mu opioid receptor antagonist naloxone and incubated for 1 hr measured for 90 secs at 1.5 sec interval by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2019,329.49,5.55,inactive,0,329.491,5.4082,-5.5,3,1,94.29,3.4623,0.45991,0.79273,5,3,3,0.38986,0.70914,-1.340106967,-0.7660608497,-0.2696885113,16,13
CHEMBL4454409,COc1ccc(Nc2nc(-c3sc(C)nc3C)cs2)c(C)c1,14000,4.85,F,CHEMBL4390642,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells coexpressing Galpha15 assessed as increase in intracellular calcium flux in presence of mu opioid receptor antagonist naloxone and incubated for 1 hr measured for 90 secs at 1.5 sec interval by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2019,331.47,4.94,inactive,0,331.463,4.6504,-4.83,4,1,103.52,3.3925,0.43239,0.79273,6,4,3,0.22286,0.70438,-1.085246902,-0.2532123161,-0.1446557145,16,13
CHEMBL4455986,Cc1nc(C)c(-c2csc(Nc3c(C)cccc3F)n2)s1,4200,5.38,F,CHEMBL4390642,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells coexpressing Galpha15 assessed as increase in intracellular calcium flux in presence of mu opioid receptor antagonist naloxone and incubated for 1 hr measured for 90 secs at 1.5 sec interval by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2019,319.43,5.07,inactive,0,319.427,4.8212,-5.126,3,1,94.29,2.1223,0.4549,0.79871,6,3,3,0.3869,0.72977,-1.245677063,-0.4365167675,-0.2761717311,16,13
CHEMBL4456958,CCc1cccc(C)c1Nc1nc(-c2sc(C)nc2C)cs1,2800,5.55,F,CHEMBL4390642,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells coexpressing Galpha15 assessed as increase in intracellular calcium flux in presence of mu opioid receptor antagonist naloxone and incubated for 1 hr measured for 90 secs at 1.5 sec interval by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2019,329.49,5.5,inactive,0,329.491,5.4799,-5.315,3,1,94.29,3.2397,0.47692,0.79602,5,4,3,0.40843,0.72018,-1.311627481,-0.6823459482,-0.1144270236,16,13
CHEMBL4457219,CCc1ccccc1Nc1nc(-c2sc(C)nc2C)cs1,4000,5.4,F,CHEMBL4390642,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells coexpressing Galpha15 assessed as increase in intracellular calcium flux in presence of mu opioid receptor antagonist naloxone and incubated for 1 hr measured for 90 secs at 1.5 sec interval by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2019,315.47,5.19,inactive,0,315.464,5.136,-4.971,3,1,94.29,3.2397,0.43423,0.78706,5,4,3,0.33854,0.71925,-1.309071244,-0.4068247048,-0.08215206301,16,13
CHEMBL4457592,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CC[N+]([O-])(CCc2ccccc2)CC1,4.4,8.36,F,CHEMBL4406915,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as cAMP accumulation incubated for 30 mins and measured after 1 hr by Eu-cAMP tracer based TR-FRET assay,1,Scientific Literature,ACS Med Chem Lett,2019,410.51,3.69,highly_active,3,410.512,2.8926,-1.369,6,0,63.68,-1.343,0.57787,0.83271,6,8,2,0.37277,0.72351,-0.8359738996,1.947291145,0.93833395,14,12
CHEMBL4458337,CC[C@@H]1CN2CC[C@]3(Nc4cccc(-c5ccccc5)c4C3=O)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,1.4,8.85,F,CHEMBL4406853,antagonist,antagonist,Inhibition of mu opioid receptor (unknown origin) in presence of DPDPE by [35S]-GTPgammaS binding assay,1,Scientific Literature,Eur J Med Chem,2019,460.57,4.52,highly_active,3,460.572,3.7343,-5.484,6,1,67.87,2.3776,0.25976,0.98993,6,6,2,0.5235,0.69608,-0.6556497801,-0.6314279582,-0.1779344931,1,1
CHEMBL4458454,CCC(=O)N(c1ccccc1)C1CCN(CC(F)c2cccc(F)c2)CC1,77.62,7.11,F,CHEMBL4304817,agonist,agonist,Agonist activity at Gi-coupled mu opioid receptor (unknown origin) expressed in HEK293T cells assessed as inhibition of cAMP production at pH 7.4 measured after 15 mins by Glo-Sensor assay,1,Scientific Literature,ACS Med Chem Lett,2019,372.46,4.74,active,2,372.457,4.1482,-4.174,3,0,23.55,7.0857,0.52937,0.77436,5,6,2,0.35626,0.71986,-1.372992867,0.1282021012,0.3104038708,14,12
CHEMBL4459117,O=C1C(CO)OC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1,125,6.9,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,380.49,2.49,intermediate,1,380.486,2.3095,-3.003,5,1,53.01,8.5374,0.39209,0.81047,5,5,2,0.32071,0.7074,-0.9404583218,1.1628099,0.1481441307,37,21
CHEMBL4460762,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cnccc2C(F)(F)F)C1=O,25,7.6,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,433.47,3.93,active,2,433.472,3.0836,-3.493,5,0,45.67,1.6756,0.40793,0.86625,8,5,2,0.3169,0.70985,-0.8624872395,0.6705347905,0.1577252173,37,6
CHEMBL4461774,O=C1N(c2cccnc2C(F)(F)F)CC2(CCN(CCc3ccccc3F)CC2)OC12CC2,195,6.71,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,463.48,4.21,intermediate,1,463.474,3.2432,-4.026,5,0,45.67,1.9803,0.40403,0.91876,9,5,2,0.36105,0.70647,-0.7513808718,0.2984490783,0.04348611852,2,1
CHEMBL4463621,CC1OC2(CCN(CCc3cccc(C#N)c3)CC2)CN(c2ccccc2)C1=O,61,7.21,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,389.5,3.39,active,2,389.497,3.0718,-4.283,5,0,56.57,4.5856,0.39817,0.81096,5,4,2,0.3274,0.69452,-1.078675162,0.2701105905,-0.1241209266,37,21
CHEMBL4463839,Cc1nc(C)c(-c2csc(Nc3ccccc3CC(F)(F)F)n2)s1,8500,5.07,F,CHEMBL4390642,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells coexpressing Galpha15 assessed as increase in intracellular calcium flux in presence of mu opioid receptor antagonist naloxone and incubated for 1 hr measured for 90 secs at 1.5 sec interval by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2019,369.44,5.73,inactive,0,369.434,5.6203,-5.711,3,1,94.29,-8.716,0.48657,0.79977,8,5,3,0.38103,0.71897,-1.026258699,-0.9966891749,-0.1199073681,16,13
CHEMBL4465237,CCc1nc(C)c(-c2csc(Nc3ccccc3CC)n2)s1,8600,5.07,F,CHEMBL4390642,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells coexpressing Galpha15 assessed as increase in intracellular calcium flux in presence of mu opioid receptor antagonist naloxone and incubated for 1 hr measured for 90 secs at 1.5 sec interval by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2019,329.49,5.44,inactive,0,329.491,5.5516,-5.13,3,1,94.29,2.5573,0.45545,0.79924,5,5,3,0.30754,0.71063,-1.283147995,-0.5986310466,0.04083446406,16,13
CHEMBL4466953,Cc1cc(C[C@H](N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)cc(C)c1O,9.55,8.02,F,CHEMBL4396910,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells co-expressing C-terminally modified Galphaqi5 assessed as induction of calcium mobilization by Fluo-4AM dye-based fluorescence assay,1,Scientific Literature,Eur J Med Chem,2019,599.73,1.81,highly_active,3,599.73,1.9513,-4.738,10,5,167.85,4.4461,0.52955,0.85376,10,12,3,0.4335,0.65581,1.162530443,-0.02641225593,0.02600373863,6,6
CHEMBL4467654,COc1cccc(Nc2nc(-c3sc(C)nc3C)cs2)c1C,3300,5.48,F,CHEMBL4390642,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells coexpressing Galpha15 assessed as increase in intracellular calcium flux in presence of mu opioid receptor antagonist naloxone and incubated for 1 hr measured for 90 secs at 1.5 sec interval by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2019,331.47,4.94,inactive,0,331.463,4.6504,-4.83,4,1,103.52,3.3925,0.41312,0.80446,6,4,3,0.25691,0.70647,-1.085246902,-0.2532123161,-0.1446557145,16,13
CHEMBL4467749,C[C@@H]1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O,264,6.58,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,364.49,3.52,intermediate,1,364.487,3.2362,-3.51,4,0,32.78,8.8656,0.38465,0.79656,4,4,2,0.318,0.71269,-1.368912998,0.7161311527,0.1343845478,37,21
CHEMBL4468844,CCC(=O)N(c1ccccc1)C1CCN(CC(F)c2ccccc2)CC1,0.7079,9.15,F,CHEMBL4304817,agonist,agonist,Agonist activity at Gi-coupled mu opioid receptor (unknown origin) expressed in HEK293T cells assessed as inhibition of cAMP production at pH 6.5 measured after 15 mins by Glo-Sensor assay,1,Scientific Literature,ACS Med Chem Lett,2019,354.47,4.6,highly_active,3,354.467,4.0474,-3.86,3,0,23.55,7.0857,0.52609,0.74499,4,6,2,0.34467,0.72089,-1.462310206,0.3497006998,0.381437006,14,12
CHEMBL4469560,O=C1NCCC(=O)N2CCC[C@@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H]1Cc1c[nH]c2ccccc12,6.1,8.21,F,CHEMBL4428100,agonist,agonist,Agonist activity at human MOR expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation by EIA method,1,Scientific Literature,J Med Chem,2016,501.59,1.43,highly_active,3,501.585,1.4069,-3.821,9,4,123.4,7.2814,0.36553,0.8737,9,4,3,0.49005,0.71645,0.3159779462,0.7834791564,-0.5286378432,1,1
CHEMBL4470425,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cncc(F)c2)C1=O,230,6.64,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,383.47,3.05,intermediate,1,383.465,2.3361,-3.029,5,0,45.67,7.5256,0.38668,0.82405,6,4,2,0.3324,0.71448,-1.037005129,1.13769268,0.07895791922,37,6
CHEMBL4471584,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1F,0.7079,9.15,F,CHEMBL4304817,agonist,agonist,Agonist activity at Gi-coupled mu opioid receptor (unknown origin) expressed in HEK293T cells assessed as inhibition of cAMP production at pH 6.5 measured after 15 mins by Glo-Sensor assay,1,Scientific Literature,ACS Med Chem Lett,2019,354.47,4.08,highly_active,3,354.467,4.2654,-4.009,3,0,23.55,3.7806,0.52479,0.78055,4,6,2,0.32309,0.71254,-1.480848631,0.2241753257,0.3764864104,14,12
CHEMBL4472177,Cc1nc(C)c(-c2csc(Nc3ccc(Br)cc3C(F)(F)F)n2)s1,13800,4.86,F,CHEMBL4390642,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells coexpressing Galpha15 assessed as increase in intracellular calcium flux in presence of mu opioid receptor antagonist naloxone and incubated for 1 hr measured for 90 secs at 1.5 sec interval by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2019,434.31,6.41,inactive,0,434.303,5.95,-6.08,3,1,94.29,-5.5177,0.46355,0.82225,9,4,3,0.34361,0.71501,-0.9339773291,-1.322008893,-0.2636495967,16,13
CHEMBL4472829,Cc1ccc(Nc2nc(-c3sc(C)nc3C)cs2)c(C)c1,8800,5.06,F,CHEMBL4390642,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells coexpressing Galpha15 assessed as increase in intracellular calcium flux in presence of mu opioid receptor antagonist naloxone and incubated for 1 hr measured for 90 secs at 1.5 sec interval by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2019,315.47,5.24,inactive,0,315.464,5.0643,-5.156,3,1,94.29,3.4623,0.414,0.78589,5,3,3,0.26261,0.71053,-1.33755073,-0.4905396063,-0.2374135507,16,13
CHEMBL4473632,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSCc2ccccc2CSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccc(F)cc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,3.4,8.47,F,CHEMBL4402550,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes incubated for 1 hr by [35S]-GTPgammaS coupling assay,1,Scientific Literature,J Med Chem,2020,1393.4,None,highly_active,3,1393.39,0.9502,-7.35,20,10,358.32,5.0143,0.40078,0.92059,24,12,5,0.6407,0.60457,5.116826198,-2.059512376,-1.279295782,1,1
CHEMBL4473746,CC1OC2(CCN(CCc3ccccn3)CC2)CN(c2ccccc2)C1=O,229,6.64,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,365.48,2.91,intermediate,1,365.475,2.2893,-2.739,5,0,45.67,8.8656,0.38182,0.80497,5,4,2,0.30144,0.70702,-1.131508479,1.335699933,0.1519226427,37,1
CHEMBL4473857,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1C/C=C/C[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,17.7,7.75,F,CHEMBL4433209,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,ACS Med Chem Lett,2019,1161.08,-1.31,active,2,1161.08,-1.5966,-5.324,20,12,325.3,1.4627,0.41714,0.87743,20,12,4,0.35714,0.58949,4.794715508,-0.1791854882,-1.163504318,2,1
CHEMBL4474914,C[C@@H](Cc1ccsc1)NC(=O)NC[C@H](Cc1ccccc1)N(C)C,4.6,8.34,F,CHEMBL4406853,antagonist,antagonist,Inhibition of mu opioid receptor (unknown origin) assessed as reduction in intracellular cAMP accumulation,1,Scientific Literature,Eur J Med Chem,2019,345.51,3.15,highly_active,3,345.509,2.8765,-3.279,4,2,72.61,6.7108,0.62502,0.64904,5,8,2,0.39983,0.71604,-0.8186950819,0.9106128715,0.3998235883,2,2
CHEMBL4475274,COc1cc(C[C@H](N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)cc(OC)c1O,7.943,8.1,F,CHEMBL4396910,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells co-expressing C-terminally modified Galphaqi5 assessed as induction of calcium mobilization by Fluo-4AM dye-based fluorescence assay,1,Scientific Literature,Eur J Med Chem,2019,631.73,1.21,highly_active,3,631.728,1.1235,-4.086,12,5,186.31,4.4945,0.53172,0.86559,12,14,3,0.45305,0.64738,1.667138149,0.4482420849,0.2115192599,6,6
CHEMBL4482942,CCOc1ccc(CN2CCCCC2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F,585,6.23,F,CHEMBL4376894,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,553.62,3.58,intermediate,1,553.62,2.9837,-4.036,6,3,87.82,-1.4606,0.55841,0.78706,6,9,2,0.34138,0.66493,-0.1122716938,0.2518744733,0.2857748082,3,1
CHEMBL4483643,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ncccc2F)C1=O,199,6.7,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,383.47,3.05,intermediate,1,383.465,2.6875,-3.554,5,0,45.67,7.5256,0.38651,0.83271,6,4,2,0.29566,0.71228,-1.05378252,0.7676144359,0.001298722664,37,5
CHEMBL448428,O=C(Cc1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5,0.26,9.59,F,CHEMBL1137387,antagonist,antagonist,Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2006,493,3.55,highly_active,3,493.001,3.6351,-5.337,6,2,78.87,5.3775,0.31662,1.0926,7,5,2,0.40881,0.73727,-0.4625335255,-0.5337943762,-0.3116571288,2,2
CHEMBL4513822,O=C1NCCCC(=O)N2CCC[C@@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H]1Cc1c[nH]c2ccccc12,183,6.74,F,CHEMBL4428100,agonist,agonist,Agonist activity at human MOR expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation by EIA method,1,Scientific Literature,J Med Chem,2016,515.61,1.82,intermediate,1,515.612,1.8613,-4.091,9,4,123.4,5.8112,0.36216,0.87401,9,4,3,0.40551,0.71601,0.297145005,0.5323911731,-0.5268422495,1,1
CHEMBL4514319,Cc1cc(O)c(Cl)c(C)c1C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,0.6166,9.21,F,CHEMBL4396910,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells co-expressing C-terminally modified Galphaqi5 assessed as induction of calcium mobilization by Fluo-4AM dye-based fluorescence assay,1,Scientific Literature,Eur J Med Chem,2019,634.18,2.46,highly_active,3,634.175,2.5573,-5.474,10,5,167.85,4.4832,0.52289,0.89773,11,12,3,0.4045,0.67592,1.237843023,-0.59962771,-0.07269987727,6,6
CHEMBL4515812,CCC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O,1,9,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,378.52,3.91,highly_active,3,378.514,3.6906,-3.78,4,0,32.78,9.8896,0.38726,0.81047,4,5,2,0.29986,0.70277,-1.342402143,0.4522303729,0.2358225399,37,21
CHEMBL4516327,CC1(C)OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O,4,8.4,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,378.52,3.91,highly_active,3,378.514,3.5342,-3.619,4,0,32.78,6.6978,0.39084,0.81047,4,4,2,0.38937,0.72014,-1.376935243,0.5869617444,0.1529675708,37,21
CHEMBL4516683,CCC(=O)N(c1ccccc1)C1CCN(CC(F)c2ccc(F)cc2)CC1,25.12,7.6,F,CHEMBL4304817,agonist,agonist,Agonist activity at Gi-coupled mu opioid receptor (unknown origin) expressed in HEK293T cells assessed as inhibition of cAMP production at pH 6.5 measured after 15 mins by Glo-Sensor assay,1,Scientific Literature,ACS Med Chem Lett,2019,372.46,4.74,active,2,372.457,4.1482,-4.174,3,0,23.55,7.0857,0.52937,0.76319,5,6,2,0.34775,0.71586,-1.372992867,1.28E-01,0.3104038708,14,12
CHEMBL4518522,CCc1ccccc1Nc1nc(-c2oc(C)nc2C)cs1,3300,5.48,F,CHEMBL4390642,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells coexpressing Galpha15 assessed as increase in intracellular calcium flux in presence of mu opioid receptor antagonist naloxone and incubated for 1 hr measured for 90 secs at 1.5 sec interval by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2019,299.4,4.72,inactive,0,299.397,4.6197,-4.345,4,1,79.19,1.5688,0.43423,0.78706,5,4,3,0.29616,0.71915,-1.292307298,0.06542791792,0.009931146019,16,2
CHEMBL4522004,C[C@H]1OC2(CCN(CCc3ccccc3F)CC2)CN(c2ncccc2C(F)(F)F)C1=O,65,7.19,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,451.46,4.07,active,2,451.463,3.5358,-4.332,5,0,45.67,1.6756,0.41508,0.90551,9,5,2,0.40539,0.71232,-0.7899456872,0.07895696129,0.009033047331,37,5
CHEMBL4522339,CCC1CC2CC3c4[nH]c5ccc(O)cc5c4CCN(C2)C13,16000,4.8,F,CHEMBL4406853,partial agonist,agonist,Partial agonist activity at mu opioid receptor (unknown origin) expressed in CHO cells by [35S]-GTPgammaS binding assay,1,Scientific Literature,Eur J Med Chem,2019,296.41,3.63,inactive,0,296.413,3.76,-3.652,3,2,39.26,4.0141,0.21301,0.93236,3,1,2,0.40835,0.77829,-1.58482533,0.6698224171,-0.1945099797,1,1
CHEMBL4524446,COC(=O)C1(N(C(=O)CCO)c2ccccc2)CCN(CCc2ccccc2)CC1,0.28,9.55,F,CHEMBL4406915,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as cAMP accumulation incubated for 30 mins and measured after 1 hr by Eu-cAMP tracer based TR-FRET assay,1,Scientific Literature,ACS Med Chem Lett,2019,410.51,2.65,highly_active,3,410.512,2.9393,-3.031,6,1,70.08,5.7951,0.52822,0.81859,6,9,2,0.45732,0.71461,-0.6099715955,0.9605749742,0.5953411095,14,12
CHEMBL4525653,CC(=O)Nc1cccc(CCN2CCC3(CC2)CN(c2ccccc2)C(=O)[C@@H](C)O3)c1,69,7.16,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,421.54,3.47,active,2,421.539,2.9399,-3.852,6,1,61.88,9.4319,0.43329,0.82089,6,5,2,0.313,0.67349,-0.7635496523,0.5161061851,0.009115574029,37,21
CHEMBL4526087,COc1ccccc1N1CC2(CCN(CCc3ccccc3)CC2)OC(C)C1=O,144,6.84,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,394.52,3.52,intermediate,1,394.513,3.1662,-3.528,5,0,42.01,8.8654,0.3751,0.83847,5,5,2,0.40316,0.70592,-1.119165419,0.6779369485,0.1948672967,37,21
CHEMBL4527584,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1cccc(O)c1,44.67,7.35,F,CHEMBL4396910,agonist,agonist,Agonist activity at human recombinant MOR expressed in CHO cells co-expressing C-terminally modified Galphaqi5 assessed as induction of calcium mobilization by Fluo-4AM dye-based fluorescence assay,1,Scientific Literature,Eur J Med Chem,2019,571.68,1.19,active,2,571.676,1.2635,-4.05,10,5,167.85,4.4795,0.52212,0.84323,10,12,3,0.40561,0.66946,1.16764308,0.5246302761,0.09055358321,6,6
CHEMBL4528962,O=C1C(COCc2ccccc2)OC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1,107,6.97,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,470.61,4.71,intermediate,1,470.611,4.1555,-4.454,5,0,42.01,7.0808,0.40709,0.82757,5,8,3,0.30868,0.64863,-0.9381754462,-0.1496400395,0.4220811724,1,1
CHEMBL4530626,CN(C)[C@H](CNC(=O)NCCc1ccsc1)Cc1cccc2ccccc12,203.4,6.69,F,CHEMBL4406853,antagonist,antagonist,Inhibition of mu opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation preincubated for 30 mins followed by forskolin-stimulation and measured after 60 mins,1,Scientific Literature,Eur J Med Chem,2019,381.55,3.92,intermediate,1,381.542,3.7116,-4.507,4,2,72.61,4.6853,0.56408,0.71292,5,8,3,0.35085,0.69011,-0.8037901269,0.00843671696,0.2256972637,2,1
CHEMBL4533745,CN(C)[C@H](CNC(=O)NCCc1cccs1)Cc1cccc2ccccc12,52.41,7.28,F,CHEMBL4406853,antagonist,antagonist,Inhibition of mu opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation preincubated for 30 mins followed by forskolin-stimulation and measured after 60 mins,1,Scientific Literature,Eur J Med Chem,2019,381.55,3.92,active,2,381.542,3.7938,-4.617,4,2,72.61,6.1069,0.57008,0.71292,5,8,3,0.3184,0.69023,-0.8083040727,-0.07058917937,0.210664623,2,1
CHEMBL4534193,CC1OC2(CCN(CCc3cccc(F)c3)CC2)CN(c2ccccc2)C1=O,13,7.89,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,382.48,3.65,active,2,382.477,3.337,-3.824,4,0,32.78,7.5256,0.39317,0.83968,5,4,2,0.31226,0.70652,-1.279595631,0.4946325955,0.06335137815,37,21
CHEMBL4535897,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cccnc2C(F)(F)F)C1=O,186,6.73,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,433.47,3.93,intermediate,1,433.472,3.1376,-3.517,5,0,45.67,1.6756,0.40428,0.87115,8,5,2,0.3506,0.72251,-0.8676732502,0.6470434455,0.1596568055,37,6
CHEMBL4536259,CC1OC2(CCN(CCc3ccccc3F)CC2)CN(c2ccccc2)C1=O,4,8.4,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,382.48,3.65,highly_active,3,382.477,3.337,-3.824,4,0,32.78,7.5256,0.3804,0.84127,5,4,2,0.31754,0.70475,-1.279595631,0.4946325955,0.06335137815,37,21
CHEMBL4537210,CCC(=O)N(c1ccccc1)C1CCN(CC(F)(F)c2ccccc2)CC1,5754.4,5.24,F,CHEMBL4304817,agonist,agonist,Agonist activity at Gi-coupled mu opioid receptor (unknown origin) expressed in HEK293T cells assessed as inhibition of cAMP production at pH 6.5 measured after 15 mins by Glo-Sensor assay,1,Scientific Literature,ACS Med Chem Lett,2019,372.46,4.69,inactive,0,372.457,4.5653,-3.662,3,0,23.55,3.6657,0.5345,0.76657,5,6,2,0.33916,0.72028,-1.445137597,0.3574588783,0.4959303384,14,12
CHEMBL4538620,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cccc(C(F)(F)F)n2)C1=O,219,6.66,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,433.47,3.93,intermediate,1,433.472,3.489,-4.042,5,0,45.67,1.6756,0.41921,0.85083,8,5,2,0.38733,0.6949,-0.8844506681,0.2769651602,0.08199764341,37,5
CHEMBL4540888,CC1OC2(CCN(CCc3ccccn3)CC2)CN(c2cnccc2C(F)(F)F)C1=O,767,6.12,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,434.46,3.32,intermediate,1,434.461,2.1367,-2.722,6,0,58.56,1.6756,0.40564,0.87147,9,5,2,0.34124,0.72718,-0.6250811629,1.290102755,0.1752635223,37,1
CHEMBL4541206,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O,14,7.85,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,364.49,3.52,active,2,364.487,3.2362,-3.51,4,0,32.78,8.8656,0.38465,0.79656,4,4,2,0.30668,0.71264,-1.368912998,0.7161311527,0.1343845478,37,21
CHEMBL4541902,Cc1cc(C)c(Nc2nc(-c3oc(C)nc3C)cs2)c(C)c1,3900,5.41,F,CHEMBL4390642,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells coexpressing Galpha15 assessed as increase in intracellular calcium flux in presence of mu opioid receptor antagonist naloxone and incubated for 1 hr measured for 90 secs at 1.5 sec interval by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2019,313.43,5.08,inactive,0,313.424,4.8919,-4.874,4,1,79.19,1.7278,0.45991,0.79273,5,3,3,0.39266,0.70798,-1.323343054,-0.2938085904,-0.17760535,16,2
CHEMBL4544352,CC1OC2(CCN(CCc3ccc(F)cc3)CC2)CN(c2ccccc2)C1=O,25,7.6,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,382.48,3.65,active,2,382.477,3.337,-3.824,4,0,32.78,7.5256,0.39317,0.83562,5,4,2,0.30403,0.70484,-1.279595631,0.4946325955,0.06335137815,37,21
CHEMBL4546925,CC[C@@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@H]2C[C@@H]1/C(=C\OC)C(=O)OC,39.2,7.41,F,CHEMBL4376854,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of cAMP accumulation incubated for 10 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,398.5,3.83,active,2,398.501,3.2432,-3.205,6,1,63.79,2.1076,0.27313,0.95369,6,6,2,0.45791,0.73419,-0.8126290373,0.854059777,0.3046208993,10,1
CHEMBL4548515,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CN)c4ccccc43)CC2)CC1,105,6.98,F,CHEMBL4354845,agonist,agonist,Agonist activity at human MOP expressed in CHO cell membrane incubated for 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,353.55,4.95,intermediate,1,353.552,4.1236,-3.357,3,1,34.19,1.7272,0.32997,0.83644,3,4,2,0.37433,0.71885,-1.521682661,0.6750511875,0.2789832649,4,4
CHEMBL4548662,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CC(=O)c2ccccc2)CC1,0.2,9.7,F,CHEMBL4406915,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as cAMP accumulation incubated for 30 mins and measured after 1 hr by Eu-cAMP tracer based TR-FRET assay,1,Scientific Literature,ACS Med Chem Lett,2019,408.5,3.32,highly_active,3,408.496,2.9777,-3.719,6,0,66.92,8.0022,0.4874,0.8236,6,8,2,0.47814,0.7153,-0.7302267501,0.5511179572,0.370911971,1,1
CHEMBL4550454,CCC(=O)N(c1ccccc1)C1CCN(CC(F)c2ccc(F)cc2F)CC1,11.75,7.93,F,CHEMBL4304817,agonist,agonist,Agonist activity at Gi-coupled mu opioid receptor (unknown origin) expressed in HEK293T cells assessed as inhibition of cAMP production at pH 6.5 measured after 15 mins by Glo-Sensor assay,1,Scientific Literature,ACS Med Chem Lett,2019,390.45,4.88,active,2,390.448,4.249,-4.488,3,0,23.55,7.0857,0.51985,0.79438,6,6,2,0.34597,0.71366,-1.28367396,-0.09329759535,0.2393708343,14,12
CHEMBL4550656,COc1cccc(N2CC3(CCN(CCc4ccccc4)CC3)OC(C)C2=O)c1,304,6.52,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,394.52,3.52,intermediate,1,394.513,3.1662,-3.528,5,0,42.01,8.8654,0.39857,0.82089,5,5,2,0.31798,0.68481,-1.119165419,0.6779369485,0.1948672967,37,21
CHEMBL4551481,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccc(F)cc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,6.2,8.21,F,CHEMBL4402550,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes incubated for 1 hr by [35S]-GTPgammaS coupling assay,1,Scientific Literature,J Med Chem,2020,1289.25,None,highly_active,3,1289.24,-0.2226,-5.374,20,10,358.32,4.7993,0.41809,0.89368,24,12,4,0.4939,0.60126,5.00158251,-0.5935255287,-0.9816014289,4,3
CHEMBL455502,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O,132.4,6.88,F,CHEMBL1149874,agonist,agonist,Agonist activity at mu opioid receptor assessed as inhibition of forskolin-induced cAMP production in human SH-SY5Y cells pretreated for 24 hrs with excess ligand after 15 mins,1,Scientific Literature,Bioorg Med Chem,2008,683.81,1.33,intermediate,1,683.807,0.8971,-5.018,13,8,221.53,3.0746,0.53547,0.86391,13,17,4,0.38962,0.61462,2.45312011,-0.1074208077,0.09072384274,1,1
CHEMBL4557264,CCOc1ccc(CN2CCOCC2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F,1020,5.99,F,CHEMBL4376894,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,555.59,2.43,inactive,0,555.592,1.8197,-3.147,7,3,97.05,-0.80539,0.55908,0.78706,7,9,2,0.35783,0.66534,0.1344851012,0.9768974104,0.306045711,3,1
CHEMBL4561162,Cc1nc(C)c(-c2csc(Nc3cccc(F)c3C)n2)s1,10100,5,F,CHEMBL4390642,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells coexpressing Galpha15 assessed as increase in intracellular calcium flux in presence of mu opioid receptor antagonist naloxone and incubated for 1 hr measured for 90 secs at 1.5 sec interval by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2019,319.43,5.07,inactive,0,319.427,4.8212,-5.126,3,1,94.29,2.1223,0.414,0.79328,6,3,3,0.25744,0.72496,-1.245677063,-0.4365167675,-0.2761717311,16,13
CHEMBL4562635,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCNCC1,17,7.77,F,CHEMBL4406915,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as cAMP accumulation incubated for 30 mins and measured after 1 hr by Eu-cAMP tracer based TR-FRET assay,1,Scientific Literature,ACS Med Chem Lett,2019,290.36,1.72,active,2,290.362,1.7649,-2.465,5,1,58.64,1.6432,0.58146,0.78878,5,5,1,0.6175,0.79939,-1.022537833,1.660836062,0.1791896687,1,1
CHEMBL4564309,CCOc1ccc(CN2CCCC2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F,168,6.78,F,CHEMBL4376894,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,539.6,3.19,intermediate,1,539.593,2.6417,-3.766,6,3,87.82,-0.040601,0.55327,0.78531,6,9,2,0.32425,0.66564,-0.1065318303,0.4834856665,0.3002208597,1,1
CHEMBL4571738,CC1OC2(CCN(CCc3cccnc3)CC2)CN(c2ccccc2)C1=O,853,6.07,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,365.48,2.91,intermediate,1,365.475,2.2353,-2.715,5,0,45.67,8.8656,0.38465,0.80291,5,4,2,0.34368,0.72391,-1.126322479,1.359191419,0.1499911128,37,1
CHEMBL4573960,CC(=O)Nc1cccc(CCN2CCC3(CC2)CN(c2ccccc2)C(=O)C(C)O3)c1,343,6.46,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,421.54,3.47,intermediate,1,421.539,2.9399,-3.852,6,1,61.88,9.4319,0.43336,0.82089,6,5,2,0.32716,0.67824,-0.7635496523,0.5161061851,0.009115574029,37,21
CHEMBL4576031,C[C@H]1OC2(CCN(CCc3ccccc3F)CC2)CN(c2cnccc2C(F)(F)F)C1=O,26,7.58,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,451.46,4.07,active,2,451.463,3.1844,-3.807,5,0,45.67,1.6756,0.40337,0.89639,9,5,2,0.39302,0.72041,-0.773168297,0.4490352053,0.08669224389,37,6
CHEMBL4577586,C[C@H](Cc1ccsc1)NC(=O)NC[C@H](Cc1ccc2ccccc2c1)N(C)C,52.41,7.28,F,CHEMBL4406853,antagonist,antagonist,Inhibition of mu opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation preincubated for 30 mins followed by forskolin-stimulation and measured after 60 mins,1,Scientific Literature,Eur J Med Chem,2019,395.57,4.3,active,2,395.569,4.0709,-4.885,4,2,72.61,6.7108,0.57798,0.7177,5,8,3,0.36061,0.69129,-0.8065758672,-0.2897768922,0.1873297434,1,1
CHEMBL4578287,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCc2ccc(O)cc2)CC1,0.028,10.55,F,CHEMBL4406915,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as cAMP accumulation incubated for 30 mins and measured after 1 hr by Eu-cAMP tracer based TR-FRET assay,1,Scientific Literature,ACS Med Chem Lett,2019,410.51,3.39,highly_active,3,410.512,3.5203,-3.242,6,1,70.08,8.2392,0.52161,0.8153,6,8,2,0.49194,0.71359,-0.7132858499,0.7484481437,0.5280335148,14,12
CHEMBL4578955,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccn2)C1=O,1987,5.7,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,365.48,2.91,inactive,0,365.475,2.5867,-3.24,5,0,45.67,8.8656,0.38511,0.83059,5,4,2,0.29734,0.69866,-1.143099859,0.9891130344,0.07233185789,37,5
CHEMBL4584335,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2F)C1=O,4,8.4,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,382.48,3.65,highly_active,3,382.477,3.337,-3.824,4,0,32.78,7.5256,0.37625,0.83271,5,4,2,0.33006,0.71978,-1.279595631,0.4946325955,0.06335137815,37,21
CHEMBL4586954,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSCc2ccccc2CSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)NNC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,7.5,8.12,F,CHEMBL4402550,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes incubated for 1 hr by [35S]-GTPgammaS coupling assay,1,Scientific Literature,J Med Chem,2020,1339.31,None,highly_active,3,1339.3,-0.376,-8.38,20,12,375.9,1.6267,0.41356,0.90297,24,12,5,1.1165,0.65823,5.470082367,-2.357947639,-1.823567655,1,1
CHEMBL4586970,CCc1cc(Br)ccc1Nc1nc(-c2sc(C)nc2C)cs1,4900,5.31,F,CHEMBL4390642,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells coexpressing Galpha15 assessed as increase in intracellular calcium flux in presence of mu opioid receptor antagonist naloxone and incubated for 1 hr measured for 90 secs at 1.5 sec interval by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2019,394.36,5.95,inactive,0,394.36,5.8612,-5.805,3,1,94.29,1.4497,0.43585,0.81194,6,4,3,0.31626,0.70768,-1.174445695,-1.100680015,-0.1806721336,16,13
CHEMBL4587201,CCOc1ccc(CN(C)Cc2ccccc2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F,33.9,7.47,F,CHEMBL4376894,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,589.66,4.23,active,2,589.653,3.2688,-4.403,6,3,87.82,0.94826,0.57957,0.79383,6,11,3,0.33941,0.64975,0.01777268919,-0.07355549034,0.4420941149,2,2
CHEMBL4587559,CCc1ccccc1Nc1ncc(-c2sc(C)nc2C)o1,13300,4.88,F,CHEMBL4390642,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells coexpressing Galpha15 assessed as increase in intracellular calcium flux in presence of mu opioid receptor antagonist naloxone and incubated for 1 hr measured for 90 secs at 1.5 sec interval by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2019,299.4,4.72,inactive,0,299.397,4.4526,-4.958,4,1,79.19,2.08,0.42685,0.78706,5,4,3,0.32849,0.71467,-1.244637119,-0.2666309508,-0.1641793443,16,1
CHEMBL4588535,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCc2cccc(O)c2)CC1,0.014,10.85,F,CHEMBL4406915,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as cAMP accumulation incubated for 30 mins and measured after 1 hr by Eu-cAMP tracer based TR-FRET assay,1,Scientific Literature,ACS Med Chem Lett,2019,410.51,3.39,highly_active,3,410.512,3.5203,-3.242,6,1,70.08,8.2392,0.52161,0.81905,6,8,2,0.48474,0.71426,-0.7132858499,0.7484481437,0.5280335148,14,12
CHEMBL4592669,CCOc1ccc(CNCc2ccccc2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F,16.7,7.78,F,CHEMBL4376894,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,575.63,3.88,active,2,575.626,3.0023,-4.765,6,4,96.61,-1.7781,0.57874,0.78413,6,11,3,0.34879,0.64411,0.1612785585,-0.2137688448,0.2667272415,2,2
CHEMBL4593220,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cncc(C(F)(F)F)c2)C1=O,721,6.14,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,433.47,3.93,intermediate,1,433.472,3.0836,-3.493,5,0,45.67,1.6756,0.42182,0.85083,8,5,2,0.31251,0.6955,-0.8624872395,0.6705347905,0.1577252173,37,6
CHEMBL4633020,Cc1ccccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5,5.53,8.26,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,584.76,7.12,highly_active,3,584.758,6.9624,-7.441,5,1,54.82,0.54372,0.26335,1.1297,5,8,4,0.39047,0.67591,-0.8206244942,-2.489442357,0.06304845258,25,19
CHEMBL4633024,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,164,6.79,F,CHEMBL4627340,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in human HEK293 cells assessed as increase in cAMP accumulation using [3H]-cAMP as substrate measured after 30mins by liquid scintillation counting method,1,Scientific Literature,Bioorg Med Chem,2020,672.74,0.9,intermediate,1,672.741,-0.3824,-4.717,15,9,260.69,-3.6053,0.50251,0.89477,15,17,4,0.58259,0.61681,3.025884221,0.3211795441,-0.1435511715,11,11
CHEMBL4633209,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314,1.27,8.9,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,570.73,6.81,highly_active,3,570.731,6.6185,-7.097,5,1,54.82,0.58474,0.2608,1.1274,5,8,4,0.36695,0.67294,-0.8180682105,-2.213921143,0.09532341794,25,19
CHEMBL4633223,Cc1cccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)c1,20.6,7.69,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,584.76,7.12,active,2,584.758,6.9624,-7.441,5,1,54.82,0.54372,0.26204,1.1288,5,8,4,0.35384,0.66339,-0.8206244942,-2.489442357,0.06304845258,25,19
CHEMBL4633348,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCc5ccc(F)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314,93.9,7.03,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,588.72,6.95,active,2,588.721,6.7193,-7.411,5,1,54.82,-0.75526,0.26023,1.1151,6,8,4,0.39376,0.68869,-0.7287508269,-2.435419518,0.02429027214,25,19
CHEMBL4633907,COc1cccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)c1,13,7.89,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,600.76,6.82,active,2,600.757,6.5485,-7.115,6,1,64.05,0.63176,0.26884,1.1297,6,9,4,0.37025,0.65586,-0.5683206409,-2.252115066,0.1558062782,25,19
CHEMBL4634007,Oc1ccc2c3c1O[C@H]1c4ncc(-c5cn[nH]c5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314,3.29,8.48,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,560.7,5.53,highly_active,3,560.696,4.5121,-5.67,7,2,83.5,2.547,0.25841,1.1298,7,8,4,0.39694,0.69213,-0.2336384913,-0.9819511557,0.03174130234,5,2
CHEMBL4634021,CN(C)c1cccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)c1,1.5,8.82,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,613.8,6.88,highly_active,3,613.799,6.5149,-7.133,6,1,58.06,1.3312,0.27741,1.1301,6,9,4,0.35199,0.65857,-0.5631105119,-2.270478562,0.1569001821,25,19
CHEMBL4634079,Oc1ccc2c3c1O[C@H]1c4ncc(-n5cccc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314,1.61,8.79,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,559.71,5.93,highly_active,3,559.708,5.1442,-7.324,6,1,59.75,0.74,0.26353,1.1271,6,8,4,0.38232,0.68299,-0.5180287634,-2.080865841,-0.1983182061,5,1
CHEMBL4634862,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314,24.8,7.61,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,584.76,7.2,active,2,584.758,7.0729,-7.367,5,1,54.82,-1.2953,0.26853,1.1274,5,9,4,0.39458,0.6582,-0.7915573745,-2.477821852,0.1967613708,1,1
CHEMBL4634908,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](CCCCNC(=N)N)NC(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,341,6.47,F,CHEMBL4627340,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in human HEK293 cells assessed as increase in cAMP accumulation using [3H]-cAMP as substrate measured after 30mins by liquid scintillation counting method,1,Scientific Literature,Bioorg Med Chem,2020,685.79,1.1,intermediate,1,685.783,-0.327,-4.167,15,10,267.47,-3.0457,0.50463,0.90064,15,18,4,0.57086,0.61242,3.170497467,0.6233404095,0.05736455081,11,11
CHEMBL4635184,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,1128,5.95,F,CHEMBL4627340,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in human HEK293 cells assessed as increase in cAMP accumulation using [3H]-cAMP as substrate measured after 30mins by liquid scintillation counting method,1,Scientific Literature,Bioorg Med Chem,2020,643.74,1.58,inactive,0,643.743,0.2863,-4.526,13,8,231.59,-5.3048,0.49385,0.89932,13,17,4,0.52377,0.62255,2.472783769,0.3282564537,0.1026071477,11,11
CHEMBL4635430,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CNC(C)=O)NC(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,1360,5.87,F,CHEMBL4627340,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in human HEK293 cells assessed as increase in cAMP accumulation using [3H]-cAMP as substrate measured after 30mins by liquid scintillation counting method,1,Scientific Literature,Bioorg Med Chem,2020,604.66,0.1,inactive,0,604.662,-0.7081,-3.389,13,7,218.88,-0.45515,0.52683,0.86221,13,15,3,0.50417,0.63865,2.254860547,1.218732487,0.08324575833,5,5
CHEMBL4636159,COc1ccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)cc1,23.5,7.63,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,600.76,6.82,active,2,600.757,6.5485,-7.115,6,1,64.05,0.63176,0.26884,1.1284,6,9,4,0.33222,0.66246,-0.5683206409,-2.252115066,0.1558062782,25,19
CHEMBL4636305,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(F)cc5F)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314,130,6.89,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,606.71,7.09,intermediate,1,606.711,6.8201,-7.725,5,1,54.82,-0.75526,0.26467,1.1249,7,8,4,0.3683,0.65922,-0.6394334769,-2.656918257,-0.04674292142,25,19
CHEMBL4636598,COc1cc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)ccn1,2.69,8.57,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,601.75,6.21,highly_active,3,601.745,5.899,-6.845,7,1,76.94,0.63176,0.2654,1.1297,7,9,4,0.35986,0.65774,-0.3425075764,-1.979133196,0.09375361792,25,3
CHEMBL4636807,Cc1cc(=O)oc2ccc(N3C(=O)C4=C(SC[C@@H](NC(=O)[C@@H](N)Cc5ccc(O)cc5)C(=O)NCC(=O)N[C@@H](Cc5ccccc5)C(=O)NNC(=O)[C@H](Cc5ccccc5)NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc5ccc(O)cc5)CS4)C3=O)cc12.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,290,6.54,F,CHEMBL4613286,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes after 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,ACS Med Chem Lett,2020,1452.39,None,intermediate,1,1452.38,-1.808,-7.839,25,12,439.58,-1.5949,0.37039,0.99595,27,13,5,0.40949,0.60957,6.517184409,-1.895868861,-1.928650574,1,1
CHEMBL4638662,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](CCN)NC(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,161,6.79,F,CHEMBL4627340,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in human HEK293 cells assessed as increase in cAMP accumulation using [3H]-cAMP as substrate measured after 30mins by liquid scintillation counting method,1,Scientific Literature,Bioorg Med Chem,2020,615.69,0.8,intermediate,1,615.689,-0.6225,-3.986,13,8,231.59,-1.6264,0.49437,0.89639,13,15,4,0.52519,0.63925,2.419762194,0.8560580172,-0.1002688786,11,11
CHEMBL4638667,Cc1cc(F)ccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5,25,7.6,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,602.75,7.26,active,2,602.748,7.0632,-7.755,5,1,54.82,-0.79628,0.26467,1.1243,6,8,4,0.36119,0.66854,-0.7313071441,-2.710941096,-0.007984740971,25,19
CHEMBL4638691,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](CCCN)NC(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,89.3,7.05,F,CHEMBL4627340,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in human HEK293 cells assessed as increase in cAMP accumulation using [3H]-cAMP as substrate measured after 30mins by liquid scintillation counting method,1,Scientific Literature,Bioorg Med Chem,2020,629.72,1.19,active,2,629.716,-0.1681,-4.256,13,8,231.59,-3.3409,0.49409,0.89827,13,16,4,0.50791,0.62658,2.446272981,0.5921572354,0.001169134578,11,11
CHEMBL4638703,CN(C)c1cccc2c(S(=O)(=O)NCCN3C(=O)C4=C(SC[C@@H](NC(=O)[C@@H](N)Cc5ccc(O)cc5)C(=O)NCC(=O)N[C@@H](Cc5ccccc5)C(=O)NNC(=O)[C@H](Cc5ccccc5)NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc5ccc(O)cc5)CS4)C3=O)cccc12.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,21,7.68,F,CHEMBL4613286,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes after 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,ACS Med Chem Lett,2020,1570.59,None,active,2,1570.59,-1.508,-7.938,27,13,471.07,0.58422,0.40051,0.98084,30,17,6,0.59771,0.5555,7.33910956,-2.154235569,-1.614746525,1,1
CHEMBL4638811,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](CCC)NC(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,337,6.47,F,CHEMBL4627340,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in human HEK293 cells assessed as increase in cAMP accumulation using [3H]-cAMP as substrate measured after 30mins by liquid scintillation counting method,1,Scientific Literature,Bioorg Med Chem,2020,614.7,2.25,intermediate,1,614.701,1.1564,-4.687,12,7,205.57,-3.7072,0.49229,0.89639,12,15,4,0.56172,0.63218,1.950475201,0.1192276838,0.07167794975,11,11
CHEMBL4640139,Oc1cccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)c1,1.12,8.95,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,586.73,6.52,highly_active,3,586.73,6.2728,-6.801,6,2,75.05,0.58474,0.26204,1.1288,6,8,4,0.36521,0.67571,-0.4929278343,-1.979369056,0.04177545434,25,19
CHEMBL4640310,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](CN)NC(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,192,6.72,F,CHEMBL4627340,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in human HEK293 cells assessed as increase in cAMP accumulation using [3H]-cAMP as substrate measured after 30mins by liquid scintillation counting method,1,Scientific Literature,Bioorg Med Chem,2020,601.66,0.41,intermediate,1,601.662,-1.0769,-3.716,13,8,231.59,-2.164,0.49292,0.89313,13,14,4,0.46998,0.6501,2.393251312,1.119958857,-0.2017069012,11,11
CHEMBL4640826,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccncc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314,56.3,7.25,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,571.72,6.21,active,2,571.719,5.6176,-6.302,6,1,67.71,0.58474,0.2608,1.1274,6,8,4,0.3751,0.66526,-0.5754777113,-1.570860807,0.1109299437,25,3
CHEMBL4641271,CN(C)c1ccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)cc1,2.1,8.68,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,613.8,6.88,highly_active,3,613.799,6.5149,-7.133,6,1,58.06,1.3312,0.27741,1.1287,6,9,4,0.31664,0.66036,-0.5631105119,-2.270478562,0.1569001821,25,19
CHEMBL4641588,Cc1cc(=O)oc2cc(NC(=O)CCN3C(=O)C4=C(SC[C@@H](NC(=O)[C@@H](N)Cc5ccc(O)cc5)C(=O)NCC(=O)N[C@@H](Cc5ccccc5)C(=O)NNC(=O)[C@H](Cc5ccccc5)NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc5ccc(O)cc5)CS4)C3=O)ccc12.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,270,6.57,F,CHEMBL4613286,agonist,agonist,Agonist activity at human MOR expressed in CHO cell membranes after 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,ACS Med Chem Lett,2020,1523.47,None,intermediate,1,1523.46,-2.0564,-7.538,27,13,468.68,-0.69385,0.38815,0.98753,29,16,5,0.47517,0.62501,7.199747118,-1.764477686,-1.688221133,1,1
CHEMBL4641670,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Br)cc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314,26.6,7.58,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,649.63,7.57,active,2,649.627,7.3437,-7.931,5,1,54.82,-1.2053,0.26204,1.1216,6,8,4,0.35407,0.65816,-0.6834426394,-2.907776734,-0.003196769337,25,19
CHEMBL4642564,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,221,6.66,F,CHEMBL4627340,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in human HEK293 cells assessed as increase in cAMP accumulation using [3H]-cAMP as substrate measured after 30mins by liquid scintillation counting method,1,Scientific Literature,Bioorg Med Chem,2020,671.76,0.71,intermediate,1,671.757,-0.7814,-3.897,15,10,267.47,-1.1657,0.50519,0.90064,15,17,4,0.51744,0.61702,3.143988203,0.8872401273,-0.04407337263,11,11
CHEMBL4642698,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CN)NC(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,1500,5.82,F,CHEMBL4627340,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in human HEK293 cells assessed as increase in cAMP accumulation using [3H]-cAMP as substrate measured after 30mins by liquid scintillation counting method,1,Scientific Literature,Bioorg Med Chem,2020,562.63,-0.07,inactive,0,562.625,-1.1163,-3.191,12,7,215.8,-2.164,0.52404,0.85157,12,14,3,0.40768,0.65533,2.05418602,1.458432245,-0.01271525161,5,5
CHEMBL4643256,Cc1nocc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5,3.46,8.46,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,575.71,6.11,highly_active,3,575.707,5.4267,-6.562,7,1,80.85,1.8987,0.26733,1.1229,7,8,4,0.40906,0.67474,-0.3732419845,-1.692280811,-0.01439394803,5,1
CHEMBL4644543,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(F)cc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314,117,6.93,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,588.72,6.95,intermediate,1,588.721,6.7193,-7.411,5,1,54.82,-0.75526,0.26204,1.1216,6,8,4,0.34808,0.66637,-0.7287508269,-2.435419518,0.02429027214,25,19
CHEMBL4644691,COc1ccccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5,7.18,8.14,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,600.76,6.82,highly_active,3,600.757,6.5485,-7.115,6,1,64.05,0.63176,0.2642,1.1311,6,9,4,0.37747,0.66053,-0.5683206409,-2.252115066,0.1558062782,25,19
CHEMBL4644694,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,128,6.89,F,CHEMBL4627340,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in human HEK293 cells assessed as increase in cAMP accumulation using [3H]-cAMP as substrate measured after 30mins by liquid scintillation counting method,1,Scientific Literature,Bioorg Med Chem,2020,633.71,0.41,intermediate,1,633.704,-0.4218,-4.192,14,8,244.9,-3.6053,0.53054,0.85413,14,17,3,0.54496,0.62573,2.686818784,0.6596529874,0.04544048974,5,5
CHEMBL4644731,Cn1cc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)cn1,659,6.18,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,574.73,5.54,intermediate,1,574.723,4.6808,-5.864,7,1,72.64,3.3071,0.25899,1.1309,7,8,4,0.3778,0.68499,-0.3469722336,-1.152644275,5.98E-02,5,2
CHEMBL4645094,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,370,6.43,F,CHEMBL4627340,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in human HEK293 cells assessed as increase in cAMP accumulation using [3H]-cAMP as substrate measured after 30mins by liquid scintillation counting method,1,Scientific Literature,Bioorg Med Chem,2020,632.72,0.23,intermediate,1,632.72,-0.8208,-3.372,14,9,251.68,-1.1657,0.53347,0.86153,14,17,3,0.56293,0.62279,2.804922766,1.225713571,0.1449182886,5,5
CHEMBL4645508,Cc1cc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)ccn1,1.88,8.73,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,585.75,6.51,highly_active,3,585.746,6.0155,-6.67,6,1,67.71,0.54372,0.26204,1.1288,6,8,4,0.36589,0.66247,-0.5832200503,-1.869873589,0.08058657716,25,3
CHEMBL4645533,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCC5CCOCC5)[C@@H](C2)N(CC2CC2)CC[C@]314,9.12,8.04,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,578.75,6.38,highly_active,3,578.75,5.8111,-6.669,6,1,64.05,-2.6953,0.2526,1.1147,6,8,3,0.39542,0.68976,-0.5822950031,-1.827936261,0.05528680363,25,1
CHEMBL4646507,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCC5CCCCC5)[C@@H](C2)N(CC2CC2)CC[C@]314,23.6,7.63,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,576.78,7.54,active,2,576.778,6.9751,-7.558,5,1,54.82,-3.4413,0.25813,1.1274,5,8,3,0.37125,0.66712,-0.8290517871,-2.552959338,0.03501584247,25,1
CHEMBL4646678,Cc1nnc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)o1,17.5,7.76,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,576.7,5.5,active,2,576.695,5.0178,-6.368,8,1,93.74,1.4023,0.25646,1.1221,8,8,4,0.39108,0.67988,-0.1719586645,-1.50574877,-0.06027287425,5,1
CHEMBL4646736,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](CCCCNC(C)=O)NC(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,934,6.03,F,CHEMBL4627340,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in human HEK293 cells assessed as increase in cAMP accumulation using [3H]-cAMP as substrate measured after 30mins by liquid scintillation counting method,1,Scientific Literature,Bioorg Med Chem,2020,685.78,1.75,intermediate,1,685.779,0.6945,-4.724,14,8,234.67,-4.5903,0.49911,0.90064,14,18,4,0.53019,0.60942,2.67345678,0.08855761343,0.1985680139,11,11
CHEMBL4647353,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5C5CC5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314,141,6.85,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,610.8,7.69,intermediate,1,610.795,7.7293,-8.054,5,1,54.82,0.58474,0.26385,1.1331,5,9,4,0.41673,0.66874,-0.7961751167,-3.020916531,0.127604268,1,1
CHEMBL4647561,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](CNC(C)=O)NC(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,272,6.57,F,CHEMBL4627340,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in human HEK293 cells assessed as increase in cAMP accumulation using [3H]-cAMP as substrate measured after 30mins by liquid scintillation counting method,1,Scientific Literature,Bioorg Med Chem,2020,643.7,0.58,intermediate,1,643.699,-0.6687,-3.914,14,8,234.67,-0.45515,0.49625,0.90116,14,15,4,0.52154,0.63451,2.593925832,0.880259088,-0.1057458827,11,11
CHEMBL4647696,Cc1ccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)cc1,2.31,8.64,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,584.76,7.12,highly_active,3,584.758,6.9624,-7.441,5,1,54.82,0.54372,0.26204,1.128,5,8,4,0.34087,0.66765,-0.8206244942,-2.489442357,0.06304845258,25,19
CHEMBL4648628,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccn5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314,526,6.28,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,571.72,6.21,intermediate,1,571.719,5.7086,-5.994,6,1,67.71,0.58474,0.25771,1.1303,6,8,4,0.36213,0.66585,-0.6002496537,-1.405238994,0.1994286568,25,1
CHEMBL4648915,COc1ccc(C2CCCN2Cc2ccc(Oc3ccc(C(=O)NO)cc3)cc2)cc1,201.5,6.7,F,CHEMBL4619756,antagonist,antagonist,Antagonist activity at human mu opiod receptor expressed in CHO cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding incubated for 4 hrs by microbeta liquid scintillation counting method,1,Scientific Literature,Bioorg Med Chem Lett,2020,418.49,4.94,intermediate,1,418.491,3.886,-5.513,6,2,71.03,3.3787,0.55218,0.76319,6,7,3,0.32712,0.68163,-0.5926904505,-0.6352401722,-0.1083219839,3,3
CHEMBL4648920,CN(C)Cc1ccccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5,28.9,7.54,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,627.83,6.87,active,2,627.826,6.2414,-6.611,6,1,58.06,2.0569,0.28875,1.1323,6,10,4,0.40101,0.68238,-0.4882500262,-1.941817122,0.3469123577,25,19
CHEMBL4649485,CN(C)c1ccccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5,233,6.63,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,613.8,6.88,intermediate,1,613.799,6.5149,-7.133,6,1,58.06,1.3312,0.27912,1.1319,6,9,4,0.37798,0.6674,-0.5631105119,-2.270478562,0.1569001821,25,19
CHEMBL4649820,Cc1cccc(C)c1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5,3.4,8.47,F,CHEMBL4627399,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2020,598.79,7.43,highly_active,3,598.784,7.3063,-7.785,5,1,54.82,0.54372,0.26126,1.1303,5,8,4,0.3647,0.68218,-0.8231823424,-2.764962726,0.0307734038,25,19
CHEMBL466067,Cc1ccc(C(c2ccccc2Cl)N2C3CCC2CC(O)(C2CCCC2)C3)c(Cl)c1,709,6.15,F,CHEMBL1138606,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GDP-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,444.45,6.94,intermediate,1,444.444,6.4914,-6.77,2,1,23.47,-0.072429,0.26046,0.88404,4,4,2,0.5312,0.75436,-1.536305042,-1.837627315,-0.1914327255,1,1
CHEMBL466847,OC1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl,337,6.47,F,CHEMBL1138606,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GDP-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,438.4,6.6,intermediate,1,438.397,6.4315,-6.391,2,1,23.47,0.68729,0.26061,0.88077,4,4,3,0.60493,0.74838,-1.556110219,-1.598293261,-0.1083127044,16,9
CHEMBL466921,NC(=O)C1(c2ccc(F)cc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl,947,6.02,F,CHEMBL1138606,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GDP-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,483.41,6.27,intermediate,1,483.413,5.6426,-7.047,3,1,46.33,0.54472,0.27927,0.90271,6,5,3,0.58962,0.74399,-1.066495348,-1.901217874,-0.3359682182,16,9
CHEMBL467313,COC(=O)NC1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl,782,6.11,F,CHEMBL1138606,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GDP-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,495.45,6.96,intermediate,1,495.448,6.6451,-6.98,4,1,41.57,-8.1795,0.29371,0.91289,6,6,3,0.61456,0.72862,-1.078180943,-2.05884863,-0.07150658649,16,9
CHEMBL467488,Cc1ccc(C(c2ccccc2Cl)N2C3CCC2CC(O)(c2cccc(F)c2)C3)c(Cl)c1,894,6.05,F,CHEMBL1138606,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GDP-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,470.42,7.04,intermediate,1,470.413,6.8762,-7.049,2,1,23.47,-0.7268,0.27317,0.90037,5,4,3,0.51964,0.73494,-1.469350718,-2.095312368,-0.2116209467,16,9
CHEMBL468952,OCC1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl,2144,5.67,F,CHEMBL1138606,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GDP-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,452.43,6.64,inactive,0,452.423,6.2892,-6.675,2,1,23.47,-3.2575,0.27878,0.87927,4,5,3,0.48144,0.76754,-1.459448926,-1.767042384,-0.09652259215,16,9
CHEMBL469189,C[C@H]1C2Cc3ccc4c(N)ncnc4c3[C@@]1(C)CCN2CC1CC1,28,7.55,F,CHEMBL1150274,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem,2008,322.46,3.15,active,2,322.454,3.0078,-4.786,4,1,55.04,4.7372,0.22788,0.94496,4,2,2,0.35817,0.77238,-1.277487329,0.08595182771,-0.4814372105,1,1
CHEMBL470005,NC(=O)c1ccc2c(c1O)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CC1)CC3,10,8,F,CHEMBL1153960,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,356.47,2.07,highly_active,3,356.464,1.889,-3.657,5,3,86.79,0.4462,0.2549,1.0085,5,3,1,0.39933,0.77707,-0.7009894882,0.9291043111,-0.3903610741,4,1
CHEMBL470617,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[I-],170,6.77,F,CHEMBL1153960,antagonist,antagonist,Antagonist activity against human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,483.35,1.67,intermediate,1,483.34,-1.5239,-2.927,5,2,66.76,0.63257,0.25637,1.0769,5,2,1,0.49802,0.81287,-0.3407252851,1.826889811,-0.7230670744,1,1
CHEMBL471048,CN1CC[C@]23CC(=O)CC[C@H]2[C@H]1Cc1ccc(C(N)=O)c(O)c13,1.6,8.8,F,CHEMBL1153960,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,314.38,1.36,highly_active,3,314.384,1.2796,-2.943,5,2,83.63,4.131,0.20649,0.99174,5,1,1,0.48785,0.80154,-0.9175464947,1.508488045,-0.4713028776,1,1
CHEMBL471049,CN1CC[C@]23c4c5ccc(C(N)=O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,110,6.96,F,CHEMBL1153960,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,312.37,1.02,intermediate,1,312.368,1.1088,-3.211,5,1,72.63,4.5789,0.18716,1.041,5,1,1,0.50766,0.8066,-1.013179053,1.368270772,-0.5126825286,7,2
CHEMBL471243,Cl.NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3,0.88,9.06,F,CHEMBL1153960,antagonist,antagonist,Antagonist activity against human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,406.91,1.25,highly_active,3,406.908,1.1806,-3.309,6,3,103.86,4.4951,0.26489,1.0365,6,3,1,0.48183,0.77855,-0.3817438912,1.212024592,-0.4399327602,1,1
CHEMBL471806,CCCCCCC(N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,26.3,7.58,F,CHEMBL1150362,agonist,agonist,Agonist activity at mu opioid receptor in human SHSY5Y cells assessed as inhibition of forskolin-stimulated cAMP production,1,Scientific Literature,Bioorg Med Chem,2008,751.93,3.13,active,2,751.926,3.0179,-6.07,13,7,212.74,-11.258,0.512,0.91361,13,19,4,0.43816,0.61843,2.332947523,-1.198329732,0.3958366483,7,7
CHEMBL473699,Cc1nc2cc3c(cc2[nH]1)[C@@]1(C)CCN(CC2CC2)C(C3)[C@@H]1C,18,7.75,F,CHEMBL1136834,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,309.46,3.81,active,2,309.455,3.413,-3.527,3,1,31.92,5.4748,0.2396,0.9215,3,2,2,0.31197,0.75732,-1.597374742,0.765176781,-0.0682979464,2,2
CHEMBL4740521,N=C(N)NCCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CS)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,178,6.75,F,CHEMBL4699661,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2020,1119.34,None,intermediate,1,1119.34,-3.8095,-5.552,25,14,495.94,2.0174,0.58667,0.92746,27,31,3,0.50657,0.5529,7.309063104,-0.08151881717,-0.06283349405,16,16
CHEMBL4741368,CNC(=O)COCC(=O)NCCCCCCCCCNC(=O)COCC(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,41.4,7.38,F,CHEMBL4715781,antagonist,antagonist,Antagonist activity at human MOR transfected in CHO cells co-transfected with Gqi5 assessed as inhibition of DAMGO-induced calcium mobilization incubated for 15 mins prior to DAMGO addition and measured for 90 secs by Fluo-4AM dye based fluorescence analysis,1,Scientific Literature,Bioorg Med Chem,2016,727.9,1.18,active,2,727.897,1.2841,-4.148,14,6,187.79,-0.74478,0.4814,1.0845,14,21,1,0.29922,0.58162,2.448134158,0.2144176233,0.8630830367,6,6
CHEMBL4741494,CCN1CC2(CCN(CCc3ccccc3)CC2)O[C@H](C)C1=O,49,7.31,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,316.45,2.33,active,2,316.443,2.1473,-1.965,4,0,32.78,10.174,0.41223,0.75329,4,4,1,0.3225,0.73511,-1.387399605,1.860398012,0.3475144079,17,17
CHEMBL4744284,COC(=O)CC[C@@H]1[C@H]2CCC[C@]1(c1cccc(O)c1)CCN2CCc1ccccc1,31.3,7.5,F,CHEMBL4680063,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by luminescence assay,1,Scientific Literature,RSC Med Chem,2020,407.55,4.7,active,2,407.552,4.7195,-4.461,4,1,49.77,-7.7148,0.44217,0.8945,4,8,2,0.46962,0.70708,-1.105588702,-0.1780894668,0.4638574741,9,2
CHEMBL4744365,N=C(N)NCCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,788,6.1,F,CHEMBL4699661,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2020,1117.33,None,intermediate,1,1117.32,-3.2407,-5.088,25,14,468.94,6.3065,0.52612,0.93236,27,23,3,0.39185,0.562,6.766851404,0.1922753349,-0.6270892833,4,1
CHEMBL4744531,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O,64.6,7.19,F,CHEMBL4699489,agonist,agonist,Agonist activity at human MOR stably expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,1338.66,None,active,2,1338.66,-4.6546,-6.818,28,16,462.04,-20.293,0.54531,0.98306,28,37,3,0.49441,0.50219,8.380953848,-0.9458813486,0.09032463976,4,4
CHEMBL4745148,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,308.2,6.51,F,CHEMBL4715798,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as reduction in forskolin-induced cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2016,1112.26,None,intermediate,1,1112.26,-4.4404,-4.329,27,15,461.43,5.8663,0.58259,0.93381,27,32,3,0.42586,0.5364,7.455621307,0.7505374607,0.2479159201,16,16
CHEMBL4745430,COC(=O)[C@@H]1C=C(OC(=O)c2cccc(OC)c2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,11,7.96,F,CHEMBL4715803,agonist,agonist,Agonist activity at human mu opiod receptor expressed in CHO-K1 cells assessed as increase in forskolin induced cAMP production measured after 30 mins by HitHunter luminescence based assay,1,Scientific Literature,J Med Chem,2016,522.55,4.43,active,2,522.548,3.2902,-4.957,9,0,118.34,-1.4228,0.27475,1.0193,9,7,2,0.33257,0.69018,-0.05371327733,-0.3181562313,-0.08957624717,12,5
CHEMBL4745899,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc(O)c2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O,6.49,8.19,F,CHEMBL4699489,agonist,agonist,Agonist activity at human MOR stably expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,1394.69,None,highly_active,3,1394.69,-2.1716,-5.56,32,20,533.8,-18.237,0.54798,0.98611,32,37,3,0.49442,0.50186,9.185381687,-0.6281904661,0.4643189615,4,4
CHEMBL4746919,N=C(N)NCCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,1548.82,5.81,F,CHEMBL4699661,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2020,1119.34,None,inactive,0,1119.34,-3.8095,-5.552,25,14,495.94,2.0174,0.58582,0.92746,27,31,3,0.42898,0.54267,7.309063104,-0.08151881717,-0.06283349405,16,16
CHEMBL4747286,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc(O)c2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O,27.4,7.56,F,CHEMBL4699489,agonist,agonist,Agonist activity at human MOR stably expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,1338.66,None,active,2,1338.66,-4.6546,-6.818,28,16,462.04,-20.293,0.54531,0.98466,28,37,3,0.4101,0.50477,8.380953848,-0.9458813486,0.09032463976,4,4
CHEMBL474755,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(OC(=O)/C=C/c5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314,34.4,7.46,F,CHEMBL1152801,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,485.58,4.09,active,2,485.578,4.1101,-5.456,6,0,65.07,1.821,0.2316,1.1054,6,7,2,0.32174,0.70059,-0.7145249444,-0.7289266385,0.02455317119,5,1
CHEMBL4748573,OCCC[C@@H]1[C@H]2CCC[C@]1(c1cccc(O)c1)CCN2CCc1ccccc1,35.2,7.45,F,CHEMBL4680063,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by luminescence assay,1,Scientific Literature,RSC Med Chem,2020,379.54,4.52,active,2,379.542,4.6412,-4.351,3,2,43.7,-4.2919,0.43347,0.88837,3,7,2,0.44295,0.72907,-1.240199977,-0.04958392941,0.3664752112,9,2
CHEMBL4748689,COC(=O)/C=C/[C@H]1[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCc1ccccc1,132,6.88,F,CHEMBL4680063,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by luminescence assay,1,Scientific Literature,RSC Med Chem,2020,405.54,4.48,intermediate,1,405.536,4.4673,-4.233,4,1,49.77,-3.0887,0.39667,0.8945,4,7,2,0.42641,0.71505,-1.13516038,0.01461755794,0.3832359298,9,6
CHEMBL4748891,Cc1nnc(C(C)C)n1[C@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccc(NC(=O)COCC(=O)NCCCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1,40,7.4,F,CHEMBL4715781,antagonist,antagonist,Antagonist activity at human MOR transfected in CHO cells co-transfected with Gqi5 assessed as inhibition of DAMGO-induced calcium mobilization incubated for 15 mins prior to DAMGO addition and measured for 90 secs by Fluo-4AM dye based fluorescence analysis,1,Scientific Literature,Bioorg Med Chem,2016,1197.48,None,active,2,1197.47,5.1682,-6.987,20,7,250.84,-6.9442,0.48496,1.1147,22,28,3,0.37499,0.51625,4.294903432,-2.64771868,1.256864227,2,1
CHEMBL4748898,CC1OC2(CCN(CCc3ccccc3)CC2)CN(Cc2ccccc2)C1=O,2,8.7,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,378.52,3.51,highly_active,3,378.514,3.1591,-2.988,4,0,32.78,8.8656,0.42058,0.78531,4,5,2,0.34039,0.71375,-1.316930578,1.010760513,0.3527764842,1,1
CHEMBL4748910,COC(=O)CC[C@@H]1[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCc1ccccc1,854,6.07,F,CHEMBL4680063,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by luminescence assay,1,Scientific Literature,RSC Med Chem,2020,407.55,4.7,intermediate,1,407.552,4.7195,-4.461,4,1,49.77,-7.7148,0.43284,0.8945,4,8,2,0.33057,0.70426,-1.105588702,-0.1780894668,0.4638574741,9,6
CHEMBL4749016,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)C[C@H](CCCCN)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C,65.4,7.18,F,CHEMBL4699489,agonist,agonist,Agonist activity at human MOR stably expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,1380.75,None,active,2,1380.74,-3.5124,-7.776,28,16,462.04,-20.293,0.54306,0.98796,28,38,3,0.46881,0.50716,8.402350491,-1.760824045,0.1272125652,1,1
CHEMBL4749564,CSCC[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,409,6.39,F,CHEMBL4715798,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as reduction in forskolin-induced cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2016,1115.33,None,intermediate,1,1115.32,-3.0715,-4.883,25,14,443.64,5.8675,0.58535,0.92768,26,32,3,0.45785,0.54594,7.00075507,0.1672788028,0.3907023875,16,16
CHEMBL4750006,N=C(N)NCCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,196,6.71,F,CHEMBL4699661,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2020,1117.33,None,intermediate,1,1117.32,-3.2407,-5.088,25,14,468.94,6.3065,0.52832,0.93236,27,23,3,0.50644,0.58087,6.766851404,0.1922753349,-0.6270892833,4,1
CHEMBL4750243,CCN1CC2(CCN(CCc3ccccn3)CC2)OC2(CC2)C1=O,1498,5.82,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,329.44,1.87,inactive,0,329.442,1.2052,-1.389,5,0,45.67,10.39,0.41293,0.79818,5,4,1,0.34318,0.73163,-1.123021661,2.352872151,0.3199148475,2,1
CHEMBL4750783,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N2Cc3ccc(O)cc3C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O,45.6,7.34,F,CHEMBL4699489,agonist,agonist,Agonist activity at human MOR stably expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,1350.68,None,active,2,1350.67,-4.757,-6.693,28,15,453.25,-20.293,0.53288,1.0152,28,34,3,0.44215,0.50698,8.152176564,-0.84096488,-0.1448358647,1,1
CHEMBL475108,C[C@H]1C2Cc3ccc4[nH]nnc4c3[C@@]1(C)CCN2CC1CC1,99,7,F,CHEMBL1136834,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,296.42,2.89,active,2,296.417,2.5586,-3.646,4,1,44.81,0.84321,0.24038,0.93361,4,2,2,0.42326,0.79281,-1.351468889,0.8579080745,-0.25731157,1,1
CHEMBL4751130,CN1CC2(CCN(CCc3ccccc3)CC2)OC(C)(C)C1=O,624,6.21,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,316.44,2.33,intermediate,1,316.443,2.039,-1.774,4,0,32.78,7.9755,0.4098,0.75329,4,3,1,0.36662,0.7497,-1.428916082,2.004462495,0.2789490549,17,17
CHEMBL4752386,CC[C@H]1OC2(CCN(CCc3ccccc3)CC2)CN(C)C1=O,505,6.3,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,316.45,2.33,intermediate,1,316.443,2.1954,-1.935,4,0,32.78,11.087,0.40691,0.75329,4,4,1,0.32869,0.73372,-1.394382987,1.869731194,0.3618040531,17,17
CHEMBL4752423,CNC(=O)COCC(=O)NCCCCNC(=O)COCC(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,8.1,8.09,F,CHEMBL4725485,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) by [35S]-GTPgammaS binding assay,1,Scientific Literature,ACS Med Chem Lett,2020,657.77,-0.77,highly_active,3,657.762,-0.9879,-2.798,14,6,187.79,3.4652,0.47113,1.0841,14,16,1,0.37552,0.62066,2.315580145,1.53392146,0.3558928946,6,6
CHEMBL4752583,OC/C=C/[C@H]1[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCc1ccccc1,2.31,8.64,F,CHEMBL4680063,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by luminescence assay,1,Scientific Literature,RSC Med Chem,2020,377.53,4.3,highly_active,3,377.526,4.389,-4.123,3,2,43.7,0.232,0.4153,0.89827,3,6,2,0.39974,0.73883,-1.269771634,0.1431228145,0.2858535503,9,6
CHEMBL4753006,C[C@H]1OC2(CCN(CCc3ccccc3)CC2)CN(C)C1=O,319,6.5,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,302.42,1.94,intermediate,1,302.416,1.741,-1.665,4,0,32.78,10.14,0.40204,0.73618,4,3,1,0.39476,0.7542,-1.420893828,2.133631995,0.2603660438,17,17
CHEMBL4754130,CCN1CC2(CCN(CCc3cccc(F)c3)CC2)O[C@H](C)C1=O,56,7.25,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,334.44,2.47,active,2,334.433,2.2481,-2.279,4,0,32.78,8.8336,0.42426,0.80083,5,4,1,0.29472,0.72725,-1.298082213,1.638899314,0.2764812483,17,17
CHEMBL4755334,CN[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,194.98,6.71,F,CHEMBL4715798,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as reduction in forskolin-induced cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2016,1126.29,None,intermediate,1,1126.28,-4.0889,-4.245,27,15,447.44,9.7118,0.58386,0.93709,27,33,3,0.42981,0.54036,7.431843063,0.7101924559,0.4405142083,16,16
CHEMBL4755342,CC(C)C1OC2(CCN(CCc3ccccc3)CC2)CN(C)C1=O,174,6.76,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,330.47,2.58,intermediate,1,330.47,2.4137,-2.095,4,0,32.78,10.056,0.40679,0.76182,4,4,1,0.29235,0.73395,-1.39077464,1.724336667,0.3563938356,17,17
CHEMBL4755446,CCN1CC2(CCN(CCc3ccccc3)CC2)OC(C)C1=O,65,7.19,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,316.45,2.33,active,2,316.443,2.1473,-1.965,4,0,32.78,10.174,0.41233,0.75329,4,4,1,0.37831,0.74251,-1.387399605,1.860398012,0.3475144079,17,17
CHEMBL4756271,COC(=O)[C@@H]1C=C(OC(=O)c2ccc(F)cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,15,7.82,F,CHEMBL4715803,agonist,agonist,Agonist activity at human mu opiod receptor expressed in CHO-K1 cells assessed as increase in forskolin induced cAMP production measured after 30 mins by HitHunter luminescence based assay,1,Scientific Literature,J Med Chem,2016,510.51,4.56,active,2,510.512,3.461,-5.253,8,0,109.11,-2.7628,0.2628,0.99887,9,6,2,0.36709,0.7058,-0.2141434189,-0.5014607529,-0.2210922246,12,5
CHEMBL4756310,CCN1CC2(CCN(CCc3c(F)cccc3F)CC2)O[C@H](C)C1=O,16,7.8,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,352.43,2.61,active,2,352.423,2.3489,-2.593,4,0,32.78,8.8336,0.40601,0.81339,6,4,1,0.33235,0.73812,-1.208764874,1.417400716,0.2054481131,17,17
CHEMBL4759079,CSCC[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,426.58,6.37,F,CHEMBL4715798,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as reduction in forskolin-induced cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2016,1172.38,None,intermediate,1,1172.38,-3.8368,-4.974,27,15,486.73,6.2214,0.58539,0.93526,28,35,3,0.43789,0.53,7.785878553,0.1734722126,0.4389265474,16,16
CHEMBL4759184,CC1OC2(CCN(CCc3ccccc3)CC2)CN(C(C)C)C1=O,21,7.68,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,330.47,2.72,active,2,330.47,2.5066,-2.343,4,0,32.78,7.9329,0.41127,0.76387,4,4,1,0.31695,0.7407,-1.390185362,1.562184613,0.3091469751,17,17
CHEMBL4761093,CCN1CC2(CCN(CCc3cc(F)ccc3F)CC2)O[C@@H](C)C1=O,910,6.04,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,352.43,2.61,intermediate,1,352.423,2.3489,-2.593,4,0,32.78,8.8336,0.41628,0.81291,6,4,1,0.31115,0.72833,-1.208764874,1.417400716,0.2054481131,17,17
CHEMBL4761165,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C,13.3,7.88,F,CHEMBL4699489,agonist,agonist,Agonist activity at human MOR stably expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,1358.74,None,active,2,1358.73,-3.9765,-9.111,25,14,414.72,-21.889,0.53895,0.97904,25,41,4,0.41229,0.52736,7.93108848,-2.51638905,0.212090776,1,1
CHEMBL4761246,N=C(N)NCCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CS)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](CS)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,169.82,6.77,F,CHEMBL4699661,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2020,1119.34,None,intermediate,1,1119.34,-3.8095,-5.552,25,14,495.94,2.0174,0.58717,0.92746,27,31,3,0.45448,0.54315,7.309063104,-0.08151881717,-0.06283349405,16,16
CHEMBL4761273,Cc1nnc(C(C)C)n1[C@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1cccc(NC(=O)COCC(=O)NCCCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)c1,17.1,7.77,F,CHEMBL4715781,antagonist,antagonist,Antagonist activity at human MOR transfected in CHO cells co-transfected with Gqi5 assessed as inhibition of DAMGO-induced calcium mobilization incubated for 15 mins prior to DAMGO addition and measured for 90 secs by Fluo-4AM dye based fluorescence analysis,1,Scientific Literature,Bioorg Med Chem,2016,1197.48,None,active,2,1197.47,5.1682,-6.987,20,7,250.84,-6.9442,0.48496,1.1166,22,28,3,0.36755,0.52077,4.294903432,-2.64771868,1.256864227,2,1
CHEMBL4761794,C[C@@H]1OC2(CCN(CCc3ccccc3)CC2)CN(C)C1=O,1780,5.75,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,302.42,1.94,inactive,0,302.416,1.741,-1.665,4,0,32.78,10.14,0.40214,0.73618,4,3,1,0.30903,0.74105,-1.420893828,2.133631995,0.2603660438,17,17
CHEMBL4761986,Cc1nnc(C(C)C)n1[C@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccc(NC(=O)COCC(=O)NCCCCCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1,21.9,7.66,F,CHEMBL4715781,antagonist,antagonist,Antagonist activity at human MOR transfected in CHO cells co-transfected with Gqi5 assessed as inhibition of DAMGO-induced calcium mobilization incubated for 15 mins prior to DAMGO addition and measured for 90 secs by Fluo-4AM dye based fluorescence analysis,1,Scientific Literature,Bioorg Med Chem,2016,1225.53,None,active,2,1225.53,6.077,-7.527,20,7,250.84,-6.9442,0.48393,1.1148,22,30,3,0.38745,0.5061,4.347934424,-3.175526068,1.459741223,1,1
CHEMBL4762816,CN1CC2(CCN(CCc3ccccc3)CC2)OC2(CC2)C1=O,442,6.36,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,314.43,2.08,intermediate,1,314.427,1.7458,-1.86,4,0,32.78,10.396,0.40742,0.77625,4,3,1,0.35366,0.74475,-1.393920337,2.006537274,0.2152283469,2,1
CHEMBL4763725,COC(=O)[C@@H]1C=C(OC(=O)c2ccccc2F)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,4.8,8.32,F,CHEMBL4715803,agonist,agonist,Agonist activity at human mu opiod receptor expressed in CHO-K1 cells assessed as increase in forskolin induced cAMP production measured after 30 mins by HitHunter luminescence based assay,1,Scientific Literature,J Med Chem,2016,510.51,4.56,highly_active,3,510.512,3.461,-5.253,8,0,109.11,-2.7628,0.2565,1.0026,9,6,2,0.37786,0.70794,-0.2141434189,-0.5014607529,-0.2210922246,12,5
CHEMBL4764587,O=C(O)CC[C@H]1[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCc1ccccc1,31.7,7.5,F,CHEMBL4680063,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by luminescence assay,1,Scientific Literature,RSC Med Chem,2020,393.53,4.61,active,2,393.525,3.3651,-4.333,4,2,60.77,-0.055053,0.43794,0.8934,4,7,2,0.444,0.73036,-0.8959830974,0.1720325032,0.1484522888,9,6
CHEMBL4776743,CCN1CC2(CCN(CCc3cccc(F)c3F)CC2)O[C@H](C)C1=O,10,8,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,352.43,2.61,highly_active,3,352.423,2.3489,-2.593,4,0,32.78,8.8336,0.4162,0.81483,6,4,1,0.37684,0.73308,-1.208764874,1.417400716,0.2054481131,17,17
CHEMBL4776924,CCN1CC2(CCN(CCc3ccccc3F)CC2)O[C@H](C)C1=O,24,7.62,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,334.44,2.47,active,2,334.433,2.2481,-2.279,4,0,32.78,8.8336,0.40681,0.80291,5,4,1,0.31088,0.73366,-1.298082213,1.638899314,0.2764812483,17,17
CHEMBL4777803,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,125.89,6.9,F,CHEMBL4715798,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as reduction in forskolin-induced cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2016,1115.33,None,intermediate,1,1115.32,-3.0715,-4.883,25,14,443.64,5.8675,0.58495,0.92768,26,32,3,0.39077,0.53226,7.00075507,0.1672788028,0.3907023875,16,16
CHEMBL4777859,CCN1CC2(CCN(CCc3ccc(F)cc3F)CC2)O[C@H](C)C1=O,53,7.28,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,352.43,2.61,active,2,352.423,2.3489,-2.593,4,0,32.78,8.8336,0.4162,0.81291,6,4,1,0.30118,0.73258,-1.208764874,1.417400716,0.2054481131,17,17
CHEMBL4777999,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,19.95,7.7,F,CHEMBL4715798,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as reduction in forskolin-induced cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2016,1126.29,None,active,2,1126.28,-4.1739,-3.967,27,14,452.64,6.6599,0.60012,0.94225,27,32,3,0.48137,0.5424,7.312104667,0.8907574944,0.4232816668,16,16
CHEMBL4781352,CCN1CC2(CCN(CCc3cc(F)ccc3F)CC2)O[C@H](C)C1=O,52,7.28,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,352.43,2.61,active,2,352.423,2.3489,-2.593,4,0,32.78,8.8336,0.4162,0.81291,6,4,1,0.30981,0.73321,-1.208764874,1.417400716,0.2054481131,17,17
CHEMBL4781853,CCC[C@H]1[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCc1ccccc1,0.95,9.02,F,CHEMBL4680063,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by luminescence assay,1,Scientific Literature,RSC Med Chem,2020,363.55,5.55,highly_active,3,363.543,5.5679,-4.858,2,1,23.47,-1.6657,0.42389,0.88404,2,6,2,0.44021,0.73713,-1.66865466,-0.4962626772,0.3527156311,9,6
CHEMBL4783674,CC(=O)O[C@@H]1C[C@H](NC(=O)c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,3,8.52,F,CHEMBL4715803,agonist,agonist,Agonist activity at human mu opiod receptor expressed in CHO-K1 cells assessed as increase in forskolin induced cAMP production measured after 30 mins by HitHunter luminescence based assay,1,Scientific Literature,J Med Chem,2016,493.56,4.01,highly_active,3,493.554,3.0207,-4.949,8,1,111.91,3.5662,0.28695,1.0142,8,5,2,0.39239,0.69795,-0.2094064024,-0.2029131111,-0.3388361318,12,2
CHEMBL4784104,CC1(C)CN2C(CS/C(N)=N\[C@H]3CC[C@H](CNC(=O)COCC(=O)NCCCCNC(=O)COCC(=O)N[C@@H]4CC[C@@]5(O)[C@H]6Cc7ccc(O)c8c7[C@@]5(CCN6CC5CC5)[C@H]4O8)CC3)=CSC2=N1,50,7.3,F,CHEMBL4725485,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) by [35S]-GTPgammaS binding assay,1,Scientific Literature,ACS Med Chem Lett,2020,980.27,2.25,active,2,980.262,1.4005,-6.813,18,7,292.37,3.9305,0.50328,1.1015,20,22,1,0.34596,0.55826,4.017181516,-1.60039138,0.09860816523,1,1
CHEMBL4784329,CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,588.84,6.23,F,CHEMBL4715798,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as reduction in forskolin-induced cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2016,1097.29,None,intermediate,1,1097.28,-2.548,-4.938,25,14,418.34,6.0008,0.58475,0.93131,25,31,3,0.44636,0.55501,6.727126403,0.07114868246,0.3971573554,16,16
CHEMBL4785222,N=C(N)NCCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](CO)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,562.34,6.25,F,CHEMBL4715798,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as reduction in forskolin-induced cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2016,1128.26,None,intermediate,1,1128.25,-5.3671,-3.822,28,16,481.66,6.956,0.5841,0.93749,28,33,3,0.39308,0.53307,7.884062054,1.197224689,0.2616741516,16,16
CHEMBL4786209,CC1OC2(CCN(CCc3ccccc3)CC2)CN(C)C1=O,787,6.1,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,302.42,1.94,intermediate,1,302.416,1.741,-1.665,4,0,32.78,10.14,0.40214,0.73618,4,3,1,0.36185,0.7524,-1.420893828,2.133631995,0.2603660438,17,17
CHEMBL4786506,COC(=O)[C@@H]1C=C(OC(=O)c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,1.2,8.92,F,CHEMBL4715803,agonist,agonist,Agonist activity at human mu opiod receptor expressed in CHO-K1 cells assessed as increase in forskolin induced cAMP production measured after 30 mins by HitHunter luminescence based assay,1,Scientific Literature,J Med Chem,2016,492.52,4.42,highly_active,3,492.522,3.3602,-4.939,8,0,109.11,-1.4228,0.26021,1.0149,8,6,2,0.36205,0.70535,-0.3034607469,-0.2799622948,-0.1500591477,12,5
CHEMBL4788060,N=C(N)NCCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1CSSC[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,3828,5.42,F,CHEMBL4699661,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2020,1117.33,None,inactive,0,1117.32,-3.2407,-5.088,25,14,468.94,6.3065,0.52752,0.93443,27,23,3,0.33948,0.56964,6.766851404,0.1922753349,-0.6270892833,4,1
CHEMBL4788431,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,250.2,6.6,F,CHEMBL4715798,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as reduction in forskolin-induced cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2016,1097.29,None,intermediate,1,1097.28,-2.548,-4.938,25,14,418.34,6.0008,0.58435,0.93131,25,31,3,0.41065,0.53377,6.727126403,0.07114868246,0.3971573554,16,16
CHEMBL4788650,CCN1CC2(CCN(CCc3ccc(F)cc3)CC2)O[C@H](C)C1=O,108,6.97,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,334.44,2.47,intermediate,1,334.433,2.2481,-2.279,4,0,32.78,8.8336,0.42426,0.79548,5,4,1,0.3181,0.73691,-1.298082213,1.638899314,0.2764812483,17,17
CHEMBL4789005,C[C@H]1OC2(CCN(CCc3ccccc3)CC2)CN(C2CC2)C1=O,7,8.15,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,328.46,2.47,highly_active,3,328.454,2.2707,-2.429,4,0,32.78,9.1325,0.38329,0.77373,4,4,1,0.29904,0.73267,-1.361864335,1.554330453,0.2537060833,1,1
CHEMBL4789659,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O,12.8,7.89,F,CHEMBL4699489,agonist,agonist,Agonist activity at human MOR stably expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by liquid scintillation counting assay,1,Scientific Literature,J Med Chem,2020,1394.69,None,active,2,1394.69,-2.1716,-5.56,32,20,533.8,-18.237,0.54798,0.98452,32,37,3,0.44705,0.50549,9.185381687,-0.6281904661,0.4643189615,4,4
CHEMBL4790011,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,245.47,6.61,F,CHEMBL4715798,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as reduction in forskolin-induced cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2016,1055.21,None,intermediate,1,1055.2,-3.6751,-4.238,25,14,418.34,5.8663,0.58544,0.91876,25,29,3,0.43514,0.55117,6.670497824,0.744344051,0.1996917602,16,16
CHEMBL4790994,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCN2CCC(Cc3ccccc3)CC2)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)C1=O,18,7.75,F,CHEMBL4765381,agonist,agonist,Agonist activity at human mu-opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 15 mins followed by forskolin addition in presence of IBMX by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2020,1014.29,None,active,2,1014.28,2.1062,-6.435,18,10,291.19,7.4682,0.49854,0.92307,18,25,4,0.44832,0.52904,4.250462883,-1.531901364,0.5203931663,1,1
CHEMBL4792870,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,28.18,7.55,F,CHEMBL4715798,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as reduction in forskolin-induced cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2016,1041.18,None,active,2,1041.18,-4.0344,-3.86,25,14,418.34,5.8663,0.59694,0.90475,25,29,3,0.41215,0.54109,6.673294564,1.042550758,0.2380603315,16,16
CHEMBL4793250,N=C(N)NCCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](CS)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,218.78,6.66,F,CHEMBL4699661,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2020,1119.34,None,intermediate,1,1119.34,-3.8095,-5.552,25,14,495.94,2.0174,0.58632,0.92746,27,31,3,0.43521,0.54462,7.309063104,-0.08151881717,-0.06283349405,16,16
CHEMBL4795160,OCCC[C@H]1[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCc1ccccc1,1.2,8.92,F,CHEMBL4680063,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by luminescence assay,1,Scientific Literature,RSC Med Chem,2020,379.54,4.52,highly_active,3,379.542,4.6412,-4.351,3,2,43.7,-4.2919,0.4295,0.88837,3,7,2,0.4626,0.72761,-1.240199977,-0.04958392941,0.3664752112,9,6
CHEMBL4796596,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,38.9,7.41,F,CHEMBL4715798,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as reduction in forskolin-induced cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2016,1055.21,None,active,2,1055.2,-3.7679,-3.498,25,13,409.55,6.6599,0.61534,0.9148,25,29,3,0.45943,0.55201,6.529777634,1.182770902,0.4134261015,16,16
CHEMBL4796605,CC1OC2(CCN(CCc3ccccc3)CC2)CN(CCc2ccccc2)C1=O,22,7.66,F,CHEMBL4673253,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,392.54,3.55,active,2,392.541,3.5892,-3.1,4,0,32.78,8.8656,0.42344,0.77625,4,6,2,0.29605,0.69687,-1.294859002,0.844121257,0.4893563487,1,1
CHEMBL4797394,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)C1=O,12,7.92,F,CHEMBL4765381,agonist,agonist,Agonist activity at human mu-opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 15 mins followed by forskolin addition in presence of IBMX by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2020,898.08,-0.95,active,2,898.079,-1.9693,-4.271,20,13,349.85,4.6329,0.53456,0.91217,20,23,3,0.48425,0.54894,5.051327493,0.6312681804,0.02729250455,1,1
CHEMBL4797451,Cc1nnc(C(C)C)n1[C@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccc(NC(=O)COCC(=O)NCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1,21.8,7.66,F,CHEMBL4715781,antagonist,antagonist,Antagonist activity at human MOR transfected in CHO cells co-transfected with Gqi5 assessed as inhibition of DAMGO-induced calcium mobilization incubated for 15 mins prior to DAMGO addition and measured for 90 secs by Fluo-4AM dye based fluorescence analysis,1,Scientific Literature,Bioorg Med Chem,2016,1169.43,None,active,2,1169.42,4.2594,-6.447,20,7,250.84,-4.6142,0.48565,1.1145,22,26,3,0.44554,0.5218,4.241888096,-2.119920927,1.053988812,1,1
CHEMBL4798954,Oc1cccc([C@@]23CCC[C@H]([C@H]2O)N(CCc2ccccc2)CC3)c1,0.017,10.77,F,CHEMBL4680063,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by luminescence assay,1,Scientific Literature,RSC Med Chem,2020,337.46,3.49,highly_active,3,337.461,3.5377,-3.759,3,2,43.7,0.46762,0.42777,0.8737,3,4,2,0.42495,0.73944,-1.339953542,0.5687310829,0.0463559249,9,1
CHEMBL4799292,COC(=O)[C@@H]1C=C(OC(=O)c2ccc(Cl)cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,30,7.52,F,CHEMBL4715803,agonist,agonist,Agonist activity at human mu opiod receptor expressed in CHO-K1 cells assessed as increase in forskolin induced cAMP production measured after 30 mins by HitHunter luminescence based assay,1,Scientific Literature,J Med Chem,2016,526.97,5.07,active,2,526.967,3.9662,-5.675,8,0,109.11,-1.3299,0.2628,0.99887,9,6,2,0.34987,0.69466,-0.2281482278,-0.8531777406,-0.2487627511,12,5
CHEMBL4800237,N=C(N)NCCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,42.66,7.37,F,CHEMBL4699661,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by competition PKA binding assay,1,Scientific Literature,J Med Chem,2020,1117.33,None,active,2,1117.32,-3.2407,-5.088,25,14,468.94,6.3065,0.52692,0.93443,27,23,3,0.47717,0.56452,6.766851404,0.1922753349,-0.6270892833,4,1
CHEMBL480426,CC1(N2CCC(n3c(-c4cccc(CN)c4)nc4ccccc43)CC2)CCCCCCC1,340,6.47,F,CHEMBL1143349,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells by [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,430.64,6.3,intermediate,1,430.638,6.1789,-5.247,4,1,47.08,0.40392,0.39935,0.86492,4,4,3,0.36774,0.70812,-1.393965921,-0.8651055423,0.09121917745,11,5
CHEMBL481366,CC1(N2CCC(n3c([C@H]4CCCNC4)nc4ccccc43)CC2)CCCCCCC1,23,7.64,F,CHEMBL1143349,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells by [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,408.63,5.64,active,2,408.632,6.2498,-3.168,4,1,33.09,1.043,0.38396,0.86625,4,3,2,0.38569,0.73234,-1.623209098,0.3779698462,0.5264242037,11,2
CHEMBL481367,CC1(N2CCC(n3c(-c4cccc(S(C)(=O)=O)c4)nc4ccccc43)CC2)CCCCCCC1,288,6.54,F,CHEMBL1143349,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells by [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,479.69,6.25,intermediate,1,479.687,6.176,-5.704,5,0,63.58,-2.3102,0.40495,0.89202,6,4,3,0.39904,0.70963,-1.153673439,-1.191034555,-0.03045427852,11,5
CHEMBL481512,CC1(N2CCC(n3c([C@@H]4CCCNC4)nc4ccccc43)CC2)CCCCCCC1,34,7.47,F,CHEMBL1143349,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells by [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,408.63,5.64,active,2,408.632,6.2498,-3.168,4,1,33.09,1.043,0.38392,0.86625,4,3,2,0.39394,0.73099,-1.623209098,0.3779698462,0.5264242037,11,2
CHEMBL481547,CC1(N2CCC(n3c(-c4ccc(F)c(Cl)c4)nc4ccccc43)CC2)CCCCCCC1,759,6.12,F,CHEMBL1143349,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells by [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,454.03,7.64,intermediate,1,454.031,7.8808,-6.337,3,0,21.06,-0.72543,0.38625,0.88227,5,3,3,0.38921,0.71262,-1.726429124,-1.832060655,0.03785955708,11,5
CHEMBL481548,CC1(N2CCC(n3c(-c4ccc5cc[nH]c5c4)nc4ccccc43)CC2)CCCCCCC1,8625,5.06,F,CHEMBL1143349,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells by [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,440.64,7.32,inactive,0,440.633,7.2134,-5.812,4,1,36.85,0.74989,0.36328,0.88433,4,3,4,0.37404,0.71608,-1.551993771,-1.37581989,1.86E-02,1,1
CHEMBL481707,CC1(N2CCC(n3c(-c4cc5ccccc5o4)nc4ccccc43)CC2)CCCCCCC1,3673,5.43,F,CHEMBL1143349,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells by [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,441.62,7.59,inactive,0,441.617,7.7166,-6.138,4,0,34.2,0.67151,0.3524,0.8972,4,3,4,0.39222,0.7087,-1.691392664,-1.66818984,0.04930083199,1,1
CHEMBL4852470,Cl.O=C(N[C@@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2cccnc12,0.96,9.02,F,CHEMBL4814025,partial agonist,agonist,Partial agonist activity at mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2021,521.02,2.41,highly_active,3,521.015,1.7729,-3.982,8,4,110.71,7.3039,0.26825,1.0973,8,4,3,0.35274,0.72286,0.1503823935,0.6044385551,-0.4779776021,10,1
CHEMBL4862035,Cl.O=C(N[C@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1n[nH]c2ccccc12,1.57,8.8,F,CHEMBL4814025,partial agonist,agonist,Partial agonist activity at mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2021,521.02,2.41,highly_active,3,521.015,1.8764,-4.455,8,4,110.71,8.5419,0.26825,1.0943,8,4,3,0.41448,0.74772,0.1600895166,0.3079406656,-0.578736816,10,1
CHEMBL4864454,Cl.O=C(N[C@@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2ccncc12,2.05,8.69,F,CHEMBL4814025,partial agonist,agonist,Partial agonist activity at mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2021,521.02,2.41,highly_active,3,521.015,1.6504,-4.087,8,4,110.71,7.3039,0.26825,1.0964,8,4,3,0.35345,0.72339,0.1694832693,0.5638278546,-0.5213659358,10,1
CHEMBL4866007,Cl.O=C(N[C@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2ncccc12,8.35,8.08,F,CHEMBL4814025,partial agonist,agonist,Partial agonist activity at mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2021,521.02,2.41,highly_active,3,521.015,1.9333,-4.932,8,4,110.71,7.3039,0.26825,1.0968,8,4,3,0.35611,0.73283,0.1754090003,0.01716163707,-0.6872083552,10,1
CHEMBL4868660,Cl.O=C(N[C@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2ccncc12,2.05,8.69,F,CHEMBL4814025,partial agonist,agonist,Partial agonist activity at mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2021,521.02,2.41,highly_active,3,521.015,1.6504,-4.087,8,4,110.71,7.3039,0.26825,1.0964,8,4,3,0.3518,0.72217,0.1694832693,0.5638278546,-0.5213659358,10,1
CHEMBL4874437,Cl.O=C(N[C@@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2ncccc12,0.73,9.14,F,CHEMBL4814025,partial agonist,agonist,Partial agonist activity at mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2021,521.02,2.41,highly_active,3,521.015,1.9333,-4.932,8,4,110.71,7.3039,0.26825,1.0968,8,4,3,0.33305,0.71829,0.1754090003,0.01716163707,-0.6872083552,10,1
CHEMBL4875882,Cl.O=C(N[C@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2cccnc12,1.97,8.71,F,CHEMBL4814025,partial agonist,agonist,Partial agonist activity at mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2021,521.02,2.41,highly_active,3,521.015,1.7729,-3.982,8,4,110.71,7.3039,0.26825,1.0973,8,4,3,0.46871,0.78764,0.1503823935,0.6044385551,-0.4779776021,10,1
CHEMBL4878105,Cl.O=C(N[C@@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2cnccc12,3.94,8.4,F,CHEMBL4814025,partial agonist,agonist,Partial agonist activity at mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2021,521.02,2.41,highly_active,3,521.015,1.6504,-4.087,8,4,110.71,7.3039,0.26825,1.0947,8,4,3,0.3602,0.71944,0.1694832693,0.5638278546,-0.5213659358,10,1
CHEMBL4878281,Cl.O=C(N[C@@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1n[nH]c2ccccc12,0.49,9.31,F,CHEMBL4814025,partial agonist,agonist,Partial agonist activity at mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2021,521.02,2.41,highly_active,3,521.015,1.8764,-4.455,8,4,110.71,8.5419,0.26825,1.0943,8,4,3,0.35136,0.71923,0.1600895166,0.3079406656,-0.578736816,10,1
CHEMBL4879114,Cl.O=C(N[C@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2cnccc12,13.57,7.87,F,CHEMBL4814025,partial agonist,agonist,Partial agonist activity at mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2021,521.02,2.41,active,2,521.015,1.6504,-4.087,8,4,110.71,7.3039,0.26825,1.0947,8,4,3,0.48264,0.78475,0.1694832693,0.5638278546,-0.5213659358,10,1
CHEMBL493621,C[C@H]1C2Cc3cc4cc[nH]c(=O)c4cc3[C@@]1(C)CCN2CC1CC1,850,6.07,F,CHEMBL1150274,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem,2008,322.45,3.46,intermediate,1,322.45,3.0603,-4.629,3,1,32.34,5.6092,0.25431,0.93004,3,2,1,0.36002,0.77083,-1.484123653,0.1650177446,-0.3874127639,1,1
CHEMBL493846,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc2ccccc2c1,0.3,9.52,F,CHEMBL4028804,agonist,agonist,Agonist activity at human mu-opioid receptor expressed in HEK293 cell membranes after 1 hr by [35S]-GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2017,496.61,3.91,highly_active,3,496.605,4.0817,-6.191,6,3,82.03,5.5016,0.266,1.0873,6,4,3,0.33511,0.71265,-0.4748702273,-1.090390691,-0.5818307687,3,1
CHEMBL494350,C[C@@H]1CN(CCO)CCN1c1cc2[nH]c(SC(C)(C)C)nc2cc1Cl,97,7.01,F,CHEMBL1150320,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cell membrane by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2008,382.96,3.61,active,2,382.958,3.4563,-3.566,5,2,80.69,-2.5794,0.46795,0.83016,7,5,2,0.27344,0.71048,-0.7471354998,0.6433641199,0.08099108767,1,1
CHEMBL495997,C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC1=O,1100,5.96,F,CHEMBL5126521,antagonist,antagonist,Antagonist activity at human MOP stably expressed in CHO cell membrane assessed as [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2022,462.55,0.95,inactive,0,462.548,1.2724,-3.404,8,3,107.61,6.776,0.38163,0.85157,8,4,2,0.57772,0.73107,-0.007040181613,1.074827058,-0.3798092386,1,1
CHEMBL499595,C[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]2CCCN2C1=O,48,7.32,F,CHEMBL1136971,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of 100 nM loperamide-stimulated GTPgammaS binding by cell based assay,1,Scientific Literature,Bioorg Med Chem Lett,2009,501.59,1.43,active,2,501.585,1.3118,-3.929,9,4,123.4,6.8439,0.36023,0.89285,9,4,3,0.39169,0.69899,0.3320251251,0.7363538112,-0.5688008405,1,1
CHEMBL501331,CN1CCC[C@H](c2nc3ccccc3n2C2CCN(C3(C)CCCCCCC3)CC2)C1,71,7.15,F,CHEMBL1143349,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells by [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,422.66,5.99,active,2,422.658,6.5027,-2.806,4,0,24.3,3.3358,0.37604,0.87115,4,3,2,0.39115,0.73519,-1.765132306,0.520540851,0.6998256758,11,2
CHEMBL502411,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1ccccc1,21,7.68,F,CHEMBL1136971,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of 100 nM loperamide-stimulated GTPgammaS binding by cell based assay,1,Scientific Literature,Bioorg Med Chem Lett,2009,577.69,2.65,active,2,577.683,2.7537,-5.064,9,4,123.4,7.3467,0.35385,0.91047,9,6,4,0.41236,0.68689,0.4245657452,-0.2799231542,-0.4269589872,2,1
CHEMBL504973,CC(C)C[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O,27.5,7.56,F,CHEMBL1149874,agonist,agonist,Agonist activity at mu opioid receptor assessed as inhibition of forskolin-induced cAMP production in human SH-SY5Y cells pretreated for 24 hrs with DMEM medium after 15 mins,1,Scientific Literature,Bioorg Med Chem,2008,593.69,-0.28,active,2,593.683,-0.9041,-3.505,13,8,221.53,3.0746,0.59213,0.82844,13,15,3,0.34062,0.62273,2.363366768,1.207068568,-0.01275046313,1,1
CHEMBL506616,O=C1N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H]1Cc1c[nH]c2ccccc12,25,7.6,F,CHEMBL1136971,antagonist,antagonist,Antagonist activity at human cloned mu opioid receptor assessed as inhibition of 100 nM loperamide-stimulated GTPgammaS binding by cell based assay,1,Scientific Literature,Bioorg Med Chem Lett,2009,577.69,2.65,active,2,577.683,2.7537,-5.064,9,4,123.4,7.3467,0.35495,0.91047,9,6,4,0.41919,0.68623,0.4245657452,-0.2799231542,-0.4269589872,2,1
CHEMBL5069961,Fc1ccc(CNCC[C@@]2(c3ccccn3)CCOC3(CCOC3)C2)cc1Cl,26.5,7.58,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,404.91,4.26,active,2,404.911,2.9133,-4.364,4,1,43.38,-2.4816,0.49963,0.88227,6,6,2,0.40757,0.71012,-0.8977975193,0.2148880045,0.01259431853,20,4
CHEMBL5070613,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CCOCC1)c1ccccc1,26,7.58,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,421.59,3.8,active,2,421.583,3.5468,-3.013,5,0,36.02,3.8134,0.50896,0.78354,5,7,2,0.54228,0.74543,-1.074363722,0.8627350868,0.5876792162,9,1
CHEMBL5070616,C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,389.05,6.41,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of calcium mobilization by Fluo-4 AM dye based analysis,1,Scientific Literature,J Med Chem,2021,1443.68,None,intermediate,1,1443.67,-8.3513,-3.948,37,24,634.61,1.6816,0.61903,0.93789,37,48,3,0.37374,0.48184,11.68466082,1.270370147,0.7112812596,8,8
CHEMBL5071286,CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4cccc(-c5ccoc5)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,10964.78,4.96,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR receptor expressed in HTLA cells co-expressing TEV-fused-beta-arrestin2 assessed as induction of beta-arrestin2 recruitment by Tango assay,1,Scientific Literature,J Med Chem,2021,450.54,4.04,inactive,0,450.533,2.954,-4.488,7,1,84.5,2.3525,0.28196,1.0101,7,6,2,0.44404,0.70095,-0.4527533426,0.1030061849,-0.08819237497,2,1
CHEMBL5072270,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cccc2ccccc12)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,15.85,7.8,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of calcium mobilization by Fluo-4 AM dye based analysis,1,Scientific Literature,J Med Chem,2021,1521.8,None,active,2,1521.79,-6.4691,-6.242,37,24,634.61,1.6816,0.60018,0.96123,37,48,4,0.40426,0.47586,11.69167673,-0.4810680559,0.4342384716,2,2
CHEMBL5073189,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1ncccc1C(F)(F)F,28,7.55,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,446.52,4.19,active,2,446.515,3.8836,-3.6,5,0,39.68,0.64,0.5839,0.84784,8,8,2,0.40619,0.73256,-0.8142526897,0.4168714213,0.5564280771,8,4
CHEMBL5073561,CCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,181.97,6.74,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of calcium mobilization by Fluo-4 AM dye based analysis,1,Scientific Literature,J Med Chem,2021,1409.66,None,intermediate,1,1409.66,-8.43,-3.623,37,24,634.61,-2.5763,0.64221,0.93277,37,49,2,0.40932,0.47545,11.67166347,1.494937933,0.8737544784,14,14
CHEMBL5073754,CN(C)C(=O)C(CCNCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1,1096.48,5.96,F,CHEMBL5046218,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293T cells assessed as Galphai2 activation preincubated for 5 mins with coelenterazine followed by compound addition and measured after 10 mins by BRET assay,1,Scientific Literature,J Med Chem,2021,567.61,5.95,inactive,0,567.603,5.3764,-4.598,5,1,38.82,8.7229,0.53155,0.80291,7,12,3,0.37844,0.64131,-0.5467795963,-0.5823938437,0.9243222551,2,2
CHEMBL5074742,Fc1ccc([C@]2(CCNCc3scc4c3CCC4)CCOC3(CCOC3)C2)cc1,0.07,10.15,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,415.57,4.76,highly_active,3,415.571,3.9356,-5.231,3,1,58.73,-3.7812,0.45356,0.86954,5,6,2,0.45396,0.72979,-1.028760818,-0.4797839028,-0.05493335039,6,1
CHEMBL5074745,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O)[C@@H](C)O,42.66,7.37,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of calcium mobilization by Fluo-4 AM dye based analysis,1,Scientific Literature,J Med Chem,2021,1425.66,None,active,2,1425.66,-9.6728,-3.372,38,25,654.84,0.13549,0.64313,0.94108,38,47,2,0.38214,0.48055,12.01268901,1.884061892,0.4802828113,14,14
CHEMBL5074977,CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4cccc(C)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,10471.29,4.98,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR receptor expressed in HTLA cells co-expressing TEV-fused-beta-arrestin2 assessed as induction of beta-arrestin2 recruitment by Tango assay,1,Scientific Literature,J Med Chem,2021,398.5,3.09,inactive,0,398.501,2.504,-3.088,6,1,71.36,2.4869,0.28595,0.9763,6,5,1,0.4375,0.72387,-0.7523709378,1.065360275,0.1162752817,10,4
CHEMBL5075152,COCC(=O)N(CC(C)(C)N1CCN(Cc2ccccc2)CC1)c1ccccc1,1468,5.83,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,395.55,3.26,inactive,0,395.545,3.0501,-2.357,5,0,36.02,6.4779,0.56746,0.74106,5,8,2,0.43057,0.74185,-1.041580421,1.34708833,0.7719713249,7,3
CHEMBL5075279,CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4ccc(-c5ccccc5)c(OC)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,104.3,6.98,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2021,490.6,4.46,intermediate,1,490.598,3.7493,-4.848,7,1,80.59,2.4869,0.29195,1.0114,7,7,2,0.341,0.67713,-0.4344258058,-0.2985019535,0.04997916467,2,1
CHEMBL5075300,c1ccc([C@]2(CCNCc3scc4c3CCC4)CCO[C@]3(CCOC3)C2)nc1,0.46,9.34,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,398.57,4.02,highly_active,3,398.569,2.8879,-4.146,4,1,71.62,-2.4412,0.45398,0.89559,5,6,2,0.40668,0.72264,-0.8806737116,0.3612836053,0.03363796244,6,1
CHEMBL5075424,CC[C@@H]1CN2CCc3c([nH]c4cccc(C)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,82.94,7.08,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2021,382.5,4.12,active,2,382.502,3.6571,-3.531,5,1,54.56,2.1076,0.2817,0.94534,5,5,2,0.44891,0.71678,-1.064932842,0.6167325975,0.2118631315,10,4
CHEMBL5075502,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1ccccc1F,73,7.14,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,395.52,3.92,active,2,395.52,3.7856,-3.406,4,0,26.79,6.49,0.55452,0.80135,5,7,2,0.58368,0.76019,-1.214583738,0.6110474993,0.5397134298,8,4
CHEMBL5075806,CC[C@@H]1CN2CCc3c([nH]c4ccc(C)c(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,369.7,6.43,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2021,412.53,4.13,intermediate,1,412.528,3.5871,-3.549,6,1,63.79,2.1076,0.29215,0.9666,6,6,2,0.41839,0.69693,-0.8151852906,0.5785383519,0.2723459148,10,4
CHEMBL5075990,CCc1cc(Cl)c(OC)c(C(=O)NCC2CCCN2CCCCNCCC(C(=O)N(C)C)(c2ccccc2)c2ccccc2)c1O,208.93,6.68,F,CHEMBL5046218,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293T cells assessed as Galphai2 activation preincubated for 5 mins with coelenterazine followed by compound addition and measured after 10 mins by BRET assay,1,Scientific Literature,J Med Chem,2021,649.28,5.65,intermediate,1,649.273,5.1838,-4.674,8,3,94.14,7.1173,0.54585,0.89202,9,16,3,0.44863,0.63396,0.4429786524,-0.6868574224,1.106645628,1,1
CHEMBL5076404,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1ccccn1,39,7.41,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,378.52,3.18,active,2,378.518,3.0353,-2.822,5,0,39.68,7.83,0.55856,0.79273,5,7,2,0.45545,0.75016,-1.078087966,1.105527938,0.5486939095,8,4
CHEMBL5076581,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H]1CSSC[C@@H](C(=O)NCC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC1=O,13.6,7.87,F,CHEMBL5029183,agonist,agonist,Agonist activity at mu-opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation incubated for 15 mins by ELISA,1,Scientific Literature,J Med Chem,2021,1150.79,None,active,2,1150.78,-2.395,-6.451,25,17,477.44,-9.1494,0.5015,0.95114,28,23,4,0.54952,0.57223,7.135285973,-0.7539424529,-0.9582137998,3,3
CHEMBL5076707,CCC(=O)N(CCN1CCN(Cc2ccccc2)CC1)c1ccccc1,515,6.29,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,351.49,3.25,intermediate,1,351.492,3.2634,-2.519,4,0,26.79,7.3437,0.58168,0.68031,4,7,2,0.34005,0.70202,-1.321414061,1.267783106,0.6859719006,7,3
CHEMBL5077091,Fc1ccc([C@]2(CCNCc3scc4c3CCC4)CCOC3(CCOCC3)C2)nc1,178,6.75,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,430.59,4.55,intermediate,1,430.586,3.3307,-4.73,4,1,71.62,-5.5872,0.45773,0.8878,6,6,2,0.43207,0.72371,-0.7970961391,-0.0918264549,-0.05184137064,1,1
CHEMBL5077114,CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2C[C@H]1C[C@@H]1CCNC(=O)c1cc2ccccc2[nH]1,2089.3,5.68,F,CHEMBL5046218,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK293T cells assessed as Galphai2 activation preincubated with compound in D-PBS for 3 hrs followed by coelenterazine addition for 5 mins once again compound addition for 10 mins by BRET assay,1,Scientific Literature,J Med Chem,2021,541.69,5.32,inactive,0,541.69,4.7993,-5.524,7,3,94.66,-3.2463,0.41942,0.9389,7,10,3,0.4172,0.64091,-0.08722294951,-0.9393564282,0.2558779298,2,1
CHEMBL5077763,c1ccc([C@]2(CCNCc3scc4c3COC4)CCOC3(CCCC3)C2)nc1,2,8.7,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,398.57,4.71,highly_active,3,398.569,2.1209,-4.462,4,1,71.62,-2.0321,0.45398,0.8762,5,6,2,0.44417,0.72546,-0.7767884271,0.3080874774,-0.1544993128,6,1
CHEMBL5077829,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CCCCC1)c1ccccc1,158,6.8,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,419.61,4.95,intermediate,1,419.611,4.7108,-3.902,4,0,26.79,2.7412,0.50474,0.78354,4,7,2,0.36632,0.74115,-1.321120568,0.1377119978,0.5674082795,9,1
CHEMBL5078349,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(Cl)cc2)C(=O)N1)C(=O)O,201.5,6.7,F,CHEMBL5029183,agonist,agonist,Agonist activity at mu-opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation incubated for 15 mins by ELISA,1,Scientific Literature,J Med Chem,2021,1083.7,None,intermediate,1,1083.69,-3.1222,-5.238,24,16,461.65,-9.3188,0.52719,0.91361,27,23,3,0.33763,0.56714,6.801334565,0.1355729326,-0.7046720344,3,3
CHEMBL5078909,FC1(F)CCc2csc(CNCC[C@@]3(c4ccccn4)CCOC4(CCCC4)C3)c2C1,11,7.96,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as beta arrestin-2 recruitment incubated for 3 days by PathHunter assay,1,Scientific Literature,Eur J Med Chem,2022,446.61,5.81,active,2,446.604,4.5331,-5.753,3,1,62.39,-7.7886,0.48539,0.90011,6,6,2,0.42518,0.71203,-0.9555489204,-0.9215281924,-0.1081269014,3,1
CHEMBL5079087,CCC(=O)N(CC1(N2CCN(CCOC)CC2)CCOCC1)c1cccc(C(F)(F)F)n1,720,6.14,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,458.53,2.66,intermediate,1,458.523,2.289,-2.143,7,0,58.14,-3.2853,0.57776,0.83354,10,9,1,0.5616,0.74656,-0.3335960707,1.530306833,0.7253165101,12,12
CHEMBL5079202,CC[C@@H]1CN2CCc3c([nH]c4c(-c5ccoc5)ccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,186.2,6.73,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2021,464.56,5.09,intermediate,1,464.56,4.0371,-4.949,7,1,76.93,1.9438,0.2695,0.99742,7,7,3,0.47672,0.67305,-0.5155676676,-0.3838156973,0.06787822371,2,1
CHEMBL5079310,CCC(=O)N(CC1(N2CCN(CC(C)(C)O)CC2)CCOCC1)c1cccc(C(F)(F)F)n1,869,6.06,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,472.55,2.78,intermediate,1,472.55,2.601,-2.502,7,1,69.14,-4.2931,0.57567,0.83847,10,8,1,0.64703,0.75839,-0.2523456326,1.278189392,0.5359410685,12,12
CHEMBL5079432,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O)c1ccccc1,2.884,8.54,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of calcium mobilization by Fluo-4 AM dye based analysis,1,Scientific Literature,J Med Chem,2021,1457.71,None,highly_active,3,1457.7,-8.1662,-4.217,37,24,634.61,1.6816,0.61098,0.94592,37,47,3,0.46616,0.47603,11.65181245,1.079345212,0.5747659714,2,2
CHEMBL5079619,CCC(=O)N(CC(C)N1CCC(Cc2ccccc2)CC1)c1ccc(F)cc1,6.07,8.22,F,CHEMBL5034029,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 60 mins by cAMP HTRF assay,1,Scientific Literature,Eur J Med Chem,2021,382.52,4.91,highly_active,3,382.521,5.0712,-4.57,3,0,23.55,5.5711,0.56435,0.74106,4,7,2,0.39114,0.72226,-1.460206357,-0.2853333808,0.4596990602,7,4
CHEMBL5079626,CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4c(-c5ccccc5)ccc(OC)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,17510,4.76,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2021,490.6,4.46,inactive,0,490.598,3.7493,-4.848,7,1,80.59,2.4869,0.27805,1.0153,7,7,2,0.40503,0.69814,-0.4344258058,-0.2985019535,0.04997916467,2,1
CHEMBL5079758,CCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,562.34,6.25,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of calcium mobilization by Fluo-4 AM dye based analysis,1,Scientific Literature,J Med Chem,2021,1395.64,None,intermediate,1,1395.63,-8.8844,-3.353,37,24,634.61,0.031866,0.64246,0.93131,37,48,2,0.39424,0.48158,11.64514798,1.758841628,0.7723159806,14,14
CHEMBL5079835,Cc1cc(C)cc(CNCC[C@@]2(c3ccccn3)CCOC3(CCOC3)C2)c1,11.6,7.94,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,380.53,4.09,active,2,380.53,2.8943,-4.002,4,1,43.38,-1.2455,0.49963,0.85376,4,6,2,0.4577,0.72055,-1.067540017,0.4585593557,0.1177811715,20,4
CHEMBL5079983,c1ccc([C@]2(CCNCc3scc4c3COC4)CCOC3(CCOC3)C2)nc1,14.1,7.85,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,400.54,3.56,active,2,400.541,0.9569,-3.573,5,1,80.85,0.48881,0.45398,0.89559,6,6,2,0.45659,0.72443,-0.5300316821,1.033110533,-0.1342283238,6,1
CHEMBL5080086,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)COC1)c1ccccc1,253,6.6,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,393.53,3.02,intermediate,1,393.529,2.8628,-2.473,5,0,36.02,7.0789,0.54141,0.76921,5,7,2,0.44962,0.74537,-1.062884111,1.325957812,0.6165714264,1,1
CHEMBL5080233,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccc(Cl)cc2)C(=O)N1)C(=O)O,189.4,6.72,F,CHEMBL5029183,agonist,agonist,Agonist activity at mu-opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation incubated for 15 mins by ELISA,1,Scientific Literature,J Med Chem,2021,1122.73,None,intermediate,1,1122.73,-3.0828,-5.763,25,17,477.44,-9.152,0.50406,0.94186,28,23,4,0.37095,0.55446,7.14040461,-0.2029033753,-0.893663212,3,3
CHEMBL5080554,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCO[C@]2(CCOC2)C1,20,7.7,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,388.53,3.54,active,2,388.53,2.0031,-3.342,5,1,80.85,0.33969,0.47494,0.87651,6,7,2,0.42172,0.71949,-0.635745626,0.9864769155,0.1712274458,15,1
CHEMBL5080654,CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCc1ccccc1,19.95,7.7,F,CHEMBL5046218,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293T cells assessed as arrestin-3 recruitment preincubated for 5 mins with coelenterazine followed by compound addition and measured after 10 mins by BRET assay,1,Scientific Literature,J Med Chem,2021,405.54,4.62,active,2,405.536,4.5785,-4.227,4,1,49.77,-5.5192,0.39808,0.90245,4,7,2,0.42931,0.69888,-1.148389773,-0.001117793662,0.4007719542,1,1
CHEMBL5080666,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1)C(=O)O,160.3,6.79,F,CHEMBL5029183,agonist,agonist,Agonist activity at mu-opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation incubated for 15 mins by ELISA,1,Scientific Literature,J Med Chem,2021,1088.29,None,intermediate,1,1088.28,-3.6888,-5.027,25,17,477.44,-9.2164,0.50428,0.92876,27,23,4,0.38211,0.55024,7.065084404,0.3703168007,-0.7949603845,3,3
CHEMBL5080761,CCCOCCN1CCN(C2(CN(C(=O)CC)c3cccc(C(F)(F)F)n3)CCOCC2)CC1,86,7.07,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,486.58,3.44,active,2,486.577,3.1497,-2.713,7,0,58.14,-2.9229,0.58728,0.83562,10,11,1,0.53433,0.7263,-0.2735910478,0.9931720089,0.9139028497,12,12
CHEMBL5081106,CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4c(C)ccc(OC)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,11.22,7.95,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2021,428.53,3.1,active,2,428.527,2.434,-3.106,7,1,80.59,2.4869,0.2762,0.99966,7,6,1,0.42402,0.70165,-0.50262341,1.027166169,0.1767581286,10,4
CHEMBL5081133,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1cccc(C(F)(F)F)n1,6,8.22,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,446.52,4.19,highly_active,3,446.515,3.9376,-3.624,5,0,39.68,0.64,0.58332,0.82449,8,8,2,0.62318,0.73224,-0.8194386894,0.3933799359,0.558359607,8,4
CHEMBL5081139,C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(N)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,371.54,6.43,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of calcium mobilization by Fluo-4 AM dye based analysis,1,Scientific Literature,J Med Chem,2021,1458.7,None,intermediate,1,1458.69,-9.0286,-4.024,38,25,660.63,1.6816,0.61919,0.9395,38,48,3,0.36469,0.47999,12.08305993,1.345374079,0.5106179917,8,8
CHEMBL5081159,CCOC(=O)CCN1CCN(C2(CN(C(=O)CC)c3cccc(C(F)(F)F)n3)CCOCC2)CC1,598,6.22,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,500.56,2.96,intermediate,1,500.56,2.8001,-2.695,8,0,75.21,-12.385,0.58637,0.83968,11,11,1,0.53769,0.71514,-0.03729947002,1.054245078,0.829758582,12,12
CHEMBL5081183,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CCN(C)CC1)c1ccccc1,738,6.13,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,434.63,3.71,intermediate,1,434.626,3.6562,-2.515,5,0,30.03,11.584,0.49298,0.78935,5,7,2,0.49535,0.7627,-1.109551711,1.123479199,0.7356711146,9,1
CHEMBL5081432,C[C@H](NC(=O)CNC(=O)[C@H](Cc1cccc2ccccc12)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,831.76,6.08,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of calcium mobilization by Fluo-4 AM dye based analysis,1,Scientific Literature,J Med Chem,2021,1493.74,None,intermediate,1,1493.73,-7.1569,-5.554,37,24,634.61,1.6816,0.59928,0.9526,37,48,4,0.38827,0.48189,11.6967799,0.06998054033,0.498787498,2,2
CHEMBL5081900,C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,173.78,6.76,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of calcium mobilization by Fluo-4 AM dye based analysis,1,Scientific Literature,J Med Chem,2021,1459.68,None,intermediate,1,1459.67,-8.697,-3.652,38,25,654.84,1.6816,0.61919,0.9395,38,48,3,0.40594,0.47643,12.00980281,1.50492109,0.6577335427,8,8
CHEMBL5081955,CCC(=O)N(C[C@@H](C)N1CCC(Cc2ccccc2)CC1)c1ccccc1,189.9,6.72,F,CHEMBL5034029,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 60 mins by cAMP HTRF assay,1,Scientific Literature,Eur J Med Chem,2021,364.53,4.77,intermediate,1,364.531,4.9704,-4.256,3,0,23.55,6.9111,0.54593,0.71581,3,7,2,0.38784,0.73112,-1.549523707,-0.06383464185,0.5307322537,7,4
CHEMBL5081993,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,2.291,8.64,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as dynamic mass redistribution by DMR assay,1,Scientific Literature,J Med Chem,2021,1515.79,None,highly_active,3,1515.78,-7.3214,-5.028,38,25,654.84,1.6816,0.61926,0.95865,38,48,3,0.41861,0.48191,11.99958085,0.4028338954,0.5286339572,8,8
CHEMBL5082031,CCC(=O)N(CC1(N2CCNCC2)CCOCC1)c1cccc(C(F)(F)F)n1,1237,5.91,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,400.44,2.3,inactive,0,400.443,2.1286,-2.584,6,1,57.7,-5.461,0.55834,0.82494,9,6,1,0.55458,0.79055,-0.5519428906,1.403870421,0.269480137,12,12
CHEMBL5082465,CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCCCNC(=O)c1cc2ccccc2[nH]1,3548.13,5.45,F,CHEMBL5046218,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK293T cells assessed as Galphai2 activation preincubated with compound in D-PBS for 3 hrs followed by coelenterazine addition for 5 mins once again compound addition for 10 mins by BRET assay,1,Scientific Literature,J Med Chem,2021,515.65,5.07,inactive,0,515.652,4.6663,-5.118,7,3,94.66,-4.9823,0.44187,0.9294,7,10,3,0.38118,0.6383,-0.1306468314,-0.6524442301,0.3319218381,1,1
CHEMBL5082522,FC1(F)CCc2c(csc2CNCC[C@@]2(c3ccccn3)CCOC3(CCOC3)C2)C1,0.5,9.3,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,448.58,4.65,highly_active,3,448.576,3.3691,-4.864,4,1,71.62,-7.9312,0.48164,0.91574,7,6,2,0.39757,0.70904,-0.7087921364,-0.196505115,-0.08785594022,3,1
CHEMBL5082661,CN1CCN(C2(CNC(=O)C(C)(c3ccccc3)c3ccccc3)CCCCC2)CC1,1167,5.93,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,419.61,4.06,inactive,0,419.611,3.4599,-2.731,4,1,35.58,4.3275,0.49576,0.7473,4,6,2,0.49898,0.74702,-1.157148919,1.070377737,0.5273758362,1,1
CHEMBL5082714,FC1(F)Cc2csc(CNCC[C@@]3(c4ccccn4)CCOC4(CCCC4)C3)c2C1,0.1,10,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,432.58,5.42,highly_active,3,432.577,4.1911,-5.483,3,1,62.39,-7.7886,0.4657,0.8945,6,6,2,0.42853,0.71108,-0.9498091151,-0.6899168298,-0.09368079631,6,1
CHEMBL5082892,CN1C(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)CNC(=O)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)NC(=O)[C@@H]1Cc1ccccc1,238,6.62,F,CHEMBL5034023,agonist,agonist,Agonist activity at MOR (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins in presence of 3-isobutyl-1-methylxanthine followed by forskolin and compound addition by competitive PKA binding assay,1,Scientific Literature,J Med Chem,2021,1110.24,None,intermediate,1,1110.24,-4.8477,-3.459,27,14,438.65,7.4161,0.52026,0.95114,27,23,3,0.47674,0.56946,6.888362612,1.434495446,-0.4296607793,1,1
CHEMBL5083135,Clc1ccc(CNCC[C@@]2(c3ccccn3)CCOC3(CCOC3)C2)s1,22.3,7.65,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,392.95,4.18,active,2,392.95,2.8838,-4.077,4,1,71.62,0.75068,0.47984,0.87211,6,6,2,0.43491,0.72003,-0.8332417303,0.4059724729,0.03746126119,15,1
CHEMBL5083271,CCCCN1CCN(C2(CN(C(=O)CC)c3cccc(C(F)(F)F)n3)CCOCC2)CC1,510,6.29,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,456.55,3.81,intermediate,1,456.551,3.6966,-3.062,6,0,48.91,-3.4964,0.57137,0.83354,9,9,1,0.60009,0.73293,-0.6073487587,0.7454048811,0.7329062595,12,12
CHEMBL5083403,Fc1ccc([C@]2(CCNCc3cccc(Cl)c3)CCO[C@]3(CCOC3)C2)nc1,5.09,8.29,F,CHEMBL5042488,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293 assessed as increase in calcium mobilization incubated for 60 mins by FLIPR assay,1,Scientific Literature,Eur J Med Chem,2022,404.91,4.26,highly_active,3,404.911,2.9133,-4.364,4,1,43.38,-2.4816,0.48959,0.88462,6,6,2,0.42734,0.7163,-0.8977975193,0.2148880045,0.01259431853,20,1
CHEMBL5083736,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1ncccc1F,24,7.62,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,396.51,3.31,active,2,396.508,3.1361,-3.136,5,0,39.68,6.49,0.56107,0.80135,6,7,2,0.38996,0.74287,-0.9887706268,0.8840293397,0.4776607743,8,4
CHEMBL5084034,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1)C(=O)O,154,6.81,F,CHEMBL5029183,agonist,agonist,Agonist activity at mu-opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation incubated for 15 mins by ELISA,1,Scientific Literature,J Med Chem,2021,1049.25,None,intermediate,1,1049.25,-3.7282,-4.502,24,16,461.65,-9.383,0.52738,0.89747,26,23,3,0.48043,0.55407,6.726029799,0.7087835487,-0.6059676111,3,3
CHEMBL5084268,Fc1ccc([C@]2(CCNCc3cncc(Cl)c3)CCOC3(CCOC3)C2)cc1,12.8,7.89,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,404.91,4.26,active,2,404.911,2.8593,-4.34,4,1,43.38,-2.4816,0.49052,0.84479,6,6,2,0.47205,0.72939,-0.8926114698,0.2383792504,0.01066263749,20,1
CHEMBL5084344,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CCOCC1)c1cccc(C(F)(F)F)n1,9,8.05,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,490.57,4.21,highly_active,3,490.568,3.7996,-3.545,6,0,48.91,-3.3766,0.53267,0.84166,9,8,2,0.68552,0.74746,-0.5899013811,0.4235689539,0.5352922535,9,4
CHEMBL5084395,CCC(=O)N(CC1(N2CCN(CCOCC(F)(F)F)CC2)CCOCC1)c1cccc(C(F)(F)F)n1,314,6.5,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,526.52,3.59,intermediate,1,526.52,3.1796,-3.183,7,0,58.14,-2.5534,0.59569,0.83644,13,11,1,0.61747,0.7253,-0.01728932785,0.6672081078,0.7747095334,12,12
CHEMBL5084697,CCC(=O)N(CC(C)(C)N1CCN(Cc2ccccc2)CC1)c1ccccc1,299,6.52,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,379.55,4.03,intermediate,1,379.546,4.0033,-3.006,4,0,26.79,7.2837,0.56493,0.73369,4,7,2,0.35376,0.74172,-1.341843975,0.8260872981,0.6781231405,7,3
CHEMBL5084800,Fc1ccc([C@]2(CCNCc3scc4c3CCCC4)CCO[C@]3(CCOC3)C2)nc1,0.2,9.7,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,430.59,4.55,highly_active,3,430.586,3.3307,-4.73,4,1,71.62,-6.1112,0.46296,0.90802,6,6,2,0.42281,0.72248,-0.7970961391,-0.0918264549,-0.05184137064,3,1
CHEMBL5084960,CC[C@@H]1CN2CCc3c([nH]c4cccc(-c5ccccc5)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,83.16,7.08,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2021,444.58,5.48,active,2,444.573,4.9724,-5.273,5,1,54.56,2.1076,0.28404,0.96693,5,6,3,0.37901,0.68599,-0.9967352764,-0.7089354264,0.08508426033,2,1
CHEMBL5085013,CN1C(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)CCCCNC(=O)C[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)NC(=O)[C@@H]1Cc1ccccc1,167,6.78,F,CHEMBL5034023,agonist,agonist,Agonist activity at MOR (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins in presence of 3-isobutyl-1-methylxanthine followed by forskolin and compound addition by competitive PKA binding assay,1,Scientific Literature,J Med Chem,2021,1152.32,None,intermediate,1,1152.32,-3.4845,-4.269,27,14,438.65,3.8085,0.51289,0.9493,27,23,3,0.41246,0.56958,6.831862096,0.6812324503,-0.4242741133,4,1
CHEMBL5085090,C[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(c1ccccc1)c1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,165.96,6.78,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of calcium mobilization by Fluo-4 AM dye based analysis,1,Scientific Literature,J Med Chem,2021,1519.78,None,intermediate,1,1519.77,-6.8237,-5.097,37,24,634.61,1.8524,0.59293,0.94515,37,49,4,0.44049,0.48506,11.72252191,0.2438090255,0.7624396749,1,1
CHEMBL5085104,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H]1CSSC[C@@H](C(=O)NCC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)[C@H](Cc2ccccc2)NC1=O,14.3,7.84,F,CHEMBL5029183,agonist,agonist,Agonist activity at mu-opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation incubated for 15 mins by ELISA,1,Scientific Literature,J Med Chem,2021,1111.75,None,active,2,1111.74,-2.4344,-5.926,24,16,461.65,-9.3173,0.52434,0.92484,27,23,3,0.3918,0.56085,6.796215928,-0.4154661449,-0.7692226222,3,3
CHEMBL5085161,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,831.76,6.08,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of calcium mobilization by Fluo-4 AM dye based analysis,1,Scientific Literature,J Med Chem,2021,1409.66,None,intermediate,1,1409.66,-8.6661,-3.513,37,24,634.61,1.8487,0.64314,0.93277,37,48,2,0.41857,0.47943,11.64876091,1.613444104,0.7669063378,14,14
CHEMBL5085321,Fc1ccc([C@]2(CCNCc3cccs3)CCOC3(CCOC3)C2)cc1,19.9,7.7,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,375.51,4.27,active,2,375.506,3.1208,-4.409,3,1,58.73,-0.26709,0.47007,0.83685,5,6,2,0.45795,0.73527,-1.033580299,0.1836036124,0.02217337885,15,2
CHEMBL5085455,CN1C(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)CCCCNC(=O)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)NC(=O)[C@@H]1Cc1ccccc1,93.33,7.03,F,CHEMBL5034023,agonist,agonist,Agonist activity at MOR (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins in presence of 3-isobutyl-1-methylxanthine followed by forskolin and compound addition by competitive PKA binding assay,1,Scientific Literature,J Med Chem,2021,1152.32,None,active,2,1152.32,-3.4845,-4.269,27,14,438.65,3.8085,0.51227,0.9493,27,23,3,0.47313,0.55571,6.831862096,0.6812324503,-0.4242741133,4,1
CHEMBL5085710,CN1CCN(C2(CNC(=O)c3ccccc3Oc3ccccc3)CCCCC2)CC1,4527,5.34,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,407.56,4.16,inactive,0,407.556,3.7196,-4.293,5,1,44.81,3.3905,0.49063,0.77309,5,6,2,0.45045,0.72518,-0.985135587,0.1185755407,0.1515684561,1,1
CHEMBL5085771,CCC(=O)N(CC1(N2CCN(C(C)c3ccccc3)CC2)CCOCC1)c1cccc(C(F)(F)F)n1,142,6.85,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,504.6,4.77,intermediate,1,504.595,4.0863,-3.616,6,0,48.91,-3.6168,0.53737,0.8512,9,8,2,0.5317,0.73418,-0.5983557903,0.3187369554,0.5615388204,9,4
CHEMBL5085974,CN(C)C(=O)C(CCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1,12.3,7.91,F,CHEMBL5046218,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293T cells assessed as Galphai2 activation preincubated for 5 mins with coelenterazine followed by compound addition and measured after 10 mins by BRET assay,1,Scientific Literature,J Med Chem,2021,496.48,5.58,active,2,496.48,5.0343,-4.273,4,0,26.79,9.5141,0.50186,0.807,6,7,3,0.4629,0.69694,-1.105325768,-0.2139360787,0.5122073088,1,1
CHEMBL5086376,CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4ccc(C)c(OC)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,30.2,7.52,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2021,428.53,3.1,active,2,428.527,2.434,-3.106,7,1,80.59,2.4869,0.29627,0.99768,7,6,1,0.43201,0.72924,-0.50262341,1.027166169,0.1767581286,10,4
CHEMBL5086463,CN1C(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)CCCCNC(=O)C[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)NC(=O)[C@@H]1Cc1ccccc1,588.84,6.23,F,CHEMBL5034023,agonist,agonist,Agonist activity at MOR (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins in presence of 3-isobutyl-1-methylxanthine followed by forskolin and compound addition by competitive PKA binding assay,1,Scientific Literature,J Med Chem,2021,1152.32,None,intermediate,1,1152.32,-3.4845,-4.269,27,14,438.65,3.8085,0.51266,0.9493,27,23,3,0.4272,0.56882,6.831862096,0.6812324503,-0.4242741133,4,1
CHEMBL5086564,CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2C[C@@H]1C[C@H]1CCNC(=O)c1cc2ccccc2[nH]1,5754.4,5.24,F,CHEMBL5046218,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in HEK293T cells assessed as Galphai2 activation preincubated with compound in D-PBS for 3 hrs followed by coelenterazine addition for 5 mins once again compound addition for 10 mins by BRET assay,1,Scientific Literature,J Med Chem,2021,541.69,5.32,inactive,0,541.69,4.7993,-5.524,7,3,94.66,-3.2463,0.41942,0.9389,7,10,3,0.47131,0.65046,-0.08722294951,-0.9393564282,0.2558779298,2,1
CHEMBL5086571,CCC(=O)N(CC1(N2CCN(CC(C)C)CC2)CCOCC1)c1cccc(C(F)(F)F)n1,183,6.74,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,456.55,3.67,intermediate,1,456.551,3.4605,-2.952,6,0,48.91,-8.8448,0.57768,0.83354,9,8,1,0.53063,0.75152,-0.6302512508,0.8639113156,0.6260580738,12,12
CHEMBL5086601,CN1C(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)CCCCNC(=O)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)NC(=O)[C@@H]1Cc1ccccc1,72.44,7.14,F,CHEMBL5034023,agonist,agonist,Agonist activity at MOR (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins in presence of 3-isobutyl-1-methylxanthine followed by forskolin and compound addition by competitive PKA binding assay,1,Scientific Literature,J Med Chem,2021,1152.32,None,active,2,1152.32,-3.4845,-4.269,27,14,438.65,3.8085,0.51251,0.9493,27,23,3,0.43497,0.56847,6.831862096,0.6812324503,-0.4242741133,4,1
CHEMBL5086786,CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4cccc(-c5ccccc5)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,19200,4.72,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR receptor expressed in HTLA cells co-expressing TEV-fused-beta-arrestin2 assessed as induction of beta-arrestin2 recruitment by Tango assay,1,Scientific Literature,J Med Chem,2021,460.57,4.45,inactive,0,460.572,3.8193,-4.83,6,1,71.36,2.4869,0.28685,0.99689,6,6,2,0.39823,0.69489,-0.6841733445,-0.2603077072,-0.01050362394,2,1
CHEMBL5087383,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,15.49,7.81,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of calcium mobilization by Fluo-4 AM dye based analysis,1,Scientific Literature,J Med Chem,2021,1487.73,None,active,2,1487.73,-8.0092,-4.34,38,25,654.84,1.6816,0.62011,0.94893,38,48,3,0.42576,0.48037,12.00469951,0.9538726921,0.5931844284,8,8
CHEMBL5087458,CCC(=O)N(CC1(N2CCN(CCOCC(C)C)CC2)CCOCC1)c1cccc(C(F)(F)F)n1,30,7.52,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,500.61,3.68,active,2,500.604,3.368,-2.873,7,0,58.14,-3.1775,0.59265,0.83603,10,11,1,0.47747,0.71407,-0.2699827123,0.8477776224,0.9084926905,12,12
CHEMBL5087472,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1ccccc1,34,7.47,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,377.53,3.78,active,2,377.53,3.6848,-3.092,4,0,26.79,7.83,0.55826,0.75761,4,7,2,0.44928,0.75247,-1.303901077,0.8325460978,0.610746565,8,4
CHEMBL5087703,Fc1ccc([C@]2(CCNCc3scc4c3COC4)CCOC3(CCOC3)C2)cc1,6.8,8.17,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,417.55,4.3,highly_active,3,417.543,2.0046,-4.658,4,1,67.96,-0.85119,0.45356,0.86954,6,6,2,0.44932,0.73519,-0.6781187899,0.1920430047,-0.2227996247,6,1
CHEMBL5087973,CCC(=O)N(C[C@H](C)N1CCC(Cc2ccccc2)CC1)c1ccccc1,0.73,9.14,F,CHEMBL5034029,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 60 mins by cAMP HTRF assay,1,Scientific Literature,Eur J Med Chem,2021,364.53,4.77,highly_active,3,364.531,4.9704,-4.256,3,0,23.55,6.9111,0.56265,0.71581,3,7,2,0.39506,0.72796,-1.549523707,-0.06383464185,0.5307322537,7,4
CHEMBL5088382,CC[C@@H]1CN2CCc3c([nH]c4ccc(-c5ccccc5)c(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,3763,5.42,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2021,474.6,5.49,inactive,0,474.599,4.9024,-5.291,6,1,63.79,2.1076,0.28908,0.98247,6,7,3,0.32763,0.67058,-0.7469876974,-0.7471296307,0.1455670092,2,1
CHEMBL5088860,Cc1cccc(CNCC[C@@]2(c3ccccn3)CCOC3(CCOC3)C2)c1,6.1,8.21,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,366.51,3.78,highly_active,3,366.503,2.5504,-3.658,4,1,43.38,-1.2455,0.49134,0.85157,4,6,2,0.43941,0.72446,-1.064983753,0.7340806404,0.1500560976,20,4
CHEMBL5089000,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CCSCC1)c1cccc(C(F)(F)F)n1,4,8.4,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,506.64,4.93,highly_active,3,506.635,4.2065,-4.231,5,0,64.98,0.41569,0.53546,0.86758,9,8,2,0.49565,0.7363,-0.5879730953,-0.06487081403,0.4113755141,9,1
CHEMBL5089365,CCC(=O)N(CC1(C2CCN(Cc3ccccc3)CC2)CCOCC1)c1cccc(C(F)(F)F)n1,84,7.08,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,489.58,5.55,active,2,489.58,4.9454,-4.912,5,0,45.67,-3.7346,0.55494,0.81905,8,8,2,0.53476,0.72001,-0.7913384976,-0.5795617613,0.3872885954,9,1
CHEMBL5089366,CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4ccc(-c5ccoc5)c(OC)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,537.03,6.27,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2021,480.56,4.05,intermediate,1,480.559,2.884,-4.506,8,1,93.73,2.3525,0.28809,1.0203,8,7,2,0.37942,0.68671,-0.2030057788,0.06481194008,-0.02770959695,2,1
CHEMBL5089489,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1ccccc1O,35,7.46,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,393.53,3.49,active,2,393.529,3.3391,-2.796,5,1,47.02,7.7974,0.55452,0.79048,5,7,2,0.56704,0.76165,-0.9787606944,1.067098114,0.5571986459,8,4
CHEMBL5089655,N#CC(CCNCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1,10471.29,4.98,F,CHEMBL5046218,agonist,agonist,Agonist activity at human mu opioid receptor expressed in HEK293T cells assessed as Galphai2 activation preincubated for 5 mins with coelenterazine followed by compound addition and measured after 10 mins by BRET assay,1,Scientific Literature,J Med Chem,2021,521.54,6.39,inactive,0,521.534,5.6781,-5.641,4,1,42.3,2.5777,0.51819,0.7569,6,11,3,0.3065,0.64054,-0.7577196193,-1.191436891,0.6176038289,2,2
CHEMBL5089766,CCC(=O)N(CC1(N2CCN(CCOC(C)C)CC2)CCOCC1)c1cccc(C(F)(F)F)n1,53,7.28,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,486.58,3.44,active,2,486.577,3.0546,-2.821,7,0,58.14,-3.3233,0.58167,0.83562,10,10,1,0.45584,0.70882,-0.3028876544,0.9588593199,0.7740973956,12,12
CHEMBL5090298,CN1C(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)CC(=O)NCCCC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)NC(=O)[C@@H]1Cc1ccccc1,66.3,7.18,F,CHEMBL5034023,agonist,agonist,Agonist activity at MOR (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins in presence of 3-isobutyl-1-methylxanthine followed by forskolin and compound addition by competitive PKA binding assay,1,Scientific Literature,J Med Chem,2021,1152.32,None,active,2,1152.32,-3.4845,-4.269,27,14,438.65,3.8085,0.51227,0.94874,27,23,3,0.46151,0.56202,6.831862096,0.6812324503,-0.4242741133,1,1
CHEMBL5090537,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCO[C@@]2(CCOC2)C1,1930.2,5.71,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,388.53,3.54,inactive,0,388.53,2.0031,-3.342,5,1,80.85,0.33969,0.47494,0.87651,6,7,2,0.45565,0.71365,-0.635745626,0.9864769155,0.1712274458,15,1
CHEMBL5090595,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CCOC(C)(C)C1)c1cccc(C(F)(F)F)n1,6,8.22,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,518.62,4.99,highly_active,3,518.622,4.4223,-4.032,6,0,48.91,-2.3303,0.51759,0.86692,9,8,2,0.59251,0.72063,-0.5966789513,0.002181514504,0.5105081745,9,4
CHEMBL5090993,CCOCCN1CCN(C2(CN(C(=O)CC)c3cccc(C(F)(F)F)n3)CCOCC2)CC1,210,6.68,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,472.55,3.05,intermediate,1,472.55,2.6953,-2.443,7,0,58.14,-4.2887,0.58104,0.83479,10,10,1,0.53665,0.72325,-0.3001019032,1.257072789,0.8124648576,12,12
CHEMBL5091110,c1ccc([C@]2(CCNCC3CCCCC3)CCOC3(CCOC3)C2)nc1,61.6,7.21,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,358.53,3.85,active,2,358.524,2.5388,-3.617,4,1,43.38,-5.7056,0.47453,0.84632,4,6,1,0.42822,0.74193,-1.077848741,0.7678242671,0.1571654827,20,1
CHEMBL5091560,CN1C(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)CCNC(=O)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)NC(=O)[C@@H]1Cc1ccccc1,38.02,7.42,F,CHEMBL5034023,agonist,agonist,Agonist activity at MOR (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins in presence of 3-isobutyl-1-methylxanthine followed by forskolin and compound addition by competitive PKA binding assay,1,Scientific Literature,J Med Chem,2021,1124.27,None,active,2,1124.27,-4.3933,-3.729,27,14,438.65,7.0985,0.51884,0.94967,27,23,3,0.45705,0.55758,6.869534326,1.183404569,-0.4278646971,1,1
CHEMBL5091787,CC[C@@H]1CN2CCc3c([nH]c4cccc(-c5ccoc5)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,93.73,7.03,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2021,434.54,5.08,active,2,434.534,4.1071,-4.931,6,1,67.7,1.9438,0.27882,0.98039,6,6,3,0.4506,0.69298,-0.7653152373,-0.3456217746,0.00739536349,2,1
CHEMBL5091971,CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4c(-c5ccoc5)ccc(OC)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,1560,5.81,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2021,480.56,4.05,inactive,0,480.559,2.884,-4.506,8,1,93.73,2.3525,0.27318,1.0247,8,7,2,0.45124,0.69802,-0.2030057788,0.06481194008,-0.02770959695,2,1
CHEMBL5092009,c1ccc([C@]2(CCNCc3ccc4ccccc4c3)CCOC3(CCOC3)C2)nc1,174.2,6.76,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,402.54,4.62,intermediate,1,402.536,3.4009,-4.92,4,1,43.38,-1.2435,0.47693,0.86659,4,6,3,0.41667,0.70791,-1.05030821,-0.190787686,-0.03016279244,2,1
CHEMBL5092388,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,6.457,8.19,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of calcium mobilization by Fluo-4 AM dye based analysis,1,Scientific Literature,J Med Chem,2021,1471.74,None,highly_active,3,1471.73,-7.6635,-4.636,37,24,634.61,1.6816,0.61973,0.94743,37,48,3,0.39841,0.47663,11.6795574,0.7193215842,0.6467322831,8,8
CHEMBL5092587,CCC(=O)N(CC1(N2CCN(CCOc3ccccc3)CC2)CCOCC1)c1cccc(C(F)(F)F)n1,133,6.88,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,520.6,4.09,intermediate,1,520.594,3.8065,-3.472,7,0,58.14,-2.9229,0.54346,0.84008,10,10,2,0.44889,0.7024,-0.307954982,0.4128294391,0.728791798,1,1
CHEMBL5093051,CCCN1CCN(C2(CN(C(=O)CC)c3cccc(C(F)(F)F)n3)CCOCC2)CC1,180,6.75,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,442.53,3.42,intermediate,1,442.524,3.2422,-2.792,6,0,48.91,-2.8345,0.56856,0.83186,9,8,1,0.59662,0.74357,-0.6338595862,1.009305702,0.631468233,12,12
CHEMBL5093143,CC[C@@H]1CN2CCc3c([nH]c4c(-c5ccccc5)ccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,1113,5.95,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2021,474.6,5.49,inactive,0,474.599,4.9024,-5.291,6,1,63.79,2.1076,0.27472,0.98682,6,7,3,0.4732,0.66355,-0.7469876974,-0.7471296307,0.1455670092,2,1
CHEMBL5093399,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,194.98,6.71,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of calcium mobilization by Fluo-4 AM dye based analysis,1,Scientific Literature,J Med Chem,2021,1487.73,None,intermediate,1,1487.73,-8.0092,-4.34,38,25,654.84,1.6816,0.61832,0.94985,38,48,3,0.44597,0.47721,12.00469951,0.9538726921,0.5931844284,8,8
CHEMBL5093645,Clc1cccc(CNCC[C@@]2(c3ccccn3)CCOC3(CCOC3)C2)c1,2.6,8.59,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,386.92,4.12,highly_active,3,386.921,2.8125,-4.05,4,1,43.38,-1.1416,0.49134,0.87527,5,6,2,0.45962,0.7171,-0.9871148945,0.4363864916,0.08362739067,20,4
CHEMBL5093673,CC[C@@H]1CN2CCc3c([nH]c4c(C)ccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,70.79,7.15,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2021,412.53,4.13,active,2,412.528,3.5871,-3.549,6,1,63.79,2.1076,0.27128,0.96856,6,6,2,0.43828,0.69253,-0.8151852906,0.5785383519,0.2723459148,10,4
CHEMBL5093833,CCC(=O)N(CC1(N2CCN(C(CO)c3ccccc3)CC2)CCOCC1)c1cccc(C(F)(F)F)n1,972,6.01,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,520.6,3.74,intermediate,1,520.594,3.1596,-3.109,7,1,69.14,-4.1069,0.54006,0.85875,10,9,2,0.54928,0.74507,-0.1699011419,0.7654156615,0.5752984377,9,4
CHEMBL5093937,Cc1ccsc1CNCC[C@@]1(c2ccc(F)cc2)CCOC2(CCOC2)C1,4.1,8.39,F,CHEMBL5042488,agonist,agonist,Agonist activity at mu opioid receptor (unknown origin) assessed as increase in cAMP level incubated for 40 mins by spectrophotometry,1,Scientific Literature,Eur J Med Chem,2022,389.54,4.58,highly_active,3,389.533,3.4647,-4.753,3,1,58.73,-0.66182,0.46959,0.84166,5,6,2,0.50527,0.73873,-1.03613661,-0.09191764328,-0.01010155205,15,2
CHEMBL5094439,C[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,154.88,6.81,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of calcium mobilization by Fluo-4 AM dye based analysis,1,Scientific Literature,J Med Chem,2021,1429.65,None,intermediate,1,1429.65,-8.854,-3.529,37,24,634.61,1.6816,0.61069,0.93628,37,47,3,0.44368,0.47818,11.65693135,1.630384116,0.639316451,2,2
CHEMBL5094492,CC[C@@H]1CN2CCc3c([nH]c4ccc(-c5ccoc5)c(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,85.11,7.07,F,CHEMBL5030540,agonist,agonist,Agonist activity at human MOR expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay,1,Scientific Literature,J Med Chem,2021,464.56,5.09,active,2,464.56,4.0371,-4.949,7,1,76.93,1.9438,0.28492,0.99243,7,7,3,0.35337,0.67889,-0.5155676676,-0.3838156973,0.06787822371,2,1
CHEMBL5094655,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(N)cc1)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,15.14,7.82,F,CHEMBL5032494,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of calcium mobilization by Fluo-4 AM dye based analysis,1,Scientific Literature,J Med Chem,2021,1486.75,None,active,2,1486.74,-8.3408,-4.712,38,25,660.63,1.6816,0.62011,0.94893,38,48,3,0.37202,0.47372,12.07794133,0.794335365,0.4460674516,8,8
CHEMBL5094675,CN1C(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)CCCNC(=O)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)NC(=O)[C@@H]1Cc1ccccc1,169.82,6.77,F,CHEMBL5034023,agonist,agonist,Agonist activity at MOR (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins in presence of 3-isobutyl-1-methylxanthine followed by forskolin and compound addition by competitive PKA binding assay,1,Scientific Literature,J Med Chem,2021,1138.3,None,intermediate,1,1138.29,-3.9389,-3.999,27,14,438.65,5.6885,0.5158,0.9493,27,23,3,0.45181,0.55004,6.850690571,0.9323232112,-0.4260701764,1,1
CHEMBL5094899,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1cccc(F)c1,12,7.92,F,CHEMBL5032513,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay,1,Scientific Literature,J Med Chem,2021,395.52,3.92,active,2,395.52,3.7856,-3.406,4,0,26.79,6.49,0.56118,0.79161,5,7,2,0.62933,0.75954,-1.214583738,0.6110474993,0.5397134298,8,4
CHEMBL5094951,CCC(=O)N(CC(C)N1CCC(Cc2ccccc2)CC1)c1ccccc1,2.3,8.64,F,CHEMBL5034029,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 60 mins by cAMP HTRF assay,1,Scientific Literature,Eur J Med Chem,2021,364.53,4.77,highly_active,3,364.531,4.9704,-4.256,3,0,23.55,6.9111,0.56265,0.71581,3,7,2,0.41287,0.7349,-1.549523707,-0.06383464185,0.5307322537,7,4
CHEMBL509528,CCCCCCC(N)C(=O)N[C@@H](Cc1c(C)cc(O)cc1C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,0.32,9.49,F,CHEMBL1150362,agonist,agonist,Agonist activity at mu opioid receptor in human SHSY5Y cells assessed as inhibition of forskolin-stimulated cAMP production,1,Scientific Literature,Bioorg Med Chem,2008,779.98,3.75,highly_active,3,779.98,3.7057,-6.758,13,7,212.74,-11.258,0.50973,0.92616,13,19,4,0.39852,0.61565,2.327834901,-1.749372244,0.3312867865,7,7
CHEMBL511302,C[N+]1(CC2CC2)CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13.[I-],52,7.28,F,CHEMBL1153960,antagonist,antagonist,Antagonist activity against human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,512.39,1.4,active,2,512.382,-1.9201,-3.044,6,3,100.62,0.58709,0.32346,1.0408,6,3,1,0.46122,0.78574,0.119592956,1.804440028,-0.8021993231,1,1
CHEMBL511621,NC(=O)c1ccc2c3c1O[C@H]1CCC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314,54,7.27,F,CHEMBL1153960,antagonist,antagonist,Antagonist activity against human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,354.45,1.74,active,2,354.448,1.7182,-3.925,5,2,75.79,2.6913,0.2214,1.0584,5,3,1,0.39219,0.77774,-0.7966220322,0.7888870583,-0.4317407424,6,6
CHEMBL511645,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@]1(O)CC[C@@H](O)C3,0.86,9.07,F,CHEMBL1153960,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,386.49,1.44,highly_active,3,386.49,1.3789,-3.528,6,4,107.02,4.115,0.27593,1.0231,6,3,1,0.36208,0.76306,-0.3273390903,1.080453446,-0.5063315302,10,4
CHEMBL511816,Oc1ccc2c3c1O[C@H]1CCC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314,4.4,8.36,F,CHEMBL1153960,antagonist,antagonist,Antagonist activity against human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,327.42,2.35,highly_active,3,327.423,2.2852,-3.54,4,2,52.93,2.2667,0.1932,1.0606,4,2,1,0.50616,0.81707,-1.161306151,0.9515532278,-0.311228588,6,6
CHEMBL512150,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@]1(O)CC[C@H](O)C3,26,7.58,F,CHEMBL1153960,antagonist,antagonist,Antagonist activity against human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,386.49,1.44,active,2,386.49,1.3789,-3.528,6,4,107.02,4.115,0.27578,1.0231,6,3,1,0.40787,0.77253,-0.3273390903,1.080453446,-0.5063315302,10,4
CHEMBL512258,NC1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl,4525,5.34,F,CHEMBL1138606,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GDP-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,437.41,6.56,inactive,0,437.412,6.0337,-6.467,2,1,29.26,-0.076987,0.26797,0.88077,4,4,3,0.73083,0.76848,-1.488768667,-1.572041447,-0.1925812974,16,9
CHEMBL512394,COCCN[C@@H]1c2ccccc2CC[C@H]1c1ccsc1,2600,5.58,F,CHEMBL1152717,agonist,agonist,Agonist activity at human cloned mu opioid receptor by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2009,287.43,3.76,inactive,0,287.426,3.4804,-3.206,2,1,49.5,0.6205,0.33405,0.81578,3,5,2,0.45741,0.75894,-1.520107929,0.9267037937,0.2959683834,1,1
CHEMBL512411,Cc1ccc(C(c2ccccc2Cl)N2C3CCC2CC(O)(c2ccncn2)C3)c(Cl)c1,1695,5.77,F,CHEMBL1138606,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GDP-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,454.4,5.7,inactive,0,454.4,5.2662,-5.755,4,1,49.25,0.6132,0.24871,0.91193,6,4,3,0.55049,0.75504,-1.102799853,-1.0322988,-0.1874249977,16,1
CHEMBL512414,NC(=O)C1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl,376,6.42,F,CHEMBL1138606,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GDP-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,465.42,6.13,intermediate,1,465.422,5.5418,-6.733,3,1,46.33,1.8847,0.27478,0.89827,5,5,3,0.71383,0.76693,-1.155814255,-1.679718177,-0.2649351817,16,9
CHEMBL512950,COC1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl,545,6.26,F,CHEMBL1138606,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GDP-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,452.43,7.25,intermediate,1,452.423,6.8594,-6.519,2,0,12.47,-0.04828,0.27259,0.8934,4,5,3,0.61473,0.74294,-1.657792075,-1.78787091,0.07321366774,16,9
CHEMBL513136,Cc1ccccc1C(c1ccccc1C)N1C2CCC1CC(O)(c1ccccc1)C2,693,6.16,F,CHEMBL1138606,agonist,agonist,Agonist activity at human mu opioid assessed as stimulation of GDP-induced [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,397.56,5.91,intermediate,1,397.56,5.9073,-5.607,2,1,23.47,0.55875,0.26061,0.84047,2,4,3,0.57987,0.74943,-1.71184947,-1.002904287,0.02454443582,16,9
CHEMBL5171242,Cc1ccccc1[C@@H]1NC(=O)[C@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)CCCCNC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](c2ccccc2)NC1=O,5.62,8.25,F,CHEMBL5126521,agonist,agonist,Agonist activity at human recombinant MOP expressed in CHO cells by calcium mobilization assay,1,Scientific Literature,J Med Chem,2022,713.84,1.05,highly_active,3,713.833,0.0403,-4.758,14,8,234.84,-1.5477,0.38639,0.89368,14,7,3,0.7159,0.6787,2.296355274,0.2961905163,-0.9962075808,7,7
CHEMBL5171420,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCCCNC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](c2ccccc2)NC(=O)[C@H](c2ccccc2)NC1=O,1.73,8.76,F,CHEMBL5126521,agonist,agonist,Agonist activity at human recombinant MOP expressed in CHO cells by calcium mobilization assay,1,Scientific Literature,J Med Chem,2022,699.81,0.74,highly_active,3,699.806,-0.3036,-4.414,14,8,234.84,-1.5477,0.39228,0.87866,14,7,3,0.40632,0.65192,2.298911591,0.5717117803,-0.9639326569,7,7
CHEMBL5171745,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1,0.94,9.03,F,CHEMBL5126521,agonist,agonist,Agonist activity at human MOP expressed in CHO-K1 cell membrane assessed as [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2022,738.85,0.34,highly_active,3,738.843,0.0534,-5.089,15,9,250.63,-1.3787,0.39818,0.8945,15,9,4,0.5024,0.67075,2.698569973,0.06423969071,-0.9444426408,1,1
CHEMBL5172639,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1)C(=O)NC1CC1,4256,5.37,F,CHEMBL5107935,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells co-expressing beta-arrestin2 assessed as beta-arrestin2 recruitment measured after 90 mins by PathHunter assay,1,Scientific Literature,RSC Med Chem,2021,595.72,2.16,inactive,0,595.713,2.4994,-4.988,10,6,162.65,4.3531,0.59076,0.78295,11,16,2,0.38571,0.61207,1.415671471,-0.3073525727,0.403716502,1,1
CHEMBL5173456,CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1,7215,5.14,F,CHEMBL5107935,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells co-expressing beta-arrestin2 assessed as beta-arrestin2 recruitment measured after 90 mins by PathHunter assay,1,Scientific Literature,RSC Med Chem,2021,569.68,1.63,inactive,0,569.676,1.9697,-4.224,10,6,162.65,5.0223,0.61209,0.76987,11,15,2,0.3462,0.62395,1.356643581,0.2719479821,0.4103766243,4,4
CHEMBL5173837,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccccc1,2.27,8.64,F,CHEMBL5126521,agonist,agonist,Agonist activity at MOP (unknown origin) stably expressed in HEK293 cells assessed as forskolin stimulated cAMP accumulation incubated for 30 mins by radioactivity based scintillation counter analysis,1,Scientific Literature,J Med Chem,2022,610.72,2.22,highly_active,3,610.713,1.3254,-4.103,11,6,183.64,0.9266,0.52283,0.88345,11,13,4,0.39063,0.64503,1.527713657,0.4474199708,0.1199259024,1,1
CHEMBL5174391,CCCC(=O)N(Cc1ccc(F)cc1)C1CCN(CCc2ccccc2)CC1,121.8,6.91,F,CHEMBL5108017,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 45 mins by cAMP HTRF assay,1,Scientific Literature,Eur J Med Chem,2022,382.52,4.66,intermediate,1,382.521,4.6981,-3.888,3,0,23.55,4.592,0.54985,0.71292,4,8,2,0.42147,0.69793,-1.40278128,0.1681542757,0.6722736766,2,2
CHEMBL5175678,Cc1cccc([C@@H]2NC(=O)[C@H](c3ccccc3)NC(=O)[C@H](NC(=O)[C@@H](N)Cc3c(C)cc(O)cc3C)CCCCNC(=O)C[C@@H](C(N)=O)NC2=O)c1,1.1,8.96,F,CHEMBL5126521,agonist,agonist,Agonist activity at human recombinant MOP expressed in CHO cells by calcium mobilization assay,1,Scientific Literature,J Med Chem,2022,713.84,1.05,highly_active,3,713.833,0.0403,-4.758,14,8,234.84,-1.5477,0.39277,0.88752,14,7,3,0.43999,0.62892,2.296355274,0.2961905163,-0.9962075808,7,7
CHEMBL5178409,CC[C@@H]1CN2CC[C@]3(O)c4c(cccc4OC)NC3[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,34.5,7.46,F,CHEMBL5126521,agonist,agonist,Agonist activity at MOP (unknown origin),1,Scientific Literature,J Med Chem,2022,416.52,2.5,active,2,416.516,1.9245,-2.992,7,2,80.26,2.5808,0.28409,0.98481,7,6,1,0.41716,0.71732,-0.3795693559,1.205672156,0.09570596981,10,1
CHEMBL5179132,O=C(c1ccco1)N(Cc1cccc(F)c1)C1CCN(CCc2ccccc2)CC1,48.5,7.31,F,CHEMBL5108017,partial agonist,agonist,Partial agonist activity at human MOR expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 45 mins by cAMP HTRF assay,1,Scientific Literature,Eur J Med Chem,2022,406.5,4.77,active,2,406.499,4.4218,-4.2,4,0,36.69,6.8396,0.50053,0.78055,5,7,3,0.37431,0.70793,-1.202658617,0.02471155264,0.4253640734,2,2
CHEMBL5180599,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=C(F)F)CC[C@@]3(O)[C@H]1C5,24,7.62,F,CHEMBL5107961,antagonist,antagonist,Antagonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in fentanyl induced cAMP production incubated for 30 mins by Lance ultra cAMP assay,1,Scientific Literature,RSC Med Chem,2022,361.39,2.88,active,2,361.387,2.897,-5.229,4,2,52.93,-2.5923,0.19548,1.0796,6,2,1,0.49328,0.82344,-0.9847512599,-0.1854603594,-0.6538993762,7,1
CHEMBL5186887,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccc(CO)cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,0.03,10.52,F,CHEMBL5126521,agonist,agonist,Agonist activity at human MOP stably expressed in CHO-K1 cells assessed as inhibition of forskolin-induced cAMP accumulation,1,Scientific Literature,J Med Chem,2022,524.57,3.79,highly_active,3,524.564,2.686,-4.721,9,1,129.34,-1.6551,0.28128,1.0143,9,7,2,0.32851,0.68564,0.1336692033,-0.0624932338,-0.1680119999,12,5
CHEMBL518712,C[C@H]1C2Cc3cc4nc[nH]c4cc3[C@@]1(C)CCN2CC1CC1,9.8,8.01,F,CHEMBL1136834,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,295.43,3.5,highly_active,3,295.429,3.1796,-3.899,3,1,31.92,5.3213,0.24324,0.91313,3,2,2,0.35049,0.78354,-1.574744342,0.5998764506,-0.195218238,2,2
CHEMBL5188741,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccccc1,4.39,8.36,F,CHEMBL5126521,agonist,agonist,Agonist activity at MOP (unknown origin) stably expressed in HEK293 cells assessed as forskolin stimulated cAMP accumulation incubated for 30 mins by radioactivity based scintillation counter analysis,1,Scientific Literature,J Med Chem,2022,571.68,1.74,highly_active,3,571.676,1.286,-3.578,10,5,167.85,0.79379,0.55649,0.83847,10,13,3,0.4225,0.65699,1.188648364,0.7858933591,0.308917552,1,1
CHEMBL518950,CN1CCC[C@@H](c2nc3ccccc3n2C2CCN(C3(C)CCCCCCC3)CC2)C1,67,7.17,F,CHEMBL1143349,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells by [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,422.66,5.99,active,2,422.658,6.5027,-2.806,4,0,24.3,3.3358,0.376,0.87115,4,3,2,0.38499,0.71476,-1.765132306,0.520540851,0.6998256758,11,2
CHEMBL5189745,Cc1cccc([C@@H]2NC(=O)[C@H](NC(=O)[C@@H](N)Cc3c(C)cc(O)cc3C)CCCCNC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](c3ccccc3)NC2=O)c1,2.95,8.53,F,CHEMBL5126521,agonist,agonist,Agonist activity at human recombinant MOP expressed in CHO cells by calcium mobilization assay,1,Scientific Literature,J Med Chem,2022,713.84,1.05,highly_active,3,713.833,0.0403,-4.758,14,8,234.84,-1.5477,0.39277,0.88752,14,7,3,0.41285,0.63089,2.296355274,0.2961905163,-0.9962075808,7,7
CHEMBL5190232,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,4.11,8.39,F,CHEMBL5126521,agonist,agonist,Agonist activity at MOP (unknown origin) stably expressed in HEK293 cells assessed as forskolin stimulated cAMP accumulation incubated for 30 mins by radioactivity based scintillation counter analysis,1,Scientific Literature,J Med Chem,2022,561.64,1.33,highly_active,3,561.637,0.4747,-3.26,11,5,180.99,0.99303,0.55967,0.8577,11,13,3,0.39806,0.65784,1.414882352,1.125715901,0.2331603935,5,5
CHEMBL519100,CC1(N2CCC(n3c(-c4cccc(C(F)(F)F)c4)nc4ccccc43)CC2)CCCCCCC1,10000,5,F,CHEMBL1143349,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells by [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,469.6,7.86,inactive,0,469.593,8.0223,-6.065,3,0,21.06,-6.5952,0.41107,0.89007,6,4,3,0.38514,0.70336,-1.627223817,-1.726003251,0.2153304299,11,5
CHEMBL5192115,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1)C(N)=O,2644,5.58,F,CHEMBL5107935,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells co-expressing beta-arrestin2 assessed as beta-arrestin2 recruitment measured after 90 mins by PathHunter assay,1,Scientific Literature,RSC Med Chem,2021,555.65,1.37,inactive,0,555.649,1.6182,-4.308,10,6,176.64,5.2758,0.61425,0.76113,11,15,2,0.32213,0.62427,1.425754812,0.2994868475,0.3174196357,4,4
CHEMBL5194625,Cc1ccc([C@@H]2NC(=O)[C@H](NC(=O)[C@@H](N)Cc3c(C)cc(O)cc3C)CCCCNC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](c3ccccc3)NC2=O)cc1,2.82,8.55,F,CHEMBL5126521,agonist,agonist,Agonist activity at human recombinant MOP expressed in CHO cells by calcium mobilization assay,1,Scientific Literature,J Med Chem,2022,713.84,1.05,highly_active,3,713.833,0.0403,-4.758,14,8,234.84,-1.5477,0.39277,0.88227,14,7,3,0.49461,0.63831,2.296355274,0.2961905163,-0.9962075808,7,7
CHEMBL5196331,NC(=O)[C@@H]1CCCCNC(=O)CC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1,1.5,8.82,F,CHEMBL5126521,agonist,agonist,Agonist activity at human MOP expressed in CHO-K1 cell membrane assessed as [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2022,713.84,0.25,highly_active,3,713.833,0.4684,-4.834,14,8,234.84,-1.5715,0.41545,0.85157,14,9,3,0.40844,0.65762,2.340671637,0.1516251146,-0.7536553751,1,1
CHEMBL5197033,Oc1ccc2c3c1O[C@H]1C(=C(F)F)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314,5.1,8.29,F,CHEMBL5107961,antagonist,antagonist,Antagonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in fentanyl induced cAMP production incubated for 30 mins by Lance ultra cAMP assay,1,Scientific Literature,RSC Med Chem,2022,375.42,3.11,highly_active,3,375.414,2.9462,-5.536,4,2,52.93,1.2933,0.17825,1.0809,6,2,1,0.48344,0.80663,-0.9546812181,-0.3881256187,-0.7197064922,4,1
CHEMBL5197271,NC(=O)[C@@H]1CCC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1,0.43,9.37,F,CHEMBL5126521,agonist,agonist,Agonist activity at human MOP expressed in CHO-K1 cell membrane assessed as [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2022,752.87,0.73,highly_active,3,752.87,0.5078,-5.359,15,9,250.63,-1.4241,0.39501,0.89285,15,9,4,0.38263,0.6202,2.67973698,-0.1868482706,-0.9426470459,2,2
CHEMBL5198168,CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1,2238.72,5.65,F,CHEMBL5107935,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells co-expressing beta-arrestin2 assessed as beta-arrestin2 recruitment measured after 90 mins by PathHunter assay,1,Scientific Literature,RSC Med Chem,2021,583.71,2.02,inactive,0,583.702,2.376,-4.524,10,6,162.65,4.9113,0.61367,0.77499,11,16,2,0.31716,0.61197,1.390136253,-0.001285113145,0.4975248022,4,4
CHEMBL5198915,NC(=O)CNC(=O)[C@@H]1CCC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1,1.01,9,F,CHEMBL5126521,agonist,agonist,Agonist activity at human MOP expressed in CHO-K1 cell membrane assessed as [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2022,809.92,-0.15,highly_active,3,809.922,-0.4085,-5.126,17,10,279.73,-0.88406,0.40276,0.90219,17,11,4,0.48784,0.62407,3.376209313,0.04638180105,-0.9171947514,2,2
CHEMBL5199190,Cc1ccc([C@@H]2NC(=O)[C@H](c3ccccc3)NC(=O)[C@H](NC(=O)[C@@H](N)Cc3c(C)cc(O)cc3C)CCCCNC(=O)C[C@@H](C(N)=O)NC2=O)cc1,7.76,8.11,F,CHEMBL5126521,agonist,agonist,Agonist activity at human recombinant MOP expressed in CHO cells by calcium mobilization assay,1,Scientific Literature,J Med Chem,2022,713.84,1.05,highly_active,3,713.833,0.0403,-4.758,14,8,234.84,-1.5477,0.39277,0.88227,14,7,3,0.29745,0.62916,2.296355274,0.2961905163,-0.9962075808,7,7
CHEMBL5199205,Cc1ccccc1[C@@H]1NC(=O)[C@H](c2ccccc2)NC(=O)[C@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)CCCCNC(=O)C[C@@H](C(N)=O)NC1=O,5.62,8.25,F,CHEMBL5126521,agonist,agonist,Agonist activity at human recombinant MOP expressed in CHO cells by calcium mobilization assay,1,Scientific Literature,J Med Chem,2022,713.84,1.05,highly_active,3,713.833,0.0403,-4.758,14,8,234.84,-1.5477,0.38639,0.89773,14,7,3,0.51527,0.65835,2.296355274,0.2961905163,-0.9962075808,7,7
CHEMBL519925,CC1CN(c2nc3ccccc3n2C2CCN(C3(C)CCCCCCC3)CC2)CC(C)N1,193,6.71,F,CHEMBL1143349,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHOK1 cells by [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,437.68,5.36,intermediate,1,437.673,6.0754,-4.136,5,1,36.33,2.7096,0.39905,0.85875,5,3,2,0.48542,0.72336,-1.38414048,-0.1890500451,0.2479348993,11,2
CHEMBL5199625,CCCCCCCCC(N)C(=O)N[C@@H](Cc1c(C)cc(O)cc1C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,1.3,8.89,F,CHEMBL5126521,agonist,agonist,Agonist activity at MOP in human SH-SY5Y cells assessed as forskolin stimulated cAMP accumulation incubated for 30 mins by Biotrak-EIA kit method,1,Scientific Literature,J Med Chem,2022,808.04,4.53,highly_active,3,808.033,4.6145,-7.298,13,7,212.74,-14.128,0.51168,0.92659,13,21,4,0.45927,0.60084,2.380855047,-2.277172957,0.5341626872,7,7
CHEMBL5200686,CCCCCCCCC(N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,31.4,7.5,F,CHEMBL5126521,agonist,agonist,Agonist activity at MOP in human SH-SY5Y cells assessed as forskolin stimulated cAMP accumulation incubated for 30 mins by Biotrak-EIA kit method,1,Scientific Literature,J Med Chem,2022,779.98,3.91,active,2,779.98,3.9267,-6.61,13,7,212.74,-14.128,0.5148,0.91408,13,21,4,0.46657,0.60229,2.385969084,-1.726131316,0.5987126918,7,7
CHEMBL5200728,CCNC(=O)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCCNC(=O)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O,5.01,8.3,F,CHEMBL5126521,agonist,agonist,Agonist activity at human recombinant MOP expressed in CHO cells by calcium mobilization assay,1,Scientific Literature,J Med Chem,2022,1373.58,None,highly_active,3,1373.57,-0.7173,-7.864,28,16,469.68,-0.52856,0.53229,0.94206,28,40,6,0.49504,0.51642,8.185522474,-2.314282473,0.6971307957,1,1
CHEMBL5203813,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1)C(=O)N(C)C,17782.79,4.75,F,CHEMBL5107935,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells co-expressing beta-arrestin2 assessed as beta-arrestin2 recruitment measured after 90 mins by PathHunter assay,1,Scientific Literature,RSC Med Chem,2021,583.71,1.97,inactive,0,583.702,2.2362,-3.862,10,5,153.86,5.6825,0.61692,0.77499,11,15,2,0.3478,0.62729,1.21313612,0.4121623041,0.5857433425,4,4
CHEMBL5203994,C[C@@H]1C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1C,321,6.49,F,CHEMBL5126521,antagonist,antagonist,Antagonist activity at human MOP stably expressed in CHO cell membrane assessed as [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2022,565.67,2.51,intermediate,1,565.672,2.4036,-4.678,9,4,123.4,7.8969,0.38794,0.89091,9,6,4,0.48296,0.6816,0.4290270426,0.01949056747,-0.3849905154,1,1
CHEMBL5208375,CCC(=O)N(Cc1ccc(F)cc1)C1CCN(CCc2ccccc2)CC1,231.3,6.64,F,CHEMBL5108017,partial agonist,agonist,Partial agonist activity at human MOR expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 45 mins by cAMP HTRF assay,1,Scientific Literature,Eur J Med Chem,2022,368.5,4.27,intermediate,1,368.494,4.2437,-3.618,3,0,23.55,7.5663,0.54977,0.70389,4,7,2,0.3933,0.70652,-1.429292108,0.4320550968,0.5708356501,2,2
CHEMBL5208537,O=C(c1ccco1)N(Cc1ccccc1)C1CCN(CCc2ccccc2)CC1,7.24,8.14,F,CHEMBL5108017,agonist,agonist,Agonist activity at human MOR expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 45 mins by cAMP HTRF assay,1,Scientific Literature,Eur J Med Chem,2022,388.51,4.63,highly_active,3,388.509,4.321,-3.886,4,0,36.69,8.1796,0.49876,0.73701,4,7,3,0.40357,0.70895,-1.291975956,0.2462101512,0.4963972086,2,2
CHEMBL5208747,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1,1.45,8.84,F,CHEMBL5126521,agonist,agonist,Agonist activity at MOP (unknown origin) stably expressed in HEK293 cells assessed as forskolin stimulated cAMP accumulation incubated for 30 mins by radioactivity based scintillation counter analysis,1,Scientific Literature,J Med Chem,2022,600.68,1.81,highly_active,3,600.674,0.5141,-3.785,12,6,196.78,0.99303,0.52543,0.89773,12,13,4,0.46811,0.65657,1.753947641,0.7872425076,0.04416874821,11,11
CHEMBL522375,C[C@H]1C2Cc3ccc(C(N)=O)c(N)c3[C@@]1(C)CCN2CC1CC1,31,7.51,F,CHEMBL1150274,antagonist,antagonist,Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem,2008,313.44,2.3,active,2,313.443,1.99,-3.853,4,2,72.35,5.1267,0.32221,0.92217,4,3,1,0.36923,0.76799,-1.024954899,0.8226863588,-0.3599636647,2,2
CHEMBL525580,C[C@@H]1NC(=O)[C@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC1=O,1470,5.83,F,CHEMBL5126521,antagonist,antagonist,Antagonist activity at human MOP stably expressed in CHO cell membrane assessed as [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2022,501.59,1.43,inactive,0,501.585,1.3118,-3.929,9,4,123.4,6.8918,0.36023,0.89285,9,4,3,0.46911,0.70405,0.3320251251,0.7363538112,-0.5688008405,1,1
CHEMBL542581,Cl.c1ccc(C2(N3CCCCC3)CCCCC2)cc1,6290,5.2,F,CHEMBL1201862,agonist,agonist,PubChem BioAssay. Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization. (Class of assay: confirmatory),7,PubChem BioAssays,,,279.86,4.33,inactive,0,279.853,4.1372,-3.467,1,0,3.24,-0.43123,0.43194,0.66071,1,2,1,0.51385,0.81821,-2.150465614,0.6861441926,0.153154673,1,1
CHEMBL557937,CN1CC[C@]23Cc4c(c5ccccc5n4C)C[C@]2(Cc2ccc(O)cc23)C1,173.9,6.76,F,CHEMBL1153456,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding by scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2009,358.49,3.8,intermediate,1,358.483,3.8981,-3.771,3,1,28.4,6.3767,0.10418,1.0271,3,0,3,0.53317,0.76162,-1.669149581,0.5157281084,-0.2446424366,1,1
CHEMBL562340,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)C[C@@]1(C2)Cc1c([nH]c2ccccc12)C3,33,7.48,F,CHEMBL1153456,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding by scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2009,384.52,4.57,active,2,384.521,4.4897,-4.924,3,2,39.26,5.1207,0.16461,1.0234,3,2,3,0.36078,0.75732,-1.429804035,-0.3023358067,-0.2868650733,1,1
CHEMBL565679,CC(CCCCCCC(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)C(=O)O,13,7.89,F,CHEMBL1154777,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,523.76,7.15,active,2,523.755,6.1685,-6.839,5,1,66.84,-1.4487,0.45181,0.94206,5,13,1,0.29143,0.64625,-0.5838895636,-2.001020975,0.5676082966,10,4
CHEMBL566346,O=C(O)CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3,3,8.52,F,CHEMBL1154777,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,495.7,6.66,highly_active,3,495.701,5.7319,-6.519,5,1,66.84,-11.548,0.40378,0.9391,5,13,1,0.25454,0.64984,-0.5911063121,-1.710232004,0.5784288005,10,4
CHEMBL56695,NC(=O)c1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314,4.9,8.31,F,CHEMBL1153960,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,Bioorg Med Chem Lett,2009,368.43,0.92,highly_active,3,368.432,1.0098,-3.577,6,2,92.86,4.9661,0.22978,1.0822,6,3,1,0.49889,0.80007,-0.5337171906,1.106478558,-0.4869998588,4,3
CHEMBL568877,COc1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1,6.8,8.17,F,CHEMBL2046406,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting,1,Scientific Literature,J Med Chem,2012,416.61,5.78,highly_active,3,416.607,4.9659,-5.715,3,1,24.5,-0.41062,0.38374,0.9395,3,6,2,0.34499,0.7016,-1.355024287,-0.9470979106,0.04640988236,5,5
CHEMBL573214,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4,120,6.92,F,CHEMBL1155455,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2010,661.8,3.82,intermediate,1,661.796,3.5223,-5.354,9,5,121.65,5.647,0.15377,1.2087,9,4,3,0.40271,0.69557,0.470510378,-0.6268760347,-0.6044798431,1,1
CHEMBL579408,CCC1(C)CC(CCNCc2ccccc2O)(c2ccccc2OC)CCO1,1100,5.96,F,CHEMBL4406853,antagonist,antagonist,Inhibition of mu-opioid receptor (unknown origin) by [35S]-GTPgammaS binding assay,1,Scientific Literature,Eur J Med Chem,2019,383.53,4.8,inactive,0,383.53,3.9653,-4.34,4,2,50.72,1.7293,0.54225,0.8236,4,8,2,0.49626,0.73043,-0.9687060764,0.05861497544,0.3455077417,6,6
CHEMBL582930,CC(CCCCCCC(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3,7.1,8.15,F,CHEMBL1154777,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,817.21,11.53,highly_active,3,817.207,11.694,-11.264,6,0,59.08,-0.86295,0.44499,1.0398,6,17,2,0.30224,0.59291,-0.3845043553,-5.908233322,0.7560223665,5,3
CHEMBL58362,CC[C@@H]1CN2CC[C@]3(Nc4cccc(OC)c4C3=O)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,1.7,8.77,F,CHEMBL4406853,antagonist,antagonist,Inhibition of mu opioid receptor (unknown origin) in presence of DPDPE by [35S]-GTPgammaS binding assay,1,Scientific Literature,Eur J Med Chem,2019,414.5,2.87,highly_active,3,414.5,2.0051,-3.416,7,1,77.1,2.3776,0.24588,0.97904,7,6,1,0.54758,0.71205,-0.4715436033,0.9315674839,0.04160230226,1,1
CHEMBL584790,CC(C)(CCCCCCC(C)(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3,11,7.96,F,CHEMBL1154777,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,845.27,12.31,active,2,845.261,12.825,-11.618,6,0,59.08,-2.0175,0.47809,1.0416,6,17,2,0.34016,0.60346,-0.4566117936,-6.339371197,0.837224315,5,3
CHEMBL584791,C=CCN1CC[C@]23c4c5ccc(OC(=O)CCCCCCCCC(=O)Oc6ccc7c(c6)[C@@]68CCCC[C@H]6C(C7)N(CC6CCC6)CC8)c4O[C@H]2CCC[C@H]3[C@H]1C5,2,8.7,F,CHEMBL1154777,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,1,Scientific Literature,J Med Chem,2009,775.09,9.79,highly_active,3,775.083,10.349,-10.339,7,0,68.31,-11.493,0.38865,1.0809,7,17,2,0.35609,0.60911,-0.1864602641,-5.088712443,0.7520674993,1,1
CHEMBL58646,C[C@H]1C2Cc3ccc(C(N)=O)cc3[C@@]1(C)CCN2CC1CC1,2.7,8.57,F,CHEMBL2346652,partial agonist,agonist,Partial agonist activity at human mu opioid receptor expressed in CHO cell membrane assessed as stimulation of [35S]GTPgammaS binding after 60 mins by liquid scintillation counting,1,Scientific Literature,Bioorg Med Chem Lett,2013,298.43,2.72,highly_active,3,298.428,2.6673,-3.777,3,1,46.33,5.1267,0.32661,0.8945,3,3,1,0.36807,0.77223,-1.423346391,0.7476775359,-0.1592996516,2,2
CHEMBL596,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,5.495,8.26,F,CHEMBL4304817,agonist,agonist,Agonist activity at Gi-coupled mu opioid receptor (unknown origin) expressed in HEK293T cells assessed as inhibition of cAMP production at pH 6.5 measured after 15 mins by Glo-Sensor assay,1,Scientific Literature,ACS Med Chem Lett,2019,336.48,4.14,highly_active,3,336.477,4.4164,-3.826,3,0,23.55,8.7647,0.5155,0.69646,3,6,2,0.33632,0.71507,-1.593469924,0.3248923665,0.451856536,14,12
CHEMBL607,CCOC(=O)C1(c2ccccc2)CCN(C)CC1,9400,5.03,F,CHEMBL1152717,agonist,agonist,Agonist activity at human cloned mu opioid receptor by [35S]GTPgammaS binding assay,1,Scientific Literature,Bioorg Med Chem Lett,2009,247.34,2.21,inactive,0,247.337,2.0717,-2.188,3,0,29.54,4.6181,0.47343,0.68629,3,4,1,0.44231,0.7871,-1.60445791,1.807422339,0.2922623166,10,8
CHEMBL607351,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(OCc2ccccc2)[C@H]1C5,0.32,9.49,F,CHEMBL4028881,agonist,agonist,Agonist activity at recombinant human MOR expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2017,391.47,2.97,highly_active,3,391.466,2.6984,-3.827,5,1,59,4.1172,0.23527,1.0905,5,3,2,0.41151,0.78214,-1.00188139,0.6265108179,-0.2031340515,1,1
CHEMBL61630,CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4cccc(OC)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC,34.5,7.46,F,CHEMBL4376854,agonist,agonist,Agonist activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of cAMP accumulation by HTRF assay,1,Scientific Literature,J Med Chem,2020,414.5,2.79,active,2,414.5,2.0901,-2.762,7,1,80.59,2.4869,0.28015,0.98481,7,6,1,0.41805,0.70852,-0.5000671458,1.302687454,0.2090330548,10,4
CHEMBL656,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,17,7.77,F,CHEMBL4354824,agonist,agonist,Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay,1,Scientific Literature,J Med Chem,2020,315.37,1.05,active,2,315.368,1.1281,-2.69,5,1,59,4.9034,0.12162,1.0727,5,1,1,0.49293,0.83273,-1.079557084,1.666214517,-0.3630404081,7,3
CHEMBL70,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,70.79,7.15,F,CHEMBL5034023,agonist,agonist,Agonist activity at MOR (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins in presence of 3-isobutyl-1-methylxanthine followed by forskolin and compound addition by competitive PKA binding assay,1,Scientific Literature,J Med Chem,2021,285.34,1.2,active,2,285.342,1.2567,-2.547,4,2,52.93,5.0881,0.12658,1.0331,4,0,1,0.61952,0.84352,-1.242903177,1.780220242,-0.4227671341,12,1
CHEMBL80,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,45,7.35,F,CHEMBL4038325,antagonist,antagonist,Antagonist activity at recombinant human MOR expressed in HEK293T cells assessed as reduction in DAMGO-induced inhibition of forskolin-stimulated cAMP level preincubated for 15 to 20 mins followed by DAMGO and forskolin addition by GloSensor assay,1,Scientific Literature,J Med Chem,2017,327.38,1.3,active,2,327.379,1.5276,-2.885,5,2,70,0.78037,0.2061,1.0722,5,2,1,0.54004,0.82894,-0.9284728904,1.471811126,-0.3006807217,7,3
CHEMBL8234,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O,1.3,8.89,F,CHEMBL4732045,agonist,agonist,Agonist activity at human mu opioid receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-induced cAMP accumulation incubated for 30 mins by luminescence-based assay,1,Scientific Literature,J Med Chem,2020,555.63,-0.16,highly_active,3,555.63,-2.2725,-2.904,12,7,199.95,-12.376,0.627,0.76856,12,15,2,0.35848,0.62598,2.158108176,1.818510249,0.01098838425,14,14
CHEMBL895,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,14,7.85,F,CHEMBL1147138,agonist,agonist,Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding,1,Scientific Literature,J Med Chem,2007,357.45,1.71,active,2,357.448,1.7751,-3.411,5,3,73.16,3.6567,0.22403,1.0748,5,2,1,0.51682,0.82697,-0.7876572702,1.102903343,-0.427199229,1,1
CHEMBL963,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,7.8,8.11,F,CHEMBL4028881,agonist,agonist,Agonist activity at recombinant human MOR expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay,1,Scientific Literature,J Med Chem,2017,301.34,0.75,highly_active,3,301.341,0.8524,-2.376,5,2,70,4.8562,0.12192,1.0684,5,0,1,0.62555,0.85631,-1.004164259,1.938960768,-0.4770711019,7,3